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The neuronal ceroid lipofuscinoses (NCLs or Batten disease) are inherited 
neurodegenerative diseases of children. In all types of NCL glial activation, the innate 
immune response of the brain, precedes neurodegeneration. However, it is unclear 
whether adaptive immune responses are also involved in these diseases, or if they 
directly contribute to disease pathogenesis. Therefore, we examined the role of 
adaptive immune cells in mouse models of Infantile NCL (Ppt1-/- mice) and Juvenile 
NCL (Cln3-/- mice) by identifying, localising, and subsequently genetically removing 
immune components.  
Characterising the adaptive immune response within Ppt1-/- and Cln3-/- mice, we 
revealed evidence for progressive CNS infiltration by different classes of T-cells in 
both forms of NCL. To analyse the pathogenic impact of these lymphocytes, we 
crossbred Ppt1-/- mutants with mice deficient in Rag-1, which lack T- and B-
lymphocytes. Disease progression was significantly delayed in immune deficient    
Ppt1-/-/Rag-1-/- mice, which displayed ameliorated neuroinflammation and neuron loss. 
We also crossed our Infantile and Juvenile NCL mouse models with mice deficient in 
sialoadhesin (Sn), a binding protein found on macrophages and microglia, and is 
involved in pro-inflammatory T-cell regulation. Disease progression was also slowed 
down, with significantly increased neuron survival in both Sn deficient NCL mice.  
However, contrasting effects on glial activation were observed between Ppt1-/-/Sn-/- 
and Cln3-/-/Sn-/- mice. Whereas glial activation was only marginally attenuated in    
Cln3-/-/Sn-/- mice, significantly decreased microglial activation and enhanced 
astrocytosis were observed in Ppt1-/-/Sn-/- mice. These latter findings suggest an 
unexpected link between macrophage-expressed Sn and astrocytosis in Ppt1-/- mice. 
Taken together, our findings prove that adaptive immune cells and sialoadhesin each 
appear to contribute to disease progression in Infantile and Juvenile NCL mice. 
Therefore, both immune components could prove to be suitable therapeutic targets 
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The neuronal ceroid lipofuscinoses (NCLs) are a group of recessively inherited 
lysosomal diseases that affect mainly children (Santavuori, 1988). The NCLs are 
collectively considered to be the most common inherited neurodegenerative storage 
disorders of childhood (Haltia, 2006; Jalanko and Braulke, 2009). They are now 
classified as lysosomal storage disorders (LSDs), which characteristically due to a 
specific monogenetic defect, impact the function of the endosomal/lysosomal system 
(Neufeld, 1991; Schultz et al., 2011). The NCLs in particular have widely varying ages 
of onset, rates of progression and underlying disease mechanisms, but ultimately lead 
to similar clinical manifestations (Cooper, 2010). The neuropathological features of the 
different forms of NCLs have been systematically characterised in animal models, and 
well-defined landmarks of disease progression have been identified (Bible et al., 2004; 
Pontikis et al., 2004; Oswald et al., 2005; Pontikis et al., 2005; Kielar et al., 2007; 
Partanen et al., 2008; von Schantz et al., 2009; Kuronen et al., 2012; Schmiedt et al., 
2012), with early glial activation and selective neuron loss in the thalamocortical 
system being identified as key pathologies. Whereas the innate immune response in 
terms of this glial activation has been well characterised (Pontikis et al., 2005; Kielar et 
al., 2007), the role of the adaptive and peripheral immune responses in the NCLs have 
so far been overlooked. Inspired by recent evidence of the presence and putative role 
of adaptive immune cells in NCL disease pathogenesis (Macauley et al., 2011; Seehafer 
et al., 2011), we created immune deficient INCL (Ppt1-/-) and JNCL (Cln3-/-) mice. This 
was achieved by crossing our NCL mouse models with mice deficient in Rag-1, which 
is essential for the maturation of T- and B-cells, and also by crossing with mice 
deficient in sialoadhesin (Sn), a T-cell activating binding protein expressed on 
macrophages, and subsequently characterising the impact of these immune 
deficiencies in the resultant double knockout (Ppt1-/-/Rag-1-/-, Ppt1-/-/Sn-/- and Cln3-/-
/Sn-/-) mice. As such, this thesis provides new insights into the role of adaptive 
immune cells and macrophages in the pathogenesis of two NCL forms, and potentially 
lays the foundation for treatment strategies targeting the immune system in NCLs.  
1.1 Lysosomal storage disorders (LSDs) 
Since the discovery of the lysosome (De Duve et al., 1955), it took about 10 years for 
the concept of LSDs to become established (Hers, 1965), and defined as being a group 
of inherited disorders all displaying an intra-lysosomal accumulation of undegraded 
material or catabolic products (Hers, 1972). Over 70 different LSDs have been 
27 
 
identified and these have been intensively studied and characterised over the years 
(Neufeld, 1991; Lachmann, 2010; Schultz et al., 2011). Although individually rare, the 
LSDs have a collective incidence of approximately 1 in 7,700 live births (Meikle et al., 
1999), and therefore place a significant burden on health systems worldwide. 
However, this number is probably an underestimate because many LSDs remain 
undiagnosed due to their variable and heterogeneous clinical presentation. An 
important consequence of investigating the LSDs is that this has enriched our 
knowledge about lysosomal function and its involvement in general cell biology.   
a) The lysosomal proteins and pathways 
The lysosome is a membrane bound acidic organelle in which the cell recycles and 
degrades macromolecules via a variety of acid hydrolases (De Duve, 1963). For this 
degradation to function properly two processes are essential: firstly, a correct delivery 
of proteins destined to be degraded via the endocytic pathway and secondly, proper 
sequestering of the lysosomal hydrolases necessary for this process (Kornfeld and 
Mellman, 1989; Mellman, 1996). 
Macromolecules destined for lysosomal degradation can either reach the lysosome via 
endocytosis from the extracellular environment, or by intracellular routes from within 
the cytosol (Zhang et al., 2009). Proteins from the extracellular space can enter the cell 
either via endocytosis or phagocytosis, depending on the nature of the protein 
(Dunina-Barkovskaya, 2004; Doherty and McMahon, 2009; Flannagan et al., 2012). 
Receptor mediated endocytosis is a common process for internalising a variety of 
substances, and occurs after binding to specific cell surface receptors (Goldstein et al., 
1985). This kind of internalisation relies most commonly on a clathrin mediated 
vesicular process (Doherty and McMahon, 2009), whereas phagocytosis is mediated by 
phagosome creation (Flannagan et al., 2012). However, both vesicular structures end 
up fusing with endosomes, and eventually with lysosomes. In contrast, proteins from 
the cytosol reach the lysosome via the process of autophagy (Stromhaug and Klionsky, 
2001; Levine and Klionsky, 2004), or after normal protein synthesis from the 
endoplasmic reticulum (ER) via the Golgi apparatus (Braakman and Bulleid, 2011).   
In addition, to guarantee the correct degradation of macromolecules in the lysosome, 
soluble hydrolases have to be delivered to the lysosomal lumen. After protein 
synthesis, these hydrolases that are destined for the lysosomal lumen become tagged 
with mannose oligosaccharide side chains as they are trans-located into the ER lumen 
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(Helenius and Aebi, 2001). This is part of the sorting and control mechanism to 
guarantee correctly folded proteins. Furthermore, hydrolases that are targeted for the 
lysosome have to be linked to mannose-6-phosphate (M-6-P) residues (Kaplan et al., 
1977). If misfolding occurs, the proteins are directly degraded in the ER (Gething and 
Sambrook, 1992), otherwise correctly folded proteins are transported to the Golgi 
apparatus (Saraste and Kuismanen, 1992).  In the Golgi apparatus, proteins that will 
be targeted to the lysosome are recognized by the M-6-P receptor, by which lysosomal 
hydrolases are segregated from other proteins (Kornfeld and Mellman, 1989; 
Kornfeld, 1992). These proteins are transported along the trans-Golgi-network (TNG) 
to the pre-lysosomal compartment and/or endosome where the low pH dissociates 
the receptor and enzyme, after which the M-6-P receptor is recycled to the Golgi 
network (Dell'Angelica and Payne, 2001).  
In stark contrast to these soluble lysosomal proteins, the trafficking of lysosomal 
membrane proteins does not depend on M-6-P receptors, but instead upon a tyrosine-
based and/or dileucine-based sorting signal at the cytoplasmic domain of the protein 
(Peters et al., 1990; Braulke and Bonifacino, 2009). Lysosomal membrane proteins 
have been shown to reach the lysosome by two pathways: either directly or indirectly 
(Kornfeld and Mellman, 1989; Hunziker and Geuze, 1996). In the direct pathway 
lysosomal membrane proteins are transported directly to early or late endosomes and 
then subsequently to lysosomes. In the indirect pathway, these proteins are instead 
transported to the plasma membrane of the cell surface where they are internalised 
into early endosomes and eventually delivered to the endosomes and lysosomes 
(Braulke and Bonifacino, 2009). Once these lysosomal membrane proteins have 
correctly reached the lysosome they are crucial for the acidification of the lysosomal 
lumen, transport of molecules across the lysosomal membrane and mediating 
membrane fusion (Saftig and Klumperman, 2009).  
b) Lysosomal function 
Originally the lysosome was only regarded as the waste disposal and recycling 
machinery of the cell (Kornfeld and Mellman, 1989). However, with increasing 
research into intracellular trafficking, the lysosome is now seen as a more dynamic 
organelle that contributes to a variety of intracellular cell processes. Indeed, apart from 
being the final destination of the endosomal/lysosomal pathway after endocytosis, 
phagocytosis or autophagy of molecules targeted for destruction or recycling, the 
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lysosome has been shown to be the centre of many cellular functions (see Figure 1) 
(Luzio et al., 2007; Walkley, 2007; Saftig and Klumperman, 2009). These include 
cellular recycling and repair, homeostatic control (Stinchcombe and Griffiths, 1999), in 
particular cholesterol homeostasis (Chang et al., 2006), cell surface receptor down 
regulation (Carpentier et al., 1985), bone and tissue remodelling, cell death (Guicciardi 
et al., 2004), cell signalling and inactivation of pathogenic organisms (Saftig and 
Klumperman, 2009). Furthermore, lysosomes are also involved in cell-specific 
functions like the correct loading of major histocompatibility complex (MHC) class II 
molecule receptor with peptides, before enabling antigen presentation at the cell 
surface of T-cells (Raposo et al., 2002), or secretory vesicle formation in cytotoxic T-
cells at the immunological synapse (Luzio et al., 2007). Taken together, the 
endosomal/lysosomal system is essential for correct protein sorting and trafficking 
within each cell of the body. This becomes even more significant in highly polarized 
cells like neurons of the central nervous system (CNS). 
c) Lysosomes in neurons 
As in every other cell in the body, all the basic lysosomal functions mentioned above 
are also essential for the long term survival of neurons and the crosstalk within, and 
between, cells of the CNS (Nixon and Cataldo, 1995). However, neurons above all 
other cell types have a fundamental need for a functional endosomal/lysosomal 
system, and in particular for endocytosis (Parton and Dotti, 1993). The considerable 
spatial separation of the cell soma, where most proteins are made, and synapses means 
that a functioning vesicular and protein trafficking system is critically required for 
neuronal function (Lasiecka and Winckler, 2011). Furthermore, after neurotransmitter 
release at the synapse, a series of rapid endocytic events are needed to maintain 
synaptic vesicle numbers (Murthy and Stevens, 1998). Indeed, neurons also rely on 
endocytosis to mediate communication with peripheral tissues, which may be essential 
for survival (Sofroniew et al., 2001). Many different hormones and growth factors 
from the extracellular space regulate neuronal function and activity by triggering 
intracellular signals (Howe et al., 2001; Schlett, 2006; Ascano et al., 2012), and all 
depend on precise intracellular trafficking.  
Besides these necessities imposed by neuronal morphology and function, some 
specific features of lysosomal involvement in neurobiology should also be considered. 
These processes all start during brain development, when late endosomes/lysosomes 
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play an essential role in neurite outgrowth and arborisation by adding new membranes 
to developing neurite extensions (Arantes and Andrews, 2006), or by guaranteeing 
vesicular protein trafficking during axonal and dendritic growth (Sann et al., 2009). 
Whereas lysosomes are essential for axonal growth, they have also been shown to be a 
central feature of synapse elimination, via their degradative activity during the process 
of axon pruning (Song et al., 2008). Studies in Niemann-Pick disease, another LSD, 
revealed the key role of the lysosome in cholesterol homeostasis, which is necessary 
for the maintenance of synaptic structure and function and effective 
neurotransmission (Mitter et al., 2003; Wasser et al., 2007), and last but not least, the 
lysosome is important for effective autophagy and mitochondrial turnover in neurons 
(Settembre et al., 2008; Batlevi and La Spada, 2011; Marino et al., 2011). When neurons 
Figure 1. The numerous functions of the lysosome. As a central organelle within a cell, the 
acidic compartment (H+ of the lysosome is created by V-type H+-ATPase activity which ensures 
optimal conditions for lysosomal hydrolases). The lysosome is involved in various pathways:  
During macro-autophagy, lysosomal fusion with autophagosomes is essential for the turnover of 
cytoplasmic components. Essential for adaptive immune responses, major histocompatibility 
complex (MHC) class II dependent antigen presentation and exosome release depend on 
lysosomal proteases and membrane proteins. Fusion of the lysosome with phagosomes is required 
for successful phagocytosis in pathogen defence processes. Furthermore, exocytosis, plasma 
membrane repair, chaperone-mediated autophagy, lysosomal cell death all rely on functional 
lysosomal activity. Several lysosomal (transport) processes are regulated by membrane bound 
lysosomal proteins including lysosome-associated membrane proteins (LAMPs), lysosome-
integrated membrane protein (LIMP2), chloride channel 7 (CLC7), synaptotagmin 7 (SYT7) and 
cluster of differentiation molecule 63 (CD63 The deficiency of the membrane protein Niemann-
Pick C1 (NPC1) leads to cholesterol accumulation, suggesting its involvement in cholesterol 




age it has been suggested that lysosomes can inhibit or induce neuronal death via 
lysosomal rupture or permeabilization, which is comprised in the so-called 
‘mitochondrial–lysosomal axis theory of aging’ (Yamashima and Oikawa, 2009; 
Terman et al., 2010).  
It may not come as a surprise, with so many crucial functions for the lysosome in 
healthy neurons that altered lysosomal function has been described as a cause of many 
neurodegenerative disorders. Apart from LSDs, lysosomal dysfunction has been 
considered in relation to Alzheimer disease, in which disturbances of the 
endosomal/lysosomal pathways are one of the earliest known manifestations of 
Alzheimer disease (Nixon and Cataldo, 2006). Likewise, in Parkinson disease the 
disease-associated mutant α-synuclein can inhibit autophagy-lysosomal pathways in 
neurons (Pan et al., 2008). Furthermore, anterograde lysosomal transport seems to be a 
key factor in motor neuron degeneration (Lim and Kraut, 2009). Therefore, lysosomal 
dysfunction could perhaps be used as an early marker for axon degeneration and, vice 
versa, the proper maintenance of lysosomal transport function could be potentially 
therapeutic for many neurodegenerative disorders (Zheng et al., 2010). Moreover, 
other candidates for neurodegenerative disorders with lysosomal involvement include 
frontotemporal dementia (Lee et al., 2007a) and amyotrophic lateral sclerosis (ALS) 
(Filimonenko et al., 2007). Nevertheless, the prime examples of neuronal dysfunction 
due to endosomal/lysosomal pathway disruptions are of course the LSDs themselves. 
Given the complexity of lysosomal functions, together with the highly polarized and 
long-distance nature of neurons and their projections, a pronounced neurological 
component is a common pathological feature in most LSDs (Scriver et al., 2001; 
Walkley, 2009). 
d) Neurodegeneration in LSDs 
About three quarters of LSDs show CNS pathology as a hallmark, and these disorders 
are considered the most common cause of paediatric neurodegeneration (Vitner et al., 
2010; Schultz et al., 2011). Yet, the actual cause of neuronal death is a topic that has 
been debated for many years. Whereas originally, the storage material itself was 
thought to be the main cause and driving force of cell death (Desnick et al., 1976), the 
key contributor to the pathogenesis of LSDs is now considered to be a consequence 
of the deficiencies in the endosomal/lysosomal system (Walkley and Vanier, 2009). 
The loss of gene function may cause both primary and secondary damage to cells and 
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tissues, with storage material contributing directly or indirectly to pathogenesis. In 
addition, various secondary pathological cascades as a downstream consequence of the 
loss of lysosomal function and/or storage accumulation are likely to contribute and 
accelerate pathogenesis. The pathological cascades will inevitably vary between each 
form of LSDs, as a consequence of different gene deficiencies. In many LSDs the 
storage material accumulates as a direct cause of the gene deficiency and is likely to 
have upstream effects on pathogenesis (e.g. in several sphingolipidoses Tay Sachs 
disease or gangliosidoses like Mucopolysaccharidosis (MPS) type I) and this situation 
is further complicated by the accumulation of secondary molecules that may also have 
pathological consequences (Futerman and van Meer, 2004). However, in the NCLs, 
with very little known about the normal function of the deficient genes it is harder to 
link storage material accumulation to downstream pathology. This issue is made more 
complicated by the finding that while storage material accumulation is widespread 
within the CNS (Haltia, 2003), neuron loss is relatively selective (Pontikis et al., 2005; 
Cooper et al., 2006; Kielar et al., 2007), and there does not appear to be a direct 
correlation between these events. However, secondary downstream events caused by 
storage accumulation could still indirectly influence disease pathogenesis and have to 
be considered in interpreting disease mechanisms. It is important to disentangle such 
primary and secondary pathogenic events when considering therapeutic strategies, as 
certain events are probably only secondary downstream consequences of primary 
causes of gene deficiency, and the ‘wrong’ therapeutic targets will not be able to 
reverse neurodegenerative processes per se (Walkley and Vanier, 2009). 
e) Clinical features of LSDs 
The LSDs are classically childhood disorders, with some rarer adult onset forms, as 
for example CLN4 disease/Kufs disease (see below and Table 1; (Rapola, 1994; 
Goebel, 1995; Schultz et al., 2011)). All LSDs are monogenetic with the vast majority 
of disease-causing mutations inherited in an autosomal recessive fashion (Winchester 
et al., 2000), except for Fabry disease and Mucopolysaccharidosis (MPS) type II 
(Hunter syndrome) which are X-linked (Desnick et al., 1989; Hopwood et al., 1993a), 
and the autosomal dominant inherited CLN4 disease (originally associated with Kufs 
Disease, Parry type) (Nijssen et al., 2003; Benitez et al., 2011; Velinov et al., 2012). 
These genetic defects may include lysosomal hydrolases, lysosomal membrane 
proteins or proteins expressed elsewhere in the endosomal/lysosomal system resulting 
in heterogeneous clinical outcomes (Winchester et al., 2000; Walkley, 2009). 
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Nevertheless, common clinical manifestations can be described: normal early 
development is followed by developmental delay, leading to motor deficits often 
accompanied by loss of vision continuing through to a later stage when neurological 
symptoms arise with seizures, dementia, behavioural changes, and eventually 
premature death (Wraith, 2004). However, different forms of LSDs show large 
discrepancies in age of onset, severity and which organs are affected, due to the 
distinct genetic differences between them and other unidentified reasons (Beck, 2001; 
Wilcox, 2004). One explanation can be found in the fact that in each disease-causing 
gene, numerous mutations can result in different molecular consequences and clinical 
manifestations. As such, often no straightforward genotype-phenotype correlation can 
be observed in each specific form of LSD (Mole et al., 2011). Typical examples include 
the neuronal ceroid lipofuscinoses (NCLs), in which patients with mutations in the 
same disease-causing gene typically show heterogeneous ages of onset and rates of 
progression (see NCL classification in Table 1).  
1.2 Neuronal Ceroid Lipofuscinoses (NCLs) 
The NCLs are considered to be the most common inherited neurodegenerative 
storage disorders of childhood (Goebel, 1995; Jalanko and Braulke, 2009), with an 
incidence of up to 1 in 12,500 live births in Scandinavian countries and 1:100,000 
worldwide (Santavuori, 1988; Kyttala et al., 2006; Jalanko and Braulke, 2009). Despite 
the first observation of NCL cases by Dr Otto Stengel in 1826 (Brean, 2004), these 
diseases are more commonly called Batten disease after the British paediatrician 
Frederick Batten who reported Juvenile NCL cases in 1903 (Zeman and Dyken, 1969).   
a) Classification of the NCLs 
Since the discovery of the first genes causing NCL in 1995 (Lerner et al., 1995; Vesa et 
al., 1995), roughly 400 mutations have been described in thirteen different genes. 
Traditionally the classification of the NCLs has always been by age of onset, which 
grouped the diseases into four main categories: Infantile NCL (INCL), Late-infantile 
NCL (LINCL), Juvenile NCL (JNCL) and Adult NCL (ANCL) (Goebel et al., 1999). 
However, progress in identifying the genetic basis of these disorders made it possible 
to classify them according to the disease-causing gene (Cooper, 2003; Mole, 2004; 
Siintola et al., 2006; Jalanko and Braulke, 2009). Subsequent years have seen the 
identification of an increasing number of mutations and variant forms of NCL 
(Siintola et al., 2006; Jalanko and Braulke, 2009) (see NCL mutation database 
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http://www.ucl.ac.uk/ncl/mutation.shtml). Whereas for most NCL genes a characteristic 
disease phenotype is associated with a complete loss of gene function, additional 
‘milder’ cases with some remaining gene function and with delayed disease onset 
and/or progression added complexity to the classification system (Lake and Cavanagh, 
1978; Santavuori et al., 1982). Therefore, recently a new nomenclature has been 
proposed based upon combining the genetic defect with the age of onset (see Table 
1). However, in everyday practice the classical nomenclature is still in use. Likewise, in 
this study any notation of a NCL disease will always refer to a complete loss of 
function mutation and for that reason, we will stick to a simplified ‘classical’ 
description based on the age of onset (‘Infantile NCL’ instead of ‘CLN1 disease, 
infantile’ or ‘Juvenile NCL’ instead of ‘CLN3 disease, juvenile’). The studies described 
in this thesis focus upon two of the three most common forms of NCL: Infantile 
NCL (INCL/CLN1) and Juvenile NCL (JNCL/CLN3). Hence these two forms shall 
be summarised in more detail.  
b) Infantile NCL (INCL/CLN1) 
Infantile NCL (INCL) is a rare disease form (~1:2,000,000 live births worldwide), but 
it has a particularly high incidence in the Finnish population (~1 in 20,000 live births) 
(Santavuori, 1988; Mole et al., 2011). INCL is caused by mutations in the CLN1 gene 
which encodes a soluble lysosomal enzyme, palmitoyl protein thioesterase 1 (PPT1) 
(Vesa et al., 1995). So far, 49 different mutations have been identified for PPT1 with 
missense mutations (23 of 49) being the most prominent (http://www.ucl.ac.uk/ 
ncl/mutation.shtml). The biochemical function of PPT1 is mainly to cleave palmitate or 
fatty acyl chains from proteins and peptides (Camp and Hofmann, 1993; Camp et al., 
1994), whereas the exact cellular function in vivo still remains elusive. PPT1/Ppt1 has 
been shown to participate in several cellular processes including endocytosis 
(Ahtiainen et al., 2006), apoptosis (Cho and Dawson, 2000; Tardy et al., 2009), vesicular 
trafficking and synaptic function (Lehtovirta et al., 2001; Virmani et al., 2005; Kim et al., 
2008). Consistent with these suggestions, additional cellular localisations of 
PPT1/Ppt1 have been described in axonal varicosities and presynaptic terminals of 
neurons (Heinonen et al., 2000; Ahtiainen et al., 2003; Virmani et al., 2005). 
Furthermore, PPT1 transport along the endosomal/lysosomal pathways is suggested 
to be mediated by the mannose-6-phosphate receptor (M6PR) (Hellsten et al., 1996; 
Verkruyse and Hofmann, 1996). In mice and rats, Ppt1 protein expression can be 
expressed during developmental stages and has been associated with neuronal 
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Table 1. New classification nomenclature of the neuronal ceroid lipofuscinoses (NCLs). All diseases 
listed are autosomal recessive disorders unless marked differently. Adapted from (Williams and Mole, 2012) 
and (Mole et al., 2011). 
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maturation (Isosomppi et al., 1999; Heinonen et al., 2000). The clinical manifestations 
of Infantile NCL normally appear between 6-12 months of age, followed by loss of 
vision and speech, cognitive decline, microcephaly and seizures leading to premature 
death between 9-13 years of age (Santavuori, 1988; Santavuori et al., 1993; Santavuori 
et al., 2000).  
c) Juvenile NCL (JNCL/CLN3) 
Juvenile NCL (JNCL) is the most common form of NCL worldwide with the highest 
incidence in Scandinavia (~ 1 in 15,000-50,000) (Mole et al., 2011). JNCL is caused by 
mutations in the CLN3 gene, which encodes for a conserved transmembrane protein 
of unknown function (The International Batten Disease Consortium (TIBDC), 1995; 
(Lerner et al., 1995)). To date, 50 mutations have been discovered in CLN3, but 
interestingly, 85-90% of all JNCL cases share the same mutation caused by a 1kb 
deletion. (http://www.ucl.ac.uk/ncl/mutation.shtml) (Lerner et al., 1995). Expression of 
CLN3 in human tissue is widespread in many organs (lung, liver, muscle, kidney etc.) 
(TIBDC, 1995). In the CNS, CLN3 expression levels are not particularly high, but 
constitutively expressed and therefore CLN3 is suggested to incorporate 
‘housekeeping’ cell functions (Mole et al., 2011). The structure of CLN3 has been 
defined as a type III transmembrane protein with six membrane-spanning domains 
and cytosolic facing N- and C-termini (Kyttala et al., 2004), which indicate possible 
functions in luminal environment changes or modulation of other membrane proteins 
(e.g. ion channels) (Mole et al., 2011). For largely technical reasons CLN3 has been 
assigned to many intracellular compartments, with the most favourable localisation 
currently being in the endosomal/lysosomal system trafficking through ER and Golgi 
apparatus (Kida et al., 1999; Haskell et al., 2000; Kyttala et al., 2004). Further locations 
have been reported in the synaptosomal fraction of the mouse brain and the early 
endosomes of neurons (Luiro et al., 2001; Kyttala et al., 2004; Storch et al., 2007), in the 
Golgi apparatus (Codlin and Mole, 2009), a small fraction (~10 %) in the plasma 
membrane (Mao et al., 2003; Storch et al., 2007), and also in membrane lipid raft 
preparations (Rakheja et al., 2004). However, the exact cellular function of CLN3 still 
remains elusive. No known protein is homologous to CLN3, but its topology is 
suggestive of a membrane transporter function (Mole et al., 2011). It is postulated that 
CLN3 is involved in lysosomal acidification (Pearce et al., 1999; Padilla-Lopez and 
Pearce, 2006), mitochondrial function (Palmer et al., 1992; Jolly et al., 2002; Fossale et 
al., 2004), intracellular trafficking via interactions with the cytoskeleton (Uusi-Rauva et 
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al., 2008; Getty et al., 2011), membrane fusion and synaptic vesicle transport (Luiro et 
al., 2001; Fossale et al., 2004; Kama et al., 2007), autophagy (Cao et al., 2006; Cotman 
and Staropoli, 2012), developmental cell polarity and proliferation processes 
(Tuxworth et al., 2009; Weimer et al., 2009), as well as Ca2+ level regulation (Chang et 
al., 2007; An Haack et al., 2011). Furthermore, CLN3 has been suggested to take on a 
protective role against apoptosis (Puranam et al., 1999; Persaud-Sawin and Boustany, 
2005). In JNCL patients clinical manifestations usually begin with visual impairment 
between 4-7 years of age, leading to blindness caused by retinal degeneration at 5-10 
years, proceeded by mental deterioration, epilepsy and motor deficits, and premature 
death at a mean age of 24 years (Williams et al., 2006; Jalanko and Braulke, 2009; Mole 
et al., 2011).   
d) NCL animal models 
The discovery of the molecular basis of most disease-causing genes (TIBDC, 1995) 
has laid the foundation for developing genetically accurate models of NCL (Cooper et 
al., 2006; Jalanko and Braulke, 2009). A series of animal models have been established 
over the years to investigate NCL pathogenesis. These models range from yeast 
(Pearce and Sherman, 1998; Pearce et al., 1999; Kama et al., 2007), nematode worms 
(de Voer et al., 2005; Phillips et al., 2006), Drosophila (Tuxworth et al., 2009), to 
zebrafish (Cooper et al., 2006). But, as in many other disorders, the most commonly 
used models are genetically engineered mutant mice (reviewed by (Cooper et al., 
2006)), but a series of spontaneous mutants in larger animal species including dogs 
and sheep have also been identified (Melville et al., 2005; Tammen et al., 2006). Each 
model system has its own advantages and disadvantages. Whereas for example, yeast is 
very useful for investigating biochemical and cellular pathways (Codlin and Mole, 
2009), Drosophila is the best-characterised tool for single gene – cell interactions (Bier, 
2005; Marsh and Thompson, 2006). Zebrafish are ideal for drug screening with their 
transparent bodies (Sukardi et al., 2011), although larger animal species more closely 
resemble the human brain (Mole et al., 2011). In this study we focused only on mouse 
models of Infantile and Juvenile NCL (see summary in Table 2). Numerous mouse 
models with differently constructed mutations on several background strains have 
been created. It is important to note that discrepancies in mutations as well as strain 
backgrounds can dramatically modify disease phenotypes in the mice (de la Hoz et al., 
2003; McLin and Steward, 2006; Adams et al., 2010; Finn et al., 2010; Kousi et al., 
2012). Therefore, it is of uppermost importance that reliable comparisons can only be 
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made between mice of the same background strain (Mole et al., 2011). Nowadays, 
most commonly used are mice on the C57Bl/6 strain background, although earlier 
studies also utilised 129Sv strains of mice.  
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Non-human model systems serve two main purposes. First of all, the investigation of 
the functional consequences of each gene mutation and the underlying disease 
mechanisms of each NCL form can be conducted. When compared to studies on post 
mortem tissue from NCL patients, a main advantage of these model systems is the 
possibility of obtaining important information about progressive pathogenesis, even 
from before the onset of overt disease manifestations. Secondly, animal models 
provide a controlled system for systematic and accurate assessment of therapeutic 
interventions in an ethically acceptable manner. Therefore, they are vital in paving the 
way towards successful pre-clinical therapies and eventually clinical trials in humans 





1.3 Therapeutic approaches for Infantile and Juvenile NCL  
Several therapeutic approaches have been tested in mouse models of INCL and JNCL 
(see Table 2). To successfully treat each of the NCL forms, the basic biology of the 
deficient proteins has to be considered. As described above, PPT1 has been shown to 
be a soluble late-endosomal/lysosomal protein that can diffuse throughout and 
between cells (Hellsten et al., 1996; Verkruyse and Hofmann, 1996). CLN3 is a 
hydrophobic integral membrane protein of so far disputed location and function in 
the cell (Janes et al., 1996; Kaczmarski et al., 1999; Mao et al., 2003). This difference in 
solubility and the so-called principle of ‘cross-correction’ (see next section 1.3a) 
define which therapeutic approaches are suitable for each form of NCL. 
a) Principle of cross-correction  
As mentioned above, some proteins, including PPT1, are glycosylated during 
trafficking throughout the rough endoplasmic reticulum (RER) to the Golgi to 
guarantee efficient transport to the lysosomal compartment or for cell secretion. These 
proteins can be recognized by the mannose 6-phosphate/IGF II receptor (M6PR) 
(Achord et al., 1978; Kornfeld, 1992). As M6PR is also expressed on the cell surface 
where it mediates endocytosis and trafficking to the lysosomal compartment of 
glycosylated proteins (Hawkes and Kar, 2004; Coutinho et al., 2012), extracellular 
PPT1 can bind to this receptor and reach its correct location within the cell (Sands 
and Davidson, 2006; Wong et al., 2010). This mechanism provides the enticing 
possibility that, as long as the missing protein can be introduced into the extracellular 
space in some fashion (either via secretion from other cells or via direct injection), it 
could correct the diseased phenotype of a Ppt1 deficient cell. This principle was 
termed ‘cross-correction’ and is particularly important in enzyme replacement and 
gene therapy approaches (Fratantoni et al., 1968; Sands and Davidson, 2006). 
However, these molecular mechanisms are not relevant for proteins like CLN3 which 
are integral membrane bound proteins and cannot be secreted to cross-correct 
neighbouring deficient cells.    
By capitalising on the knowledge of possible cross-correction, several therapies have 
been tested with promising or less promising effects on experimental model systems. 
These include experimental therapeutic approaches including enzyme replacement 
therapy (ERT) and gene therapy (Griffey et al., 2004; Hu et al., 2012). Furthermore, cell 
based therapies like bone marrow transplantation (BMT), ex vivo gene therapy or 
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neuronal stem cell therapies have increased the understanding of cellular contribution 
to disease amelioration (Lake et al., 1997; Zheng et al., 2003; Tamaki et al., 2009). 
Additionally, small molecule therapies including glutamate receptor antagonists and 
chemical chaperones resulted in some moderate effects upon NCL disease progression  
(Sleat et al., 1999; Dawson et al., 2010; Kovacs et al., 2011), whereas dietary therapies 
had limited success (Santavuori et al., 1989; Wei et al., 2011), and encouraging storage 
material degradation did not seem to affect disease outcome in patients or mice 
(Zhang et al., 2001). Last but not least, immune modulatory or combinational therapies 
have recently also been attempted (see Chapter 7 for more detail and (Seehafer et al., 
2011; Macauley et al., 2012)). As beneficial therapies are the main goal of the studies 
presented in this thesis, in the following sections the benefits and implications of each 
therapeutic strategy shall be discussed in relation to Infantile and Juvenile NCL.  
b) Enzyme replacement therapy (ERT) 
Based on the possibility of cross-correction, straightforward administration of the 
missing enzyme seems the ideal solution for INCL, but is clearly not applicable to 
JNCL. ERT studies in other non-neuropathic lysosomal disorders, for example 
Gaucher disease (Barton et al., 1991; Beutler et al., 1991), Fabry disease (Eng et al., 
2001) or the mucopolysaccaridoses (MPSs) greatly reduced disease symptoms (Kakkis 
et al., 2001; Harmatz et al., 2004), but so far ERT does not appear to have a beneficial 
influence on LSDs with CNS involvement. A major problem is the delivery method of 
the enzyme with intravenously injected (lysosomal) enzymes prevented from accessing 
the CNS by the blood brain barrier (BBB), whereas direct intracranial injections, in 
addition to being very invasive, run the risk of provoking an immune response and 
neutralisation of the delivered enzyme by antibodies (Harmatz et al., 2004; Linthorst et 
al., 2004). A recent study focused on PPT1 intravenous delivery to Infantile NCL mice 
(Hu et al., 2012), and treated mice showed marked reduction in visceral storage, but 
PPT1 could only reach the brain if it was delivered neonatally before the BBB forms 
properly. As such, ERT with PPT1 may have potential in treating visceral pathology, 
even when administered at later time points, but other strategies will be needed for the 
CNS.  
c) Gene therapy 
By definition gene therapy manipulates gene expression in diseased cells or organisms 
to achieve therapeutic benefit (Mole et al., 2011). The most commonly used tools to 
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achieve this goal are viral vectors. Besides retrovirus and adenoviruses, the use of 
adeno-associated viruses (AAVs) has shown promising results. Their non-pathogenic 
nature in humans plus their ability to transduce non-replicating cell types like neurons 
make them well suited for CNS gene therapy (McCown, 2005). Since gene therapy is 
also based on the principle of cross-correction, this approach has its main potential in 
treating enzyme deficient forms of NCL, including INCL. In JNCL it would only be 
beneficial if every cell could be transfected (and therefore genetically corrected), which 
is unlikely. In Infantile NCL, successful PPT1 gene delivery has been performed after 
intracranial injections of an AAV2 vector expressing PPT1 in new-born Ppt1-/- mice 
(Griffey et al., 2004). However, other than reduced storage material in the brain, 
alongside improved neuropathology and behaviour, AAV2-PPT1 had no impact upon 
the lifespan of these mice (Griffey et al., 2006). Nevertheless, two recent studies in 
Ppt1-/- mice using a newer and more efficient AAV2/5 vector have demonstrated 
significant motor function and lifespan improvements, alongside significantly reduced 
neuroinflammation and brain pathology (Macauley et al., 2012; Roberts et al., 2012). 
These gene therapy approaches represent the best single treatment of INCL mice so 
far (with an improvement of 19 weeks or 54% in lifespan). Furthermore, these 
treatments were used as control groups in combinational therapeutic studies, which 
shall be discussed in more detail in Chapter 7, but which produced even greater 
therapeutic effects. As a side note, the most promising gene therapy studies, in any 
form of NCL, have been conducted in Late Infantile NCL (Sondhi et al., 2007) which 
led to clinical trials I and II (in progress) in humans (Worgall et al., 2008). However, 
gene therapy may soon be revolutionised by the delivery of capsid-modified vector 
(and hence enzyme) into the CNS via intravenous injections using the therapeutic 
principle of ‘phage panning’, with which disease specific peptide patterns on 
endothelial cells are identified and used to modify the viral capsid to overcome the 
BBB (Chen et al., 2009). First tests in a Late Infantile NCL canine model system 
resulted in improved motor behaviour and decreased disease symptoms (Davidson, 
2012; Wininger, 2012) and further developments will be awaited with interest. 
d) Bone marrow transplantation (BMT) 
The principle behind BMT is the donation of healthy haematopoietic stem cells 
(HSCs) to diseased patients (Mole et al., 2011). HSCs can develop into all types of 
immune cells, lymphocytes, macrophages and particularly into microglia. Therefore, 
these cell types could potentially act as vehicles to deliver the missing enzyme into the 
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CNS. This possibility seems attractive for enzyme deficient forms of NCL. Successful 
BMT has been conducted in patients with lysosomal storage disorders such as MPS I 
that primarily affect the viscera and have little CNS involvement (Hopwood et al., 
1993b), and the life quality of these patients was significantly improved. However, 
attempts of BMT in Late Infantile NCL (Lake et al., 1997), Infantile (Lonnqvist et al., 
2001; Macauley et al., 2012) and Juvenile NCL (Lake et al., 1997) have not been 
successful due to limited CNS migration of HSCs and only low levels of enzyme 
secretion. Therefore, this approach, so far, seems unsuitable for either Infantile or 
Juvenile NCL, but does show potential when part of a combination therapy with gene 
transfer (see Chapter 7).  
e) Ex vivo gene therapy 
As a mix of gene therapy and BMT, another approach tries to amplify the enzyme 
secretion of HSCs via ex vivo gene therapy to enhance gene expression of the donor 
cells before subsequent transplantation into the recipient mice/patients. This 
approach has proved to be successful in neuropathic LSDs like MPS I (Zheng et al., 
2003) or a metachromatic leukodystrophy (Biffi et al., 2004). In addition to traditional 
BMT, enzyme overexpressing HSCs cells have also been directly implanted into the 
ventricles of the brain of a MPSVII mouse model, which overcomes the necessity 
HSCs to migrate into the CNS (Sakurai et al., 2004). All of these examples resulted in 
improved behavioral and ameliorated brain pathology. However, this strategy has not 
yet been applied to any form of NCL, but could be an encouraging method for the 
future.  
f) Stem cell therapy 
Apart from HSCs, other cell-mediated therapies have been attempted via the 
implantation of neuroprogenitor cells (NPCs) into the brain of mice or patients. These 
cells have the potential to develop into neurons or glial cells. They are not only 
potentially able to become functional cells which can build connections with existing 
neurons, but first and foremost could also function as a long-term living enzyme 
delivery pool within the brain (Mole et al., 2011). Stem cell therapy has recently been 
investigated in Infantile NCL where researchers transplanted human neural stem cells 
(huNSCs) into immune deficient NSCID Ppt1-/- mice (Tamaki et al., 2009). Early 
transplantation led to improved motor performance, significant neuroprotection and 
decrease of autofluorescent storage material (Tamaki et al., 2009). Detailed 
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characterization of the fate of the transplanted stem cells showed that most huNSCs 
did not develop into functional neurons. Nevertheless, many of the transplanted cells 
persisted in a relatively undifferentiated state and were capable of secreting the missing 
PPT1 enzyme. As a consequence, this approach is probably more promising for 
soluble enzyme deficient disorders for which long-term viable enzyme secretion is 
needed.  Therefore, since little cell replacement was seen after such transplants this 
method does not seem applicable for Juvenile NCL treatment, but this remains 
untested experimentally. Due to the common development of tumors in NSCID mice 
(Leblond et al., 1997; Nishimura et al., 1999; Huang et al., 2011), no lifespan analysis 
could be performed in this study. However, the time of sacrifice of the mice with the 
highest dose transplantation was 188 days, whereas untreated mice in this study had a 
life expectancy of about 162 days (Tamaki et al., 2009). Thus, this proof of principle 
study demonstrated the therapeutic benefit of stem cells for Infantile NCL, which led 
to the initiation of a clinical phase I safety trial in INCL and LINCL patients (see 
http://www.stemcellsinc.com/therapeutic-programs/clinical-trials.htm for more information). 
The results of this phase I trial showed no safety concerns, but unfortunately an 
anticipated phase II trial has been suspended by the sponsoring company for 
unknown reasons. However, this approach seems to have great potential for the 
future, at least for Infantile NCL disease. 
g) Chemical chaperones 
A completely different therapeutic approach potentially has some benefits for certain 
types of Infantile NCL (Dawson et al., 2010). Based on the assumption that the genetic 
mutation might lead to a misfolding and not a complete eradication of the encoded 
protein, chemical chaperones could facilitate the correct folding and consequent 
trafficking of the mutated protein. This approach has showed promising results in 
other LSDs like Fabry or Gaucher disease (Fan et al., 1999; Sawkar et al., 2005). 
Unfortunately, the majority of NCL forms are the consequence of a null mutation or a 
mutation in the active site of the enzyme which rules out this chaperone approach. 
Nevertheless, in some mutations of PPT1 where a missense mutation creates only a 
misfolded and unstable protein, chaperones have been proven to double enzyme 
activity in patient lymphoblasts (Dawson et al., 2010), although it is unclear whether 
this would also work in vivo. This approach may also be beneficial for a subset of other 
NCL forms, even in membrane-bound deficiencies. But this is unlikely to work for 
Juvenile NCL due to the nature of its most common mutation (1kb deletion 
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mutation). Furthermore, the difficulties of this approach lie in the identification of a 
compound and its direct targeting in the host cells to the ER where protein folding 
takes place (Mole et al., 2011).   
h) Stop codon read-through therapies 
Since many mutations are caused by premature stop codons of the transcriptional 
gene (McCaughan et al., 1995), inducing the read-through of these mutations, a 
mechanism that also exists in natural circumstances, could theoretically recover 
protein translation. Several antibiotics are known to promote stop codon read-through 
and have been tested and shown to function in fibroblasts from Hurler disease or Late 
Infantile NCL patients (Sleat et al., 1999; Keeling et al., 2001). There have been 
successful clinical trials of this approach for cystic fibrosis (Wilschanski et al., 2003), 
and safety assessments in healthy controls (Hirawat et al., 2007). This approach could 
be of importance for some forms of NCL, for example, a large percentage (40% of 
29) of PPT1 mutations in families affected by INCL encode for a stop mutation (Das 
et al., 1998). Similar values were seen in a survey of 58 families affected by Late 
Infantile NCL (28%) (Sleat et al., 1999). In the Juvenile form of NCL roughly 85% of 
all cases result from a truncation of the CLN3 protein by a premature stop codon 
mutation which leads to the classical JNCL phenotype (see section 1.2c above and 
(Haskell et al., 2000)). Therefore, JNCL could be even more suitable for this 
therapeutic approach. However, the use of antibiotics brings with it potential side 
effects of toxicity and other off target effects. For this reason, this approach has not 
been followed up seriously for any form of NCL. Although it may have theoretical 
potential, in reality its usage still leaves room for doubt.  
i) Receptor modulation 
The findings that elevated glutamate levels are present in Juvenile NCL brains (Pears et 
al., 2005), and that Cln3 deficient neurons show vulnerability to AMPA-mediated 
neurotoxicity (Kovacs et al., 2006) have led to the idea that a targeted blocking of the 
glutamate receptor via an AMPA antagonist could have beneficial consequences 
(Cooper et al., 2006). Indeed, studies on 1 month and 6-7 month old Cln3 deficient 
mice showed clear motor function improvements after administration of an AMPA 
antagonist (Kovacs and Pearce, 2008; Kovacs et al., 2011). Recent findings indicated a 
glutamate receptor alteration is also present in Ppt1-/- neurons. A down-regulation of 
AMPA receptors in favor of a hyper-function of the NMDA receptor was observed in 
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Ppt1-/- cerebellar granule cell cultures (Finn et al., 2012). Based on the observation of a 
disrupted glutamatergic function in PPT1/Ppt1 deficient cells and mice (Sitter et al., 
2004; Ahtiainen et al., 2007), possible therapeutic targets for INCL mice include 
NMDA receptor antagonists or positive modulation of AMPA receptor function. 
Therefore, this approach may be promising in the future for both the Infantile as well 
as the Juvenile form of NCL. 
j) Immune modulatory therapies  
The involvement of the immune system in NCLs has gained more and more attention 
in the last years leading to therapeutic approaches in which the immune system is 
modulated (Chattopadhyay et al., 2002a; Seehafer et al., 2011). As main focus of this 
thesis, they shall be discussed in Chapter 7 in the context of the findings presented in 
this study.  
k) Other therapeutic approaches 
Since the discovery of the NCLs the accumulation of storage material within cells was 
assumed to directly kill neurons. However, several studies addressing this issue have 
not shown any significant improvement in neuron survival after a reduction of the 
storage load in these cells, and neuronal loss does not appear to correlate directly with 
the accumulation of these waste products (Palmer et al., 2002; Bible et al., 2004; Griffey 
et al., 2004; Oswald et al., 2005; Cooper, 2010).  
Another strategy addressed the neurodegenerative mechanisms that may operate in the 
NCLs itself. After it has been shown that the non-opioid analgesic substance flupirtine 
disrupt chemically induced apoptosis of NCL neurons in tissue culture (Dhar et al., 
2002), several families administered flupirtine to their affected patients. However, no 
positive effects were seen, which emphasizes the fact that simply attempting to rescue 
dysfunctional neurons does not improve disease course and the restoration of the 
deficient protein is likely to be of greater importance (Cialone et al., 2011; Mole et al., 
2011).  
Furthermore, it has been shown that antioxidant mechanisms are apparently impaired 
(Westermarck et al., 1997), and a reduction of polyunsaturated fatty acids is present in 
JNCL patients (Bennett et al., 1994). However, giving antioxidant or other food 
supplements to correct these phenotypes does not appear to have any distinct effects 
on JNCL disease progression in patients (Santavuori et al., 1989; Mole et al., 2011). In 
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contrast, a recent study in Cln3-/- lymphoblasts demonstrated the reduction of ER 
stress and apoptosis markers after treatment with the anti-oxidant resveratrol (Yoon et 
al., 2011). Likewise, in Ppt1-/- mice the reduction of mitochondrial and oxidative stress 
via application of resveratrol as a food supplement increased lifespan by roughly 6 % 
(Wei et al., 2011). While not a cure in itself, this method is under consideration to be 
used in conjunction with other therapeutic approaches, such as gene therapy, as a 
means to boost their efficacy (JD Cooper, personal communication). 
l) Combination therapies  
All the above mentioned therapeutic approaches so far only partially ameliorated the 
outcome of INCL and JNCL (see Table 3 for overview). Therefore, performing 
combination therapies has been postulated to potentially enhance the efficacy of each 
single approach. This aspect shall also be discussed in more detail in Chapter 7, in the 
context of the findings of our studies. 
Table 3. Overview of therapeutic approaches and their suitability for Infantile and Juvenile NCL. 
Signs: = therapy suitable and tested, ()? = therapy potentially suitable but not tested yet in INCL resp. 
JNCL,  = therapy not suitable,  () = therapy only hypothetically possible so far. ()? = therapy tested 
but not suitable so far. 
 Infantile NCL (CLN1) Juvenile NCL  (CLN3) 
Enzyme replacement therapy (ERT)  
Gene therapy  () 
Bone marrow transplantation (BMT) ()? 
Ex vivo gene therapy  () 
Stem cell therapy  
Chemical chaperone therapy ()?  
Stop codon read through therapy ()? ()? 
Receptor modulation therapy ()? 
Anti-oxidant therapy  ()? 
Immune modulation therapy  
Combination therapy  ()? 
 
1.4 NCL Pathogenesis 
Despite their wide genetic heterogeneity, all NCL patients show relatively similar 
clinical phenotypes with blindness, epilepsy and mental impairment invariably leading 
to premature death (Haltia, 2003; Goebel and Wisniewski, 2004; Jalanko and Braulke, 
2009). Likewise, broad similarities can be found in the pathological phenotypes of the 
different forms of NCL. Being considered LSDs, all NCL forms show intra-lysosomal 
accumulation of autofluorescent material in neural and peripheral tissue (Haltia, 2003, 
2006). Furthermore, post mortem tissue from NCL patients revealed pronounced 
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neuron loss and glial activation (Suzuki et al., 1968; Haltia et al., 1973a; Cooper, 2003; 
Tyynela et al., 2004; Weimer et al., 2009). Similar to the findings in humans, NCL 
mouse models have demonstrated wide similarities between all forms of NCL, 
although marked differences between nature and timing of disease phenotypes have 
also become increasingly apparent (Cooper et al., 2006; Cooper, 2010). Common 
features across all NCL subtypes include, apart from the autofluorescent storage 
material, an early glial response (Pontikis et al., 2004; Cooper et al., 2006; Kay et al., 
2006; Macauley et al., 2009), synaptic pathology (Kim et al., 2008; Partanen et al., 2008; 
Kielar et al., 2009) and selective neuron loss (Mitchison et al., 2004; Pontikis et al., 2005; 
Cooper et al., 2006; Kielar et al., 2007). These pathological landmarks in mouse models 
of NCL are useful for comparing the extent of disease progression between each NCL 
form, but are also crucial for evaluating therapeutic efficacy (Cooper et al., 2006; 
Shacka, 2012).  
a) Storage material 
Giving the NCLs their name, the autofluorescent storage material that accumulates in 
every cell was first described as being similar to ceroid and lipofuscin (Zeman and 
Dyken, 1969). However, we know now that the major component of the storage 
material in the NCLs is subunit C of the mitochondrial ATP synthase (Palmer et al., 
1992), except in Infantile and Congenital NCL where sphingolipid activating proteins 
(saposins) A and D accumulate instead  (Tyynela et al., 1993). For a long time it was 
assumed that the storage material itself contributes to pathogenesis and the 
neurodegeneration in the NCLs as often seen in other LSDs (Suzuki, 1998; Walkley, 
2009; Parkinson-Lawrence et al., 2010). However, recent studies have suggested that 
there is no direct relationship or spatiotemporal link between the storage material and 
the pathogenesis of NCL (Cooper, 1990; Cooper et al., 2006). These findings were 
supported by other studies in which pharmacological induction or therapeutic 
reduction of the storage material had no significant effect on neuron survival or 
lifespan (Ivy et al., 1984; Griffey et al., 2006). However, secondary effects as a 
consequence of storage accumulation upon pathogenesis on cellular level and 
intercellular level cannot be completely ruled out because the normal substrate and/or 
location of the deficient protein are for most of the NCLs so far unknown. Therefore, 
although storage material accumulation does not seem to be the primary cause of 
neuron loss, or cannot be directly linked with it, downstream cues resulting from this 
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storage may possibly influence other mechanisms including inflammation or leukocyte 
migration.   
b) Neuron loss 
Based on the first observations in human post mortem tissue, neuron loss was thought 
to be a widespread and homogenously distributed throughout the NCL brain (Haltia et 
al., 1973a; Hofmann et al., 1999). However, after studying mouse models, it has 
become apparent that neuron loss actually shows regional specific selectivity in the 
majority of NCL mice (reviewed in (Mitchison et al., 2004; Cooper et al., 2006)), and 
similar data can also be seen in human JNCL cases (Tyynela et al., 2004). This 
selectivity is particularly evident in the early stages of the disease leading to more 
widespread neuron loss at the end stage of the disease (Cooper, 2010). Several studies 
demonstrated an increased vulnerability of GABA-ergic interneurons both in human 
cases, as well as in animal models of NCL (Cooper et al., 1999; Bible et al., 2004; 
Pontikis et al., 2004; Tyynela et al., 2004; Oswald et al., 2008). Interneurons in different 
subfields of the hippocampus seem to be especially affected (Bible et al., 2004; 
Mitchison et al., 2004; Tyynela et al., 2004), as are for example, pyramidal neurons in 
the hippocampal CA2 and CA3 sub-regions in JNCL (Tyynela et al., 2004). 
Furthermore, the thalamocortical system of the brain has emerged to be a particular 
pathological target in all forms of NCL. Even though pronounced cortical atrophy can 
be observed at the end stage of the disease, it has been consistently demonstrated that 
neuron loss starts in the thalamus of most forms of NCL (Pontikis et al., 2005; Weimer 
et al., 2006; Kielar et al., 2007; Partanen et al., 2008), except in Cln5-/- mice where a 
reverse order of neuron loss has been observed, starting in the cortex and only 
subsequently reaching the thalamus (von Schantz et al., 2009). Another cell specific 
neurodegeneration has been reported in the cerebellum of Cln3-/- mice where Purkinje 
cells, but not granule cells, die off first and foremost (Weimer et al., 2009), and similar 
data are seen in murine INCL (Macauley et al., 2009). Interestingly, even though most 
of these studies were conducted in mouse models, studies in more complex brains like 
sheep models and human cases reveal similar phenotypes, but these appear to be 
much more severe (Oswald et al., 2005; Oswald et al., 2008; Cooper, 2010).  
However, the fundamental question of which mechanisms are responsible for 
neuronal death in NCLs is still unanswered. As suggested in other neurodegenerative 
diseases, neuronal death can probably not only be described in terms of an apoptotic 
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vs. necrotic dichotomy (Graeber and Moran, 2002). Likewise, the NCLs probably 
display a variety of cell death mechanisms. Apoptotic events have been suggested to 
cause cell death in INCL as well as JNCL (Lane et al., 1996; Gupta et al., 2001; Kim et 
al., 2006), but the evidence is not compelling, as reviewed in (Mitchison et al., 2004). 
These apoptotic events have been linked to ER, mitochondrial and oxidative stress in 
INCL (Kim et al., 2006; Zhang et al., 2006). Additionally, autophagy coincides with cell 
death in JNCL (Persaud-Sawin and Boustany, 2005; Cao et al., 2006; Chang et al., 2011) 
and glutamate mediated excitotoxicity has also been reported in INCL and JNCL 
model systems (Kovacs et al., 2006; Finn et al., 2011, 2012). Furthermore, calcium 
dependent alterations have been postulated to induce cell death in JNCL (Chang et al., 
2007; Chang et al., 2011). However, besides all these mainly cell intrinsic events, other 
pathological changes in the brain, such as synaptic alterations and glial activation 
precede, and therefore possibly also influence, neuron loss (reviewed in (Cooper et al., 
2006)).  
c) Synaptic changes 
The first key phenotype that has been shown in several NCL forms to predict 
subsequent neuron loss is early synaptic pathology. These changes include anterograde 
transport defects and postsynaptic receptor reductions (Rinne et al., 2002; Weimer et 
al., 2007), rearrangement of presynaptic compartments, impaired recycling of synaptic 
vesicle components, altered SNAP/SNARE complex formation and synapse 
elimination (Kim et al., 2008; Partanen et al., 2008; Kielar et al., 2009). These changes in 
distribution of synaptic proteins are often supplemented by axonal pathology 
(Partanen et al., 2008; Kielar et al., 2009). The exact impact of such synaptic changes on 
neuron loss is currently still unknown. However, these synaptic changes follow the 
same temporal and regional specific pathways as the subsequent neuron loss, starting 
first in the thalamus and only later occurring in the cortex (Partanen et al., 2008; Kielar 
et al., 2009). Therefore, it seems possible that a direct relationship may exist between 
these two disease phenotypes.  
d) Glial activation 
The second key feature of NCL pathogenesis and very reliable predictor of 
subsequent neurodegeneration is glial activation. Glial activation is uniformly present 
in all forms of NCL (Cooper, 2003; Cooper et al., 2006; Shacka, 2012) and represents 
the initial response of the innate immune system. Work in CLN6 sheep models 
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demonstrated that glial up-regulation even occurs prenatally (as early as 40 to 20 days 
before birth) (Kay et al., 2006). Likewise, in a variety of LSDs there is emerging 
evidence for an early immune response, which highlights the importance of the 
immune system in these diseases (Allen et al., 1997; Wada et al., 2000; Jeyakumar et al., 
2003; Pontikis et al., 2004; Kielar et al., 2007). 
1.5 Immune system 
Throughout the body inflammation has two general purposes. On the one hand, there 
is tissue homeostasis via removing dead cells, promoting the death of damaged cells 
and wound healing (Lo et al., 1999; Elward and Gasque, 2003). On the other hand, 
inflammation serves as defence against pathogens via production of cytotoxic 
substances, of chemokines to recruit specific immune cells and of cytokines to 
coordinate immune responses and alter resident vascular or tissue cells (Rosenberg, 
2002; Carson et al., 2006b; Rivest, 2009).  
Immune responses can be divided into two main parts the (unspecific) innate immune 
response and the (specific) adaptive immune response (Abbas and Lichtman, 2011). 
Each of the immune responses is the product of complex interactions between 
various types of immune cells, which are collectively called ‘leukocytes’ or ‘white blood 
cells’ (Abbas and Lichtman, 2011). Immune cells are distinguished via expression of 
immunologically active proteins on the cell surface, referred as ‘cluster of 
differentiation’ (CD) molecules (Bernard and Boumsell, 1984b). Being mainly integral 
membrane proteins with one or more transmembrane domain, CD molecules act as 
ligands and receptors on leukocytes (Koubek, 2008). The original CD nomenclature 
was devised by the Human Leukocyte Differentiation Antigens Workshop (HLDA) in 
1984 (Bernard and Boumsell, 1984a), and since then new molecules have been steadily 
discovered and included. To date, over 350 different CD molecules have been 
identified and are commonly used to identify and distinguish between classes of 
adaptive immune cells (Zola et al., 2007; Koubek, 2008). 
Simplistically, in the case of an acute inflammation in the tissues of the body 
periphery, the innate immune response is initiated with the activation of mainly tissue 
resident dendritic cells and macrophages (Steinman, 1991; Abbas and Lichtman, 2011; 
Ingersoll et al., 2011). These immune cells express so called ‘pattern recognition to as 
receptors’ (PRRs) that traditionally recognise foreign antigens on pathogens, referred 
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‘pathogen-associated molecular patterns’ (PAMPs) (Janeway, 1989; Medzhitov and 
Janeway, 1997). As a consequence, dendritic cells and macrophages on the one hand, 
release pro-inflammatory cytokines and chemokines to activate other innate immune 
cells (like neutrophils, natural killer cells, mast cells, basophil or eosinophil), but on the 
other hand, often also initiate the adaptive immune response consisting of T- and B-
cells (Iwasaki and Medzhitov, 2010; Schenten and Medzhitov, 2011). Dendritic cells 
and macrophages, and also B-cells, are capable of displaying antigens, after 
phagocytosis or receptor mediated endocytosis, on MHC molecules to naïve T-cells 
and therefore, are often referred to as ‘professional antigen presenting cells’ (APCs) 
(Mellman et al., 1998; Murtaugh and Foss, 2002; Abbas and Lichtman, 2011). 
Depending on the type of tissue disturbance, the immune response results in the 
recruitment of different immune cells. Whereas for example, soluble pathogens in the 
blood system result in complement activation and antibody production by B-cells 
(Nielsen and Leslie, 2002; Mix et al., 2006; Abbas and Lichtman, 2011; Trouw and 
Daha, 2011), T-cell based immune responses are required for the effective clearance of 
intracellular microbes, for example during virus infections (Wiesel et al., 2009; 
Kennedy, 2010; Abbas and Lichtman, 2011; Kreijtz et al., 2011; Zeromski et al., 2011).  
a) Neuroinflammation 
Since the brain is considered an immune privileged organ (Galea et al., 2007a), specific 
cell types and immune reactions lead to distinctive immune responses. Astrocytes and 
microglia take over the role of the innate immune system by carefully monitoring their 
surroundings, and in case of disturbance or injury, activate and recruit other (including 
adaptive) immune cells (Garden and Moller, 2006; Sofroniew and Vinters, 2010). 
These complex interactions between the immune and nervous system that occur in the 
brain are comprised in what is termed ‘neuroinflammation’ (Czirr and Wyss-Coray, 
2012). 
Neuroinflammation occurs in two stages: The activation of the innate immune 
responses results from the interactions between neurons and astrocytes and microglia, 
which accurately regulate and monitor the physiological brain environment (Garden 
and Moller, 2006; Sofroniew and Vinters, 2010). Microglial activation is a common 
feature in most forms of NCL (Haltia, 2003), but is also apparent in other lysosomal 
disorders, for instance Sandhoff disease (Wada et al., 2000), MPSI and IIIB (Ohmi et 
al., 2003) or neurodegenerative disorders like Krabbe disease (Suzuki, 2003) – to 
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mention only a few examples. Astrocytosis is similarly a prominent feature in the 
NCLs (Tyynela et al., 2004), but is also seen for example in Niemann-Pick disease type 
C (German et al., 2002).  
In chronic (as seen in the NCLs) or persistent brain damage or insults, these cellular 
activations can lead to disruption of the BBB and the recruitment of the adaptive 
immune responses via pro-inflammatory cytokine release (Finsen and Owens, 2011; 
Ransohoff and Brown, 2012). In this second stage of neuroinflammation this 
transition to an adaptive immune response results in a subsequent arrival of systemic 
effector cells (T-cell, B-cells, NK, macrophages, monocytes), facilitating either cell 
death or cell survival (Amor et al., 2009). Leukocyte infiltration has been observed in 
mouse models of LSDs like globoid cell leukodystrophy (Wu et al., 2000), Sandhoff 
disease (Jeyakumar et al., 2003), and also Juvenile and Infantile NCL (see Chapter 3 
and (Lim et al., 2007b; Macauley et al., 2011)). The adaptive immune cell response may 
arise from primary glial activation and/or neurodegenerative processes in these 
childhood disorders. Additionally, neuroinflammation may also be a secondary 
consequence of lysosomal storage, as has been seen for example in Sandhoff disease 
(Jeyakumar et al., 2003). The degree of these immune responses are defined by either 
the extent of glial activation, the presence of auto-antibodies and/or antigenicity of 
storage material or by-products of neuronal degradation (Lim, 2011).   
b) Immune privilege of the brain 
As an important feature to understand neuroinflammation, the specific immune 
properties and privileges of the brain have to be explained. For a long time the brain 
has been regarded as an organ of complete immune privilege, but these assumptions 
have been challenged over the years. Nowadays, it is thought that the immune 
privilege is an active and relative process that is only confined to the CNS parenchyma 
(Galea et al., 2007a). Other compartments of the brain, including the ventricles 
containing the choroid plexus, the cerebrospinal fluid (CSF), circumventricular organs 
(CVO) and the meninges have shown similar immune reactivity to the periphery 
(Mason et al., 1986; Andersson et al., 1992; Matyszak and Perry, 1996a; Blond et al., 
2002). Therefore, the supposed immunological privilege of the brain appears to be 
relative. Immune responses in the brain can be divided into an afferent (= sensing) 
and an efferent (= effector) arm. Only the afferent arm of the CNS immune system 
seems to be privileged and restricted (Galea et al., 2007a), i.e. it is mainly reliant on 
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transport of a soluble (auto) antigen to the cervical lymph nodes (Yamada et al., 1991; 
Kida et al., 1993; Weller et al., 1993), or alternatively the cellular migration of T-cells 
(Goldmann et al., 2006) or dendritic cells (DC) from the CSF (Hatterer et al., 2006) 
and/or even the brain parenchyma (Gottfried-Blackmore et al., 2009; Felger et al., 
2010) to the cervical lymph nodes. The efferent arm is definitively active and systemic 
cells can enter the brain parenchyma under surveillance or non-pathological 
conditions (Hickey, 2001), but especially in the case of inflammation they can do so 
without any hindrance, as long as the right binding partners or receptors are up-
regulated in the brain (endothelial cells, antigen presenting cells) (Greenwood et al., 
2002). 
c) Blood brain barrier (BBB) 
One of the main features of the ‘immune privilege’ in the CNS is the BBB. It results 
from the selectivity of tight junctions of endothelial cells of brain capillaries, which are 
surrounded and supported by perivascular pericytes and the endfeet of astrocytes 
(Abbott et al., 2010). The role of pericytes in BBB function is not well studied and the 
role of astrocytes is controversial (see section 1.6a below), but all three cell types 
result in a diffusion barrier that controls the permeability and entry of substances and 
cells on the basis of polarity and size into the brain (Ballabh et al., 2004; Abbott et al., 
2006). Furthermore, there are three main interfaces of the BBB. In the brain and 
spinal cord of all mammals the main ‘classical’ interface is formed by cerebrovascular 
endothelial cells between blood and brain interstitial fluid (ISF), secondly by the 
choroid plexus epithelium between blood and the ventricular CSF, and thirdly by the 
arachnoid epithelium between blood and subarachnoid CSF (Abbott et al., 2006) (see 
Figure 2). But the BBB is not fixed and can be modulated and regulated according to 
physiological and pathological state (Abbott, 2005). Therefore, it is important to 
consider these features of the BBB when interpreting experimental data and directing 
therapeutic approaches into the brain. 
1.6 Innate immune responses in the brain 
Besides dendritic cells and infiltrated macrophages from the systemic circulation, the 
main two cell types of the innate immune system of the brain are astrocytes and 
microglia. Each of the two has its specific roles and functions in the brain under 
healthy, as well as inflammatory conditions (Garden and Moller, 2006; Sofroniew and 
Vinters, 2010). Their activation is a characteristic feature of NCL pathology (Oswald et 
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al., 2005; Pontikis et al., 2005; Kay et al., 2006; Kielar et al., 2007; von Schantz et al., 
2009; Kuronen et al., 2012; Schmiedt et al., 2012; Thelen et al., 2012), and therefore 
shall be described in more detail.  
 
a) Astrocytes 
The entire CNS is contiguously covered in a non-overlapping manner by astrocytes 
(Nedergaard et al., 2003; Halassa et al., 2007b). Once regarded as the ‘glue of the brain’, 
nowadays numerous functions have been assigned to astrocytes in the healthy brain 
(see review (Sofroniew and Vinters, 2010)). During brain development, astrocytes are 
Figure 2. Location of barrier sites in the CNS and the blood brain barrier (BBB). (A) There 
are three main barrier sites with interfaces between blood and neural tissue or fluid spaces in the 
CNS:  (1) the cerebrovascular endothelial cells of the BBB between blood and brain interstitial 
fluid (ISF), (2) the choroid plexus epithelium between blood and cerebrospinal fluid (CSF) and (3) 
the arachnoid epithelium as the middle layer of the meninges between blood and subarachnoid 
CSF. At each site tight junctions reduce the permeability of paracellular pathways of molecular 
substances and cell migration. (B) Schematic illustration of the BBB. The barrier is formed by 
capillary endothelial cells surrounded by the basal lamina, pericytes and the endfeet of astrocytes. 
Tight junctions between the endothelial cells provide the main barrier function. Astrocytes 
provide a cellular link to neurons (not shown). Microglia are also in close proximity to the BBB. 
Adapted from (Abbott et al., 2006). 
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thought to be important for the formation of synapses and induction of neurite 
pruning (Christopherson et al., 2005; Stevens et al., 2007; Barres, 2008). In the adult 
brain, astrocyte processes envelop essentially all synapses, where they perform crucial 
maintenance functions related to fluid, ion, pH and transmitter homeostasis at the 
synaptic cleft (Simard and Nedergaard, 2004; Obara et al., 2008). Via their high 
expression of neurotransmitter transporters astrocytes can rapidly clear the synaptic 
clefts of excessive glutamate, GABA or glycine (Sattler and Rothstein, 2006; Seifert et 
al., 2006). In this context, there is supporting evidence that astrocytes are directly 
involved in synaptic transmission and alter neuronal excitability by release of synaptic 
active molecules, so called ‘gliotransmitters’ (Nedergaard et al., 2003; Shigetomi et al., 
2008). This idea gave rise to the hypothesis of the ‘tripartite synapse’ postulating that 
astrocytes exchange information, respond to and regulate synaptic activity of neurons 
at the synapses (Halassa et al., 2007a; Perea et al., 2009). These processes are linked to a 
form of astrocyte excitability mediated via regulated increases in intracellular calcium 
concentrations (Cornell-Bell et al., 1990; Charles et al., 1991), which can even be 
propagated to neighbouring astrocytes and create an internal communication network 
between astrocytes via Ca2+ waves (Volterra and Meldolesi, 2005). Furthermore, the 
release of growth factors, as seen during development (Barres, 2008), astrocyte 
regulation of blood flow (Gordon et al., 2007; Iadecola and Nedergaard, 2007), and the 
direct contribution of astrocytes to CNS energy metabolism have been demonstrated 
in the adult brain (Brown and Ransom, 2007). The latter contribution is made possible 
because astrocytes can interlink blood and neurons via their processes, and therefore 
their uptake of glucose from the blood can directly enable the transfer of energy 
metabolites to neuronal cells (Brown et al., 2004; Pellerin et al., 2007). Last but not 
least, astrocytes are involved in the formation of the BBB along with endothelial cells 
and perivascular pericytes (see section 1.5c above). Whether astrocytes take on the 
function of the actual barrier or not, or whether it is only the tight junctions between 
the endothelial cells that are responsible for the selectivity, is still disputed (Ballabh et 
al., 2004; Haseloff et al., 2005; Saunders et al., 2008). Nevertheless, astrocytes have 
been shown to influence BBB permeability, particularly in the state of inflammation 
(Beck et al., 1984; Abbott, 2005).   
Under inflammatory conditions, astrocytes play a role in innate immune responses, 
responding by their activation and hypertrophy (Perry et al., 1992; Farina et al., 2007). 
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This astrocytosis or reactive gliosis is easily identified by astrocytes developing 
thickened fibrous processes (Luse, 1958; Graeber and Kreutzberg, 1986). Up-
regulation of intermediate filament (IF) proteins, in particular glial fibrillary acidic 
protein (GFAP), by reactive astrocytes is perhaps the best known hallmark of 
astrocytosis and an important histopathological sign of CNS injury (Eng et al., 1971; 
Raivich et al., 1999; Pekny and Nilsson, 2005). Astrocytes display a wide range of 
receptors involved in innate immunity, including Toll-like, mannose and scavenger 
receptors (Husemann and Silverstein, 2001; Sasaki et al., 2001; Bsibsi et al., 2002; Liu et 
al., 2004; Farina et al., 2005; Farina et al., 2007; Hanke and Kielian, 2011). Even 
nucleotide-binding oligomerization domains and components of the complement 
system can be found on astrocytes (Gasque et al., 2000; Sterka et al., 2006). Especially 
after activation, astrocytes are also able to secrete soluble mediators that have an 
impact on both innate and adaptive immune responses (Dorf et al., 2000; Ambrosini 
and Aloisi, 2004; Farina et al., 2007).  
The exact influence of astrocytosis upon neuron survival has been debated at length. 
It becomes increasingly apparent that astrocytosis is not an ‘all or nothing’ process 
with only one consequence, but instead can have neuroprotective as well as neurotoxic 
effects in the brain (see reviews (Sofroniew, 2009; Sofroniew and Vinters, 2010)). 
Astrocytosis occurs as a response to a wide variety of CNS disturbances including 
injury and disease (Faulkner et al., 2004; Myer et al., 2006; Drogemuller et al., 2008). 
These responses display a graded spectrum of molecular signals and altered gene 
expression, which lead to astrocyte hypertrophy and various effects on neurons 
(Eddleston and Mucke, 1993; John et al., 2005; Lovatt et al., 2007; Cahoy et al., 2008; 
Daginakatte et al., 2008). Moreover, different diseases, different stages of disease 
progression, and different brain locations result in various outcomes, suggesting that 
these astrocyte responses are very much context dependent (Wilhelmsson et al., 2006; 
Hewett, 2009; Sofroniew, 2009; Yeh et al., 2009). The traditional view of astrocytosis 
being negative per se (Ramon y Cajal, 1928) has been revised in recent years with 
several studies describing protective roles for astrocytosis, for example via uptake of 
extracellular glutamate (Rothstein et al., 1996), BBB repair (Bush et al., 1999), reduction 
of inflammatory spread (Faulkner et al., 2004; Li et al., 2008) and others (see review 
(Sofroniew and Vinters, 2010) for further details/examples). However, at the same 
time other studies have attributed detrimental roles to astrocytosis by compromising 
BBB integrity (Argaw et al., 2009), and also exhibiting an increased inflammatory 
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response and immune cell infiltration via cytokine release (Brambilla et al., 2009), 
reducing neuronal regeneration (Wilhelmsson et al., 2004), releasing excitotoxic 
glutamate (Takano et al., 2005) or even contributing to seizure genesis (Tian et al., 
2005). All in all, astrocytes can take on several functions and have heterogeneous roles 
in the healthy and diseased brain, which should be considered in the context of the 
NCLs.  
b) Microglia 
The role of microglial cells in neurologically normal brains ranges from apoptotic cell 
removal and induction of cell death (Bessis et al., 2007; Streit and Xue, 2009), 
extensive tissue remodeling (Pollard, 2009) to axon guidance in white matter during 
development (Milligan et al., 1991). Microglia are also thought to act as synaptic 
sensors and may be involved in synaptogenesis and synapse degeneration (Bessis et al., 
2007; Wake et al., 2009). However, the main roles of microglia are in surveillance by 
monitoring their immediate proximity in the brain. Microglia are very mobile and 
constantly surveying the brain which enables them to quickly respond to any 
disturbance (Kreutzberg, 1996; Hailer et al., 1997; Stence et al., 2001). This has been 
shown in vitro, and in histological studies, but also recently in the living brain via two-
photon microscopy (Nimmerjahn et al., 2005). These properties have given microglia 
the reputation of being the ‘brain’s immune system’ (Graeber and Streit, 1990).  
Accordingly, innate immune responses within the CNS largely involve microglial 
activation (Perry and Gordon, 1988; Kreutzberg, 1996). Once a threat has been 
identified microglial cells respond quickly to destroy the infectious agents before they 
damage neural tissue (Stoll and Jander, 1999). As part of this stimulation process 
microglia transform from their quiescent ramified morphology into activated microglia 
(Ransohoff and Perry, 2009). But in extreme cases of inflammation or brain injury, 
they further transform into brain macrophages (Raivich et al., 1999; Streit, 2002; 
Hanisch and Kettenmann, 2007), which act as phagocytic cells in the CNS (Perry and 
Gordon, 1988). Since antibodies cannot cross the BBB due to their large size (Seitz et 
al., 1985; Azzi et al., 1990; Dai et al., 2002), microglia must be able to recognise 
antigens, incorporate them, and act as antigen-presenting cells (via MHC II) to activate 
the adaptive immune system and recruit T-cells (Fischer and Reichmann, 2001; Kim 
and de Vellis, 2005). In addition, microglial cells are increasingly recognised to play an 
important role in inflammatory responses within the CNS via the secretion of 
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cytokines, chemokines and trophic factors (Lee et al., 1993; Presta et al., 1995; Elkabes 
et al., 1996; Hanisch, 2002; Lee et al., 2002; Kim and de Vellis, 2005). This pro-
inflammatory release of chemotactic substances by activated microglia seems to be 
crucial for immune responses in the CNS (Thomas, 1992; Garden and Moller, 2006).  
However, whereas several studies have demonstrated that microglia are fundamentally 
neuroprotective and have beneficial effects on neuronal survival (Neumann et al., 
2006; Gowing et al., 2008; Hines et al., 2009), in other studies microglia often 
contribute directly to the pathogenesis of a variety of neurodegenerative diseases 
(Dickson et al., 1991; Kreutzberg, 1996; Gonzalez-Scarano and Baltuch, 1999; 
Lobsiger and Cleveland, 2007).  
Therefore, microglial activation should perhaps be considered as a ‘double-edged 
sword’ in neurodegenerative diseases, depending on the extent and stage of disease 
progression, microglia may be initially neuroprotective and subsequently exert a 
negative effect on neuron survival. There is a precedent for this happening in 
amyotrophic lateral sclerosis (ALS) (Fendrick et al., 2007), where motor neuronal death 
was linked to microglial dysfunction, attributing neurodegeneration to a loss of 
microglial-mediated neuroprotection. These properties are consistent with the theory 
of functional ‘microglial plasticity’ (Streit et al., 1988), which proposes that not only 
resting or activated microglia are present in the brain, but rather a mix of several 
subpopulations of macrophage-like cells expressing different genes and cytokines. Just 
as macrophages outside the CNS originally have been identified as classical (M1) or 
alternative (M2) activated macrophages (Gordon, 2003), similarly different activation 
states have also been identified for microglia (Michelucci et al., 2009). However, the 
strict definition of these two activation states of macrophages becomes increasingly 
blurred by the discovery of intermediate activation states (Mosser and Edwards, 2008), 
and microglia can also adopt different phenotypes depending on various stimuli and 
secondary challenges (Hanisch and Kettenmann, 2007; Colton and Wilcock, 2010). 
There is even evidence of regionally specific activation within the brain (Choi et al., 
2012). This issue is exacerbated by the ambiguity of contemporary microglial markers, 
as typified by CD68 or F4/80. Such commonly used microglial markers are only cell 
specific to the extent that they do not label other glial cells or neurons, but are unable 
to discriminate microglia from peripheral macrophages. This ambiguity had to be 
considered when interpreting microglial staining results in our experiments on NCL 
brains, but this matter will be discussed in more detail in Chapter 7.   
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1.7 Adaptive immune responses in the brain  
As a second part of the immune system, the adaptive immune response consists of 
two major types of immune cells, T- and B-cells (collectively known as lymphocytes) 
(Abbas and Lichtman, 2011). These cell types guarantee a more specific immune 
response against pathogens or antigens in the body, as well as in the brain. One main 
advantage of this system is that the adaptive immune response can not only target and 
clear pathogens more efficiently, it also supplies memory cell functions that enable 
rapid responses to re-occurring infections (Lefrancois, 2006; Abbas and Lichtman, 
2011; Masopust and Picker, 2012). The antigen specificity of T- and B-cells is 
accomplished by the display of a large diversity of cell surface receptors, which can 
bind to an unlimited number of antigens (Boudinot et al., 2008; Jhunjhunwala et al., 
2009). For successful activation of lymphocytes, T-cell and B-cell receptors (TCR and 
BCR) have to recognise antigens bound to MHC molecules on APCs (mainly dendritic 
cells, macrophages and B-cells) (Mondino and Jenkins, 1994; Medzhitov and Janeway, 
1998; Dustin, 2008; Abbas and Lichtman, 2011), besides several other co-stimuli 
(Fathman and Lineberry 2007; Mor et al. 2007). This complex is often referred to as 
the ‘immunological synapse’ (Bromley et al., 2001; Sims and Dustin, 2002). To generate 
the necessary variation of antigen-recognition regions, genes of TCR and BCR are 
assembled via a so called ‘V(D)J recombination’ which is directed by the lymphocyte-
specific recombinases RAG-1 and RAG-2, and ubiquitously expressed DNA repair 
proteins (Bassing et al., 2002). Recombination-activating gene-1 and 2 (RAG-1 or 
RAG-2) proteins cleave the DNA at well-conserved recombination signal sequences 
(RSSs) that flank variable (V), diversity (D) and joining (J) TCR gene segments (Schatz 
et al., 1989; Oettinger et al., 1990; Schlissel et al., 1993). Subsequently, the ends of the 
recombination signals (RS) are joined precisely, while coding ends are modified, 
rearranged and resolved by non-homologous end joining (Tonegawa, 1983). The 
V(D)J recombination takes place in the primary lymphoid tissue (thymus for T-cells 
and bone marrow for B-cells), after which a stringent selection process of TCR/BCR 
specificity against MHC molecules and auto-antigens determines the survival of 
functional adaptive immune cells (Hardy et al., 2000; Starr et al., 2003). Released from 
the thymus/bone marrow into the body periphery, B-cells and T-cells are potent 
antigen recognising cells, with a high concentration of lymphocytes found in the 
lymph and lymphoid tissues like the spleen or lymph nodes (Crivellato et al., 2004; 
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Abbas and Lichtman, 2011; Boehm et al., 2012). As one of the main focuses of this 
thesis it is important to consider T-cells in more detail. 
a) T cells 
Various subsets of T-cells exist with different functions, but each can be distinguished 
via their expression of different CD molecules. The main distinction is made between 
CD8+ve T-cells, also known as ‘cytotoxic T-cells’, and CD4+ve T-helper cells (Abbas 
and Lichtman, 2011). CD8 is a transmembrane glycoprotein that acts as a co-receptor 
for the TCR during interactions at the immunological synapse (Miceli and Parnes, 
1991; Abbas and Lichtman, 2011; Laugel et al., 2011). Antigen specific binding of 
peptides displayed on the major histocompatibility complex (MHC) molecule class I 
proteins by both receptors (TCR and CD8) initiates CD8+ve T-cell activation 
(Engleman et al., 1981; Meuer et al., 1982; Norment and Littman, 1988; Connolly et al., 
1990). Most nucleated cells express MHC I molecules on which endogenous (possibly 
foreign) peptides are displayed for potential activation of CD8+ve T-cells (Germain, 
1994; Abbas and Lichtman, 2011). Additionally, some APCs, in particular dendritic 
cells, can also activate CD8+ve T-cells after digestion of extracellular antigens and 
peptide presentation on MHC I, in a process called ‘cross-presentation’ (Brossart and 
Bevan, 1997; Amigorena and Savina, 2010; Joffre et al., 2012). The main function of 
activated CD8+ve T-cells is to induce apoptosis (Shresta et al., 1998; Trapani et al., 
2000) of virus or pathogen infected, damaged or dysfunctional nucleated cells after 
identifying specific antigenic peptides bound to MHC class I molecules (Townsend 
and Bodmer, 1989; Cohen et al., 1992; Germain, 1994; Page et al., 1998). Cytotoxic T-
cells initiate death cascades, either via Fas Ligand (FasL)-Fas interactions at the cell 
surface, or release secretory proteins from lysosome-like compartments which are 
referred to as lytic granules (Peters et al., 1991; Suda et al., 1995). Additionally, CD8+ve 
T cells are capable of producing pro-inflammatory and regulatory cytokines (Koide 
and Engleman, 1990; Salgame et al., 1991; Ciubotariu et al., 1998; Filaci et al., 2004).    
CD4 is, like CD8, a glycoprotein that assists the TCR as a co-receptor while 
recognising MHC class II molecules on the surface of APCs (Janeway, 1991; Abbas 
and Lichtman, 2011). MHC II molecules display (via phagocytosis or receptor 
mediated endocytosis) internalised and processed extracellular antigens that can initiate 
T-helper cell activation after successful recognition by CD4 and TCR. (Schwartz et al., 
1978; Germain, 1994; Abbas and Lichtman, 2011). CD4+ve T-helper cells facilitate 
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antibody production via B-cell activation, enhance macrophage activity and recruit 
other immune cells (like neutrophils, eosinophils, basophils) to inflammation sites 
(Zhu and Paul, 2008; Abbas and Lichtman, 2011). In general, CD4+ve T-helper cells 
are important for the coordination of the immune response via the production of 
various cytokines and chemokines (Germain, 1994; Zhu and Paul, 2008; Zhu and Paul, 
2010). Traditionally, it was thought that CD4+ve T-helper cells are essential for the 
activation and proliferation of CD8+ve T-cells (Bach et al., 1977; Keene and Forman, 
1982; Guerder and Matzinger, 1989). However, the prevailing view is currently that 
CD4+ve T-cells can be dispensable for CD8+ve T-cell expansion, but generally 
facilitate proliferation and activation of CD8+ve T-cell responses indirectly via 
dendritic cell differentiation, which in turn promotes CD8+ve T-cell activation 
(reviewed in (Castellino and Germain, 2006)). Furthermore, CD4+ve T-cells are 
required for the generation of CD8+ve memory T-cells (Janssen et al., 2003; Shedlock 
and Shen, 2003). CD4+ve T-helper cells themselves can be divided into Th1 and Th2 
cells (Mosmann et al., 1986), depending on cells they interact with and the cytokines 
that they release (Romagnani, 1997; Dong and Flavell, 2001). Th1 cells provide 
immunity against intracellular pathogens or disturbances. Therefore, they promote 
cellular immune responses by maximising the killing efficacy of macrophages and 
assist in priming of CD8+ve T-cells (Mosmann and Coffman, 1989; Paul and Seder, 
1994). In contrast, Th2 cells provide immunity against extracellular pathogens by 
binding to B-cells and accelerating the humoral immune response via increased 
antibody production (Mosmann and Coffman, 1989; Paul and Seder, 1994). 
Furthermore, in recent years, CD4+ve T-regulatory cells, as well as Th17 cells have 
been identified (Sakaguchi, 2004; Harrington et al., 2005). In contrast to other effector 
T-cells, which are suggested to begin with pro-inflammatory cytokine expression and 
switch later in their life-cycle to inhibitory cytokines (Zhu and Paul, 2008; Zhu and 
Paul, 2010; Cope et al., 2011), CD4+ve T-regulatory cells exhibit solely an anti-
inflammatory role in the immune response (Sakaguchi, 2000; Shevach, 2002). This is 
mainly via transforming growth factor β (TGF-β), interleukin-10 (IL-10) and 
interleukin-35 (IL-35) release (Li et al., 2006; Collison et al., 2007; Rubtsov et al., 2008). 
On the other hand, CD4+ve Th17 cells characteristically produce interleukin 17 (IL-
17) and have been originally assigned to a pathogenic role in autoimmune diseases 
(Harrington et al., 2005; Stockinger and Veldhoen, 2007). However, in recent years 
Th17 cells have been shown to have their own effector and regulatory functions, 
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particularly in the host defence against bacteria and fungi (Weaver et al., 2006), and 
therefore, illustrate an example of the recently suggested functional plasticity of 
immune responses as an intrinsic factor of T-helper cells (Zhu and Paul, 2010; Hirota 
et al., 2011; Larsen et al., 2011). Last but not least, to confuse matters even more, 
cytotoxic abilities of CD4+ve T-cells have also been identified. Cytotoxic CD4+ve T-
cells can induce apoptosis either via FasL-Fas interactions with target cells or via 
granzymes and perforin release (Hahn et al., 1995; van de Berg et al., 2008). 
Controversially, in humans these processes seem to happen in an antigen- and MHC-
independent manner, whereas in mice they mainly happen in a MHC II-dependent 
manner (Soghoian and Streeck, 2010). However, the cytotoxic functions of CD4+ve 
T-cells have been suggested to be important as an immunomodulatory process for 
eliminating activated MHC II expressing target cells (APCs) or other T-cells (Hahn et 
al., 1995; van de Berg et al., 2008). But more commonly, cytotoxic CD4+ve T-cells 
have been associated with viral infections where they can assist the clearance of virus-
infected cells, and furthermore, may be generated through repeated antigen 
stimulation in chronic infections (Brown, 2010; Soghoian and Streeck, 2010). 
Therefore, cytotoxic CD4+ve T-cells putatively represent another example of the 
suggested functional plasticity of CD4+ve lymphocytes (Appay, 2004; Brown, 2010; 
Zhu et al., 2010), that is discussed above.   
In many neurodegenerative diseases CD4+ve T-helper cells have been identified as 
contributing to pathogenesis, including for example multiple sclerosis (Stadelmann et 
al., 2011), Parkinson (Brochard et al., 2009) and Alzheimer disease (Heneka and 
O'Banion, 2007) amongst many others. Likewise, CD8+ve cytotoxic T-cells have also 
often been identified as making a harmful contribution to disease pathogenesis. 
Rasmussen’s Encephalitis is a classic example of cell based epilepsy and a MHC-I 
related disease in which CD8+ve cytotoxic T-cells are directly associated with brain 
pathogenesis (Bien et al., 2002). Furthermore, CD8+ve T-cells also play a major role in 
ALS (Holmoy, 2008), where they are found in the precentral gyrus (Kawamata et al., 
1992) and cortico-spinal tracts (Troost et al., 1990), or in perivascular distributions in 
the parietal cortex and hippocampus of Alzheimer disease patients (Itagaki et al., 1988; 
Town et al., 2005). 
b) T cells in the brain 
Because of the seclusion of the brain from the body periphery by means of specialised 
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structures like the BBB, meninges and/or ventricular system, the entry of lymphocytes 
into the brain is not as straight forward as in other organs of the body (Galea et al., 
2007a; Engelhardt, 2008). Thus, three main preferred routes of leukocytes into the 
brain have been described: Firstly, via the choroid plexus into the ventricles and CSF; 
secondly, via the blood system of the meninges into the subarachnoid space; or 
thirdly, directly from cerebral blood vessels via the perivascular space into the brain 
parenchyma (see Figure 3) (Ransohoff et al., 2003; Wilson et al., 2010). Compared to 
the first two pathways, the latter requires the lymphocytes to cross the tightly regulated 
vascular endothelium of the BBB (Ransohoff et al., 2003; Owens et al., 2008). On a 
side note, T-cells are thought to exit the brain via the same pathways along which the 
CSF drains: they get back into the blood system via arachnoid villi and granulations at 
the major venous sinuses (see Figure 3) (Ransohoff et al., 2003; Johanson et al., 2008; 
Wilson et al., 2010).   
As a first requirement for crossing the BBB, T-cells (or leukocytes in general) have to 
exit blood vessels, a process termed ‘extravasation’. This is a tightly regulated event 
that involves the interaction of molecular cues between the endothelial and immune 
cells. A precise sequence of steps controlled by adhesion molecules and activation 
factors has been characterised and summarised into a so-called ‘multistep paradigm’ 
(Butcher, 1991; Springer, 1994). Classically, four simplified steps of transmigration 
have been defined: Firstly, T-cells are captured and roll along the endothelial wall, 
partly via the help of selectins (L-selectin, P-selectin and E-selectin (Kansas, 1996) 
which interact with P-selectin glycoprotein ligand 1 (PSGL1) and other glycosylated 
ligands (McEver and Cummings, 1997)) and also by means of integrins that bind 
members of the immunoglobulin family (Ley et al., 2007; Constantin, 2008). As second 
step, the immune cells characteristically become activated by chemokines (or other 
chemoattractants) that have been released either from the brain parenchyma or are 
presented on glycosaminoglycans (GAGs) on the endothelial cells (Johnson et al., 
2005). These chemokines interact with G-protein coupled receptors to activate 
intracellular signalling leading to leukocyte integrin activation (so called ‘inside-out 
signalling’) (Simon et al., 1991; Laudanna et al., 2002; Kinashi, 2005). As a third step, 
the immune cells arrest, due to binding of the activated integrins (most studied are 
‘lymphocyte function-associated antigen 1’ (LFA1) and ‘very late antigen 4’ (VLA4)) to 
immunoglobulin superfamily members like ‘intercellular adhesion molecule’ (ICAM-1) 
and ‘vascular cell-adhesion molecule 1’ (VCAM1), expressed by endothelial cells (‘so  
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called ‘outside-in signalling’) (Campbell et al., 1996; Campbell et al., 1998). Finally, 
these steps lead to ‘diapedesis’ or transmigration. Recent research has defined 
additional steps: capture (or thethering), slow rolling, adhesion strengthening and 
spreading, intravascular crawling and paracellular or transcellular transmigration (Feng 
et al., 1998; Engelhardt and Wolburg, 2004; Ley et al., 2007). Having successfully 
penetrated the endothelial-cell barriers, leukocytes migrate through the endothelial 
basement membrane and, most commonly, the pericyte sheath to reach the 
perivascular space (Ley et al., 2007). Interestingly, leukocyte extravasation only occurs 
in post-capillary venules where less strong shearing forces of the blood flow act on the 
leukocytes and more favourable anatomic features (like the separation of glia limitans 
Figure 3. Schematic illustration of the brain showing the routes of leukocyte entry and 
traffic. The brain is surrounded by the skull and the three layers of the meninges: dura mater, 
arachnoid membrane and pia mater. Between the latter two, the subarachnoid space contains the 
cerebrospinal fluid (CSF), which is produced by the epithelium cells of the choroid plexus within 
the ventricles. From there the CSF circulates around the brain parenchyma and drains into the 
blood/venous sinus via arachnoid villi. Meningeal blood vessels extend from the subarachnoid 
space over the pia mater creating the perivascular space (also known as ‘Virchow-Robin space’). 
Arterial branches divide into capillaries to supply blood deep inside the brain parenchyma. 
Leukocytes can enter the CSF via the choroid plexus (1), the blood veins in the meninges (2) or 
directly to the parenchyma via blood capillaries within the brain (3). In the latter case, leukocytes 
have to migrate over the tightly regulated vascular endothelium as part of the blood brain barrier 
(BBB), crossing the subarachnoid space, pia mater and glia limitans. Leukocytes can circulate and 
exit the brain via pathways of the flowing CSF ending up in the venous sinus (4). Adapted from 
(Wilson et al., 2010) 
65 
 
and the endothelial layer) promote cell migration as opposed to the environment of 
(arterial) capillaries (Lewinsohn et al., 1987; Carlos and Harlan, 1994; Engelhardt and 
Ransohoff, 2005; Bechmann et al., 2007).  
On a side note, these distinct differences between blood vessels can lead to confusion 
when referring to the term ‘BBB’ in the context of leukocyte infiltration. On the one 
hand, the term ‘BBB’ physiologically refers to the ability of the vascular segment of 
the capillaries to regulate diffusion of solutes, but on the other hand, in the context of 
neuroinflammation, the term refers to the postcapillary venules from which leukocytes 
migrate into the CNS (Bechmann et al., 2007; Owens et al., 2008). Likewise, the term 
‘BBB permeability’ can encompass soluble diffusion and/or cellular migration into the 
brain.  
Nevertheless, the vasculature will also differ between CNS compartments which will 
influence immune cell entry (Owens et al., 2008). For example, the fenestrated 
endothelium of the choroid plexus and circumventricular organs or the mono-layer 
structure of blood vessels in the meninges allow easier access of leukocytes to the 
CSF, compared to the double membrane barrier present in the brain parenchyma 
(Wilson et al., 2010).     
However, in all steps the endothelial cells play a crucial role, depending on their state 
of activation (under physiological or inflammatory conditions) different ligands and 
cell adhesion molecules are expressed, which control selective leukocyte (or in 
particular T-cell) transmigration (Carlos and Harlan, 1994; Springer, 1994; Fabbri et al., 
1999). Yet, leukocytes themselves can also alter vascular properties (Dahlen et al., 
1981). Generally, successful immune cell migration into the CNS varies depending on 
the immune subtype, the condition of the migrating cell, the state of the neural 
parenchyma and the endothelial cells (Hickey, 1999).  
Furthermore, as a second step after migrating into the perivascular space, T-cells have 
to cross the glia limitans, which consists primarily of the parenchymal basement 
membrane and astrocytic endfeet, to reach the brain parenchyma. Whereas 
chemokines and integrins have been suggested to exert the major influence upon 
leukocyte extravasation (Campbell et al., 1996; Johnson et al., 2005), matrix 
metalloproteases have been shown to play a crucial role for the migration across the 
glia limitans as second barrier (Toft-Hansen et al., 2006). This migration process is 
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tightly regulated by astrocytes via the secretion of chemokines and/or overall changes 
to the BBB permeability (Ransohoff et al., 2003; Farina et al., 2007). Thus, leukocytes 
(like T-cells) often remain in the perivascular space in the absence of favourable 
parenchymal conditions like on-going neuroinflammation (Owens et al., 2008). 
With regard to T-cells, the current consensus view proposes that it is mainly activated 
T-cells that enter the brain parenchyma (Wekerle et al., 1986; Hickey et al., 1991; 
Neumann and Wekerle, 1998; Carrithers et al., 2002), apart from CD4+ve T-memory 
cells that survey the brain under healthy conditions (Kivisakk et al., 2003; Goverman, 
2009). Interestingly, each subset of T-cells has been suggested to utilise a different 
route of entry. Whereas CD4+ve T-cells rely on APCs and their MHC II expression in 
the perivascular space to successfully enter the brain parenchyma (Ransohoff et al., 
2003; Greter et al., 2005; Becher et al., 2006), antigen-specific CD8+ve T-cells have 
been shown to gain entry independent of APCs, but via the expression of MHC I 
molecules upon cerebral endothelial cells (Galea et al., 2007b; Melzer et al., 2009).  
Nevertheless, how and where these T-cells are primed or activated to become able to 
enter the brain is a highly debatable point. Some authors suggest that the activation of 
T-cells occurs in the deep cervical lymph nodes by APCs (Yamada et al., 1991; Ling et 
al., 2003; Karman et al., 2004; Hatterer et al., 2006), while others favour perivascular 
priming or activation in the meninges, CSF or choroid plexus (Fischer and 
Reichmann, 2001; Greter et al., 2005; Serafini et al., 2006). Moreover, it has even been 
proposed that T-cell activation occurs directly in the brain parenchyma itself by APCs 
during normal CNS surveillance, or even after entry as naïve T-cells (Becher et al., 
2000; Krakowski and Owens, 2000; Greter et al., 2005; McMahon et al., 2005; Bailey et 
al., 2007; Zozulya et al., 2009; Jain et al., 2010). In the particular case of chronic or 
autoimmune related inflammation, as often seen in neurodegenerative diseases 
including the NCLs (DeLegge and Smoke, 2008; Amor et al., 2009; Goverman, 2009; 
Lynch and Mills, 2011), the activation of T-cells may be mediated via soluble antigen 
drainage into the cervical lymph nodes (Cserr et al., 1992). However, even after 
activation, effector T-cells have to be re-activated either in the CSF or brain 
parenchyma after entry (Shrikant and Benveniste, 1996; Aloisi et al., 2000b), due to 
short-lived activation and lifespan of these cells (Bauer et al., 1998).  
Once in the brain parenchyma T-cells face a variety of challenges, with the largest 
being to avoid death by apoptosis. All cells in the CNS express Fas ligand (FasL) and 
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infiltrating Fas-positive T-cells can experience apoptosis irrespective of antigen 
specificity (Bauer et al., 1998; Bechmann et al., 1999; Choi and Benveniste, 2004). 
Therefore, in order to survive, infiltrating lymphocytes have to recognise their specific 
antigen on MHC molecules in the brain (Shrikant and Benveniste, 1996; Aloisi et al., 
2000a; Melzer et al., 2009). In the healthy CNS MHC expression is minimal, but under 
inflammatory conditions CNS MHC expression is markedly up-regulated (Shrikant 
and Benveniste, 1996; Neumann et al., 1997; Kimura and Griffin, 2000; Neumann, 
2001; Olson et al., 2001). Furthermore, the CNS microenvironment is rather hostile 
for adaptive immune cells as, under normal conditions, both astrocytes and microglia 
help sustain an anti-inflammatory environment in the brain (Garden and Moller, 2006; 
Melzer et al., 2009; Sofroniew and Vinters, 2010). Astrocytes have been shown to 
inhibit T-cell proliferation and induce T-regulatory cells (Meinl et al., 1994; Trajkovic et 
al., 2004). Likewise, microglia can negatively regulate T-cell activation and cytokine 
production (Kwidzinski et al., 2005; Magnus et al., 2005), and last but not least, 
neurons have also been shown to influence T-cells in their proximity (Liu et al., 2006).  
1.8 Neurons can influence immune cells 
Neurons are very sensitive to their milieu and once their health is compromised, they 
do not have an inherent capacity to regenerate. In the crosstalk between different CNS 
cell types, neurons have always been considered as passive victims of reactions and/or 
insults from astrocytes (Farina et al., 2007) or microglia (Hanisch and Kettenmann, 
2007). However, recent studies have elucidated that neurons actually play a larger role 
than previously appreciated in controlling both innate and adaptive immune responses 
in the CNS (Biber et al., 2007; Levite, 2008).  
Whereas the innate immune response (consisting of dendritic cells and macrophages 
in the meninges or the perivascular space (Matyszak and Perry, 1996b; McMenamin, 
1999; Bechmann et al., 2001; McMenamin et al., 2003), and of astrocytes and microglia 
inside the parenchyma) is very sensitive to microclimate changes, the adaptive immune 
cell activation in the brain is harder to provoke and is usually avoided for as long as 
possible (Garden and Moller, 2006; Melzer et al., 2009; Sofroniew and Vinters, 2010). 
Under normal healthy conditions, this relative retention of adaptive immune responses 
is controlled in the first instance by the BBB, by the absence of draining lymphatic 
vessels in the brain and by ensuring that astrocytes and microglia have a poor antigen 
presenting capacity (Carson et al., 2006a). However, T-cells routinely enter the 
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parenchyma in an activated state to perform their surveillance function (Kivisakk et al., 
2003; Engelhardt and Ransohoff, 2005) see also Chapter 3). Therefore, maintaining 
glial cells as inefficient at antigen presentation is of major importance to avoid 
provoking unnecessary immune responses. As a consequence, neurons have 
developed ways to modify or influence these activation processes. On the one hand, 
neurons can suppress or down-regulate (micro)glial activation in a contact-
independent manner via neurotransmitters, neurotrophins, neuropeptides or cytokines 
(Pavlov and Tracey, 2004; Reinke and Fabry, 2006; Biber et al., 2007; Levite, 2008). 
These processes take place predominantly in the perivascular space and are essential to 
keep the integrity of the brain and BBB under healthy conditions. Alternatively, after 
an insult or on-going inflammation, direct contact-dependent interactions between 
neurons, glia and T-cells become more important. Presently, three important 
interactions are recognised (Tian et al., 2009). Firstly, neurons can down-regulate the 
APC properties of glial cells and suppress for example the nitric oxide (NO) or 
tumour necrosis factor-α (TNF-α) release of microglia via cell-cell receptor 
interactions (e.g. NCAM or CD22) (Chang et al., 2000; Mott et al., 2004). These 
mechanisms potentially allow stressed neurons to protect themselves from further 
microglial damage (Minghetti et al., 2005). Secondly, it has been suggested that neurons 
are directly able to suppress T-cell activation via cell adhesion molecules (i.e. 
cadherins) (Grundemann et al., 2006; Ito et al., 2006), and also to change the Th1 and 
Th2 balance of T-cells (Liu et al., 2006; Dittel, 2008), although direct evidence for this 
is rather limited. Last but not least, neurons (as well as glial cells) express Fas Ligand, 
which can promote apoptosis of activated T-cells (Bechmann et al., 1999; Choi and 
Benveniste, 2004). Additionally, stressed neurons can secrete a protein called Sema-3A 
to induce apoptosis of activated microglia after binding to the microglial neuropilin-1 
and plexin-1 receptor complex (Majed et al., 2006). Furthermore, direct interaction 
with apoptotic neurons forces microglia to release anti-inflammatory cytokines and 
neuroprotective agents, and to simultaneously reduce the secretion of nitric oxide and 
pro-inflammatory proteins (Minghetti et al., 2005). Interestingly, many cell adhesion 
molecules (CAMs) (like cadherins) are also involved in synaptic plasticity and are 
strongly expressed on neurons in regions of neurogenesis and on neuronal stem cells 
(Tai et al., 2008; Tian et al., 2009). CAMs not only administer normal regeneration 
processes in these regions, but at the same time are proposed to ensure that the 
inflammatory response is kept to a minimum (Pluchino et al., 2005; Ben-Hur, 2008).  
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In summary, with the secretion of different neuroprotective substances, as well as 
direct cell-cell interactions, neurons have the ability to influence both glial cells and T-
cells to enhance a neuroprotective environment and to reduce the likelihood of 
adaptive immune responses. 
Finally, it should be mentioned that neurons can also enhance inflammatory responses 
under certain circumstances, for example after injury to accelerate innate immune 
responses and clearance of cell debris (Rubartelli and Lotze, 2007; Pais et al., 2008; 
Tian et al., 2009). This raises the question of what determines which direction this 
neuronal influence will tilt, to either suppress or promote inflammation. Moreover, it 
could be speculated that neurons also take on different roles during the progression of 
neurodegenerative disorders like the LSDs. As such, this possibility shall be 
considered when interpreting our findings on the NCLs in Chapter 7.  
1.9 Lysosomes in immune cells 
As described above (see section 1.1b), the lysosome is involved in a variety of 
intracellular processes (Saftig and Klumperman, 2009). Therefore, it is not surprising 
that any dysfunction in the complex endosomal/lysosomal pathways due to protein 
deficiency could lead to numerous functional consequences in a range of cell types (as 
for example described in neurons above in section 1.1c). However, immune cells in 
particular, with their many varied interactions with antigens and other (immune) cells, 
seem especially prone to such functional alterations. This hypothesis is supported by 
several findings of immune irregularities in the LSDs and in some forms of NCL 
(Castaneda et al., 2008).   
Firstly, the accumulation of lysosomal storage material is evident in immune cells in 
many LSDs (Aula et al., 1975; Bruck et al., 1991; Kieseier and Goebel, 1994). Before 
genetic tools became available, the storage inclusions in T-cells in the blood periphery 
were used as a reliable diagnostic tool for the NCLs (Dolman et al., 1980; Bruck et al., 
1991). In Late Infantile NCL 12-21%, and in Juvenile NCL 20-70% of lymphocytes, 
are reported to contain vacuolated inclusions (Dolman et al., 1980; Ikeda et al., 1982; 
Kimura and Goebel, 1988). However, a direct effect of such storage material on 
function of these immune cells has still to be unambiguously shown. Studies 
addressing this issue, after deriving leukocytes from peripheral blood monocytes from 
NCL patients, did not reveal any differences in reactive oxygen species, cytokine 
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production or cell proliferation compared to control cells (Kieseier et al., 1997). 
Nevertheless, an increase in apoptotic cell death and cellular turnover was detected in 
NCL-patient derived leukocytes (Kieseier et al., 1997). However, certain immune cell 
functions do require a properly functional lysosome, which could be impaired in the 
NCLs. Lysosomes are particularly involved in antigen presenting functions via MHC I 
and MHC II receptors, cytotoxic T-cell functions and natural killer T-cell 
development (reviewed in (Castaneda et al., 2008)).  
Via MHC I molecules the majority of nucleated cells present endogenous peptide 
antigens to the immune system, in particular CD8+ve T-cells, providing a powerful 
surveying tool for the immune system to recognise viral infected, transformed or 
diseased cells (Germain, 1994; Davis et al., 1998). Although the majority of 
degradation of the endogenous proteins destined for MHC I presentation occurs in 
the cytosol by the proteasome (Tanaka et al., 1997), a lysosomal enzyme (TPPII) has 
been shown to also independently generate epitopes for MHC I (Seifert et al., 2003), 
therefore suggesting a role of the endosomal/lysosomal pathways in MHC I peptide 
presentation. As such, these mechanisms could be affected in LSDs and NCLs, as for 
example an altered MHC I expression has been shown in Gaucher disease (Balreira et 
al., 2005). 
More obviously the lysosome is directly involved in cleavage of antigens and their 
loading onto MHC II proteins (Watts, 2001; Schmid and Munz, 2005). MHC II 
expression is normally only found in professional APCs, including macrophages, 
dendritic cells, activated T- and B-cells (Drozina et al., 2005). Generally, these cell 
types present their antigens displayed on MHC II molecules to CD4+ve T-helper 
cells, the main regulators of the immune system (Germain and Margulies, 1993; Zhu 
and Paul, 2008). To date, no direct evidence for these processes being altered has been 
reported in any LSD. Nevertheless, alterations in pH (Bach et al., 1999; Virmani et al., 
2005; Yanagawa et al., 2007), oxidation/reduction states (Deganuto et al., 2007), 
protein sorting (Cooper, 2003; Fraldi et al., 2010), and of course storage accumulation, 
have been demonstrated in several LSDs. Each of these factors alone, or in 
combination, could have considerable potential to modify antigen processing in the 
lysosome and therefore the APC functions of immune cells.  
Another involvement of lysosomes in immune cell function is in their control of 
CD8+ve cytotoxic T-cell activity. As described previously (see section 1.7a), cytotoxic 
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T-cells can recognise foreign or transformed cells via MHC I molecule interactions 
(Townsend and Bodmer, 1989; Abbas and Lichtman, 2011), and can induce cell 
apoptosis via FasL-Fas interactions at the cell surface or the release of lytic granules 
(Peters et al., 1991; Suda et al., 1995; Page et al., 1998). The delivery of FasL to the cell 
surface and the secretion of lytic granules are carefully regulated by the lysosome, and 
drugs that increase the pH of the lysosomal compartment have been shown to block 
cytotoxic T-cell activity (Kataoka et al., 1994). As already mentioned, lysosomal pH is 
altered in a subset of LSDs (Bach et al., 1999; Yanagawa et al., 2007) including the 
NCLs (Virmani et al., 2005), and it is possible that cytotoxic T-cell functions are 
deficient as well. Furthermore, it has been shown that during the secretory process of 
CD8+ve T-cells, storage material in LSDs ends up in the extracellular space (Klein et 
al., 2005a). Similar events and storage clearance have been proposed as a general 
consequence of plasma membrane repair and exoctytosis (Medina et al., 2011). 
Speculatively, such secretory events could also be important in the induction of 
autoimmune responses (Castaneda et al., 2008).  
Last but not least, the accumulation of storage material has been proposed to alter 
natural killer T-cell (NKT) development in the thymus (Godfrey et al., 2006; Castaneda 
et al., 2008). Most NKT cells are a subset of T-cells, which are characterised by a 
partially invariant T-cell receptor and they are mainly involved in regulatory functions 
of the immune response via the production of various cytokines (van der Vliet et al., 
2004). NKTs recognise lipids and glycolipids mainly via CD1d molecules that are 
expressed on the surface of cells, similar to the expression of MHC molecules (Brigl 
and Brenner, 2004). For the correct development of these cells in the thymus, 
lysosomes have to appropriately load the CD1d protein in the thymus (MacDonald, 
2002), and in the complete absence of CD1d NKT cells do not develop (Mendiratta et 
al., 1997). Similarly, reduced levels of NKT cells have been described in various LSD 
mouse models, which has been linked to incorrect processing and presentation of 
antigen by CD1d protein (Daly et al., 2000; Gadola et al., 2006). However, similar 
events have not yet been reported in the NCLs, but it would indeed be quite likely. 
Nevertheless, the direct effect of such impairments on the maturation and 
development of the immune system and response is still unknown in these disorders.   
Furthermore, such lysosomal deficiencies are likely to affect not only the classical 
immune cells, but also glial cells as part of the innate immune response. The same 
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potential impairments of MHC II and MHC I dependent antigen presentation are 
valid for dendritic cells, macrophages, microglia and astrocytes. There is also emerging 
evidence for general glial dysfunction in both INCL and JNCL (Dihanich, 2010; Milà, 
2012; Parviainen, 2012) which shall be discussed below (see section 1.10a).   
In summary, although there are several potential links and correlations between 
endosomal/lysosomal deficiencies and altered adaptive immune cell function, the 
exact consequences of such altered immune responses on the pathogenesis of LSDs, 
including the NCLs, remains unclear. However, these possible alterations should be 
kept in mind while investigating disease progression and pathogenesis, as it is certainly 
plausible that defects in the lysosomal system may also directly affect immune 
responses in the NCLs.  
1.10 Immune responses in Infantile and Juvenile NCL 
All forms of NCL display pronounced innate immune responses within the brain, 
including both astrocytosis and microglial activation. Glial responses have been 
reported in most neurodegenerative disorders ranging from Alzheimer and Parkinson 
disease, to trauma or ischemia (Neumann, 2001; Rogers et al., 2007), and also in other 
lysosomal storage disorders (Jeyakumar et al., 2003; Ohmi et al., 2003).  
Gliosis can be found in post mortem tissue of individuals who succumbed to JNCL 
(Braak and Goebel, 1978, 1979; Tyynela et al., 2004), and in other forms of NCL 
(Haltia et al., 1973a; Haltia et al., 1973b; Tyynela et al., 1997; Tyynela et al., 2004). 
Analogous innate inflammatory responses can be seen in mouse models of various 
forms of NCL (Oswald et al., 2005; Cooper et al., 2006; Kay et al., 2006; von Schantz et 
al., 2009; Kuronen et al., 2012; Schmiedt et al., 2012; Thelen et al., 2012), similarly in 
Juvenile or Infantile NCL (Bible et al., 2004; Pontikis et al., 2004; Pontikis et al., 2005; 
Kielar et al., 2007; Macauley et al., 2009; Weimer et al., 2009; Macauley et al., 2011)  
As in human INCL, at the end stage of the disease, Ppt1-/- mice display a widespread 
and pronounced neuron loss and glial activation in the cerebellum, the cortex and 
numerous subcortical regions (Gupta et al., 2001; Bible et al., 2004; Kielar et al., 2007; 
Macauley et al., 2009). However, in the course of disease progression a distinct regional 
and cellular selectivity can be observed, especially within the thalamocortical system 
(Kielar et al., 2007), and in the cortex and hippocampus at the end stage of the disease 
(Bible et al., 2004). Moreover, as mentioned above, in Ppt1-/- mice, an early localized 
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astrocytosis precedes neuron loss, with subsequent microglial activation in the 
thalamocortical system from 3 months onwards and in the cerebellum from 1 month 
onwards (Kielar et al., 2007; Macauley et al., 2009). These inflammatory responses are 
complemented by early up-regulation of inflammatory genes and mediators (Qiao et 
al., 2007; Saha et al., 2008), which can recruit peripheral immune cells to the brain 
(Zhang et al., 2007). Nonetheless, the adaptive immune responses involved in Infantile 
NCL have not been investigated so far, even though the first indications of immune 
cell infiltration have recently been reported, albeit briefly (Macauley et al., 2011).  
Astrocytosis and microglial activation also occur in Cln3 deficient mice, but in a much 
more subtle manner (Pontikis et al., 2004; Pontikis et al., 2005). In the cerebellum, 
GFAP and F4/80 glial up-regulation have already been observed in Cln3-/- mice 7 days 
after birth (Weimer et al., 2009), or at 3 months of age in Cln3 knock-in mice 
(Herrmann et al., 2008b). From 5 months onwards a clear astrocytosis and microglial 
cell activation was detected in the forebrain of Cln3-/- mice (Pontikis et al., 2004). 
These findings were confirmed in 12 month old Cln3 knock-in mice (Pontikis et al., 
2005), and in the oldest (19 month old) Cln3 knock-in mice analysed so far (Herrmann 
et al., 2008b). As in other forms of NCL, this glial activation is predominantly seen in 
the cerebellum and the thalamocortical system, and is followed by subsequent selective 
neuron loss (Pontikis et al., 2004; Pontikis et al., 2005; Weimer et al., 2009). However, 
these glial responses in JNCL mice appear to be atypical with incomplete 
morphological transformation of glial cells (see section 1.10a below) (Pontikis et al., 
2004; Tyynela et al., 2004; Pontikis et al., 2005; Dihanich, 2010; Parviainen, 2012). 
Furthermore, specific to JNCL pathogenesis, and not observed in other NCL forms 
so far, JNCL patients and Cln3-/- mice demonstrate an early autoimmune response 
(Chattopadhyay et al., 2002a; Chattopadhyay et al., 2002b; Castaneda and Pearce, 2008). 
The presence and deposition of autoantibodies in the JNCL brain has been described 
(Lim et al., 2007b), and immunosuppressive drugs or genetic deletion of B-cells proved 
their direct influence on JNCL pathogenesis ((Seehafer et al., 2011) and Chapter 7). 
However, apart from this presence of autoantibodies the involvement of adaptive 
immune cells has not been investigated in Juvenile NCL.   
To date, it is not known what triggers immune cell activation in the CNS. The glial 
response in other more chronic diseases is thought to be triggered variously by 
abnormal β-amyloid protein accumulation or initial neuronal loss/brain injury (Stoll 
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and Jander, 1999; Minagar et al., 2002). In the NCLs, glial responses are most likely 
triggered as a consequence of the gene deficiency itself, and disturbances in cell 
homeostasis resulting in a slow onset of excitotoxicity in selective neuron populations 
of the brain (Das et al., 2001; Luiro et al., 2006). Subtle neuronal homeostatic changes 
could already warn surveillance cells like microglia and astrocytes to induce an 
inflammatory response. To mention only a few such changes (see section 1.2b and 
section 1.2c above):  ER and oxidative stress and misfolded protein responses (Kim et 
al., 2006; Zhang et al., 2006), compromised lipid metabolism and trafficking (Ahtiainen 
et al., 2007; Lyly et al., 2008), disturbances in autophagic pathways (Cao et al., 2006) or 
calcium homeostasis (Chang et al., 2007). Similarly, early synaptic pathology (Virmani et 
al., 2005; Song et al., 2008; Kielar et al., 2009), or excitotoxicity via increased glutamate 
levels (Chattopadhyay et al., 2002a; Pears et al., 2005) may also contribute to the 
initiation of immune reactions in the brain. In any case, innate immune reactions are 
always present in NCL brains. In addition to these well-characterised innate immune 
responses, the adaptive immune responses shall be investigated in this thesis and the 
impact of each immune response upon neurodegeneration discussed in Chapter 7.  
a) Glial dysfunction in INCL and JNCL 
Another important aspect to consider is the entire idea of ‘gliodegeneration’, 
according to which glial cells are dysfunctional and consequently cause 
neurodegeneration (Croisier and Graeber, 2006). Although mainly referred to in aging 
and age-dependent disorders (Streit and Xue, 2009), dysfunctional glia may also play a 
role in the NCLs. There is in vitro evidence that the biology of astrocytes is 
compromised in both JNCL and INCL, and in JNCL that these changes may exert a 
negative influence on neuron health (Dihanich, 2010; Milà, 2012; Parviainen, 2012). 
Pure microglial cultures derived from Cln3 deficient mice also show an impaired 
morphological response to stimulation and a series of specific alterations in cytokine 
release, yet retain normal phagocytic properties (Dihanich, 2010). Furthermore, similar 
results have been obtained for Cln3-/- astrocytes, which show a broader range of 
functional defects. They also show an impaired morphological response to 
stimulation, marked cytoskeletal abnormalities and pronounced secretion defects. 
These defects extend to a dramatic reduction in glutathione secretion, the major anti-
oxidant in the brain (Dringen, 2000; Fernandez-Fernandez et al., 2012), together with 
evidence for altered internal calcium responses (Parviainen, 2012). Most intriguingly, 
mutant glia appear to directly harm the survival of both healthy and mutant neurons 
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when co-cultured with primary cortical neurons, but this can be ameliorated by 
substituting wildtype glia, suggesting that a therapeutic benefit can be gained by 
treating glia alone. 
Likewise, first indications from cell culture experiments on Ppt1-/- astrocytes suggest 
that they display also abnormalities (Milà, 2012). Under basal conditions they already 
resemble stimulated astrocytes and morphologically only partly respond to stimulation 
(Milà, 2012). Nevertheless, further detailed characterisation of Ppt1-/- glial cells is still 
required. However, if glial dysfunction can be confirmed in both INCL and JNCL 
mice, a direct comparison of glial defects in these mice may reveal the role of each 
deficient protein (Ppt1 and Cln3) in the different types of glia. Secondly it may also 
give us clues as to where the initial pathological symptoms arise: in astrocytes, or 
microglia or neurons, or indeed a combination of these cell types.  
1.11 Modification of immune responses 
The field of neuroinflammation has gained increasingly more interest in recent years, 
in particular in the context of neurodegenerative diseases. There are potentially 
convergent mechanisms between classical inflammatory diseases like multiple 
sclerosis, which demonstrate neurodegenerative features, and classical 
neurodegenerative disorders like Alzheimer disease, Parkinson disease or the NCLs 
which show increasing evidence of the pathogenic role of inflammation (Zipp and 
Aktas, 2006; Aktas et al., 2007; Infante-Duarte et al., 2008; Lim, 2011).  
Both innate and adaptive inflammatory responses can lead to, or possibly be caused 
by, neurodegeneration. To determine the answer to such a ‘chicken or egg’ question 
will be crucial for any successful treatment of these diseases. This relationship will very 
likely vary between disease types and at different stages of disease progression. 
However, potential confounders of neuroinflammation will also have to be 
considered. An acute systemic inflammation can increase brain pathology and 
neuroinflammation (Perry, 2004; Holmes et al., 2009). Alternatively impaired immune 
cells may contribute directly to disease pathology (Gadola et al., 2006). As discussed 
above, this is particularly likely in lysosomal storage disorders like the NCLs, because 
the lysosome has been shown to be involved in antigen presenting mechanisms (see 
section 1.9 above and (Hsing and Rudensky, 2005)).   
It will be essential to define the pathogenic role of each immune response (and con- 
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founding factors) to develop effective treatments. Indeed, each part of the immune 
response can have different implications for disease progression. In this thesis we 
investigate the role of adaptive immune cells, as well as the role of an immune 
regulatory protein called sialoadhesin that is expressed on macrophages. By knocking 
out either, an essential enzyme for T- and B-cell maturation called RAG-1, or 
sialoadhesin in NCL mice, we aimed to identify the exact role of these two immune 
responses in the disease pathogeneses and establish a further link between 
neurodegenerative disorders and neuroinflammation. Hence, the properties and 
functions of the proteins RAG-1 and sialoadhesin will be defined in more detail.  
a) RAG-1  
V(D)J rearrangement is an essential process during the maturation of B- and T-
lymphoid cells and is activated by enzymes called recombination-activating gene-1 and 
-2 (RAG-1 and RAG-2) (see also section 1.7 above and (Schatz et al., 1989; Oettinger 
et al., 1990). Their first identification was ex vivo in fibroblasts and both proteins are 
required for a successful execution of V(D)J recombination (Oettinger et al., 1990). 
They are lymphoid specific enzymes that carry out the cutting of DNA after the initial 
recognition of RSSs, whereas the other processes are linked to ubiquitously expressed 
DNA repair molecules (Schlissel et al., 1993). RAG-1 and RAG-2 are sufficient to 
induce V(D)J recombination activity when expressed in non-lymphoid cells (Schatz et 
al., 1989; Oettinger et al., 1990). Mice lacking Rag-1 or Rag-2 are completely defective 
in V(D)J recombination, and therefore contain no mature B or T cells (Mombaerts et 
al., 1992; Shinkai et al., 1992). These mice show no other overt defects, indicating that 
Rag genes are lymphocyte specific and only expressed in T- and B-cells. Therefore Rag-
1 and Rag-2 deficient mice have become useful model systems for studying adaptive 
immune responses and have been used in several studies in numerous disease settings 
(Matthews et al., 2002; Bieber et al., 2003; Berghoff et al., 2005; Ip et al., 2006). An 
additional advantage of Rag-1 or Rag-2 deficient mice is that after cell specific re-
constitution of subsets of T-cells or B-cells (via BMT for example), the direct impact 
of a specific adaptive immune cell type on disease progression can be investigated 
(Sun et al., 2001; Ip et al., 2006; Dimayuga et al., 2011). For the same reasons, the 
crossbreeding of Rag-1 deficient mice with NCL mouse models represents an ideal 
means to investigate the role of adaptive immune cells in the pathogenesis of different 
forms of NCL.   
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b) Sialoadhesin (Sn) 
Sn was first described in 1985 as a non-phagocytic sheep erythrocyte receptor (SER) 
on resident bone marrow macrophages (Crocker and Gordon, 1985, 1986). The 
production of a monoclonal antibody four years later was essential for the 
characterisation (Crocker and Gordon, 1989), purification (Crocker et al., 1991) and 
eventually molecular cloning of this gene, which led to the renaming of the receptor to 
Sn (Crocker et al., 1994). Thus, Sn was defined as a sialic-acid dependent macrophage 
adhesion molecule as a member of the immunoglobulin superfamily (IgSF) with an 
extracellular region of 17 immunoglobulin domains (Crocker et al., 1994). Since they 
are used by antibodies and T-cell receptors these immunoglobulin domains make use 
of the structural diversity of glycans in their recognition function and can bind to a 
vast number of molecules (Williams and Barclay, 1988; Powell and Varki, 1995; 
Angata and Brinkman-Van der Linden, 2002). Sn is a well conserved protein in 
mammals and belongs to a subset of the immunoglobulin superfamily called ‘siglecs’ 
(sialic-acid binding immunoglobulin-like lectins) (Kelm et al., 1994). All siglecs are 
transmembrane proteins that contain extracellular V-like immunoglobulin (IgV) 
domains, which bind sialic acids and a variable number (16 in the case of Sn) of C2-
type immunoglobulin (IgC2) domains (see Figure 4, (Crocker et al., 1998)). 
Intracelluar tyrosine based signalling motifs are common in most siglecs, but 
interestingly Sn lacks these signalling motifs in its cytoplasmic tail suggesting a 
predominant role in cell-cell interactions rather than in cell signalling (Crocker, 2002).  
To date, 15 different siglecs have been identified in humans and 9 in mice, while most 
of them can be found on haemotopoietic and immune cells (Pillai et al., 2012). Apart 
from resting T-cells, in mice and humans most immune cells express at least one 
siglec, or sometimes even several (Crocker et al., 2007) (see Figure 4). The exact role 
of siglecs is still unknown, but it is assumed that their recognition of sialic 
acid/sialylated glycans is important to regulate adhesion, cell signalling and 
endocytosis (Crocker and Varki, 2001; Crocker, 2002; Varki and Angata, 2006), and 
especially in regulating innate and adaptive immune cells. Siglecs are able to regulate 
the functions of innate and adaptive immune cells via sialic acid compounds, which 
are modified during immune cell development and activation (Pillai et al., 2012), as for 
example the regulation of cell proliferation or cell survival (Vitale et al., 1999; Nutku et 
al., 2003; von Gunten et al., 2005). Furthermore, a role for siglecs as self and non-self 














utilise the fact that all mammalian cells express glycolipids and glycoproteins, to which 
they can bind via sialic acid containing glycans, and hence recognise ‘self’ (Ohtsubo 
and Marth, 2006; Crocker et al., 2007). Therefore, most siglecs are believed to carry out 
an immune inhibitory role and have often been linked to autoimmune responses 
(Paulson et al., 2012; Pillai et al., 2012).  
However, in contrast to all other siglecs, Sn (also known as siglec-1 or CD169) is 
thought to act as a pro-inflammatory binding protein of macrophages. Its special role 
compared to the other siglecs is also supported by its unique structure, with a lack of 
Figure 4. Siglec proteins in humans and mice. Sialic-acid-binding immunoglobulin-like lectins 
(siglecs) are type 1 membrane proteins and consist of an amino-terminal V-set immunoglobulin 
domain, which recognises sialic acid, and varying numbers of C2-set immunoglobulin domains. 
According to their evolutionary conservation and sequence similarity, they can be divided into 
“common siglecs” and “CD33-related siglecs”. CD33-related siglecs show high sequence 
similarity in their extracellular regions and often contain conserved tyrosine-based signalling 
motifs in their cytosolic domains, but differ in composition between species. In contrast, 
sialoadhesin, CD22, myelin-asociated glycoprotein (MAG) and siglecs-15 exhibit lower sequence 
similarity, but represent orthologues in all mammals examined. Siglecs are expressed on various 
immune cells. To date, 15 human and 9 murine siglecs have been identified (human siglecs-12 and 
siglecs-16 are not shown). B = B cells, Ba = basophils, cDCs = conventional dendritic cells, Eo = 
eosinophils, GRB2 = growth factor-receptor-bound protein 2, ITIM = immunoreceptor tyrosin-
based inhibitory motif, Mac = macrophages, Mo = monocytes, MyP = myeloid progenitors, N = 
neutrophils, ND = not determined, NK = natural killer cells, OligoD = oligodendrocytes, pDCs 
= plasmacytoid dendritic cells, Schw = schwann cells, Troph = trophoblasts. Reproduced from 
(Crocker et al., 2007). 
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intracellular and the extended extracellular domains (see Figure 4) (Crocker et al., 
1994). Sn is expressed under normal conditions on macrophages in lymphoid tissues 
(particularly in spleen, lymph nodes) and adrenal gland (Dijkstra et al., 1985; Crocker 
and Gordon, 1986; van den Berg et al., 2001). In the brain Sn immunoreactivity is 
normally only found on macrophages in the meninges or choroid plexus (Perry et al., 
1992). However, under inflammatory conditions, Sn expression is rapidly up-regulated 
and found on macrophages at sites of inflammation in body tissue of both humans 
and rodents (van den Berg et al., 1992; Hartnell et al., 2001), but also on infiltrated 
macrophages and on nearby microglia in the brain (Perry et al., 1992). It has been 
shown that mainly interferon-α (IFN-α), but also other glucocorticoid, cytokines and 
inflammatory stimuli can up-regulate Sn expression on macrophages (van den Berg et 
al., 1996; York et al., 2007). The exact function of Sn is still debatable, but since it is 
exclusively expressed on macrophages and displays cell-cell interaction properties, a 
role in endocytic or phagocytic processes has been postulated (Jones et al., 2003; 
Delputte et al., 2011). Sn can mediate interactions with immune cells in both sialic 
acid-dependent, but also sialic acid-independent, manner. Whereas for example CD43 
on T-cells is a putative Sn ligand in a sialic acid-dependent manner (van den Berg et al., 
2001), Sn has also been shown to bind to the mannose receptor of several myeloid 
cells, and other lectin receptors (MGL1) in an sialic acid-independent manner 
(Martinez-Pomares et al., 1996; Kumamoto et al., 2004). Furthermore, Sn has been 
shown to facilitate interactions with various (sialylated) pathogens including bacteria 
(Jones et al., 2003; Heikema et al., 2010), viruses (Rempel et al., 2008; Seyerl et al., 2010; 
Van Breedam et al., 2010) and even parasites (Monteiro et al., 2005). However, most 
strikingly recent studies have demonstrated the involvement of Sn+ve macrophages in 
lymphocyte activation and regulation of T- and B-cell responses (reviewed in 
(Martinez-Pomares and Gordon, 2012)), suggesting their importance in antigen 
presentation and self vs. non-self recognition in the spleen or lymph nodes (see next 
section 1.11c and (Junt et al., 2007; Miyake et al., 2007; Backer et al., 2010; McGaha et 
al., 2011). To what extent Sn itself is involved as a ligand in these processes, is still 
controversial (Revilla et al., 2009; Klaas and Crocker, 2012). However, recent studies 
with Sn deficient mice have confirmed its role as a regulator of adaptive immune cells, 
particularly in the context of neurodegenerative disorders, resulting in decreased 
(CD8+ve) T-cell activation and infiltration as well as overall disease amelioration 
(Jiang et al., 2006; Kobsar et al., 2006; Ip et al., 2007). As a consequence, Sn has gained 
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interest as a potential target for immunotherapy, on the one hand, by specifically 
targeting antigens or drugs to macrophages or on the other hand, by specifically 
blocking Sn and its function as an immune system regulator (Halkes et al., 2003; 
Ducreux et al., 2009; O'Reilly and Paulson, 2009; Kratzer et al., 2010; De Baere et al., 
2011; Delputte et al., 2011). To highlight the potential role of Sn in the body and 
putatively in the brain, the specific role of Sn expressing macrophages will be 
addressed in more detail.   
c) Sialoadhesin positive macrophages 
In general, macrophages act as one of the first frontiers of the body’s innate immune 
system. They are essential for phagocytic cell clearance, as well as presenting antigens 
to B- and T-cells via MHC II molecules (Badwey and Karnovsky, 1980; Unanue, 1984; 
Abbas and Lichtman, 2011). In the rest of the body, as well as in the brain, 
macrophages are distinguishable by their expression of different receptor and binding 
molecules, such as mannose receptor (MR) and PECAM-1 for example (Watt et al., 
1995; Takahashi et al., 1998; Gordon and Taylor, 2005). The expression of different 
receptors depends on tissue location and activation status (Gordon et al., 1995). 
Therefore, each subset of macrophages represents a functional specialization, as for 
example also Sn+ve macrophages.  
Three types of Sn+ve macrophages can be found systemically in mice: marginal zone 
metallophilic (MZM) macrophages in spleen, and subcapsular sinus (SS) and medullary 
(Med) macrophages in lymph nodes (Crocker and Gordon, 1989). In the spleen, as 
well as in the lymph node, Sn+ve macrophages are strategically (and ideally) located at 
the cross-road between blood and lymph to activate adaptive immune cells (Martinez-
Pomares and Gordon, 2012). Sn+ve macrophages have been shown to be involved in 
three main regulatory processes in which Sn putatively plays a role: T-cell activation, 
B-cell priming and self vs. non-self discrimination (Umansky et al., 1996; Junt et al., 
2007; Miyake et al., 2007).   
First of all, direct cell-cell contacts between Sn+ve macrophages and T-cells have been 
suggested in previous studies where cluster formations of Sn+ve macrophages and 
CD8+ve T-cells were observed in the body periphery (Muerkoster et al., 1999), and 
speculatively also in the brain (Ip et al., 2007). The molecular structure of Sn would 
favour possible direct cell-cell interactions, which was supported by the finding of a 
putative Sn counter-receptor on T-cells, called CD43 (van den Berg et al., 2001).   
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Secondly, although dendritic cells are regarded as the master antigen presenting cells 
(Segura and Villadangos, 2009), the ideal location of Sn+ve macrophages in the spleen 
and lymph nodes where they are in constant contact with blood and lymph drainage, 
would place them at an ideal antigen presenting cell frontier. Because cell-free antigens 
reach the lymph nodes hours before migratory DCs arrive, Sn+ve macrophages could 
evaluate, capture, process incoming material and eventually present it to lymphocytes 
more quickly (Martinez-Pomares and Gordon, 2012). Indeed, Sn+ve macrophages 
have been described as having antigen-presenting functions. They have been shown to 
act as APCs to B-cells (Carrasco and Batista, 2007; Junt et al., 2007; Gonzalez et al., 
2011), CD4+ve cells (Umansky et al., 1996) and iNKT cells (Barral et al., 2010) via 
complement/MHC II/CD1b pathways. Furthermore, recent findings have shown that 
Sn+ve macrophages in the spleen also transfer, or cross-present, antigen to CD8+ve 
dendritic cells, which then activate CD8+ve T-cells via MHC I receptors (Harshyne et 
al., 2001; Backer et al., 2010). Indeed, in the lymph nodes Sn+ve macrophages even 
present dead cell debris (as antigen) directly to CD8+ve T-cells and activate their 
immune responses (Asano et al., 2011). 
Thirdly, Sn+ve macrophages in the spleen have been postulated to be involved in 
recognition and discrimination of self and non-self of apoptotic cell associated 
antigens (Klaas and Crocker, 2012). There is a fine line between this discrimination, 
binding protein expression and the carefully regulated phagocytosis, all of which are 
essential for a correct immune response. Sn+ve macrophages must determine which 
antigens to oppose B-cells, and which ones to take up and render cryptic to the 
immune system. Malfunctions of these phagocytic processes, or of putative antigen 
discrimination via Sn, could lead to a breakdown in tolerance and development of 
autoimmune responses. Such processes are postulated for systemic sclerosis (York et 
al., 2007) and this could possibly be the case in Juvenile NCL since the CLN3 protein 
is thought to function in the ER-Golgi (Cotman and Staropoli, 2012), as well as 
endocytotic pathways (Uusi-Rauva et al., 2008). Depletion of Sn+ve macrophages in 
other model systems has led to increased autoimmune responses, including T-cell 
activation and pro-inflammatory cytokine production, by suppressing the tolerance 
towards apoptotic cells (Miyake et al., 2007; McGaha et al., 2011). The suppression of 
immune responses to cell-associated antigens also normally involves CD8+ dendritic 
cells in the spleen, which selectively capture apoptotic cells. However, this mechanism 
seems orchestrated by Sn+ve macrophages (Miyake et al., 2007). Therefore, Sn 
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deficiency on macrophages results in malfunctioning apoptotic cell engulfment by 
CD8+ dendritic cell, which leads to increased (auto-)immune reactivity.  
However, the involvement of the binding protein Sn itself in each of these processes 
has not yet been unambiguously demonstrated (Revilla et al., 2009; Klaas and Crocker, 
2012). Nevertheless, because Sn+ve macrophages in the spleen and lymph nodes are 
considered as potential gatekeepers of adaptive immunity, it is likely that Sn itself plays 
a role in the regulation of these processes, including immune activation and facilitating 
the distinction between self- and non-self-antigens (Klaas and Crocker, 2012). This is 
of particular interest as similar reactions may also occur in the brain. But how, and if, 

















1.12 Overall aim 
The first aim of this thesis was to investigate the nature and extent of adaptive 
immune responses in the brains of Infantile and Juvenile NCL mice. We wanted to 
characterise, in particular, the relative timing of T-cell infiltration in relation to other 
well described features of the innate immune response and neurodegeneration of both 
forms of NCL.  
Furthermore, we strived to identify the influence of adaptive immune cells upon the 
pathogenesis of Infantile NCL by genetically removing adaptive immune components. 
By comparing characteristic features of glial activation and neuron loss in Ppt1-/- mice 
to immune deficient Ppt1-/-/Rag-1-/- mice, we aimed to determine whether the adaptive 
immune system acts as a pathogenic or beneficial contributor to disease progression.  
As a second goal of this thesis, we wanted to characterise the role of Sn, a binding 
protein of inflammatory macrophages, on disease progression in Infantile and Juvenile 
NCL. Recent studies have demonstrated the regulatory and often pro-inflammatory 
role of Sn on adaptive immune responses in the brain (Jiang et al., 2006; Kobsar et al., 
2006; Ip et al., 2007). Therefore, by genetically creating and characterising Sn deficient 
Infantile NCL (Ppt1-/-/Sn-/-) as well as Juvenile NCL (Cln3-/-/Sn-/-) mice, we wanted to 
identify the putative pathogenic role of Sn and Sn+ve macrophages/microglia on 
disease progression in both Infantile and Juvenile NCL.  
In summary, this thesis will not only provide detailed characterisation of the 
involvement of adaptive immune responses in Infantile and Juvenile NCL, but also 
assess, as proof of principle, the potential and suitability of two different (adaptive) 
immune system manipulations as possible immune modulatory therapies for Infantile 












Chapter 2  
Material and methods   
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This thesis examines the impact of immune-related cells on NCL disease progression. 
The differences between normal diseased NCL mice, immunodeficient NCL mice and 
their corresponding control mice have been investigated using immunohistochemistry, 
stereology and other quantitative morphological techniques.   
2.1 Mice  
In total 8 different genotypes of mice have been used in this thesis (see Table 4). 
These include NCL mouse models (Ppt1-/-, Cln3-/-), immunocompromised double 
knockout NCL mice (Ppt1-/-/Rag-1-/-, Ppt1-/-/Sn-/- and Cln3-/-/Sn-/-) and the 
corresponding control mice (wildtype (WT), Rag-1-/- and Sn-/-). As detailed below, 
several laboratories kindly supplied us with these mice. All Ppt1-/- mouse studies were 
performed using mice maintained on the C57BL/6 background while Cln3-/- mice 
were bred either on a C57BL/6 background (pure Cln3-/- mice in Chapter 3), or on a 
129/Sv (control Cln3-/- mice in Chapter 6) and a mixed C57BL/6 / 129/Sv 
background (Cln3-/-/Sn-/-). All animal procedures were carried out in accordance with 
Institutional and UK Animals (Scientific Procedures) Act (1986) guidelines or under 
the guidance of the respective local university committee on animal use (if procedures 




The Ppt1 deficient mice (Ppt1-/-) used in this study were kindly supplied from 
Washington University, USA. These mice were originally generated using homologous 
recombination to produce a null mutation, which eliminates the last exon in the 
coding sequence of Ppt1 (see Table 2 in Chapter 1, (Gupta et al., 2001)), and were 
subsequently bred onto C57BL/6 mouse background. In humans mutations in the 
CLN1/PPT1 gene cause Infantile NCL, and similar disease phenotypes can be seen in 
these mice. They develop a characteristic accumulation of osmiophilic storage 
material, display marked neurodegeneration and glial up-regulation, visual, motor and 
cognitive deficits and develop spontaneous seizures, which eventually lead to 
premature death around 8 to 8.5 months (Gupta et al., 2001; Bible et al., 2004; Griffey 
et al., 2004; Griffey et al., 2005). Previously the laboratory has characterised the onset 
and progression of pathological changes in these mice (Kielar et al., 2007), and in this 
thesis the same well-defined age groups of 1, 3, 5 and 7 months of age were collected, 







The most commonly used Cln3 deficient (Cln3-/-) mouse strain was originally 
generated as a null mutant by targeted disruption of the Cln3 gene (Mitchison et al., 
1999). These authors replaced the start codon and the first six exons with a neo 
cassette and the resulting mice were ultimately backcrossed onto a C57BL/6 
background. Previous studies using Cln3Δex1-6 mice were mainly conducted on the 
129/Sv background strain, whereas this study also included besides Cln3Δex1-6 mice on 
129/Sv (in Chapter 6), for the first time also Cln3Δex1-6 mice on C57BL/6 background 
(in Chapter 3). However, recent unpublished findings suggest no overt differences 
between Cln3Δex1-6 mice on C57BL/6 or 129/Sv background (JD Cooper, personal 
communication). Therefore, mice on a mixed C57BL/6 and 129/Sv background strain 
(as used for Chapter 6, see section 2.1f below) are not likely to show overtly different 
phenotype aberrations compared to congenic mice, and based on previous 
investigations in these mice similar phenotypes will be assumed for each Cln3-/- mouse 
strain used in this study (JD Cooper, personal communication). Nevertheless, it has to 
be kept in mind that strain specific alterations may influence immune functions and 
treatment responsiveness (van der Spoel et al., 2008; Sellers et al., 2012). Congenic 
129/Sv Cln3Δex1-6 mice demonstrate early glial up-regulation in the cerebellum already 
at 1 week of age, followed by motor deficits from 2 weeks onwards leading to 
significant neuron loss at 6 months of age in the cerebellum (Kovacs et al., 2006; 
Weimer et al., 2009). Thalamocortical pathology is evident at 5 months of age with 
initial glial up-regulation leading to optic nerve pathology at 1 year of age and specific 
interneuron loss at 14 months of age in the hippocampus (Sappington et al., 2003; 
Pontikis et al., 2004). In general, Cln3Δex1-6 mice survive for up to 22 months 
(Mitchison et al., 1999; Cooper et al., 2006). To investigate the adaptive immune cell 
infiltration 6.5, 12 and 21 month old C57BL/6 Cln3-/- mice have been used in 
Chapter 3. These three age groups were chosen to examine the temporal course of 
disease manifestations representing mice at early (6.5 months), middle (12 months) 
and end stage (21 months) of disease progression. These mice have been bred and 
housed in an animal facility at University College London (UK). For the sialoadhesin 
(Sn) deficient knockout experiments in Chapter 6, 18 month old 129/Sv Cln3-/- mice 
were used as control animals which were generously supplied by our collaborators in 
Prof. R Martini’s laboratory at the Department of Neurology, Julius-Maximilians-






The Rag-1 deficient (Rag-1-/-) mice used in this study were generously supplied by our 
collaborators in Würzburg, Germany, but are also commercially available 
(http://jaxmice.jax.org/strain/002216.html). These Rag-1-/- mice were originally created 
by introducing a null mutation in the Rag-1 via gene targeting in embryonic cells 
resulting in a 1356 dp deletion in the 5’ end of the coding sequence of Rag-1 
(Mombaerts et al., 1992). Although originally crossed onto 129Sv background, this 
study used congenic C57BL/6 Rag-1-/- mice after being backcrossed with C57BL/6 
mice for six to eight generations. Besides greatly diminished lymphoid organs, Rag-1-/- 
mice show no overt brain pathology, or other pronounced phenotypes other than 
lacking mature T- and B-cells (Mombaerts et al., 1992). In non-sterile conditions, their 
life expectancy can be restricted to approximately 1 year as these mice potentially 
display Pneumocystis carinii pneumonia and thoracic or abdominal abscesses 
(Mombaerts, 1995). Furthermore, compared to the adaptive immune deficient 
alternative, the SCID-mice which spontaneously can produce low levels of functional 
T- and B-cells (a process described as “leaky”) at increased age (Bosma et al., 1983; 
Schuler et al., 1986; Bosma et al., 1988; Bosma and Carroll, 1991), so far no “leakage” 
of functioning adaptive immune cells has been detected in Rag-1-/- mice. Thus, Rag-1-/- 
mice represent a consistent and unambiguous way to investigate the impact of 




The sialoadhesin deficient (Sn-/-) mice used in this study were generously supplied by 
Prof. P Crocker at the College of Life Sciences, University of Dundee, Scotland. 
Originally the mutation was created in embryonic stem (ES) cells by inserting a 
neomycin resistance gene expression cassette, via homologous recombination, in exon 
III which encodes the second immunoglobulin-like domain of Sn. Subsequently, the 
resulting chimeric mice were backcrossed to C57BL/6 mice for at least 8 generations 
(Oetke et al., 2006). These mice have also been previously used by our collaborators in 
Würzburg (Kobsar et al., 2006; Ip et al., 2007). In comparison to Rag-1 deficient mice, 
Sn-/- mice show a much more subtle immune deficiency. Under normal specific 
pathogen-free conditions, Sn-/- mice are viable and fertile and do not reveal gross 
alterations from wildtype mice, except for alterations in T-cell subpopulations (slightly 
more CD8+ve T-cells have been found in Sn-/- mice than in wildtype mice, while 
CD4+ve T-cell populations are unaltered) and a decrease in CD45+ve (i.e. B220+ve) 
88 
 
cells in spleen and lymph nodes. Furthermore in the spleen, a small decrease in 
follicular B-cells, but an increase in marginal zone B cells could be observed, which 
reflects itself in lower immunoglobulin M (IgM) but unaltered immunoglobulin G 
(IgG) levels in the serum of Sn-/- mice (Oetke et al., 2006). As such, their relatively mild 
phenotype suggests Sn is more involved in immune system regulation than in steady-









 double knockout mice 
To ensure the required supply of mice, both NCL double knockout strains were 
simultaneously created by our collaborators, as well as in our own animal facility. As 
an initial step, homozygous Ppt1-/- mice were crossbred with Rag-1-/- or Sn-/- mice 
respectively, resulting in heterozygous offspring for both genes (F1). These 
heterozygous mice were then further interbred to generate the initial double mutants 
(F2) as future colony founders. Since this is the first time such mice have been 





 double knockout mice 
These mice were kindly supplied by our collaborators, in Würzburg, Germany. 
However, due to lack of time and resources, Sn-/- mice on C57Bl/6 background have 
been crossbred with Cln3Δex1-6 on 129/Sv background, resulting in a mixed 
background double mutant Cln3-/-/Sn-/- mouse strain. Even though, mixed 
background breeding can bias data, the experiments were nevertheless conducted as a 
proof of principle study. This is again the first time such mice have been created, thus 
no information exists yet about their survival and pathology.  
g) Wildtype mice 
All wildtype (WT) mice used in this study were animals on C57BL/6 background and 
have been originally created by breeding heterozygous Ppt1+/- mice. But the same WT 
mice are also commercially available (http://jaxmice.jax.org/strain/000664.html). Average 
survival age is around 27-28 months (Crawley, 2007). Mice have been bred and housed 
either in our own animal facility at King’s College London (UK) or at our 
collaborators facilities in Würzburg, Germany and subsequently shipped to the 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































h) Determination of genotype 
To determine and verify the genotype of mice several polymerase chain reactions 
(PCRs) were performed and reaction products run on agarose gels (see example 
Figure 5) using primers below. For each characterisation a triple primer approach has 
been used with each time a common, WT and knockout/neomycin primer 
(Distributor: Sigma, UK): 
Ppt1 genoptyping: Common forward (PG59): GTACATAGTTCATGCTCAGCC, 
reverse WT (PG60): CTGCTAGGTACCTCTAGAGGG and reverse Ppt1 allele 
primer (S125): GATTGGGAAGACAATAGCAGGCATGC, resulting in a 448 bp 
product for the WT allele and a 420 bp product for the mutated Ppt1 allele. 
Cln3 genotyping: Common (Ex1f): TGTATAGCAGACAGCGGAACC, reverse WT 
(M6R): CACTCCGACTATCCAACCGA and reverse Cln3 allele primer (NIHNeo3): 
TCGCCTTCTTGACGAGTTCT, resulting in a 380 bp product of WT allele and a 
580-bp product for the mutated Cln3 allele.  
Rag-1 genotyping: Common (oIMR1746): CCGGACAAGTTTTTCATCGT, forward 
WT (oIMR1746): GAGGTTCCGCTACGACTCTG reverse Rag-1 allele primer: 
TGGATGTGGAATGTGTGCGAG, resulting in a 474-bp product for WT allele and 
a 530-bp product for the mutated Rag-1 allele. 
Sn genotyping: Common forward (SND1F3): CACCACGGTCACTGTGACAA; 
reverse WT (SND2R2): GGCCATATGTAGGGTCGTCT and reverse Sn allele 
primer (Neo): CGTTGGCTACCCGTGATATTGC. This resulted in a 468-bp 
product for WT allele and a 1729-bp product for the mutated Sn allele.  
2.2 Processing of brain tissue 
All mice were anesthetized with “Euthatal” (200mg sodium pentobarbital/ml, Merial 
Animal Health Ltd, UK) and transcardially perfused with Phosphate buffered Saline 
(PBS: 50 mM Phosphate buffered Saline, with MgCl2 and CaCl2 , pH 7.4, D8662, 
Sigma Gillingham, Dorset, UK) and 4% paraformaldehyde in 0.1 M Sodium 
Phosphate buffer, pH = 7.4 (PFA). All brains were carefully dissected at each required 
time point and then immersion fixed for at least 24 hours in 4% PFA and 
subsequently, cryoprotected in a solution of 30% sucrose in Tris buffered saline (TBS: 









weighed after separating any remaining spinal cord from the brainstem at a consistent 
level (along the rostral end of the cerebellum). Next, the cerebellum was cut off 
coronally and the hemispheres separated with a clean, straight cut using a razorblade 
(see Figure 6). Between each step the weights of the brain parts were recorded. This 
thesis concentrates upon well-defined pathological changes that occur within the 





Figure 6. Schematic sagittal section of the mouse brain. Areas indicated according to 
schematic distinction in Paxinos and Franklin atlas. Ventricles are shown in black. The position of 
skull marks (bregma, lambda and interaural) are indicated. Red line indicates coronal separation of 
cerebellum. Only mid- and forebrain have been analysed and looked at in this study, including the 
regions such as the thalamus, hippocampus and cortex where the most prominent pathology 
occurs in Ppt1 and Cln3 deficient mice (Bible et al., 2004; Pontikis et al., 2004; Pontikis et al., 2005; 
Kielar et al., 2007). Adapted from (Paxinos and Franklin, 2001).   
Figure 5. Genotyping example: Rag-1-/- and Ppt1-/- mice. Via polymerase chain reaction 
(PCR) different genotypes of mice can be identified. Rag-1 PCR and Ppt1 PCR products have 
been run on the same gel. (A) Due to their different sized reaction products, the wildtype (WT) 
Rag-1 allele (474 bp) shows up as a lower band than the knockout (KO) Rag-1 allele (530 bp). (B) 
In contrast, in the Ppt1 PCR reaction the wildtype Ppt1 allele (448 bp) is seen with a higher band 
than the knockout allele (420bp). Heterozygous individuals can be readily identified as bearing 
both wild type and mutant alleles. L = control ladder, Het = heterozygous individual, WT = 
wildtype, F0, F1 = Breeding generations. 
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Subsequently, all brains were cut coronally into 40µm thick sections on a Leitz 1321 
freezing microtome (Microm HM 430/Carl Zeiss Ltd, Cambrigde, UK) (Bible et al., 
2004; Pontikis et al., 2004; Kielar et al., 2007) and stored in 96 well plates containing an 
anti-freeze cryoprotectant solution (TBS/30 % ethylene glycol/15% sucrose/0.05 % 
sodium azide) at 4 ºC (see Figure 7).  
2.3 Immunohistochemistry 
To determine the degree of astrocytosis and microglial activation, 1 in 6 series of 
sections were stained for glial fibrillary associated protein (GFAP, 1:4,000, Dako, Ely, 
Cambridgeshire, UK) or the microglial marker CD68 (1:2,000, Serotec, Oxford, UK). 
In addition, immune cell and lymphocyte infiltration was assessed by staining for 
CD45 (1:250 Serotec), CD169 (1:100, Serotec), CD8 (1:100, Serotec) and CD4 (1:35, 
Serotec) (see Table 5). Immunohistochemical staining for each antigen was generally 
conducted in the same manner (see Figure 8), except for slightly modified protocols 
for CD8 and CD4 (see paragraph below).  
Sections were incubated in 1 % H2O2 in TBS for 30 minutes to quench endogenous 
peroxidase activity, subsequently rinsed in TBS, and then blocked with 15% normal 
serum in TBS-T (TBS containing 0.3% Triton X-100) for 45 minutes. Next, sections  
Figure 7. Schematic illustration how mouse sections are produced. After freezing the brains 
with dry ice, 40 µm sections are cut on a microtome and collected in 96 well plates containing an 
anti-freeze cryoprotectant solution (TBS/30 % ethylene glycol/15% sucrose/0.05 % sodium 
azide), in which they can be stored at 4 ºC until further processing. 
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Table 5. Overview of antibodies used for immunohistochemistry. (Conc = concentration, rab = 
rabbit, GFAP = glial fibrillary acidic protein, CD = cluster differentiation antigen)  
Marker for 1
st
 Antibody Company & Product code Conc 2
nd
 Antibody (for DAB) 
Astrocytes rab α GFAP Dako Z0334 1:4,000 swine α rab, 1:1,000, Dako 
Microglia rat α CD68 Serotec MCA1957 1:2,000 rab α rat, 1:1,000, Vector 
Cytotoxic T-cells rat α CD8 Serotec MCA609G 1:100 rab α rat, 1:1,000, Vector 
T-helper cells rat α CD4 Serotec MCA1767 1:35 goat α rat, 1:1,000, Vector 
Leukocytes rat α CD45 Serotec MCA1031GA 1:250 rab α rat, 1:1,000, Vector 
Sialoadhesin rat α CD169 Serotec MCA884 1:100 rab α rat, 1:1,000, Vector 
 
 
were incubated overnight at 4 ºC with the appropriate concentration of primary 
antibody diluted in TBS-T and 10 % normal serum. On the following day, sections 
were rinsed in TBS and incubated in TBS-T and 10% normal serum for 2 hours at 
room temperature containing the appropriate concentration of biotinylated secondary 
antisera (1:1,000, Vector Laboratories, Peterborough, UK) was added. After washing 
anew, sections were incubated for 2 hours in TBS with avidin-biotin peroxidase 
complex (Vestastain Elite ABC kit, Vector Laboratories), prepared at least 30 minutes 
before use. With a subsequent wash in TBS, immunoreactivity was visualised by 
incubation in 0,05% 3,3 – diaminobenzidine tetrahydrochloride HCl (DAB, Sigma) 
and 0.001% H2O2 in TBS for a precise predetermined time (up to 15 minutes, 
depending on antigen) that represents saturation for this reaction. Staining was 
stopped by adding ice-cold TBS and rinsed several times, before sections were 
mounted onto microscope slides, air-dried overnight, rinsed in 100% industrial 
methylated spirits (I.M.S.) and cleared in xylene for at least 30 minutes, before being 
coverslipped with DPX [p-xylene-bis(pyridinium bromine)] (VWR, Lutterworth, 
Leicestershire, UK).  
To ensure reproducibility, each antigen was developed for exactly the same time and 
for each antigen mice from each age group were stained simultaneously as one batch 
rather than separately. 
For the lymphocytic antigens CD8 and CD4 two amendments to the above protocol 
were made due to an initial appearance of variable amounts of background staining 
(punctate dots of immunoreactive deposits that were most pronounced within the 
white matter, of both mutant and control wildtype mice). Firstly, a higher 
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concentration of normal serum (30%) blocking solution was applied and secondly, an 
additional 2 hours blocking step in 30% normal serum in TBS-T was introduced 
before the application of the secondary antibody. These changes to the protocol 
ensured an unambiguous quantification of the CD4+ve and CD8+ve immune 
reactions, with a minimum of background staining.  
2.4 Photomicroscopy 
To document and provide an overview of the resulting immunohistochemical staining 
high-resolution, representative photomicrographs were taken with a x5, x10, x20, x40 
or x63 objective on a Leica DMRB microscope (Leica Mikroskopie & Systeme 
GmbH, Wetzlar) with a Zeiss AxioCam HRc Rev 2 digital camera using the software 
AxioVision (version 4.7.2). 
2.5 Nissl staining 
To visualise neuronal cytoarchitechture and permit stereological analyses, a 1 in 6 
series of 40µm sections from each brain was mounted onto gelatin-chrome alum 
coated Superfrost microscope slides (VWR) and air-dried overnight. All sections were 
then incubated for at least 45 min at 60ºC in 0.05% cresyl fast violet and 0.05% acetic 
acid (VWR) (see Figure 9). 
Figure 8. Schematic illustration of immunohistochemical procedure. After the initial 
quenching step (1% H2O2 in TBS) and the first block (15% normal serum), the first antibody is 
applied and the sections incubated overnight. Followed by enhancing the signal via application of 
secondary antibodies and avidin-biotin complex molecules, the procedure is finalised with a DAB 
development. Between each step all sections are washed three times with TBS and eventually 
mounted onto slides. 
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Subsequently, they were rinsed in distilled water and differentiated through a series of 
graded alcohols (70%, 80%, 90%, 95%, 100% I.M.S.) before clearing in 50:50 
Xylene:I.M.S., followed by clearing in 100% Xylene and then finally coverslipped with 
DPX (VWR).  
2.6 Stereology 
To quantify differences between morphological and pathological phenotypes in the 
brains of the mice generated in this study, we used design-based stereology which 
enables us to estimate regional volumes, cell numbers, mean cellular volumes and 
length/thickness of biological structures (Schmitz and Hof, 2005). These methods are 
defined as design-based as the sampling scheme is ‘designed’ a priori, ensuring that the 
samples/probes become independent of size, shape spatial orientation and spatial 
distribution (West and Thomas Sutula, 2002). By considering the three-dimensional 
features of sections and spatial independence, systemic errors in calculations can be 
eliminated and data collection is more reliable than more biased qualitative sampling 
methods (Gundersen, 1988; West, 1993). As such, the design-based stereology 
methods enable unbiased comparisons between diseased, modified/treated or healthy 
brain phenotypes without prior assumptions about shape and size of brain structures 
as a result of disease.  
While all stereological estimates are independent of specific brain structures, the 
accuracy of this estimation method does depend on reliable identification of structures 
being measured or counted. Therefore, the cytoarchitecture of each section was 
visualised by Nissl staining which enables identification of discrete boundaries 
between white and grey matter and different nuclei in each section. Each measurement 
was undertaken between clearly defined landmarks of rostral-caudal position. To 
assess the boundaries of each region/area of interest (ROI) the neuroanatomical 
landmarks described in ‘The mouse brain in stereotactic co-coordinates’ (Paxinos and Franklin, 
2001) were used. Furthermore, the delineation of different functional regions of the 
cortex was also defined with (Paxinos and Franklin, 2001). 
Figure 9. Representative Nissl sections. Coronal sections through the fore- and midbrain were 
cut at 40 µm and subsequently stained with the Nissl dye cresyl fast violet. 
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Within this study, to characterise the impact of genetically removing immune-related 
cells, the entire brain volume, cortical volume, the thickness of the primary somatosensory 
barrel field (S1BF) of the cortex as well as neuronal counts of the ventral posteromedial and 
posterolateral (VPM/VPL) nuclei of the thalamus have been measured (see Figure 10). 
These parameters were chosen because their onset and progression have already been 
well-defined in Ppt1 and Cln3 deficient mice (Bible et al., 2004; Pontikis et al., 2004; 
Pontikis et al., 2005; Kielar et al., 2007), therefore providing neuropathological 
landmarks for assessing the impact of removing different subclasses of immune cells.   
All stereological estimates were obtained using StereoInvestigator software 
(Microbrightfield Inc, Williston, VT) which enables semi-automated data collection. 
All measurements were performed on a Zeiss Axioskop 2 MOT (Zeiss, Germany) 
linked to a DAGE-MTI CCD-100 camera (Dage-MTI, Michigan City, IA) and were 
conducted blind to genotype and consistently across all diseased, double mutant and 
control brains. 
a) Volume measurements 
To estimate regional and total volumes without bias, volumes were calculated 
according to the Cavalieri principle (Cavalieri, 1665). Cavalieri realised that a series of 
sections through an object can be used to estimate its total volume. Conditions for a 
correct estimation are: The sections must be separated by a regular interval of a known 
distance, with the first section lying at a uniform random location within the section 
Figure 10. Schematic illustration of the somatosensory thalamocortical system. Boundaries 
of the primary somatosensory barrel field (S1BF) (blue) and the ventral posteromedial and posterolateral 
(VPM/VPL) nuclei of the thalamus (red) are highlighted in schematic illustrations of coronal 
sections of a mouse brain. A representative sub-sample of sections is depicted in rostrocaudal 
order (from top left to bottom right). Adapted from (Paxinos and Franklin, 2001). 
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interval. In this study all sections were cut with a thickness of 40µm and analysed as 
either 1 in 6, or 1 in 12 series of sections (depending on the area of interest). The 
volume of the object can be estimated by multiplying the total area (sum of all selected 
areas on each section) of the region of interest with the distance/interval between 
each section (Lucocq, 2007). By placing a grid with suitable point probes on top of 
each section and counting all points falling upon the region of interest, a precise 
estimate of volume can be calculated (see Figure 11 for formula). Due to the inability 
to separate the top from bottom surfaces of a section and thus by measuring only the 
visible cross-sectional area of the object, volume estimations are vulnerable to over-
projection (systematic overestimation of volume fraction). Therefore, all calculated 
volume estimations were corrected for over-projection (Gundersen et al., 1999) and 
finally, the accuracy of the process assessed by coefficient errors (CE)/variance 
estimates (Cruz-Orive, 1999; Gundersen et al., 1999). As long as there is sufficient 
point density - irrespective of the shape of the object - to estimate the area on the 
section, the Cavalieri method is a powerful tool which is applicable to many scientific 
questions and has therefore been regularly used in the past (Bahmer et al., 1996; 
Roberts et al., 1997; Bible et al., 2004; Pontikis et al., 2004; Bible et al., 2005; Pontikis et 
al., 2005; Kielar et al., 2007; Sapara et al., 2007; Trigylidas et al., 2008; Acer et al., 2011).  
In this study, total brain volume, as well as regional volume of the cortex, were 
estimated in μm3 with an appropriately spaced sampling grid (250μm for both: total 
brain volume and cortex) superimposed over Nissl stained sections. The size of the 
sampling grid for each region was determined so that the coefficient of error (CE) was 
always less than 0.1. As mentioned above, the number of points was counted using an 
x5 objective on a Zeiss Axioskop, using StereoInvestigator software. 
b) Cortical thickness measurements  
To determine whether differences in cortical atrophy were apparent between different 
genotypes and mouse populations, regional thickness measurements were performed 
on Nissl stained sections. The cortical primary somatosensory barrel field (S1BF) sub-region 
as defined in (Paxinos and Franklin, 2001) was measured in three consecutive sections 
by tracing 10 perpendicular, evenly spaced lines from the border of the white matter 
(corpus callosum) to the pial surface of the cortex. All measurements were undertaken 
blind to genotype and age. The results were expressed in µm as average length of all 
lines, respective of thickness of each cortical region as previously described (Bible et 




c) Neuronal cell counts 
Since it is often unfeasible to count all cells of a region of interest in histological tissue, 
the optical fractionator technique (West et al., 1991) has been developed to count only 
a subsample of particles/objects and subsequently estimate the total number (see 
Figure 12). This method combines the two major developments in stereology: the 
optical dissector, a method to count neuronal nuclei in a three dimensional context 
and the fractionator, a systematic uniform sampling scheme (West, 1993). The optical 
dissector incorporates optical section planes by moving the focal plane up or down 
and estimates neuron numbers free of assumptions about their size or shape and is 
unaffected by lost caps (tissue alterations due to the histological sectioning process) 
Figure 11. Diagrammatic representation of volume estimations using the Cavalieri 
method. (A) The Cavalieri method is applied onto any sectioned object/organelle/brain. Sections 
(of the brain) that are consistently in-between spaced (k) are randomly selected. (B) Investigator 
draws around the boundary of the region of interest in each section if it is present. (C) By 
superimposing a sampling grid with a known spacing distance (d1 and d2) onto each section, every 
cross/point falling into the region of interest gets counted (P). Strict counting rules are applied: 
Points are only counted if the intersection of the sampling crosses falls within the region (arrow). 
By multiplying the sum of all points counted within the region of interest on each section with the 
distance of points on the lattice results in the cross-sectional area per section (a). Taking all cross-
sectional areas together, the total area (A) of the region of interest is then described with   
∑       . Thus, the overall volume can be estimated by multiplying the total cross-sectional 
area with the constant distance between the sections:        Adapted from (Lucocq, 2007). 
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and over-projection (see above section 2.6a). This is important, because in diseased 
brains neurons often change size and could therefore be counted differently to healthy 
control neurons. The fractionator (Gundersen, 1986) overcomes this problem by 
applying systematic sampling to estimate the total number of neurons unaffected by 
shrinkage before, during, and after processing of the tissue (Schmitz and Hof, 2005).  
To conduct unbiased design-based cell counts, the investigator first of all traces lines 
around, and thus, defines the boundaries of the brain region of interest. Secondly, a 
grid is superimposed and random dissector “counting frames” are applied onto the 
section according to the sampling grid size. Only cells within the frame are counted. 
Particular counting rules apply when only cells within - or cells touching - the green 
acceptance line are counted, while cells touching the red exclusion line are not 
included (see Figure 12). The overall numbers can be calculated/estimated, by taking 
into account the number of analysed sections vs. total number of sections (‘section 
sampling fraction’ = ssf), the area of the unbiased counting frames vs. the sampling 
area in each section (‘area sampling fraction’ = asf) and the unbiased height of the 
counting frame/space vs. the height/mean thickness of the whole section after 
histological processing (‘height sampling fraction’ = hsf) (Schmitz and Hof, 2005). 
Including the total number of cells counted (Q) this translates into following optical 
fractionator formula (West et al., 1991; Howard and Reed, 1998):  
 ̂    
 
   
 
 
   
 
 
   
 
In this study all of these calculations were performed by StereoInvestigator 
(Microbrightfield Inc., Williston, VT) and the total estimate of neuronal numbers of all 
replicates of each genotype and age were presented as mean number of neurons.   
To estimate the neuronal number in the ventral posteromedial and posterolateral 
(VPM/VPL) nuclei of the thalamus, the technique of the optical fractionator 
(Gundersen, 1986; West et al., 1991) was used on Nissl stained sections as previously 
described (Bible et al., 2004; Pontikis et al., 2005; Kielar et al., 2007). Nissl stains like 
cresyl violet stain all cells in the brain (neurons, astrocytes, microglia, oligodendrocytes 
etc.), and neurons have to be distinguished according to their cell morphology and 
staining characteristics (see Figure 13). To ensure the best possible visualisation of 
structures, all measurements were performed using an x100 oil-objective with a high 
numerical aperture of 1.4. Only healthy neurons with clearly identifiable nucleus, large 
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cell body and clear (and light coloured) Nissl staining within their cytoplasm were 
counted. In contrast, astrocytes and microglia which are also visible in Nissl stained 
sections were not counted and could be distinguished by their small soma and darkly 
stained and granular cytoplasmic Nissl appearance. Obviously, this method is subject 
to the morphological identification skills of the investigator. Therefore, to minimise 
the mis-identification, strict criteria were used and only cells displaying all required 
characteristics and criteria were counted as neurons. Despite this potential limitation 
of Nissl staining, many researchers choose it in preference to immunohistochemical 
Figure 12. Schematic illustration of counting procedure using the optical fractionator 
calculation method. To estimate the total number of neurons in the regionn of interest, three 
parameters have to be considered: ssf, asf and hsf. (A) “Section sampling fraction”: Every nth section 
containing the region of interest is selected at an equal interval after a random start to guarantee 
equal probabilities of being sampled. Thus, the selected sections constitute a known fraction of 
the sections in the series (ssf). (B) “Area sampling fraction”: Boundaries of region of interest are 
traced by an investigator and a grid superimposed over the sections. Objects/neurons are counted 
within a known fraction of the section area (asf). (C) This fraction corresponds to the combined 
area of each counting frame (a(frame)) (black boxes in (B) and gray boxes in (C)) and the profile 
area of the region of interest (a(grid)) (calculated from the grid size: a(grid) =          ), in 
mathematical terms:                    ⁄ . (D) Neurons are counted by focusing up and 
down the section within the height (h) of each counting frame (indicated as black box) which in 
relation to the section thickness (t) after histological processing results in “height sampling fraction” 
(hsf). After counting all neurons (Q) within this known (sub)fraction of the whole region of 
interest, the total number of neurons (N) can be calculated by applying the  following formula:  
 ̂         ⁄      ⁄      ⁄ . Adapted from (West, 2001; Schmitz and Hof, 2005). 
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methods (McCormack et al., 2002; Loos et al., 2003; Dawodu and Thom, 2005; Payes et 
al., 2008). This is because all such immostaining methods (e.g. the commonly used 
neuron marker NeuN) depend on visualising proteins that can be down-regulated 
below the threshold of immunohistochemical detection, leading to not counting 
unstained cells which are still present in the section. This is a risk in all pathological 
studies, since dying cells change their expression of many proteins, before they actually 
die (Andersson et al., 2009; Kielar et al., 2009). Therefore, in this study exclusively Nissl 
stained sections have been used to quantify neuronal numbers.  
The neurons in the thalamic VPM/VPL nuclei have been counted in a 1 in 6 series of 
sections using a 175 x 175 µm grid and 74 x 42 µm counting frame and therefore 
ensuring a CE value of less than 0.1 to indicate sufficient sampling efficiency.  
d) Lymphocyte counts 
To characterise the extent and distribution of lymphocyte infiltration in Ppt1-/-, Cln3-/- 
and wildtype brains, parallel 1 in 6 series of sections through each brain were stained 
for CD4 and CD8 following the immunohistochemical procedure described in 
section 2.3 and mounted onto slides. Due to the sparse and arbitrary distribution of 
positively stained cells, stereological methods of quantification would prove 
inefficient. Instead, to determine the total number of lymphocytes in each brain, every 
mounted section (every sixth section through the brain) was manually counted by 
systematically scanning the section using a x20 objective on a Leica DMRB 
Figure 13. Counting frames explaining counting criteria for neurons. (A) Schematic and (B) 
real image of Nissl stained cells with superimposed counting frame. The investigator counts 
neurons applying strict criteria while focusing up and down the whole thickness of the section: 1) 
Morphological features: Only clearly distinguishable neurons (large cell body and clear nucleus 
and homogeneous Nissl staining within cytoplasm) are counted, while small cells (glia cells) with 
granular Nissl staining are neglected (marked blue x). 2) Only cells within counting frame (neuron 
no. 2 in (A) and yellow * in (B)) or cells touching the inclusion lines (dashed line in (A) and green 
lines in (B)) are counted, while cells hitting exclusion lines (solid lines in (A) and red lines in (B)) 
are not counted.  Adapted from (Schmitz and Hof, 2005). 
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microscope (Leica Mikroskopie & Systeme GmbH, Wetzlar). During all counts the 
investigator was blinded for age and genotype of the brains. Subsequently, the counts 
were multiplied by 6 to obtain the total number of lymphocytes per brain and the 
average number of lymphocytes per age and genotype calculated. Additionally, to 
provide more detailed information about the distribution of specific lymphocyte 
classes within the brain, each brain was divided rostral-caudally into 5 different brain 
regions (see Figure 14 and Table 6). Last but not least, the lymphocyte counts were 
combined with brain volume measurements (of the total brain as well as of each of the 
5 defined brain regions) using the Cavalieri method (see section 2.6a) and the cell 
density per brain volume (lymphocytes/mm3) calculated. In this fashion, the total 
number of lymphocytes and a complete distribution map of CD4+ve and CD8+ve 
lymphocyte infiltration throughout the whole brain were obtained. 
Table 6. Rostral-caudal breakdown of the mouse brain into five regions according to 
morphological landmarks. The cerebellum is not listed as it has been excluded from all measurements 
and analyses. 
Brain region Defining boundaries and content 
I Olfactoy bulb 
II Forebrain: Beginning of cortex until appearance of hippocampus 
III Forebrain with hippocampal structures 
IV Midbrain with superior colliculus 
V Midbrain with pons 
2.7 Thresholding image analysis 
To quantify and compare the relative levels of immune reactivity of GFAP+ve and 
CD68+ve staining between each genotype and age groups, we performed thresholding 
image analyses as described in earlier studies (Bible et al., 2004; Pontikis et al., 2004; 
Pontikis et al., 2005; Kielar et al., 2007). Blinded for genotype and treatment, 40 non- 
overlapping pictures were captured in 4 consecutive sections throughout the thalamus 
(VPM/VPL nuclei) and the cortical S1BF sub-region. All images were taken with a 
live video camera (JVC, 3CCD, KY-F55B), mounted onto a Zeiss Axioplan 
microscope using an x40 objective. Lamp intensity, video camera setup and 
microscope calibration have been kept constant during the entire analysis. 
Subsequently, using the Image-Pro Plus 4.0 (Media Cybernetics) image analysis software, 
an appropriate threshold was chosen to distinguish between specific immunoreactivity 
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for each antigen and non-specific background. Once a suitable threshold has been 
defined, it was kept constant for all images analysed. Macros were setup and recorded 
to transfer the analysed data to an Excel spread sheet for further statistical analysis. 
The results of each region and antigen were presented as mean percentage area of 
immunoreactivity per (measured) field (± SEM).  
2.8 Statistical analysis 
To test for potential differences in quantitative data between genotypes and age 
groups two-way ANOVA’s (with age and genotype as independent variables) or one-
way ANOVA’s (if only one age group was analysed) (Graph Pad Prism 4.03, Graph Pad 
software, Inc.) were conducted. In all cases, Bonferroni post hoc tests were performed 
and statistical significance considered at p≤0.05. The mean coefficient of error (CE) 
for all opticial fractionator and Cavalieri estimates were calculated according to the 
method of Gundersen and Jensen (Gundersen and Jensen, 1987) and was less than 0.1 
in all samples (except for the late staged Ppt1-/- brains where the CE reached maximally 
1.5-1.7 due to extreme neuron loss). 
Figure 14. Illustration of regional breakdown of the mouse brain. Top: Representative Nissl 
stained sections, with brain regions of interest labelled and defining landmarks highlighted in red. 
Brain regions: I = Olfactory bulb, II = Forebrain from start of cortex (red) until hippocampus 
appears, III = Hippocampal (red) forebrain, IV = Midbrain with superior colliculus (red), V = 
Midbrain with pons (red). Bottom: Schematic lateral view of mouse brain with most important 
brain parts explained. The cerebellum is not considered as it has been excluded from all 












Chapter 3  




An inflammatory component to pathogenesis is not uncommon in neurodegenerative 
disorders (see Chapter 1), and has been described in Parkinson disease (Brochard et 
al., 2009; Stone et al., 2009), Alzheimer disease (McGeer and McGeer, 2003; Heneka 
and O'Banion, 2007), multiple sclerosis (Stadelmann et al., 2011), amyotrophic lateral 
sclerosis (ALS) (Sta et al., 2011) and other lysosomal storage disorders (LSDs) 
(Castaneda et al., 2008) like Gaucher disease (Shoenfeld et al., 1995; Mizukami et al., 
2002), GM1/2 gangliosidosis (Jeyakumar et al., 2003), Krabbe disease (Wu et al., 2000; 
Suzuki, 2003) and  the mucopolysaccharidoses (MPSs) (Ohmi et al., 2003; Ausseil et al., 
2008).  
Similarly, immune reactions have also been described in the Infantile and Juvenile 
form of NCL (Pontikis et al., 2004; Pontikis et al., 2005; Kielar et al., 2007; Lim et al., 
2007b; Macauley et al., 2009; Weimer et al., 2009). However, the main focus of this 
research has so far been on the increased innate immune responses in Ppt1 and Cln3 
deficient mice (Pontikis et al., 2004; Kielar et al., 2007; Macauley et al., 2009; Weimer et 
al., 2009), with only recent appreciation of adaptive immune responses in these mice 
(Lim et al., 2007b; Macauley et al., 2011; Seehafer et al., 2011). However, no extensive 
characterisation of adaptive immune cell responses in the brain of INCL and JNCL 
mice has been provided so far. To obtain this, a full series (n=5) of Ppt1 and Cln3 
deficient and age-matched control brains at different stages of disease progression 
(Ppt1-/-: 1, 3, 5 and 7 months of age/Cln3-/-: 6.5, 12 and 21 months of age) were 
immunohistochemically stained for the general leukocyte marker (CD45) and the 
adaptive immune cell markers: cytotoxic T-cell (CD8) and T-helper cell (CD4).  
In addition to surveying the distribution of cells immunoreactive for each marker and 
taking representative pictures, detailed cell counts of positively stained lymphocytes 
throughout the whole brain were complemented with total brain and regional volume 
measurements. Combining these measures allowed the calculation of relative 
lymphocyte density per region at each time point. Furthermore, by dividing the brain 
into defined rostrocaudal levels (see Figure 14 and Table 6 in Chapter 2 for detail), 
we have obtained a detailed description of lymphocyte distribution throughout the 
brain and how it changes over time. This is the first time, the adaptive immune 





3.1 Leukocytes in the CNS of Infantile and Juvenile NCL mice 
To obtain a general overview of immune reactions occurring in NCL and control 
brains, a series of sections from each brain were stained for CD45, the ‘general leukocyte 
marker’. The CD45 molecule, also known as ‘leukocyte common antigen’, describes the 
enzyme ‘protein tyrosine phosphatase receptor type C’ (PTPRC) and is a 
transmembrane protein found on all differentiated hematopoeic cells, except for 
erythrocytes (Thomas, 1989). As a member of the protein tyrosine phosophatase 
(PTP) family its function combines regulation of various cellular processes concerning 
cell cycle, growth and differentiation (Cool et al., 1990; Denhertog et al., 1993; Denu 
and Dixon, 1998; Paul and Lombroso, 2003). Additionally, it is an essential regulator 
in antigen presenting function of activated T- and B-cells (Brown et al., 1994; 
Alexander, 2000; Huntington and Tarlinton, 2004), as well as being found on 
monocytes that serve as progenitors for macrophages and/or microglia (Patterson and 
Caldwell, 1992; Seta and Kuwana, 2007). Since various states of activation and 
morphologies of microglia and macrophages can be observed in the brain, and it not 
being possible to unambiguously distinguish between these cell types on the basis of a 
single marker, we will refer to ‘microglia’ as stained cells with elongated and/or 
branched processes in contrast to ‘macrophages’ with enlarged round, amoeboid-like 
cell bodies with no processes (see Figure 15). However, because microglia transform 
into brain macrophages during disease progression, several intermediate states of 
activation are often present in the brain, in which case cells will be described as the 
most morphologically appropriate cell type. 
Figure 15. Distinction between microglial and macrophage morphology. 
Immunohistochemical staining for the microglial marker CD68, the macrophage marker CD169 and the 
leukocyte marker CD45 revealed both microglia and macrophage-like cells. Since these cell types cannot be 
unambiguously distinguished using these markers and because microglia transform into brain macrophages 
during disease progression, we will refer to ‘microglia’ as cells with distinct processes (top row) and 
‘macrophages’ as cells with round cell bodies lacking processes (bottom row). Scale bar = 10 μm. 
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a) CD45 positive leukocytes in Ppt1
-/- 
mice 
Immunohistochemical staining for CD45 of the Ppt1-/- mouse model of INCL and 
age-matched wildtype mice at all four ages (1, 3, 5 and 7 months) revealed distinct 
CD45 immunoreactivity in the brain parenchyma of Ppt1-/- mice from 3 months 
onwards (see representative pictures of the thalamus in Figure 16 and Table 7 for a 
detailed summary of the distribution of CD45 immunoreactivity in Ppt1-/- mice over 
time). Almost no CD45+ve cells were detectable in either wildtype (at any age) or in 1 
month old mutant mice. In wildtype mice CD45 stained cells could be seen only 
sporadically in the brain parenchyma, whereas most CD45+ve cells were present in 
the meninges, choroid plexus or at the edges of the ventricles (data not shown). 
Judged by their morphology, these CD45+ve cells in wildtype mice resembled either 
T-cells with round and small cell bodies, lacking any cell processes, or macrophages 
with elongated, crescent-shaped or amoeboid cell bodies. Generally comparing the 
staining of these two cell types, T-cells were often more intensely stained and clearer 
to detect than macrophages in wildtype and Ppt1-/- mice, which potentially could be 
explained by different levels of CD45 expression at the plasma membrane of each cell 
type.   
i) 1 month old Ppt1
-/-
 mice 
In 1 month old mice, many CD45+ve cells could be detected within the olfactory 
bulb, and morphologically resembled T cells with round, small cell bodies and no 
processes (data not shown). In two of the five mutant mice at this age point there was 
a hint of microglial activation in the thalamus with faintly stained CD45 
immunoreactive cells present in this brain region. As such, it could be speculated that 
the first signs of immune cell activation already occur at this time point, with T-cell 
like cells being the first detectable CD45+ve cells in the brain parenchyma (olfactory 
bulb).  
ii) 3 month old Ppt1
-/-
 mice 
Between 1 and 3 months microglial and/or macrophage activation appears to begin in  
Ppt1-/- mice within the thalamus, showing first clear signs of immunological up-
regulation at 3 months of age, as previously described (Kielar et al., 2007). But in spite 
of intense CD45 staining, no single cell type could be identified in this region, with 
numerous different cellular morphologies evident (see Figure 16). These cells were 




T-cells were present. Interestingly, morphologically distinct cell types were present 
within different thalamic regions. Whereas weaker CD45+ve macrophage-like cells 
were mainly located in the ventral posteromedial and posterolateral nuclei (VPM/VPL), 
darkly stained cells with brain macrophage-like morphology could be found in the 
ventrolateral thalamic nucleus (VL) and the posterior thalamic nuclei (PO), as defined by 
landmarks described in (Paxinos and Franklin, 2001). Additionally, the thalamic medial 
geniculate nuclei (MG) and the dorsal lateral geniculate nucleus (LGNd) showed intensely 
stained, brain macrophage-like CD45+ve cells scattered with sporadic T-cells.  
Figure 16. Progressive immune cell activation in Ppt1-/- mice. (A) Immunohistochemical 
staining for the general leukocyte marker CD45 in the thalamus of 1, 3, 5 and 7 month old Ppt1-/- 
and wildtype (WT) mice revealed widespread immune cell and lymphocyte activation within the 
ventral posterior nucleus (VPM/VPL) (---) in Ppt1-/- mice. From 3 months onwards, localised 
immune cell activation could be observed in the VPM/VPL nuclei of Ppt1-/- mice, which spread 
to involve the whole thalamus with increased age. In contrast, almost no CD45 immunoreactivity 
was seen at any age in the thalamus of WT brains. Scale bar = 200 μm. (B) Higher magnification 
pictures of CD45+ve cells in the thalamus of 1, 3, 5 and 7 month old Ppt1-/- mice and WT mice 
revealed various immune cells in mutant mice from 3 months onwards. Judged on their 
morphology, CD45+ve cells resembled macrophages and microglia, as well as lymphocytes. 
Whereas at 3 months of age microglia with elongated cell processes stained for CD45, with 
increased age and disease progression, more brain-macrophage like cells with round cell bodies 
and short (or no) processes displayed CD45 immunoreactivity (particularly at 7 months of age). 
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In addition to the thalamus, other brain regions also showed the first signs of 
microglial activation at 3 months of age: in the cortex this activation was mainly in 
layer VI of several cortical regions immediately adjacent to the corpus callosum, but was 
most pronounced in the somatosensory cortex (mostly in S1BF and more scarcely in S2) 
and the retrosplenial granular cortex (RSG) - both of which connect to the thalamic nuclei. 
Whereas this microglial activation in the cortex appeared rather weak, other structures 
contained more intensely stained and presumably activated cells at this age. From 
rostral to caudal these included the caudate putamen (striatum) and lateral globus pallidus 
(LGP) which connect to the substantia nigra – all parts of the basal ganglia; ventral nucleus 
of lemniscus (VLL) which connect to the secondary sensory cortex, subiculum as the last 
part of the hippocampus, external cortex of the inferior Colliculus (ECIC) which receives 
projections from the somatosensory cortex and the thalamic medial geniculate nuclei 
(MG). Only in its rostral, but not in the caudal, parts did the piriform cortex show signs 
of microglial activation. Notably, no trace of immune cell up-regulation (in terms of 
CD45 immunoreactivity) could be seen in the hippocampus at 3 months, except for 
faintly stained microglia in the dentate gyrus (DG) and subiculum. In the most rostral part 
of the brain, the olfactory bulb was infiltrated by many CD45+ve T-cells (on the basis 
of their morphology) and also showed weakly stained microglia at this time point (data 
not shown).  
Based on these morphological data a generalised weak immunological activation 
appears to occur at this 3 month time point, but this immune up-regulation always 
seemed to be confined to distinct regions, as seen for example in the rostral part of 
the cortex where microglial activation was observed, but not in the underlying anterior 
olfactory nucleus (Paxinos and Franklin, 2001).  
iii)  5 month old Ppt1
-/- 
mice 
With increased age and disease progression, immune cell activation spread to other 
brain regions, with CD45 positive cells more widely present within the CNS. At 5 
months of age, the cortex and most parts of the brain contained activated microglia 
and were also infiltrated by CD45+ve immune cells. In the olfactory bulb, besides 
morphologically identified T-cells, intensely stained activated microglia could be 
detected at 5 months of age. Furthermore, mostly microglia, macrophages, and 
occasionally T-cells, were positively stained for CD45 in the same nuclei of the 
thalamus (VPM/VPL, LGNd, MG) as seen at 3 months of age. As at 3 months of 
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age, the most activated macrophage-like cells could be found in PO and VL (see 
Figure 16). Within the cortex, immune cell activation was present in layer VI of most 
cortical regions. However, besides the generally higher overall activation of immune 
cells within the whole brain and especially in all those regions already described at 3 
months of age, several additional brain regions also contained CD45+ve cells at 5 
months of age: a distinct and intense microglial infiltration/activation was present in 
all layers of the auditory cortex (Au1, AuV and AuD), and to a lesser extent in the 
secondary somatosensory cortex (S2), along with an up-regulation of CD45 
immunoreactivity in the rostral portions of the brain, namely the cingulate cortex. 
Additionally, faintly stained CD45+ve cells could be found in laminae II/III and 
sometimes also in lamina VI of the motor cortex (mainly M1, little M2). In the 
hippocampus an intensely stained band of CD45+ve activated microglia was present 
in the CA1 subfield and to a lesser extent in the dentate gyrus (DG) (data not shown).  
iv)  7 month old Ppt1
-/- 
mice 
At 7 months of age, intensely stained CD45+ve microglia, many with brain- 
macrophage morphology, together with T-cells were evident in most, if not all brain 
regions. Particularly intensely stained microglia could be seen, not just within thalamic 
nuclei (as most prominently seen in VPM/VPL, LGNd, MG, PO and VL) (see 
Figure 16A), but also in the CA1 subfield and dentate gyrus of the hippocampus. 
Interestingly, the highly activated macrophage-like cells which were seen in PO and 
VL at the previous two ages, could not be detected at 7 months of age, but instead 
more brain-macrophages with round cell soma were present in these nuclei (see 
Figure 16B). Furthermore, CD45+ve cells were present in widespread cortical 
regions. This not only included staining in laminae II/III and VI of M1/2 at this time 
point, but was also within most cortical layers of the visual cortex (V1) and also the 
lateral entorhinal cortex (LEnt), but most prominently in layer II/III of these cortical 
regions. Interestingly, at this age S1BF and Au, which had displayed intense CD45 
staining at earlier ages, now displayed weaker immune/microglial activation at 7 
months of age. Last but not least, pronounced macrophage/microglial activation 
could be detected in the pons and the external cortex of the inferior Colliculus (ECIC) of 






b) CD45 positive leukocytes in Cln3
-/- 
mice 
As conducted in Ppt1-/- mice, a series of sections from Cln3-/- brains, as murine model 
of Juvenile NCL, were also stained for CD45 at 3 age groups (6.5, 12 and 21 months). 
The first clear signs of CD45 immunoreactivity were apparent in Cln3-/- mice from 12 
months onwards, and increased in intensity and abundance with disease progression 
(see Figure 17 for representative pictures and Table 8 for a detailed summary of the 
distribution of CD45 immunoreactivity in Cln3-/- mice over time). In wildtype (and 6.5 
month old Cln3-/-) mice CD45+ve cells (morphologically resembling T-cells and 
macrophages) could be detected mainly along the brain borders (in the meninges, 
choroid plexus or at the edges of the ventricles). In these mice, only sporadic 
CD45+ve cells (resembling T-cells) could be detected in the mid and forebrain 
parenchyma, whereas in the olfactory bulb many CD45 immunoreactive T-cells had 
accumulated (data not shown). 
i) 6.5 month old Cln3
-/-
 mice 
As seen in wildtype mice at all ages, in 6.5 month old Cln3-/- mice CD45+ve cells 
could be mainly detected within the olfactory bulb or along the borders of the brain 
(namely in the meninges, the choroid plexus or along the ventricle walls). In the 
olfactory bulb, these CD45+ve cells morphologically resembled T cells with round, 
small cell bodies and no processes (data not shown), whereas a mixed population of 
T-cells and macrophages aligned along the brain borders. But T-cells showed more 
distinct CD45 immunoreactivity than macrophages, suggesting higher levels of CD45 
expression on T-cells at this age (data not shown).  
ii) 12 month old Cln3
-/-
 mice  
As at 6.5 months of age, CD45 immunoreactivity was also seen in the olfactory bulb 
of Cln3-/- mice at 12 months of age though many more CD45+ve cells were present. 
Besides most cells morphologically resembling lymphocytes, weak microglial staining 
could also be detected in the olfactory bulb. Yet, the clearest immune cell activation in 
the forebrain was observed in the ventral posteromedial and posterolateral (VPM/VPL) 
nuclei in Cln3-/- mice at this time point (see Figure 17A). A variety of cell shapes and 
morphologies were stained for CD45 in the VPM/VPL nuclei: cells resembling 
microglia with elongated processes, macrophages with short processes as well as some 
T-cells with darkly stained, very small cell bodies and no processes (see Figure 17B).  
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According to landmarks in (Paxinos and Franklin, 2001), additional thalamic 
macrophage/microglial staining in the thalamus could be detected in the 
mediodorsalthalamic nucleus (MD) and the posterior thalamic nuclei (PO), but to a weaker 
extent than seen in VPM/VPL. Besides the thalamus, other brain regions also showed 
Figure 17. Progressive immune cell activation in Cln3-/- mice. (A) Immunohistochemical 
staining for the general leukocyte marker CD45 in the thalamus of 6.5, 12 and 21 month old  
Cln3-/- and wildtype (WT) mice revealed widespread immune cell and lymphocyte activation within 
the ventral posterior nucleus (VPM/VPL) (---) in Cln3-/- mice. From 12 months onwards, immune 
cell activation could be clearly observed in the VPM/VPL nuclei of Cln3-/- mice which increased 
in intensity and spread to involve the whole thalamus at 21 months of age. In contrast, almost no 
CD45 immunoreactivity was seen at any age in the thalamus of WT brains. Scale bar = 200 μm. 
(B) Higher magnification pictures of CD45+ve cells in the thalamus of 6.5, 12 and 21 month old   
Cln3-/- and WT mice revealed various types of immune cells in the mutant mice from 12 months 
onwards. Judged on their morphology, CD45+ve cells resembled macrophages, microglia as well 
as lymphocytes (arrows). Whereas at 12 months of age microglia with elongated cell processes 
stained for CD45 in VPM/VPL nuclei of Cln3-/- mice, mainly brain-macrophage like cells with 
round cell bodies and short (or no) processes displayed CD45 immunoreactivity at 21 months of 
age. Additionally, some CD45+ve cells resembling lymphocyte (arrows) with small round or oval 
shaped morphology without any cell processes could be detected in the thalamus of Cln3-/- mice.  




weak microglial activation. These included the caudate putamen (striatum), the 
parvicellular and magnocellular part of the red nucleus (RPC and RMC), the reticulotegmental 
nucleus of the pons (RtTg) and much weaker palely stained microglial activation was seen 
in the substantia nigra and the caudal parts of the subiculum of the hippocampus (data 
not shown). In the cortex, faintly stained microglia were present in the two most 
ventral laminae VI and V, but a variety of sub-regions displayed more pronounced 
microglial activation, also mainly in the most ventral laminae (VI and V). From rostral 
to caudal, such microglial activation was seen in the cingulate cortex (Cig1, Cig2), the 
motor cortex (M1 and M2), the somatosensory cortex (mainly in S1HL, S1FL and S2, but 
only marginal in S1BF), throughout all laminae of the retrosplenial granular and partly 
also in the retrosplenial agranular cortex (RSG, RSA) and the primary and secondary auditory 
cortex (Au1, AuD and AuV). Last but not least, distinct macrophage/microglial 
staining with CD45 could be observed along the lateral nuclei of the piriform cortex 
(Pir). Apart from these defined brain regions, some intensely stained macrophages or 
microglia with an enlarged cell body and many processes could be detected randomly 
scattered throughout the brain. Interestingly, many CD45+ve lymphocyte-like cells 
were seen in the olfactory bulb and were not as often found in more caudal parts of 
the brain of Cln3-/- mice at 12 months of age (data not shown).   
iii) 21 month old Cln3
-/- 
mice 
As consequence of disease progression, in 21 month old Cln3-/- mice CD45 
immunoreactivity was clearly increased with activated microglia present throughout 
the brain. However, certain brain regions demonstrated markedly more CD45 reactive 
macrophages/microglia, mostly with round and darkly stained cell soma (see example 
in Figure 17B). Generally speaking, the number of CD45+ve cells was not only 
increased, but staining of these cells was more intense in the same brain regions 
already described above at 12 months of age. However, several additional regions also 
showed macrophage/microglial staining in Cln3-/- mice at 21 months of age. From 
rostral to caudal, the following brain regions contained many CD45+ve cells. The 
olfactory bulb was particularly full of T-cells and contained clear macrophage and 
microglia staining at 21 months of age (data not shown). Cortical activations were seen 
in more ventral laminae (VI and V) of the cortex, with particularly intense CD45 
staining in the motor cortex (M1, M2), piriform cortex (Pir) (with distinct microglial staining 
along its lateral nuclei, and especially pronounced T-cell infiltration), in the agranular 
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caudal parts of the brain also in the retrosplenial granular cortex (RSG) and lateral 
entorhinal cortex (LEnt). Furthermore, the dorsal endopiriform nucleus (DEn) in the piriform 
cortex and the nearby amygdalopiriform transition area (APir) also displayed intensely 
stained brain-macrophages. Interestingly, only faint CD45 staining was detected in the 
auditory cortex (Au1, AuD) at this age (data not shown). In the more ventral parts of the 
forebrain, the thalamus represented the most prominent site of microglial activation in 
Cln3-/- mice, consistent with previous studies (Pontikis et al., 2004; Pontikis et al., 2005). 
Darkly stained CD45+ve cells were detected in several nuclei of the thalamus, 
including the anteromedial and anteroventral thalamic nuclei (AM, AVDM, AVVL), the 
ventral posteromedial and posterolateral (VPM/VPL) nuclei (see Figure 17A), the 
ventromedial thalamic nucleus (VM), the dorsal lateral geniculate nucleus (LGNd), the medial 
geniculate nuclei (MG) and mediodorsal thalamic nucleus (MD). Other brain regions with 
CD45 immunoreactive cells included the caudate putamen (striatum), the lateral globus 
pallidus (LGP), the magnocellular preoptic nucleus (MCPO), more caudally the parvicellular 
part of the red nucleus (RPC), the subiculum of the hippocampus and to a weaker extent 
the substantia nigra. Last but not least, wide-spread CD45+ve macrophage/microglial 
activation could be detected throughout the pons, but particularly intense staining was 
found in the reticulotegmental nuclei of the pons (RtTg) (data not shown). In all these brain 
regions, a mixed population of CD45 immunoreactive T-cells, macrophages and 
microglia was observed, with all three of these cell types consistently found in these 
regions. However, in contrast to earlier ages, lymphocyte-like CD45+ve cells were not 
restricted to the olfactory bulb and were now found throughout the brain parenchyma 
of Cln3-/- mice at 21 months of age.  
Taken together, pronounced CD45 immunoreactivity was observed in the brains of 
both Ppt1-/- and Cln3-/- mice. In both mouse models, the earliest and most pronounced 
immune activation could be found in the VPM/VPL nuclei of the thalamus (see 
Figure 16 and Figure 17), although other brain regions displayed similarly intense 
CD45 immunoreactivity at later stages of these diseases. However, in both mouse 
models, CD45 immunoreactivity was detected on cells morphologically resembling 
microglia, macrophages and T-cells. Therefore, these findings confirmed that both 
activated innate and adaptive immune cells are present and that pronounced 
inflammatory responses occur in INCL and JNCL mouse brains. Furthermore, this 
data provided an overview of where these different types of immune cells are 
distributed in Ppt1-/- and Cln3-/- brains, and how these relate to one another. Broadly 
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similar regions seem to be involved (i.e. contain or are infiltrated by CD45+ve cells) in 
both forms of NCL, but specific differences between Ppt1-/- and Cln3-/- mice could 
also be determined. This activation of immune cells in the brain started at different 
time points in Ppt1 and Cln3 deficient mice (3 months in Ppt1-/- and 12 months in  
Cln3-/- mice), which represent different stages of disease progression. Besides these 
temporal differences, regionally specific differences in where this activation occurred 
could be also observed between these mouse models. For example, in Cln3-/- mice no 
overt CD45 staining could be detected in the hippocampus (apart from the subiculum 
caudally), whereas Ppt1-/- mice displayed pronounced macrophage staining in the CA1 
and dentate gyrus of this brain region. Moreover, in the cortical regions, macrophage 
activation in Cln3-/- mice was mainly restricted to laminae VI and V, whereas in Ppt1-/- 
mice more dorsal laminae (II/III) also showed pronounced CD45 immunoreactivity. 
Likewise, the visual cortex (V1) showed no obvious microglial activation at later stages 
of the disease in Cln3-/- mice, in contrast to Ppt1-/- mice which displayed a pronounced 
CD45 activation in V1 at 7 months of age (data not shown). However, vice versa, some 
brain regions only contained activated microglia in Cln3-/- mice, as for example the 
parvicellular part of the red nucleus (RPC) or the magnocellular preoptic nucleus (MCPO) 
which did not show any particular immune activation in Ppt1-/- mice at any time 
examined. Such comparisons between these mice are valid as both were bred on the 
same strain background. These differences are most likely explained by different rates 
of disease progression between INCL and JNCL, with Ppt1-/- mice, as the faster 
progressing form, displaying more widespread microglial activation. Equally, these 
findings also emphasise that these forms NCL are clearly different from one another 
(Cooper, 2010), even though they have been grouped into the same family of diseases.  
3.2 Adaptive immune cells in the CNS of Infantile and Juvenile NCL 
Having detected CD45 positive lymphocytes in the brains of both Infantile and 
Juvenile NCL mice, we wanted to characterise these cells in more detail by staining 
with specific markers of different classes of lymphocytes. Therefore, we stained a 1 in 
6 series of sections of Ppt1-/- (1, 3, 5 and 7 month old), and Cln3-/- brains (6.5, 12 and 
21 month old), and age-matched wildtype brains for CD8, the cytotoxic T-cell marker 
and CD4, the T-helper cell marker (see Figure 18, Figure 19, Figure 25 and Figure 
26). Subsequently, we performed detailed lymphocyte counts to characterise the total 
numbers of each of these subsets of lymphocytes in Ppt1-/-and Cln3-/- mice, and 
124 
 
corresponding wildtype brains (see Figure 21 and Figure 27). As a next step, we 
divided the analysed brain sections rostrocaudally into 5 different levels (see Table 6 
and Figure 14 in Chapter 2) to define the distribution of each lymphocyte subset 
throughout the fore-and midbrain in more detail (see Figure 22, Figure 23, Figure 
28 and Figure 29). Last but not least, to determine the density of lymphocytes in each 
of these rostrocaudal levels, we obtained volume measurements of each (and the 
whole brain volume) (see Appendix I for results of the volume measurements), and 
calculated the density of lymphocytes per mm3. Hence, by combining all of these 
measurements, we were able to characterise in detail the distribution pattern and 
density of cytotoxic T-cells and T-helper cells in the brains of Infantile and Juvenile 
NCL mice. Furthermore, since both NCL mouse models had been bred on the same 
background strain and the lymphocyte density data were corrected for brain volume, 
these lymphocyte data can be directly compared between these two mouse models.    
a) T-cell infiltration in the brain of Ppt1
-/-
 mice 
As described in the Chapter 1 (see section 1.7a), CD8 and CD4 are trans-membrane 
glycoproteins that act as co-receptors for the T-cell receptor (TCR) (Janeway, 1991). 
Whereas CD8 is found on cytotoxic T-cells to facilitate binding to major 
histocompatibility complex (MHC) molecule class I proteins and attached intracellular 
components (Engleman et al., 1981; Meuer et al., 1982; Norment and Littman, 1988; 
Connolly et al., 1990; Abbas and Lichtman, 2011), CD4 is a characteristic molecule on 
T-helper cells which interacts with MHC II molecules and attached extracellular 
foreign peptides on the surface of antigen-presenting cells (Engleman et al., 1981; 
Maddon et al., 1985; Abbas and Lichtman, 2011).  
Immunohistochemical staining for CD8 and CD4 markers revealed that both subsets 
of lymphocytes infiltrate the brain parenchyma of Ppt1-/- brains from 3 months 
onwards (see Figure 18 and Figure 19). In contrast, only sporadic T-cells could be 
detected in the brains of wildtype mice, in which many T-cells could be found along 
brain margins, namely the ventricle walls, the meninges or choroid plexus. CD8+ve as 
well as CD4+ve T-cells characteristically displayed a small round cell soma without 
any processes, even though some T-cells also appeared with an oval or tapered cell 
morphology, as if they were fixed during the process of squeezing through vessels or 







Figure 18. Progressive cytotoxic T-cell infiltration in Ppt1-/- mice. (A) Immunohistochemical 
staining for the cytotoxic T-cell marker CD8 in the striatum (caudate putamen) of 1, 3, 5 and 7 
month old Ppt1-/- and wildtype (WT) mice revealed CD8+ve cells (arrows) in both genotypes. But 
many more CD8 immunoreactive cells were apparent in Ppt1-/- mouse brains from 3 months 
onwards compared to WT brains. In mutant mice, the numbers of CD8+ve T-cells increased with 
disease progression and evidence for lymphocyte clustering around ventricles (V) and occasionally 
blood vessels (*) could be suggested. Scale bar = 200 μm. (B, C) Higher magnification pictures of 
CD8+ve cytotoxic T-cells (B) in the striatum of 3, 5 and 7 month old WT and Ppt1-/- mice, (C1, 
C3) in striatum near ventricles and (C2) in the basal forebrain of 7 month old mutant mice. CD8 
immunoreactive cells displayed characteristic T-cell morphology with small, round cell bodies and 
no processes. T-cells were prominently found in the olfactory bulb, near ventricles and/or white 





Figure 19. Progressive T-helper cell infiltration in Ppt1-/- mice. (A) Immunohistochemical 
staining for the T-helper cell marker CD4 in the striatum (caudate putamen) of 1, 3, 5 and 7 month 
old Ppt1-/- and wildtype (WT) mice revealed CD4+ve cells (arrows) in both genotypes. But many 
more CD4 immunoreactive cells were apparent in Ppt1-/- mouse brains from 3 months onwards 
compared to WT brains. In mutant mice, evidence for lymphocyte clustering around ventricles 
(V) and occasionally blood vessels (*) could be suggested. Scale bar = 200 μm. (B, C) Higher 
magnification pictures of CD4+ve T-helper cells (B) in the striatum of 3, 5 and 7 month old WT 
and Ppt1-/- mice, (C1) in the striatum near/along ventricles, (C2) in the piriform cortex and (C3) in 
the olfactory bulb of 7 month old mutant mice. CD4 immunoreactive cells displayed 
characteristic T-cell morphology with small, round cell bodies and no processes. T-cells were 
prominently found in the olfactory bulb, near ventricles and/or white matter tracts. Scale bar in 
(B) = 100 μm, in (C1) = 50 μm, in (C2) = 25 μm and (C3) = 20 μm. 
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Regarding their dispersion within the brain, CD8+ve and CD4+ve T-cells both 
showed similar distributions, but without any distinct pattern or obvious clustering 
around particular structures. Nevertheless, common themes could be discerned, with 
most T-cells found either in the rostral parts of the brain, in particular in the olfactory 
bulb, or in the proximity of ventricles. Furthermore, white matter tracts, in particular 
the corpus callosum or the fimbria of the hippocampus were preferential locations for 
lymphocytes, although this could equally be explained by the immediate proximity of 
these white matter tracts to the cerebral ventricles. Occasionally, some clustering of T-
cells around blood vessels could be observed, even though this distribution was not 
frequently seen. According to these rather general patterns of T-cell distribution in the 
brain, CD8+ve and CD4+ve lymphocytes could be commonly found in following 











Figure 20. Lymphocyte distribution in the brain of Ppt1-/- and Cln3-/- mice. Qualitative 
assessment of lymphocyte distribution in the brain of Ppt1-/- and Cln3-/- mice revealed preferred T-
cell accumulation (···) in the rostral parts of the brain and/or in the proximity of ventricles or 
white matter tracts. The following brain regions showed consistently increased lymphocyte 
infiltration in both NCL mice: olfactory bulb (where most T-cells were present), anterior olfactory 
nuclei, caudate putamen (striatum), corpus callosum, globus pallidus, fimbria of the hippocampus, anterior 
commissure, piriform cortex, amygdala, thalamus (throughout the thalamus, often seen in the mediodorsal 
thalamic nuclei but (particularly in Cln3-/- mice) also in the ventral postero nuclei), caudal parts of the 
hippocampus, retrosplenial agranular and granular cortex and the pons with the pontine nucleus and periolivary 
nuclei. Speculatively, this lymphocyte distribution could be explained by them being the easiest 
access routes for lymphocytes into the brain via the ventricles and olfactory bulb, or by migratory 
pathways along white matter tracts. 
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nuclei, caudate putamen (striatum), globus pallidus, corpus callosum, fimbria of the 
hippocampus, piriform cortex, area around the anterior commissure, several amygdaloid nuclei, 
throughout the thalamus including the mediodorsal thalamic nuclei and also seen in the 
thalamic ventral posterior nuclei, caudal parts of the hippocampus, retrosplenial agranular and 
granular cortex and the pons with the pontine nucleus and periolivary nuclei. The most likely 
explanation for this distribution of lymphocytes in the brain is probably found in the 
most favourable access routes, as for example the olfactory bulb or ventricles. 
Likewise, white matter tracts possibly serve as convenient migratory pathways in the 
brain. These possibilities will be discussed in more detail in Chapter 7. 
To extend these qualitative findings of CD8+ve and CD4+ve T-cell distribution in the 
brain of Ppt1-/- mice, we performed detailed cell counts of each lymphocyte sub-
population throughout the whole brain (1 in 6 series) of Ppt1-/- mice and 
corresponding wildtype mice. These total cell counts confirmed that CD8+ve 
cytotoxic T-cells infiltrate the Ppt1-/- CNS in significant numbers from 3 months 
onwards (see Figure 21A). By combining the total lymphocyte counts with whole 
brain volume (see Appendix I: Figure 77) and plotting them as the density of 
lymphocytes per mm3, it could be shown that CD8+ve lymphocyte numbers 
constantly increase over time reaching a maximum at 7 months of age with around 
280 cells/mm3 (see Figure 21A). 
In contrast, CD4+ve T-helper cells also infiltrate the Ppt1-/- CNS from 3 months 
onwards, but already reach their maximum level at this age with around 90 cells/mm3, 
a density that does not increase further with disease progression (see Figure 21B). 
Comparing the relative infiltration of CD4+ve and CD8+ve cell types, there are three 
times as many CD8+ve cytotoxic T-cells present at the end stage of the disease, than 
CD4+ve T-helper cells (see Figure 21C and Figure 21D). However, the fact that 
CD4+ve cells already seem to reach their maximum density by 3 months of age, 
suggests that they are possibly more involved in pathogenesis at early stages compared 
to CD8+ve cells, which seem to become more prominent towards the end of the 
disease. This pattern would be consistent with the hypothesis that CD4+ve T-cells 
infiltrate the inflammation site at early stages of the disease to coordinate and recruit 
other immune cells, as for example CD8+ve T-cells (see section 1.7a in Chapter 1, 
(Germain, 1994; Zhu and Paul, 2008; Nakanishi et al., 2009; Abbas and Lichtman, 
2011)).   
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After dividing the brain into five rostrocaudal levels (see Table 6 and Figure 14 in 
Chapter 2) and measuring the volume of each of these defined brain regions (see 
Appendix I: Figure 77), the rostrocaudal distribution of all T-cell counts was 
quantified to determine any regional specificity of lymphocyte infiltration. 
Unsurprisingly, the timing of these regional changes mirror the patterns of the total 
numbers of both CD8+ve cytotoxic T-cells as well as CD4+ve T-helper cells, with 
infiltration of both cell types from 3 months onwards (see Figure 22). However, for 
both T-cell markers the highest numbers of cells and the first detectable lymphocyte 
infiltration occurred in level I/the olfactory bulb. The lymphocyte infiltration appears 
to start at this most rostral part of the brain at 1 month for CD8+ve and CD4+ve 
cells, and gradually spreads and increases over time to more caudal regions of the  
Figure 21. Progressive lymphocyte infiltration in Ppt1-/- mice. Systematically quantified 
counts of (A) CD8+ve cytotoxic T-cells and (B) CD4+ve T-helper cells in 1, 3, 5 and 7 month 
old Ppt1-/- and age-matched wildtype (WT) mice revealed significant lymphocyte infiltration from 
3 months onwards in mutant mice. In contrast, only relatively few lymphocytes could be detected 
in WT mice. (C, D) Direct comparison of CD8+ve and CD4+ve immune cell infiltration 
demonstrated different dynamics and amounts of each T-cell subpopulation in Ppt1-/- (—) brains. 
Double to three times as many CD8+ve cytotoxic T-cells could be detected in mutant mice from 
3 months onwards, compared to CD4+ve T-helper cells. Furthermore, the amount of CD8+ve 
T-cells steadily increased with disease progression in Ppt1-/- mice, whereas CD4+ve T-cells already 
reached a saturated level of infiltration by 3 months of age in these mice. Similarly, in WT (∙∙∙) 
mice the amount of cytotoxic T-cells increased with age and more CD8+ve T-cells were found in 
healthy control mice, compared to CD4+ve T-cells. Values were calculated as density of 
lymphocytes/mm3. The same data are presented as both histograms (A, B, C) and line graph (D). 
Statistics: Two-way ANOVA with Bonferroni post hoc test, ***p<0.001. Data shown as mean ± 

















brain. The olfactory bulb seems to offer a convenient access route for these 
lymphocytes to enter the brain, but no other regional selectivity for the lymphocyte 
infiltration could be detected.  
Comparing both lymphocyte subsets, the amount of CD4+ve T-cells exceed that of 
CD8+ve T-cells at 1 month of age in the olfactory bulb, but become outnumbered at 
later stages (see Figure 23). This would strengthen the suggested early appearance 
Figure 22. Regional distribution of lymphocytes in Ppt1-/- brains. Regional breakdown of 
total (A) CD8+ve and (B) CD4+ve lymphocyte counts (A) into five rostrocaudal brain levels at 1, 
3, 5 and 7 months of age revealed similar infiltration patterns of both lymphocyte subpopulations. 
A significant increase in the number of CD8+ve cytotoxic T-cells and CD4+ve T-helper cells was 
detected from 3 months onwards in Ppt1-/-(—) compared to wildtype (∙∙∙) mice. In both mouse 
populations, the majority of T-cells were found in the olfactory bulb, suggesting it to be a 
common access route into the brain. In mutant mice, lymphocytes were distributed along a 
rostrocaudal gradient throughout the brain. Values were calculated as density of 
lymphocytes/mm3. Brain levels: I = olfactory bulb, II = forebrain until hippocampus, III = 
hippocampal forebrain, IV = Midbrain with superior colliculus, V = midbrain with pons. Statistics: 
Two-way ANOVA with Bonferroni post hoc test, *p<0.05, **p<0.01, ***p<0.001. Data shown 
as mean ± SEM, n = 5.        
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and influence of CD4+ve T-helper cells in Ppt1-/- brains discussed above, whereas 
CD8+ve cytotoxic    T-cells are apparently more numerous at later disease stages.   
Calculating the ratio of CD8:CD4+ve cells in the whole brain of Ppt1-/- and wildtype 
mice revealed no significant difference between these genotypes. However, certain 
trends were apparent (see Figure 24). While at 1 month of age, more CD4+ve T-cells 
could be found in both genotypes, there were two to three times more CD8+ve cells 
than CD4+ve cells at subsequent ages. Indeed, mutant as well as control brains 
showed an age dependent increase of CD8+ve T-cell influx over time.   
Taken together, our findings provide the first characterisation of adaptive immune cell 
infiltration in Ppt1-/- and wildtype mice. We not only demonstrated that increased 
numbers of T-cells are present in Ppt1-/- mice, but also defined in detail the spatial and 
temporal distribution of lymphocytes in the brains of these mice.  
 
Figure 23. Direct comparison of regional distribution of CD8+ve and CD4+ve 
lymphocytes in Ppt1-/- mice. Regional breakdown of total lymphocyte counts into five 
rostrocaudal brain levels at 1, 3, 5 and 7 months of age in Ppt1-/- (—) and wildtype (∙∙∙) mice 
revealed similar distribution patterns of CD8+ve (red) and CD4+ve T-cells (blue). Both 
subpopulations showed a significant increase from 3 months onwards in mutant mice compared 
to wildtype mice, whereas double to three times as many CD8+ve T-cells were present in the 
brain than CD4+ve T-cells. However, the distribution of both lymphocyte subpopulations 
followed a rostrocaudal gradient with most cells present in the olfactory bulb. Values were 
calculated as density of lymphocytes/mm3. Brain levels: I = olfactory bulb, II = forebrain until 
hippocampus, III = hippocampal forebrain, IV = Midbrain with superior colliculus, V = midbrain 
with pons. Statistics: Two-way ANOVA with Bonferroni post hoc test, *p<0.05, **p<0.01, 










b) T-cell infiltration in Cln3
-/- 
mice 
Analogous to the analysis of Ppt1-/- brains (see section 3.2a), we assessed the extent 
and distribution of CD4+ve and CD8+ve lymphocytes within the brains of Cln3-/- 
mice and control mice at different stages of disease progression (6.5, 12 and 21 
months). In addition to documenting data in representative pictures, lymphocyte 
counts were again made from the entire brain, as well as defined rostrocaudal levels. 
These were combined with regional volume measurements to provide lymphocyte 
density measurements and create an exact distribution map of lymphocyte infiltration 
in Cln3-/- brains over time. Furthermore, this is the first time such old (21 months) 
Cln3 deficient mice have been analysed, with previous studies only extending to 14 or 
19 months of age (Pontikis et al., 2004; Herrmann et al., 2008b).  
Immunohistochemical staining of Cln3-/- and age-matched wildtype brains for CD8 
and CD4 markers at all three ages (6.5, 12 and 21 months) revealed higher levels of 
lymphocyte infiltration in mutant mice. However, the degree of infiltration and its 
timing differed between these lymphocyte subsets. The first indication of increased 
numbers of lymphocytes of either type in Cln3-/- brains was seen at 12 months of age 
with more CD8+ve cytotoxic T-cells present in the olfactory bulb than in wildtype 
mice. However, widespread CD8+ve T-cell infiltration of the Cln3-/- brain only 
became apparent at 21 months of age (see Figure 25). In contrast, no evidence of an 
Figure 24. Unchanged CD8:CD4+ve T-cell ratios in Ppt1-/- mice. Calculation of the ratio 
between CD8+ve and CD4+ve T-cells revealed no significant difference between Ppt1-/-(―) and 
wildtype (···) (WT) mice. Whereas at 1 month of age, more CD4+ve T-cells were present in the 
brains of both mouse populations, more CD8+ve lymphocytes could be detected from 3 months 
onwards compared to CD4+ve T-cells. Thus, an age-dependent increase of CD8+ve cells influx 
could be observed in mutant and wildtype brains over time. Statistics: Two-way ANOVA with 
Bonferroni post hoc test. Data shown as mean ± SEM, n = 5. 
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increase in CD4+ve T-helper cells was seen until 21 months of age when many more 
infiltrated CD4+ve T-cells could be detected in Cln3-/- mice compared to wildtype 
mice (see Figure 26). The distribution of CD8+ve and CD4+ve lymphocytes in   
Cln3-/- brains resembled that seen in Ppt1-/- brains (see Figure 20). T-cells were 
predominantly found in the olfactory bulb, in proximity to ventricles and/or white 
matter tracts. Occasional clustering of lymphocytes around blood vessels was also 
observed in these Cln3-/- brains. Compared to Ppt1-/- mice, in Cln3-/- brains there 
appeared to be slightly more T-cells present in the ventral posteromedial and posterolateral 
(VPM/VPL) nuclei of the thalamus, a particular focus for pathology in NCL mice 
(Bible et al., 2004; Pontikis et al., 2004; Pontikis et al., 2005; Cooper et al., 2006; Kielar et 
al., 2007; Partanen et al., 2008; von Schantz et al., 2009; Kuronen et al., 2012; Schmiedt 
et al., 2012; Thelen et al., 2012), whereas no such accumulation of lymphocytes in these 
nuclei were observed in Ppt1-/- mice at any age. Furthermore, as already seen in 
younger control mice, only sporadic T-cells could be detected in the brains of aged 
wildtype mice, whereas most T-cells could be found along the brain margins, namely 
the ventricle walls, the meninges or choroid plexus of these mice. 
To quantify these qualitative findings of the CD8 (see Figure 25) and CD4 (see 
Figure 26) staining across all ages, the total number of lymphocytes were counted and 
adjusted for whole brain volume (see Appendix I: Figure 78) to provide lymphocyte 
density measurements. In Cln3-/- brains, CD8+ve cytotoxic T-cells started to infiltrate 
at 12 months of age (seen as a trend) and reached significant levels at 21 months with 
ca. 250 lymphocytes/mm3 (see Figure 27A). In contrast, CD4+ve T-helper cell 
numbers were only significantly increased at 21 months of age with ca. 55 cells/mm3 
in the brain of Cln3-/- mice (in Figure 27B), compared to age-matched wildtype mice. 
When directly comparing both lymphocyte subpopulations (see Figure 27C and 
Figure 27D), apart from the relative amount of cells (much fewer CD4+ve T-helper 
cells were present than CD8+ve cytotoxic T-cells), the sequence of infiltration was 
unexpected. CD4+ve T-helper infiltrate the brain only at later stages of the disease in 
Cln3-/- brains, in contrast to the T-cell infiltration pattern observed in Ppt1-/- mice. 
CD8+ve T-cell recruitment into the brain of Cln3-/- mice seems not to rely on the help 
of CD4+ve T-cells which traditionally are thought to orchestrate the immune 
response at the inflammation site (see section 1.7a in Chapter 1, (Germain, 1994; 




Figure 25. Progressive cytotoxic T-cell infiltration in Cln3-/- mice. (A) Immunohistochemical 
staining for the cytotoxic T-cell marker CD8 in the thalamus of 6.5, 12 and 21 month old Cln3-/- 
and wildtype (WT) mice revealed CD8+ve cells (arrows) in both genotypes. More CD8 
immunoreactive cells were marginally apparent from 12 months onwards, but obviously so at 21 
months in Cln3-/- mice compared to WT brains, in which only occasionally CD8+ve cells could be 
seen. Scale bar = 200 μm. (B, C) Higher magnification pictures of CD8+ve cytotoxic T-cells (B) 
in the striatum of 6.5, 12 and 21 month old WT and Cln3-/- mice, (C1) in white matter tracts near 
ventricles, (C2) in the thalamus and (C3) in the pons of 21 month old mutant mice. CD8 
immunoreactive cells displayed characteristic T-cell morphology with small, round or oval cell 
bodies and no processes. T-cells were prominently found in the olfactory bulb, near ventricles 
and/or white matter tracts. Occasional clustering around blood vessels was also observed in 
mutant mice (see C3 as example). Scale bars in (B) = 100 μm, in (C1) = 50 μm, in (C2) = 25 μm 





Figure 26. Progressive T-helper cell infiltration in Cln3-/- mice. (A) Immunohistochemical 
staining for the T-helper cell marker CD4 in the thalamus of 6.5, 12 and 21 month old Cln3-/- and 
wildtype (WT) mice revealed CD4+ve cells (arrows) in both genotypes. Many more CD4 
immunoreactive cells were apparent at 21 months in Cln3-/- mice, compared to WT brains, in 
which very few CD4+ve cells could be seen. Scale bar = 200 μm. (B, C) Higher magnification 
pictures of CD4+ve T-helper cells (B) in the thalamus of 6.5, 12 and 21 month old WT and Cln3-
/- mice, (C1) in the striatum, (C2) near ventricles and the corpus callosum and (C3) in the amygdala of 
21 month old mutant mice. CD4 immunoreactive cells displayed characteristic T-cell morphology 
with small, round or oval cell bodies and no processes. T-cells were prominently found in the 
olfactory bulb, near ventricles and/or white matter tracts. Scale bars in (B) = 100 μm, in (C1) = 
50 μm, in (C2) = 25 μm and (C3) = 20 μm. 
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Several explanations for this phenomenon shall be discussed below (see section 3.3c) 
and more extensively in Chapter 7. 
By splitting the brain into five different rostrocaudal levels (see Table 6 and Figure 
14 in Chapter 2) and combining regional volume measurements (see Appendix I: 
Figure 78) with all lymphocyte counts, it was possible to define the distribution of 
lymphocytes in Cln3-/- mice as a density of cells per mm3 at each rostrocaudal level (see 
Figure 28). This analysis revealed similar patterns to total number of lymphocytes, 
with CD8+ve cytotoxic T-cells infiltrating from 12 months onwards, while only a 
moderate increase in the number of CD4+ve T-helper cells occurred at 21 months of 
age (see Figure 27).  
Figure 27. Progressive lymphocyte infiltration in Cln3-/- mice. Systematically quantified 
counts of (A) CD8+ve cytotoxic T-cells and (B) CD4+ve T-helper cells in 6.5, 12 and 21 month 
old   Cln3-/- and age-matched wildtype (WT) mice revealed significant lymphocyte infiltration at 21 
months of age in mutant mice. In contrast, only relatively few lymphocytes could be detected in 
WT mice. (C, D) Direct comparison of CD8+ve and CD4+ve immune cell infiltration 
demonstrated different dynamics and amounts of each T-cell subpopulation in Cln3-/- (—) brains. 
Significantly more CD8+ve T-cells were already evident from 12 months onwards compared to 
WT (∙∙∙) mice, but this difference reached significant levels only at 21 months of age. In contrast, 
increased numbers of CD4+ve T-cell were only detected at 21 months of age in Cln3-/- mice, 
being significantly increased compared to WT mice. Furthermore, five times as many CD8+ve 
cytotoxic T-cells could be detected in mutant mice at 21 months of age, compared to CD4+ve T-
helper cells. In WT mice, the amount of cytotoxic T-cells increased with age and more CD8+ve 
T-cells were found in healthy control mice at all ages, compared to CD4+ve T-cells. Values were 
calculated as density of lymphocytes/mm3. The same data are presented as both histograms (A, B, 
C) and line graph (D). Statistics: Two-way ANOVA with Bonferroni post hoc test, *p<0.05, 
***p<0.001. Data shown as mean ± SEM, n = 5. 
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For both T-cell markers the highest numbers of cells, and the first detectable 
lymphocyte infiltration in Cln3-/- mice, occurred in level I/the olfactory bulb. This 
infiltration started at these most rostral levels of the brain at 12 months for CD8+ve, 
and 21 months for CD4+ve cells, and later spreads throughout the whole brain (see 
Figure 28). However, level III (thalamus and hippocampus, plus overlying cortex) was 
more highly infiltrated compared to levels II (rostral forebrain until appearance of 
hippocampus) or IV (midbrain before the pons including superior colliculus). This 
correlates well with the only significant effect on regional volume also occurring in 
level III of the mature Cln3-/- brain (see Appendix I: Figure 78).  
Figure 28. Regional distribution of lymphocytes in Cln3-/- brains. Regional breakdown of 
total (A) CD8+ve and (B) CD4+ve lymphocyte counts (A) into five rostrocaudal levels at 6.5, 12 
and 21 months of age revealed different infiltration patterns between each lymphocyte 
subpopulation. A significant increase in the number of CD8+ve cytotoxic T-cells was first 
detected at 12 months of age in the olfactory bulb, but spread throughout the brain at 21 months 
of age in Cln3-/-(—) compared to wildtype (∙∙∙) mice. In contrast, significantly more CD4+ve T-
helper cells were only seen at 21 months of age in mutant mice, compared to control mice. In 
both mouse populations, the majority of T-cells were found in the olfactory bulb, suggesting the 
olfactory bulb to be a common access route into the brain. In 21 month old mutant mice, 
lymphocytes were distributed in a region-specific manner with levels I, III and V showing more 
T-cell infiltration than levels II and IV. Values were calculated as density of lymphocytes/mm3. 
Brain levels: I = olfactory bulb, II = forebrain until hippocampus, III = hippocampal forebrain, 
IV = Midbrain with superior colliculus, V = midbrain with pons. Statistics: Two-way ANOVA with 
Bonferroni post hoc test, *p<0.05, **p<0.01, ***p<0.001. Data shown as mean ± SEM, n = 5. 
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Directly comparing both lymphocyte subsets, the amount of CD8+ve T-cells 
exceeded that of CD4+ve T-cells at every rostrocaudal level, irrespective of age (see 
Figure 29). Even though no difference in the degree of lymphocyte infiltration could 
be detected between wildtype and Cln3-/- mice at 6.5 months of age, in both genotypes 
roughly three times as many CD8+ve cells were already found in the olfactory bulb, 
compared to the number of CD4+ve T-cells at this time point. At 12 months of age, a 
disease related influx of CD8+ve T-cells occurred in the olfactory bulb of Cln3-/- mice, 
spreading more widely and finally resulting in five times as many cytotoxic T-cells 
throughout every brain region at 21 months of age compared to the number of 
CD4+ve T-helper cells.  
 
Figure 29. Direct comparison of regional distribution of CD8+ve and CD4+ve 
lymphocytes in Cln3-/- mice. Regional breakdown of total lymphocyte counts into five 
rostrocaudal brain levels at 6.5, 12 and 21 months of age in Cln3-/- (—) and wildtype (∙∙∙) mice 
revealed different distributions of CD8+ve (red) and CD4+ve T-cells (blue). The first significant 
increase in the number of CD8+ve T-cells was seen in the olfactory bulb of Cln3-/- mice at 12 
months of age compared to wildtype mice, but this significant difference could be detected in all 
brain regions of mutant mice at 21 months of age. In contrast, significantly increased numbers of 
CD4+ve T-cells were only seen at 21 months of age in Cln3-/- mice compared to control mice, but 
this difference was evident in every level of the brain except for level II in mutant mice. At 21 
months of age, both subsets of lymphocytes were distributed in a region-specific manner with 
levels I, III and V showing more   T-cell infiltration than levels II and IV, even though this 
pattern was more pronounced with CD8+ve T-cells. At this time point, about five times as many 
CD8+ve T-cells were found in every brain region compared to CD4+ve T-cells. Values were 
calculated as density of lymphocytes/mm3. Brain levels: I = olfactory bulb, II = forebrain until 
hippocampus, III = hippocampal forebrain, IV = Midbrain with superior colliculus, V = midbrain 
with pons. Statistics: Two-way ANOVA with Bonferroni post hoc test, *p<0.05, **p<0.01, 
***p<0.001. Data shown as mean ± SEM, n = 5. 
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Calculating the ratio of CD8:CD4+ve cells in the whole brain of Cln3-/- and wildtype 
mice at all ages confirmed the relative abundance of these two lymphocyte subsets (see 
Figure 30). In both genotypes at least two times, and up to five times as many 
CD8+ve cells than CD4+ve cells were present at all ages. In 12 month old Cln3-/- 
mice a disease-dependent influx of cytotoxic T-cells, combined with the absence of 
CD4+ve cell infiltration (see above) altered the ratio of lymphocyte sub-classes in 
mutant mice significantly from that seen in wildtype mice. Besides an age-dependent 
increase in the number of CD8+ve cells in both genotypes (as also seen in Ppt1-/- and 
their control mice), the CD8:CD4+ve ratio seems clearly affected by disease onset and 







Thus, taken together, our data provide the first detailed characterisation of the 
temporal and spatial distribution of lymphocyte infiltration (for both markers CD4 
and CD8) throughout the brains of Cln3-/- mice and their age matched controls.  
3.3 Summary and discussion  
In this chapter, we have for the first time assessed the distribution of the general 
leukocyte marker CD45 in both Ppt1-/- and Cln3-/- brains, and detailed how this 
changes over time, which illustrates simultaneously the innate and the adaptive 
immune responses in these brains. Secondly, and most importantly, we have provided 
Figure 30. Increased CD8:CD4+ve T-cell ratio in Cln3-/- mice. Calculation of the ratios of 
CD8+ve and CD4+ve T-cells revealed a significant difference between Cln3-/-(―) and wildtype 
(···) (WT) mice at 12 months of age. Besides an age-dependent increase of CD8+ve cells influx in 
mutant and WT mice, significantly more CD8+ve lymphocytes infiltrate the brain of mutant mice 
at 12 months of age, resulting in a Cln3 deficiency dependent increase of CD8:CD4+ve T-cell 
ratio at this time point. However, at all ages more CD8+ve T-cells could be detected in both 
mouse populations, compared to CD4+ve T-cells. Statistics: Two-way ANOVA with Bonferroni 
post hoc test, ***p<0.001. Data shown as mean ± SEM, n = 5. 
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the first detailed characterisation of the adaptive immune response, in particular T-
cells, in the brains of both mouse models. We have not only detailed the presence of 
T-cells in the brains of both forms of NCL, but also quantified the number of these 
T-cells, their regional distribution in the brain and how this changes during the course 
of the disease. Furthermore, making additional regional volume measurements enabled 
us to compare wildtype and NCL brains with a new rostral-caudal perspective. This 
regional atrophy data was incorporated with our T-cell counts to obtain the density of 
T-cells in each part of the brain. Last but not least, this study included 21 month old 
mice, the oldest Cln3-/- mice analysed to date, providing an important new perspective 
on the later stages of disease progression.  
a) A wide range of immune cells is present in NCL brains 
Characterising the immune responses in the NCL CNS highlighted that glial activation 
is a key feature of multiple forms of NCL (reviewed in (Cooper et al., 2006; Jalanko 
and Braulke, 2009)). In both Infantile and Juvenile NCL localised glial activation has 
been described as starting within individual thalamic nuclei or specific cortical laminae 
in several studies (Bible et al., 2004; Pontikis et al., 2004; Pontikis et al., 2005; Kielar et 
al., 2007). However, to date, no direct comparison of innate and adaptive immune 
cells has been made in NCL brains. Using CD45, a marker which stains all types of 
immune cells (‘leukocytes’), we were able to qualitatively survey the extent and 
distribution of each immunological cell type in the brains of Ppt1-/- and Cln3-/- mice at 
different stages of disease progression (see Figure 16 and Figure 17). CD45 
immunoreactive lymphocytes, microglia, and macrophages could be detected in 
widespread regions of Ppt1-/- brains from 3 months onwards, but only at much later 
stages of disease progression in Cln3-/- brains, at 12 and 21 months of age. The 
characteristic presence of microglia and macrophages could be identified in the 
thalamocortical regions of both Ppt1-/- and Cln3-/- brains, as has been described before 
(Bible et al., 2004; Pontikis et al., 2005; Kielar et al., 2007), with scattered T-cell staining 
also present throughout the brain (see Figure 16 and Figure 17). The majority of 
these CD45+ve T-cells were seen in the more rostral regions of the brain (especially in 
the olfactory bulb), but they were also consistently present in every brain region that 
displayed microglial activation. This pattern was particularly maintained in cortical 
regions, but was perhaps less obvious in the thalamic nuclei where the most intense 
CD45+ve glial activation occurred (see Figure 16 and Figure 17). By comparing the 
appearance of microglial activation in the cortex between age groups, it could be 
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speculated that T-cells always seem to be present before, during and even after a wave 
of inflammatory microglial activation passed through a cortical region. These 
observations raised the question of what is the exact role of T-cells in the pathogenesis 
of these forms of NCL, which shall be addressed in the subsequent Chapter 4. To 
date, no T-cell or CD45 staining has been described in any detail in NCL brains, just 
being mentioned briefly in one study in 6 month old Ppt1-/- brains and one in 18 
month old Cln3-/- mice, where CD45 staining was used as proof of the presence of T-
cells (Lim et al., 2007b; Macauley et al., 2011). Taken together, our CD45 
immunostaining data revealed evidence of pronounced microglial activation and T-cell 
infiltration in many brain regions of Ppt1-/- and Cln3-/- mice. This distribution of T-cells 
was widespread and exhibited a rostrocaudal gradient, mostly coinciding with, but not 
exclusively restricted to, the distribution of microglial activation.  
b) Regional atrophy in NCL brains – a new rostral-caudal perspective  
We measured the volume of the entire hemisphere and each of five rostral-caudally 
defined levels to provide a new way of looking at the progression of pathological changes 
in different brain regions (see Appendix I: Figure 77 and Appendix I: Figure 78 for 
detailed results). In Ppt1-/- mice, previously reported data of regional brain atrophy 
described only relatively late onset shrinkage of the cortex at 7 months of age ((Bible et al., 
2004) Kielar and Cooper, unpublished observations). Consistent with our data for an 
earlier onset of glial activation and neuron loss (see Figure 32, Figure 36 and Figure 40 
in Chapter 4), this study revealed an earlier onset of regional brain atrophy in Ppt1-/- mice. 
Whole brain atrophy was already detected from 5 months onwards, whereas our rostral-
caudal analysis revealed that some degree of atrophy was already evident at 3 and 5 
months of age in the mid-levels of the forebrain, spreading to become a widespread 
atrophy at 7 months of age that included almost all rostrocaudal levels of the Ppt1-/- CNS. 
The only exception was level IV, which contains the midbrain, suggesting that this 
structure is affected to a lesser degree (see Appendix I: Figure 77). In Cln3-/- mice whole 
brain atrophy was only detected towards the disease end stage in 21 month old mice, with 
the mid-levels of the forebrain (level III, containing the thalamus and hippocampus) 
being the only rostral-caudal level to show a significantly reduced volume (see Appendix 
I: Figure 78). In previous studies of the two different JNCL mouse models, Cln3Δex7/8 
knock-in mice displayed moderate atrophy in the thalamus at 12 months of age (Pontikis 
et al., 2005), whereas no significant changes in regional volume were seen in early (5 
months) and mid-staged (14 months) Cln3-/- mice (Pontikis et al., 2004). Our study being 
the first investigation of progressive regional atrophy in Cln3-/- mice on a congenic 
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C57Bl/6 background, has extended these findings and demonstrated that cortical atrophy 
does indeed occur in 21 month old mice.  
In summary, this part of this thesis has provided a novel rostral-caudal perspective on 
progressive brain atrophy in INCL and JNCL, revealing new and valuable information 
about when these changes first occur. Perhaps more importantly, these data were also 
crucial for being able to convert raw numbers of lymphocytes into cellular density 
measurements, taking into account these variations in regional atrophy. 
c) Subtype-specific T-cell infiltration in NCL brains 
As the main findings of this chapter, we provide for the first time a detailed 
characterisation of lymphocyte infiltration during disease progression in mouse models 
of both Infantile and Juvenile NCL. Indeed, our data revealed that significant 
lymphocyte infiltration occurs in both forms of NCL. Because both mouse models 
were bred onto the same congenic C57Bl/6 background, they could be directly 
compared for the first time. In mice with INCL an early T-cell infiltration could be 
described (from 3 months onwards), whereas in the mouse model of JNCL the same 
extent of lymphocyte infiltration was reached only at a late stage of disease 
progression (21 months) (see Figure 21 and Figure 27). This is perhaps surprising in 
INCL, where lymphocyte involvement in pathogenesis has only recently been 
suspected at later stages of the disease (Macauley et al. 2011). In contrast in JNCL, 
which displays an autoimmune component and compromised BBB integrity 
(Chattopadhyay et al., 2003 a, 2003b; Lim et al., 2007), more pronounced lymphocyte 
infiltration might be expected. Interestingly, in Ppt1-/- mice both CD4+ve and 
CD8+ve cells were already present in the brain parenchyma at 3 months of age (see 
Figure 18 and Figure 19). This is in contrast to the lymphocyte infiltration seen in 
Cln3-/- mice, in which only CD8+ve cytotoxic T-cells seem to infiltrate the brain, with 
the entry of CD4+ve T-helper cells delayed until the end stages of disease (see Figure 
25 and Figure 26). Qualitative assessment of the T-cell distribution in the brains of 
Infantile and Juvenile NCL mice revealed no obvious T-cell clustering in any brain 
region. The only discernible difference between the two NCL forms was that more T-
cells were present in the VPM/VPL nuclei of Cln3-/- mice than in Ppt1-/- mice, at 
equivalent late stages of disease progression. This putative difference has not been 
quantified, but could speculatively be explained by specific T-cell attraction into 
neurodegenerative regions due to the autoimmune responses that occur in Cln3-/- mice 
(Lim et al., 2007b), or perhaps the influence of astrocytes upon immune cell infiltration 
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(Voskuhl et al., 2009), since Cln3-/- astrocytes show dysfunctional activation (Pontikis et 
al., 2004; Tyynela et al., 2004; Pontikis et al., 2005; Parviainen, 2012). The other 
consistent trend in the distribution of lymphocytes that was evident in both Ppt1-/- and 
Cln3-/- mice was a tendency for T-cells to be present near ventricles and/or in white 
matter tracts. This observation is potentially linked to this being the most likely route 
of entry for T-cells into the brain, provided that favourable endothelial cell – 
lymphocyte interactions occur (Ransohoff et al. 2003; Wilson et al. 2010). All of these 
suggestions shall be discussed in more detail in Chapter 7. 
Subsequent quantitative counts of lymphocytes in the brain demonstrated that in  
Ppt1-/-mice infiltrated CD4+ve T-cells already reached their maximal density at 3 
months of age, whereas CD8+ve T-cells numbers gradually increased over time (see 
Figure 21). This resembles the typical function of each subset of T-cells (see section 
1.7a in Chapter 1), with CD4+ve T-helper cells coordinating the inflammatory 
response and/or re-activating macrophages (see section 1.7a in Chapter 1, (Germain 
and Margulies, 1993; Zhu and Paul, 2008; Abbas and Lichtman, 2011)). Only a certain 
number of these cells are needed, whereas CD8+ve cytotoxic T-cells and their 
induction of apoptosis become more essential as the disease progresses (Townsend 
and Bodmer, 1989; Shresta et al., 1998; Abbas and Lichtman, 2011)). The pattern of T-
cell infiltration observed in Cln3-/- brains, with a delayed or absent CD4+ve T-helper 
cell infiltration, is not as straight forward (see Figure 27). As described in Chapter 1 
(see section 1.7a), the general consensus is that CD4+ve T-cells are not essential for 
successful CD8+ve T-cell activation and expansion (Castellino and Germain, 2006). 
However, the initial lack of CD4+ve T-cells, or the predominant infiltration of 
CD8+ve T-cells in the Cln3 deficient brain could perhaps be linked to autoimmune 
processes (Lim et al. 2007), impaired cytokine expression by glial cells and altered 
inflammatory cues in the brain (Dihanich, 2010; Parviainen, 2012), or perhaps T-cell 
specific impairments caused by Cln3 deficiency. Similar predominantly CD8+ve 
lymphocyte infiltration of the CNS has been described in Rasmussen’s Encephalitis, 
an auto-immune disease in which cytotoxic T-cells have been identified as main 
contributors to neurodegeneration (Bauer et al., 2002; Schwab et al., 2009). Whether a 
comparable pathogenic role of CD8+ve T-cells exists in Juvenile NCL still has to be 
determined. Further explanations for the different sequences of lymphocyte 
infiltration in Ppt1-/- and Cln3-/- mice shall be discussed in Chapter 7. 
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By adding a rostrocaudal analysis of their distribution, the second part of the 
characterisation of lymphocyte infiltration also revealed distinct patterns between 
these two forms of NCL. Whereas most T-cells were found in the olfactory bulb in 
both forms of NCL, in Ppt1-/- mice both CD4 and CD8+ve T-cells spread caudally 
over long distances within the brain (see Figure 22 and Figure 23). In contrast, in 
Cln3-/- mice CD8+ve T-cells were more restricted and appeared to accumulate 
predominantly in areas of the hippocampal forebrain (level III) and the midbrain with 
the pons (level V) (see Figure 28 and Figure 29). The explanation for this region-
specific distribution of lymphocytes in JNCL mice is unclear, but the thalamus and 
hippocampus are considered the primary pathological targets of the disease (Pontikis et 
al., 2004; Pontikis et al., 2005), which could potentially explain this pattern of 
lymphocyte infiltration. However, a similar rostrocaudal distribution of T-cells could 
be observed in 21 month old wildtype mice, suggesting that this pattern of lymphocyte 
infiltration may simply be an age-dependent phenotype that may be due to changes in 
protein expression on endothelial cells over time. In summary, analysis of 
CD8:CD4+ve cell ratios in both forms of the disease confirmed our data for each 
lymphocyte subtype. In murine INCL the T-cell ratio stays similar to that seen in 
wildtype mice at all ages, and therefore no disease-specific shift to one or the other 
type T-cell type appears to occur (see Figure 24). In contrast, in Cln3-/- mice a disease 
related shift to more CD8+ve (or, vice versa, to less CD4+ve cell types) could be 
detected at 12 months of age (Figure 30). This finding may reflect the sudden 
increase in CD8+ve cell infiltration at 12 months in Cln3-/- mice, combined with the 
simultaneous lack of CD4+ve cell infiltration (see Figure 27). Ratio analyses are 
useful tools to identify shifts towards   T-cell specific inflammatory responses and 
elucidate potential key contributors to disease phenotypes (Zaffaroni et al., 1991; 
Richartz-Salzburger et al., 2007; Richards et al., 2011). For example in the substantia 
nigra of Parkinson disease where 4:1 CD8:CD4 ratios can be found, these data 
identified CD8+ve T-cells as potentially being key players in disease pathogenesis 
(McGeer et al., 1988; Brochard et al., 2009). Thus, by quantifying the exact numbers, 
characterising lymphocyte subtype ratios, and the temporal and spatial distribution of 
both subpopulations of lymphocytes in Infantile and Juvenile NCL mouse brains, we 
were able to identify where and when each T-cell subset may contribute to disease 




d) Significance of findings 
The studies in this chapter incorporate for the first time a description of the adaptive 
immune response into the documented pathogenesis of both INCL and JNCL 
(Pontikis et al., 2005; Kielar et al., 2007). Not only could we demonstrate that T-cells 
are present in the brains of both forms of NCL, but we also defined clear differences 
between the adaptive immune responses in INCL and JNCL. Encouraged by these 
findings, we undertook the immune deficient double knockout experiments described 
in the next chapter to investigate the contribution of T-cells to the pathogenesis of 
INCL. In this proof of principle study we have demonstrated that adaptive immune 
cells are a common feature in the brains of these two forms of NCL, and suggest that 
similar investigations of the adaptive immune responses should also be conducted in 


























After demonstrating in Chapter 3 that T-cells infiltrate the brain of Ppt1-/- and Cln3-/- 
mice, we wanted to investigate the contribution of these adaptive immune cells to 
disease pathogenesis, focussing upon the murine model of INCL. Therefore, we 
crossed Ppt1-/- mice with mice deficient for Rag-1, an essential protein for the 
maturation process of T- and B-cells (see section 1.11a in Chapter 1), and therefore 
lack functioning T- and B-cells. Subsequently, we compared the resulting               
Ppt1-/-/Rag-1-/- mice with single knockout Ppt1 mice for well-described disease 
landmarks including glial activation, neuron loss and cortical atrophy (Bible et al., 2004; 
Kielar et al., 2007). Based on the findings by (Kielar et al., 2007), we concentrated this 
analysis of Ppt1-/- and Ppt1-/-/ Rag-1-/- mice on the thalamocortical system, specifically 
the thalamic ventral posterior nuclei (VPM/VPL) and the cortical somatosensory barrier field 
(S1BF), as interconnected brain regions that display particularly prominent pathology.     
4.1 Increased hemisphere mass in Ppt1-/-/Rag-1-/- mice 
To get a first indication of the extent of neurodegeneration over time, the weight of 
one hemisphere from each brain was recorded after paraformaldehyde (PFA) fixation. 
Since our histological analysis focused on the forebrain, we actually recorded the mass 
of each hemisphere after separating of the cerebellum, but with olfactory bulb intact 
(see section 2.2, in Chapter 2). From 5 months onwards a significant decrease in 
hemisphere mass could be observed in Ppt1-/- mice, compared to age-matched wildtype 
mice (see Figure 31). At 5 months of age Ppt1-/- mice were 18.3% lighter and at 7 
months of age were 25.45% lighter than age-matched wildtype mice.  
Extending this analysis to include Rag-1-/- and Ppt1-/-/Rag-1-/- double knockout mice, 
none of these genotypes showed any significant difference in hemisphere weight up to 
3 months of age (see Figure 31). At 5 months of age, Ppt1-/-/Rag-1-/- double knockouts 
lost 10.2% of hemisphere weight compared to the age-matched wildtype controls, but 
this still represents an 8.1% increase in mass compared to Ppt1-/- mice. From 3 months 
onwards, the hemispheres of double knockout mice were heavier than the ones of the 
corresponding Ppt1 single knockouts. However, this amelioration of brain atrophy 
only reached significance at 5 months of age. This difference disappeared at 7 months 
of age when the hemisphere of Ppt1-/-/Rag-1-/- double knockouts showed 5.8% less 























These data give an indication of a transient phenotypic improvement of Ppt1-/-/Rag-1-/- 
double knockouts compared to Ppt1-/- mice. However, such brain weight 
measurements have to be interpreted with caution as they are susceptible to many 
variable factors such as moisture content, weight differences due to injuries resulting 
from the harvesting of the brain or inconsistency of cerebellum removal. To minimize 
the effects of such variation in the measurements, the weighing procedure was 
performed in a strictly consistent manner by the same investigator. 
 
Figure 31. Progressive loss of brain mass in Ppt1-/- and Ppt1-/-/Rag-1-/- mice. The weights 
of brain hemispheres from mice of each genotype (Ppt1-/-, Ppt1-/-/Rag-1-/-, Rag-1-/- and wildtype) 
were measured after PFA fixation and removal of the cerebellum, but before further processing. 
From 5 months onwards there was a significant loss in hemisphere mass in Ppt1-/- mice, compared 
to age-matched wildtype mice (WT). Hemispheres from Ppt1-/-/Rag-1-/- mice were significantly 
heavier than those from Ppt1-/- mice at 5 months of age, while at 7 months of age this difference 
was no longer significant. WT and Rag-1-/- controls showed no significant differences in 
hemisphere mass at any age. The same data are presented as both histogram (A) and line graph 
(B). Percentages indicate differences between Ppt1-/-and Ppt1-/-/Rag-1-/- mice in comparison to age-
matched WT mice. Statistics: Two-way ANOVA with Bonferroni post hoc test, *p<0.05. Data 
shown as mean ± SEM, n = 5.        
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4.2  Impact of Rag-1 deficiency on reactive phenotypes in Ppt1-/- mice  
Neuronal damage and dysfunction are classically accompanied by up-regulation of glial 
cell markers in the brain. The most prominent and abundant glial cells in the brain, 
astrocytes and microglia have been studied extensively and their activation has been 
identified as an early marker of on-going neuronal damage or dysfunction (Raivich et 
al., 1999). An early glial activation can be also seen in the brains of NCL mice (see 
section 1.10 in Chapter 1, (Cooper et al., 2006; Cooper, 2010) and demonstrates a 
characteristic feature of Infantile NCL and Juvenile NCL mice (Bible et al., 2004; 
Pontikis et al., 2004; Kielar et al., 2007), but also for example in the South Hampshire 
sheep model of CLN6 disease (Oswald et al., 2005; Kay et al., 2006). 
All of these studies describe a localised activation of astrocytes and/or microglia 
before overt neuron loss, and it has been proposed that this phenotype serves as the 
most accurate indicator of where this subsequent neuron loss will occur (Cooper, 
2010). In order to characterise the onset and progression of this reactive phenotype in 
Ppt1-/-/Rag-1-/- mice and to compare the findings directly to single Ppt1-/- mice, we 
stained a 1 in 6 series of sections from 5 mice of each genotype at 1, 3, 5 and 7 
months of age for glial fibrillary acidic protein (GFAP) and the microglial marker 
CD68. Both glial markers can be analysed by thresholding image analysis, which 
measures the percentage and the intensity of stained areas in relevant brain regions 
(see section 2.7 in Chapter 2). In comparison to the work of (Kielar et al., 2007), we 
chose CD68 as a microglial marker instead of F4/80. The advantage of CD68 is that it 
results in a more distinct microglial cell labelling with lower background 
immunoreactivity that, if necessary, also can also be quantified by optical fractionator 
stereological counts, as we routinely do to assess neuron survival. 
Based on the findings of (Kielar et al., 2007), we concentrated the analysis of 
astrocytosis and microglial activation in Ppt1-/- and Ppt1-/-/Rag-1-/- mice on the 
thalamocortical system: focusing on interconnected brain regions with particularly 
prominent pathology: the thalamic ventral posterior nucleus (VPM/VPL) and the cortical 
somatosensory barrier field (S1BF).     





Astrocytosis is a commonly used indicator of inflammation and is a precursor to 
neuron loss in Infantile NCL mice as described by (Kielar et al., 2007), and other 
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forms of NCL (Oswald et al., 2005; Pontikis et al., 2005; Schmiedt et al., 2012). As a 
baseline for comparison to Ppt1-/-/Rag-1-/- mice we again stained sections from 1, 3, 5 
and 7 month old wildtype and Ppt1-/- mice with the GFAP marker for activated 
astrocytes (see Figure 32) and subsequently performed thresholding image analyses to 
quantify the level of GFAP immunoreactivity in the thalamic VPM/VPL nuclei of all 
brains (see Figure 33).  
This analysis confirmed and extended the previous report of astrocytosis in these 
mutant mice. The first traces of astrocytosis could already be detected in Ppt1-/- mice 
at 1 month of age, with scattered GFAP+ve astrocytes within VPM/VPL, but 
became much more obvious from 3 months onwards when many intensely stained 
GFAP+ve astrocytes were present in the VPM/VPL of Ppt1-/- mice (see Figure 
32A). With further disease progression the intensity and distribution of GFAP staining 
increased at 5 months of age, and subsequently reached maximal intensity at the end 
stage of the disease (7 months of age). At the same time points, no overt astrocyte 
activation was seen in wildtype mice. Looking at these GFAP+ve astrocytes at higher 
magnification, hypertrophied cell soma with thickened cell processes upon an area-
wide “carpet” of astrocytes could be detected from 3 months onwards in the 
VPM/VPL of Ppt1-/- mice (see Figure 32B). With disease progression the intensity 
and darkness of astrocyte cell staining increased, also manifesting itself as more intense 
staining of a dense meshwork of GFAP+ve astrocytes within the neuropil. In 
comparison, in 1 month old Ppt1-/- mice, and at all ages of wildtype mice, only 
sporadic faintly stained protoplasmic astrocytes with thin processes could be detected.  
In Ppt1-/-/Rag-1-/- double knockout mice the first evidence for astrocytosis was seen at 
3 months of age and became more pronounced with disease progression (see Figure 
32A), similar to that seen in Ppt1-/- mice. However, at every age studied Ppt1-/-/Rag-1-/- 
double knockouts showed a reduced level of astrocytosis compared to single mutant 
INCL mice. This difference is clearly seen at higher magnification in Ppt1-/-/Rag-1-/- 
double knockout mice at 3 and 5 months of age when GFAP+ve astrocytes displayed 
a much less pronounced hypertrophy and less intense staining of their processes (see 
Figure 32B). At these earlier time points the VPM/VPL was not completely filled 
with GFAP immunoreactive astrocytes in Ppt1-/-/Rag-1-/- double knockouts, whereas at 





Figure 32. Progressive astrocytosis in the thalamus of Ppt1-/- and Ppt1-/-/Rag-1-/- double 





Quantification of GFAP immunoreactivity via thresholding image analysis confirmed 
these morphological observations (see Figure 33). GFAP immunnoreactivity was 
significantly increased in the thalamus of single as well as double Ppt1 mutant mice 
from 3 months onwards and increased with disease progression. However, a similar 
reduction in GFAP immunoreactivity could be seen in Ppt1-/-/Rag-1-/- double mutants 
at 3 and 5 months of age (15.7% at 3 months and 15.3% difference at 5 months). 
However, the level of GFAP immunoreactivity subsequently increased dramatically, 
almost reaching similar levels to those seen in Ppt1-/- single mutants at 7 months of 
age. Although a 7.8% mean reduction in GFAP immunoreactivity was measured in the 
immune deficient Ppt1-/-/Rag-1-/- brains at this time point, this difference was not 
statistically significant mainly due to a higher variability in these data. 




To complete our analysis of astrocytosis in the somatosensory thalamocortical system, 
we next analysed the relative level of GFAP+ve astrocytosis in the somatosensory 
cortical sub-region (S1BF) to which VPM/VPL projects, first comparing Ppt1-/- mice 
to age-matched wildtype animals. At 1 month of age Ppt1-/- mice already showed 
marginally increased GFAP immunoreactivity, with more darkly stained astrocytes 
throughout the S1BF cortex. But from 3 months onwards, clear widespread GFAP 
immunoreactivity could be observed throughout all laminae of S1BF (see Figure 34A) 
of Ppt1-/- mice, but most prominently in its deeper layers, in particular within lamina V.  
Figure 32. Progressive astrocytosis in the thalamus of Ppt1-/- and Ppt1-/-/Rag-1-/- double 
knockout mice. (A) Immunohistochemical staining for the astrocyte marker glial fibrillary acidic 
protein (GFAP) in the thalamus of 1, 3, 5 and 7 month old mice revealed localised astrocytosis 
within the ventral posterior nucleus (VPM/VPL) (---) of INCL mice. At all ages, Ppt1-/-/Rag-1-/- 
double knockout mice showed attenuated GFAP immunoreactivity compared to Ppt1-/- mice. 
From 3 months of age localised astrocytosis could be observed in the VPM/VPL of mutant 
mice, which spread to involve the whole thalamus with increased age. GFAP immunoreactivity 
was virtually absent in age-matched Rag-1-/- mice or wildtype (WT) mice. Scale bar = 200 μm (B) 
Higher magnification reveals the morphology of GFAP+ve astrocytes in the VPM/VPL of   
Ppt1-/- and Ppt1-/-/Rag-1-/- mice at 1, 3, 5 and 7 month of age. Compared to the faintly 
immunoreactive protoplasmic astrocytes present in 1 month old mutant mice, many intensely 
stained fibrous astrocytes were present in VPM/VPL from 3 months onwards in both strains of 
mutant mice. These astrocytes displayed thickened processes and became more numerous with 
increased age until the thalamic neuropil was completely filled with GFAP+ve astrocytes and their 
processes by 7 months of age. In direct comparison between Ppt1-/- and Ppt1-/-/Rag-1-/- mice, this 
astrocytosis was less pronounced in the double knockout mice at all ages. The Ppt1-/-/Rag-1-/- mice 
displayed delayed and attenuated GFAP+ve cell staining with distinguishable single astrocytes at 3 
months of age, and spatially inclusive and comprehensive astrocytosis only becoming apparent 
from 5 months onwards in these mice. In WT and Rag-1-/- mice only occasional faintly stained 
protoplasmic astrocytes with many long thin branched processes could be seen at all ages. Scale 















The intensity of GFAP staining increased with age and spread to involve the upper 
layers of the cortex from 5 months onwards. At 7 months of age two distinct and 
darkly stained bands of activated astrocytes could be detected with darkest staining in 
laminae V and I (see Figure 34A).  
In comparison to Ppt1-/- mice, the immune deficient Ppt1-/-/Rag-1-/- double knockout 
mice showed a reduced astrocytosis in S1BF (see Figure 34A), similar to the effects 
seen in the thalamus of these mice (see Figure 32). Whereas at 3 months of age Ppt1-/- 
mice already showed wide-spread astrocytosis in S1BF, in immune deficient Ppt1-/-
/Rag-1-/- mice GFAP+ve astrocytes could only be found in lamina V at this age. Later 
in disease progression at 5 months of age this astrocytosis spread to be present in all 
Figure 33. Reduced levels of astrocytosis in the thalamus (VPM/VPL) of Ppt1-/-/Rag-1-/- 
double knockout mice. Thresholding image analysis revealed that the mean level of GFAP 
immunoreactivity in double knockout mice was significantly reduced at 3 and 5 months, 
compared to Ppt1-/- mice. In contrast, almost no GFAP immunoreactivity was detected in the 
thalamus of either Rag-1-/- or wildtype (WT) mice. Thus, Ppt1-/- and Ppt1-/-/Rag-1-/- mice displayed 
significantly increased GFAP immunoreactivity from 3 months onwards compared to WT mice. 
The same data are presented as both histogram (A) and line graph (B). Percentages indicate 
differences between Ppt1-/-and Ppt1-/-/Rag-1-/- mice. Statistics: Two-way ANOVA with Bonferroni 





Figure 34. Progressive astrocytosis in the somatosensory barrel field (S1BF) cortex of  





other laminae of S1BF in the double mutants, but to a much lesser extent than was 
seen in Ppt1-/- mice. Finally, as in the thalamus, at 7 months of age the distribution and 
intensity of GFAP immunoreactivity was seen at similar levels in Ppt1-/-/Rag-1-/- mice 
and Ppt1-/- mice.  
Similarly, higher magnification images of the astrocytosis in lamina V of the S1BF 
cortex confirmed the delayed and attenuated up-regulation of GFAP 
immunoreactivity in Ppt1-/-/Rag-1-/- mice (see Figure 34B). Whereas in Ppt1-/-/Rag-1-/- 
mice single astrocytes were distinguishable in lamina V until 5 months of age, 
astrocytes in Ppt1-/- mice displayed a more intense staining of their processes, leading 
to a more spatially inclusive astrocytosis already from 3 months onwards (see Figure 
34B).  
Quantifying this cortical GFAP staining via thresholding image analysis confirmed the 
significantly elevated astrocytosis in S1BF from 3 months onwards in Ppt1-/- mice, 
compared to wildtype animals, and this difference increased with age (see Figure 35). 
Although consistently lower levels of GFAP immunoreactivity were seen in the cortex 
of Ppt1-/-/Rag-1-/- mice compared to Ppt1-/- mice, these changes did not reach statistical 
Figure 34. Progressive astrocytosis in the somatosensory barrel field (S1BF) cortex of 
Ppt1-/- and Ppt1-/-/Rag-1-/- double knockout mice. (A) Immunohistochemical staining for the 
astrocyte marker glial fibrillary acidic protein (GFAP) in the S1BF of 1, 3, 5 and 7 month old mice 
revealed differences between Ppt1-/- and Ppt1-/-/Rag-1-/- double knockout mice. Ppt1-/-/Rag-1-/- 
double knockout mice showed a clearly delayed and reduced astrocytosis at 3 and 5 months of 
age, compared to Ppt1-/- mice. In single mutant Ppt1-/- mice widespread astrocytosis throughout all 
laminae of the cortex could be observed which increased in intensity with disease progression. 
Most prominent GFAP immunoreactivity was seen in deeper laminae (especially lamina V) from 3 
months of age onwards, and in laminae I and II at 7 months of age. In contrast, in Ppt1-/-/Rag-1-/- 
double knockout mice, at 3 months of age only lamina V of the cortex showed pronounced 
GFAP immunoreactivity and widespread astrocytosis throughout all layers was only apparent 
from 5 months of age onwards in these mice. At 7 months of age similar intensity and pattern of 
astrocytosis could be detected in Ppt1-/-/Rag-1-/- mice as in Ppt1-/- mice. In WT and Rag-1-/- mice 
only occasional faintly stained protoplasmic astrocytes with many long thin branched processes 
could be seen at all ages. Scale bar = 100 μm. (B) Higher magnification of lamina V reveals the 
morphology of GFAP+ve astrocytes in the S1BF of Ppt1-/- and Ppt1-/-/Rag-1-/- mice at 1, 3, 5 and 
7 month of age. Compared to the faintly immunoreactive protoplasmic astrocytes present in 1 
month old mutant mice, many intensely stained fibrous astrocytes were present in lamina V of the 
S1BF from 3 months onwards in both strains of mutant mice. These astrocytes displayed 
thickened processes and became more numerous with increased age.  In direct comparison 
between Ppt1-/- and Ppt1-/-/Rag-1-/- mice, this astrocytosis was less pronounced in the double 
knockout mice at all ages. Whereas in Ppt1-/- mice the majority of the neuropil of lamina V was 
spatially inclusively filled with GFAP+ve astrocytes and their processes from 3 months onwards, 
Ppt1-/-/Rag-1-/- mice displayed delayed and attenuated GFAP+ve cell staining with distinguishable 
single astrocytes until 5 months of age. In WT and Rag-1-/- mice only occasional faintly stained 

















significance. This is probably due to the generally lower intensity of GFAP staining in 
the cortex (compared to the thalamus) and the rather indistinct staining pattern of 
GFAP+ve astrocytes. During the earlier stages of the disease a reduction in GFAP 
immunoreactivity of 5.0% at 3 months and 5.3% at 5 months of age could be 
observed. However, at 7 months of age there was no detectable difference between 
the genotypes, as had been seen in the thalamus of these mice (see Figure 33). 
Astrocytosis in S1BF followed a similar time course to its afferent thalamic relay 
nuclei, but the relative level of astrocytosis was much lower in the cortex than in the 
thalamus. This is consistent with the observations described by (Kielar et al., 2007), 
Figure 35. Marginally reduced levels of astrocytosis in the somatosensory barrel field 
(S1BF) cortex of Ppt1-/-/Rag-1-/- double knockout mice. Thresholding image analysis reveals 
that the mean level of GFAP immunoreactivity in double knockout mice was marginally reduced 
at 3 and 5 months of age, compared to Ppt1-/- mice, but this difference was not significant. In 
contrast, almost no GFAP immunoreactivity was detected in the thalamus of either Rag-1-/- or 
wildtype (WT) mice. Thus, Ppt1-/- and Ppt1-/-/Rag-1-/- mice displayed significantly increased GFAP 
immunoreactivity from 3 months onwards compared to WT mice. The same data are presented as 
both histogram (A) and line graph (B). Percentages indicate differences between Ppt1-/-and      
Ppt1-/-/Rag-1-/- mice. Statistics: Two-way ANOVA with Bonferroni post hoc test. Data shown as 
mean ± SEM, n = 5.        
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who showed that astrocytosis in the cortex of Ppt1-/- mice can be seen from 3 months 
of age onwards, but lags behind thalamic astrocytosis.   





Microglial activation has proved to be a sensitive indicator of neurological dysfunction 
and pathology (Raivich et al., 1999; Streit et al., 2004; Graeber and Streit, 2010). In 
Ppt1-/- mice the appearance of staining for the microglial marker F4/80 is a relatively 
late event, occurring at 5 months of age once neuron loss has already begun (Kielar et 
al., 2007). To gain a more complete picture of microglial activation, we firstly stained 
tissue from Ppt1-/- mice at 1, 3, 5 and 7 months of age with CD68, a widely used and 
sensitive marker of microglial activation (Holness and Simmons, 1993; Ohmi et al., 
2003; Henkel et al., 2004). This analysis revealed evidence for a much earlier microglial 
response within the thalamus of Ppt1-/- mice than had been seen via F4/80 staining 
(Kielar et al., 2007). In wildtype mice of all ages CD68+ve microglia displayed a 
relative small cell soma and faint punctate staining of thin cellular processes (see 
Figure 36). 
A very similar appearance was seen in 1 month old Ppt1-/- mice with CD68 staining 
that was perhaps slightly more intense than in age-matched wild type controls. 
However, from 3 months of age onwards intensely stained CD68+ve microglia were 
evident within the VPM/VPL of Ppt1-/- mice and displayed a range of morphologies 
see Figure 36B), many with swollen soma, but others with numerous thickened and 
branched processes and only some with an intensely stained cell soma. With disease 
progression many more darkly stained cells with swollen and intensely stained soma 
and shortened processes were evident within the VPM/VPL of Ppt1-/- mice. At 5 
months of age, many more partially activated microglia were present, surrounded by a 
distinct halo of short processes around their cell soma. At 7 months of age the 
majority of microglial cells took on the characteristic highly activated morphology of 
brain macrophages. In the corresponding age-matched control brains, CD68 positive 
cells displayed the morphology of resident or resting microglia with small soma and 
long thin processes monitoring their direct proximity.    
To identify the impact of knocking out Rag-1 upon microglial activation in INCL 
mice, we also stained a complete series of immune deficient Ppt1-/-/Rag-1-/- double 
knockout mice and Rag-1-/- single mutant mice for CD68 (see Figure 36A). At all ages 




Figure 36. Progressive microglial activation in the thalamus (VPM/VPL) of Ppt1-/- and 





staining, compared to single knockout Ppt1-/- mice. Microglial activation in             
Ppt1-/-/Rag-1-/- double knockout mice, as judged by CD68 immunoreactivity, started at 
3 months, increased over time and was most pronounced in the thalamic regions of 
these mice. CD68+ve cells in the double knockouts progressively showed the same 
age-associated increase in the appearance of microglia with an activated morphology, 
with swollen soma and thickened short processes, as had been seen in single Ppt1-/- 
mice, but with a relatively slower time-course. At 3 months of age, most CD68 
positive microglia in Ppt1-/-/Rag-1-/- mice possessed elongated thin processes, with 
only sporadic more intensely stained activated microglia, whereas in single knockout 
Ppt1-/- mice several macrophage like cell morphologies could already be found at this 
age (see third and fourth row of bottom panel in Figure 36B). At 5 months of age, 
the majority of CD68+ve cells in Ppt1-/-/Rag-1-/- double knockout mice also 
morphologically resembled brain macrophages, but clearly showed weaker staining 
intensity than in age-matched Ppt1-/- mice. The same relative differences in CD68 
staining between these genotypes could also be seen at 7 months of age, but with 
generally higher activation than at 5 months of age, with virtually all cells resembling 
highly activated and intensely stained macrophage-like cells. Interestingly, the halo of 
microglial cell processes around the soma of partially activated microglia seen in Ppt1-/- 
mice, could not be seen at all or only very weakly in Ppt1-/-/Rag-1-/- double knockout 
mice at any age.  
Quantifying these differences in CD68+ve microglial activation via thresholding image 
analysis confirmed the relative levels of staining in Ppt1-/- and Ppt1-/-/Rag-1-/- double 
knockout mice (see Figure 37). In both single and double Ppt1 mutant mice  
Figure 36. Progressive microglial activation in the thalamus (VPM/VPL) of Ppt1-/- and 
Ppt1-/-/Rag-1-/- double knockout mice. (A) Immunohistochemical staining for the microglial 
marker CD68 in the thalamus of 1, 3, 5 and 7 month old mice revealed localised microglial 
activation within the ventral posterior nucleus (VPM/VPL) (---) of INCL mice. At all ages,              
Ppt1-/-/Rag-1-/- double knockout mice showed reduced CD68 immunoreactivity compared to  
Ppt1-/- mice. Microglial activation was observed in the VPM/VPL of INCL mice from 3 months 
onwards, which spread to involve the whole thalamus and gained in intensity with increased age. 
Similar microglial activation was absent in Rag-1-/- and wildtype (WT) mice, in which only faint 
staining of quiescent microglia could be detected. Scale bar = 200 μm. (B) Higher magnification 
pictures of CD68+ve microglia in the thalamus of 1, 3, 5 and 7 month old mice revealed 
differences in cell morphology and activation between immunodeficient double and single Ppt1 
mutant mice. Ppt1-/-/Rag-1-/- double knockout mice showed reduced microglial activation in the 
thalamus at all ages in terms of cell size, staining intensity and transformation into brain 
macrophages. Microglia in Ppt1-/- mice were intensely CD68 immunoreactive with an enlarged and 
rounded cell soma from 3 months onwards, whereas microglia in Ppt1-/-/Rag-1-/- double knockout 
mice remained relatively smaller at all ages, with elongated microglial processes present until 5 
months of age. Only quiescent microglia could be detected in 1 month INCL mice and control 

















significantly increased levels of CD68 staining could be observed from 3 months 
onwards, compared to wildtype mice, which steadily increased in intensity with age 
and reached a maximum level at 7 months of age. From 3 months onwards 
significantly less CD68 immunoreactivity could be detected in the thalamus of       
Ppt1-/-/Rag-1-/- double knockout mice, compared to single knockout Ppt1-/- mice. This 
difference became more pronounced with the progression of the disease, with 8.3% 
less immunoreactivity at 3 months, 10.1% less staining at 5 months and 13.5% less 
staining at 7 months of age in the double knockout mice. However, the shape of the 
curve of CD68 immunoreactivity over time, indicative of the rate of disease 
Figure 37. Reduced levels of microglial activation in the thalamus (VPM/VPL) of         
Ppt1-/-/Rag-1-/- double knockout mice. Thresholding image analysis reveals that the mean 
level of CD68 immunoreactivity in double knockout mice was significantly reduced at 3, 5 and 7 
months of age, compared to Ppt1-/- mice. In contrast, almost no CD68 immunoreactivity was 
detected in the thalamus of either Rag-1-/- or wildtype (WT) mice. Thus, Ppt1-/- and Ppt1-/-/Rag-1-/- 
mice displayed significantly increased CD68 immunoreactivity from 3 months onwards compared 
to WT animals. The same data are presented as both histogram (A) and line graph (B). 
Percentages indicate differences between Ppt1-/-and Ppt1-/-/Rag-1-/- mice. Statistics: Two-way 
ANOVA with Bonferroni post hoc test, *p<0.05, **p<0.01, ***p<0.001. Data shown as mean ± 
SEM, n = 5.        
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progression, did not appear to change in these double knockout mice. These data 
suggest that microglial activation in the thalamus seemed to be weaker and delayed in 
the immune deficient Ppt1-/-/Rag-1-/- mice, but followed the same general pattern over 
time as that seen in Ppt1-/- mice.   





In the somatosensory cortex (S1BF) of Ppt1-/- mice CD68+ve microglial activation 
could be observed from 3 months onwards (see Figure 38). At this time point in  
Ppt1-/- mice CD68 immunoreactivity was most pronounced in deeper layers, in 
particular within lamina VI, and subsequently microglial activation spread to involve 
the upper cortical layers of S1BF from 5 months of age onwards. At 7 months of age 
microglial activation could be detected throughout the entire somatosensory cortex of 
Ppt1-/- mice, with the most prominent bands of CD68+ve cells present in laminae 
II+III and VI (see Figure 38A).  
At all ages examined, Ppt1-/-/Rag-1-/- double knockout mice displayed delayed and 
reduced levels of microglial activation in S1BF, compared to single mutant Ppt1-/- mice 
(see Figure 38A). Whereas in Ppt1-/- mice significant microglial up-regulation of CD68 
could be seen from 3 months onwards, in Ppt1-/-/Rag-1-/- double knockout mice the 
first morphological indications of microglial activation could only just be detected at 
this time point. Similar to Ppt1-/- mice, this microglial activation started off in lamina 
VI of S1BF in Ppt1-/-/Rag-1-/- double mutant mice and spread subsequently to involve 
more dorsal layers of the cortex. At 5 months of age only slightly elevated CD68 
staining of microglia could be observed in these Ppt1-/-/Rag-1-/- mice, compared to the 
markedly more pronounced staining evident in Ppt1-/- mice, indicative of a slowing of 
the innate immune response in these double mutant mice. However, at 7 months of 
age intense CD68+ve staining of microglia in Ppt1-/-/Rag-1-/- double knockout mice 
had nearly reached the levels seen in Ppt1-/- mice. Many morphologically activated 
CD68+ve microglia were dispersed throughout the cortical mantle of double mutant 
mice at this time point, but in a much more homogenous and less laminar specific 
manner than was apparent in Ppt1-/- mice (see bottom right panel in Figure 38A). 
Direct comparison of the microglial morphology in lamina VI of the S1BF of both 
mutant mice (see Figure 38B), confirmed the delayed microglial activation of        
Ppt1-/-/Rag-1-/- double knockout mice. Many intensely stained microglia with enlarged 





Figure 38. Progressive microglial activation in the somatosensory barrel field (S1BF) 





whereas microglia in Ppt1-/-/Rag-1-/- mice remained smaller, were less darkly stained 
and displayed more elongated cell processes at all ages (see third and fourth row of 
Figure 38B). 
Quantification of CD68 immunoreactivity via thresholding image analysis verified the 
qualitative observations described above. Microglial activation in S1BF of single and 
double Ppt1 mutant mice followed a similar distribution and age-related increase with 
disease progression, as was seen in the thalamus. However, this CD68 
immunoreactivity was always at much lower levels in the cortex (see Figure 39). In 
Ppt1-/- mice slightly elevated CD68 immunoreactivity could already be detected at 1 
month of age compared to wildtype (WT) mice, but this difference did not reach 
statistical significance. The first significant microglial activation in the S1BF of Ppt1-/- 
mice was evident from 3 months onwards, compared to wildtype animals. This 
difference in CD68 staining became more pronounced with age, reaching a maximum 
at 7 months of age. In double mutant mice the introduction of Rag1 deficiency also 
proved to have an effect upon microglial activation in the cortex of Ppt1-/- mice. At 1 
month of age only marginally less (0.4%) CD68 immunoreactivity could be detected in 
Ppt1-/-/Rag-1-/- mice compared to Ppt1-/- mice, whereas at 3 months of age a mean 
reduction of 1.3% and at 5 months of age of 2.4% CD68 immunoreactivity per 
analysed image were observed. However, it was only at 5 months of age that these 
differences reached significant levels. At 7 months of age, both genotypes showed  
Figure 38. Progressive microglial activation in the somatosensory barrel field (S1BF) 
cortex of Ppt1-/- and Ppt1-/-/Rag-1-/- double knockout mice. (A) Immunohistochemical 
staining for the microglial marker CD68 in the S1BF of 1, 3, 5 and 7 month old mice revealed 
differences between Ppt1-/- and Ppt1-/-/Rag-1-/- double knockout mice. Ppt1-/-/Rag-1-/- double 
knockout mice clearly showed delayed and reduced microglial activation at all ages compared to 
Ppt1-/- mice. In Ppt1-/- mice intensely stained CD68 positive microglia were most prominent in 
deeper laminae (mainly layer VI) from 3 months of age onwards, but this microglial activation 
spread to upper layers and increased in intensity with disease progression. At 7 months of age 
widespread CD68 immunoreactivity was present throughout all layers, but most prominently in 
laminae II+III and VI. In contrast, in Ppt1-/-/Rag-1-/- double knockout mice only weak microglial 
activation could be seen in lamina VI at 3 and 5 months of age, leading to microglial activation 
spread homogenously throughout all layers at 7 months of age. Similar activation was absent in 
control animals (Rag-1-/-, wildtype (WT)) where only quiescent microglial staining could be 
detected. Scale bar = 100 μm. (B) Higher magnification pictures of CD68+ve microglia in lamina 
VI of the S1BF of 1, 3, 5 and 7 month old mice revealed differences in cell morphology and 
activation between immunodeficient double and single Ppt1 mutant mice. Ppt1-/-/Rag-1-/- double 
knockout mice showed reduced microglial activation in lamina VI of the S1BF at all ages in terms 
of numbers, cell size, staining intensity and transformation into brain macrophages. Intensely 
stained microglia with an enlarged and rounded cell soma were seen in Ppt1-/- mice from 5 months 
onwards, whereas microglia in  Ppt1-/-/Rag-1-/- double knockout mice remained relatively smaller 
at all ages, with elongated microglial processes present on most cells until 7 months of age. Only 
quiescent microglia could be detected in 1 month INCL mice and control animals (Rag-1-/- and 
















similar levels of microglial activation with the reduction in CD68 immunoreactivity 
falling back to 1.5%. At this oldest time point, a higher variance prevented any 
statistical significance between the levels of CD68 staining between these genotypes.  
Taken together, all our data of glial activation (see Figure 33, Figure 35, Figure 37, 
and Figure 39) revealed that microglial activation and astrocytosis become apparent in 
the thalamus as well as in the cortex at a similar early stage of disease progression, at 3 
months of age. This coincides with the infiltration of lymphocytes (see Figure 21 in 
Figure 39. Reduced levels of microglial activation in the somatosensory barrel field 
(S1BF) cortex of Ppt1-/-/Rag-1-/- double knockout mice. Thresholding image analysis reveals 
that the mean level of CD68 immunoreactivity in double knockout mice was marginally reduced 
at all ages, compared to Ppt1-/- mice, but these differences only reached significant levels at 5 
months of age.  In contrast, almost no CD68 immunoreactivity was detected in the thalamus of 
either Rag-1-/- or wildtype (WT) mice. As such, Ppt1-/- and Ppt1-/-/Rag-1-/- mice displayed increased 
CD68 immunoreactivity from 1 month onwards compared to WT mice, but this difference only 
reached significant levels from 3 months onwards. The same data are presented as both histogram 
(A) and line graph (B). Percentages indicate differences between Ppt1-/-and Ppt1-/-/Rag-1-/- mice. 
Statistics: Two-way ANOVA with Bonferroni post hoc test, *p<0.05. Data shown as mean ± 
SEM, n = 5.        
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Chapter 3) and the first significant neuron loss (see Figure 40) in this brain region, 
highlighting its importance as a key stage in the pathogenesis of INCL. Furthermore, 
the absence of the adaptive immune system in the Ppt1-/-/Rag-1-/- mice double 
knockout mice appeared to delay the microglial response in both regions to a relatively 
similar extent, but this effect is more evident in the thalamus, perhaps due to its higher 
levels of glial activation.  Therefore, our data demonstrate that adaptive immune cells 
appear to have an enhancing effect on innate immune responses in the murine INCL 
brains. 
4.3 Impact of Rag-1 deficiency on neuron survival in Ppt1-/- mice  
After establishing that the lack of adaptive immune cells attenuates the glial activation 
in Ppt1-/-/Rag-1-/- double knockout mice, we next investigated if such differences in 
innate immune responses alter the previously described neurodegeneration in Ppt1-/- 
mice (Bible et al., 2004; Kielar et al., 2007).  





Pronounced neuron loss in VPM/VPL could first be detected from 3 months 
onwards in Ppt1-/- mice, compared to age-matched wildtype mice (see Figure 40). At 
this time point, 57.6% less neurons were present in Ppt1 deficient mice, compared to 
age-matched wildtype controls. At 5 months of age over 79 % of neurons were lost in 
these single mutant mice, while at 7 months of age only 5.2% of VPM/VPL relay 
neurons remain alive in this nucleus of the thalamus compared to age-matched 
controls. In addition to revealing the progressive loss of VPM/VPL neurons these 
data reveal that the greatest loss of these neurons occurs between 1 and 3 months of 
age, but at the later stages neuron loss continues at a much slower rate. These data 
stand in contrast to previous findings in INCL mice (Kielar et al., 2007), in which 
neuron loss in the thalamic VPM/VPL nuclei have only been detected from 5 months 
onwards. This discrepancy is most likely explained by the usage of a different cohort 
of (putatively more affected) mice and in the different counting criteria that may be 
employed by individual investigators. 
Knocking out the adaptive immune system in Ppt1-/- mice significantly improved the 
survival of VPM/VPL thalamic relay neurons in Ppt1-/-/Rag-1-/- double knockout mice 
at 3 months of age, with 19.8% more neurons present than in Ppt1-/- mice (see Figure 
















effect almost completely vanished at later stages of the disease with no significant 
difference being found subsequently between Ppt1-/- and Ppt1-/-/Rag-1-/- mice.  Indeed, 
only a minimal improvement in VPM/VPL neuron survival could be detected with 
only 2.9% more neurons at 5 months and 3.3% more neurons at 7 months of age in 
these double knockouts. Compared to age-matched wildtype mice this represents the 
survival of just 23.9% of these neurons at 5 months, and just 8.5% of VPM/VPL 
Figure 40. Progressive loss of thalamic (VPM/VPL) neurons in Ppt1-/- and Ppt1-/-/Rag-1-/- 
mice. Unbiased optical fractionator estimates of number of Nissl stained thalamic relay neurons 
in the ventral posterior nucleus (VPM/VPL) of Ppt1-/-, Ppt1-/-/Rag-1-/-, Rag-1-/- and age-matched 
wildtype (WT) control mice at different stages of disease progression. Significantly fewer 
VPM/VPL neurons were present in both single and double Ppt1 mutant mice from 3 months 
onwards compared to WT mice, and continued to decline in number with increased age. 
Nonetheless, neuron loss was significantly slowed down in Ppt1-/-/Rag-1-/- mice. Significantly more 
neurons were present in Ppt1-/-/Rag-1-/- mice at 3 months compared to Ppt1-/- mice, but 
VPM/VPL neuron number in Ppt1-/-/Rag-1-/- mice decreased to similar levels at later stages of 
the disease. Rag-1-/- and WT mice showed no significant difference in neuron numbers at any age. 
The same data are presented as both histogram (A) and line graph (B). Percentages indicate 
differences between Ppt1-/-and Ppt1-/-/Rag-1-/- mice compared to age-matched WT mice. Statistics: 
Two-way ANOVA with Bonferroni post hoc test, ***p<0.001. Data shown as mean ± SEM, n = 




neurons surviving at 7 months of age in Ppt1-/-/Rag-1-/- double knockouts. In contrast, 
VPM/VPL neuron numbers in Rag-1-/- control mice did not significantly differ from 
wildtype animals at any age examined. 
In summary, a lack of mature T- and B-cells, as a result of Rag-1 deficiency, delays and 
slows down disease progression during its early stages in the somatosensory thalamus, 
one of the most affected brain structures in Ppt1-/- mice (Kielar et al., 2007). However, 
this apparent slowing down of disease progression is abolished from 5 months 
onwards, when other pathologic driving forces appear to become more relevant. It 
appears that once a certain threshold of pathologic events is reached, the loss of 
VPM/VPL neurons is inevitable and rapidly catches up with the extent of neuron loss 
seen in Ppt1 deficient mice (see Figure 40; (Kielar et al., 2007)). Nevertheless, the 
adaptive immune system appears to accelerate the final outcome and blocking these 
responses may still have a beneficial effect in slowing disease progression. However, 
because the thalamus is the most and earliest affected region in the INCL brain, 
perhaps a more sustainable protective effect may be seen in less affected regions of 
the brain. 





VPM/VPL neurons relay somatosensory information to the barrel field cortex 
(S1BF), which also shows progressive neuron loss in Ppt1-/- mice, subsequent to events 
within the thalamus (Kielar et al., 2007). Although originally omitted in this thesis due 
to time restrictions, similar optical fractionator counts have now been performed in 
the somatosensory cortex (S1BF) of 3, 5 and 7 month old mice of all genotypes by 
Steven Duckett, a MSc student in the PSDL. He demonstrated a significant 
improvement in the survival of lamina V S1BF neurons in Ppt1-/-/Rag-1-/- mice at 5 
months of age compared to single Ppt1-/- mice (see Appendix II: Figure 79). 
However, this difference was no longer apparent at 7 months of age. Therefore, the 
genetic removal of adaptive immune cells also reduced neuron loss in the cortical 
S1BF sub-region, but in a delayed manner compared to events in the thalamus. 
However, as a prelude to performing more detailed counts of neuron survival in the 
cortex of Ppt1-/-/Rag-1-/- double knockout mice, we also obtained cortical volume 




4.4 Impact of Rag-1 deficiency on cortical atrophy in Ppt1-/- mice 
In human INCL marked cortical atrophy has already been reported (Haltia et al., 
1973a), and in mice this happens in a regionally selective manner, being more 
pronounced in sensory than motor cortex and occurring at different times (Bible et al., 
2004; Kielar et al., 2007). To determine the relative extent of cortical atrophy in 
immune deficient Ppt1-/-/Rag-1-/- double knockout mice, we measured the entire 
cortical volume of all genotypes at all four ages in Nissl stained sections using the 
unbiased Cavalieri method (see Figure 41). Firstly, comparing Ppt1-/- mice to age-













Figure 41. Cortical atrophy in Ppt1-/- and Ppt1-/-/Rag-1-/- mice. Unbiased Cavalieri estimates 
of cortical volume of Ppt1-/-, Ppt1-/-/Rag-1-/-, Rag-1-/- and age-matched wildtype (WT) control 
animals at different stages of disease progression. Cortical atrophy was significantly less 
pronounced in Ppt1-/-/Rag-1-/- mice from 3 months onwards, compared to Ppt1-/- mice. Compared 
to WT mice, Ppt1-/- mice displayed cortical atrophy from 3 months onwards, whereas cortical 
volume in Ppt1-/-/Rag-1-/- mice resembled that of WT mice until 5 months of age, and only 
showed significant atrophy at 7 months of age. Rag-1-/- and WT mice showed no significant 
difference in cortical volume at any age. The same data are presented as both histogram (A) and 
line graph (B). Percentages indicate differences between Ppt1-/-and Ppt1-/-/Rag-1-/- mice compared 
to age-matched WT mice. Statistics: Two-way ANOVA with Bonferroni post hoc test, 
***p<0.001. Data shown as mean ± SEM, n = 5.        
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in these mutant mice. From 3 months of age onwards the cortical volume was 
significantly reduced in Ppt1-/- mice with an 11.4% reduction at 3 months, a 23.8% 
reduction at 5 months and a 43.2% (almost half) reduction at 7 months of age. 
Disabling active T- and B-cells, lead to a significant improvement in cortical volume in 
Ppt1-/-/Rag-1-/- double knockout mice from 3 months onwards. At 3 and 5 months of 
age no significant difference between wildtype and double knockout mice could be 
detected, which reflects a 16.7% and a 17.9% improvement in cortical volume 
compared to single Ppt1-/- knockout mice. Yet, at 7 months the cortical volume of 
these immune deficient Ppt1-/-/Rag-1-/- double knockout mice was significantly reduced 
by 28.3% compared to age-matched WT control animals. However, even at this 
advanced time point these mice still exhibited a significantly (14.9%) larger cortex than 
age-matched Ppt1-/- mice.  
To further investigate these findings of cortical atrophy we additionally measured the 
cortical thickness in S1BF (see Figure 34 and Figure 38 for representative pictures of 
S1BF thickness). From 3 months onwards significant cortical thinning in S1BF could 
be observed in INCL mice (see Figure 42). Starting off with a rather subtle, but 
significant 6.1% reduction in S1BF thickness in Ppt1-/- mice at 3 months of age, this 
significant difference increased to 11.5% thinning at 5 months, and to 19.7% thinning 
at 7 months of age compared to age-matched wildtype mice. These data suggest that 
the cortical thinning in the somatosensory cortex actually occurs earlier than was 
previously suggested in these mice (Kielar et al., 2007).  
Extending these measurements to Ppt1-/-/Rag-1-/- double knockout and Rag-1-/- mice, 
we found that up to 5 months of age no significant cortical thinning could be detected 
in Ppt1-/-/Rag-1-/- double knockouts compared to wildtype mice (see Figure 34A and 
Figure 38A for representative pictures, and quantification in Figure 42). Significant 
cortical atrophy only appeared at 7 months of age with 8.4% cortical thinning in    
Ppt1-/-/Rag-1-/- mice compared to wildtype animals. In comparison to Ppt1-/- mice, the 
immune deficient Ppt1-/-/Rag-1-/- mice showed significantly less cortical thinning from 
3 months onwards with a mean difference of cortical thickness between these two 
mouse population of 7.2% at 3 months, 8.7% at 5 months and of 11.3% at 7 months 
of age compared to age-matched wildtype control values. These data suggest a 
significant improvement in the extent of thinning of S1BF by blocking the adaptive 
















Taken together, these data suggest that blocking the adaptive immune system in            
Ppt1-/-/Rag-1-/- mice results in a significant improvement of the overall cortical atrophy 
and particularly the cortical thinning in S1BF compared to single Ppt1-/- mice. 
Furthermore, it could be speculated that the adaptive inflammatory components make 
a greater contribution to pathogenesis in less affected regions like the cortex compared 
to the thalamus. However, alternatively, this apparently greater improvement on 
disease pathogenesis in the cortex could also simply be a result of the less pronounced 
Figure 42. Progressive thinning of the somatosensory barrel field (S1BF) cortex in Ppt1-/- 
and Ppt1-/-/Rag-1-/- mice. Cortical thickness measurements of Ppt1-/-, Ppt1-/-/Rag-1-/-, Rag-1-/- 
and age-matched wildtype (WT) control mice at different stages of disease progression revealed 
progressive thinning of S1BF. Thinning of the cortical mantle of S1BF was significantly reduced 
in Ppt1-/-/Rag-1-/- mice from 3 months onwards. Compared to WT mice, Ppt1-/- mice displayed 
significant cortical thinning in S1BF from 3 months onwards, whereas S1BF thickness in           
Ppt1-/-/Rag-1-/- mice was not significantly different from that in WT mice until 7 months of age. 
Rag-1-/- and WT mice showed no significant difference in cortical volume at any age. The same 
data are presented as both histogram (A) and line graph (B). Percentages indicate differences 
between Ppt1-/-and Ppt1-/-/Rag-1-/- mice compared to age-matched WT mice. Statistics: Two-way 
ANOVA with Bonferroni post hoc, *p<0.05, **p<0.01, ***p<0.001. Data shown as mean ± 
SEM, n = 5.     
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influence of Ppt1 deficiency upon cortical regions. These different possibilities shall be 
discussed in more detail in Chapter 7.   
4.5 Increased lifespan in Ppt1-/-/Rag-1-/- mice 
Lastly, to determine the influence of Rag-1 deficiency upon the lifespan of Ppt1-/- mice 
our collaborators in Würzburg, Germany, compared the lifespan of Ppt1-/- mice and 
Ppt1-/-/Rag-1-/- mice. This analysis revealed that Ppt1-/-/Rag-1-/- double knockout mice 
had a prolonged life span living 265 days, which is approximately 8% longer than  
Ppt1-/- mice that have an average lifespan of 245 days (unpublished data, J Groh, 
University of Würzburg, Germany). These findings, together with the improvement in 
pathological phenotypes in the brain of the Ppt1-/-/Rag-1-/- double knockout mice 
suggest that removing the adaptive immune response has beneficial effects in this 
murine model of INCL.  
4.6 Summary and discussion  
The data presented in this chapter not only reveal new information about the nature 
and extent of glial activation in Ppt1-/- mice, but also provide evidence that cells of the 
adaptive immune system actively contribute to the pathogenesis of INCL (see also 
Table 9, Table 10 and Figure 43 for a summary overview). 
Table 9. Summary of the comparison between Ppt1-/- and WT mice. Table was based on all 
experiments described in Chapter 4. In the left column: “type of analysis”, across the top: “age of mice”. 
Symbols: = no difference, ↑ significant increase, ↓ significant decrease, = (↑) increasing trend without 
significance, = (↓) decreasing trend without significance. 
   1 Month 3 Months 5 Months 7 Months 
 Brain weight  = = ↓ ↓ 
 Astrocytosis Thalamus = ↑ ↑ ↑ 
  S1BF = ↑ ↑ ↑ 
 Microglial activation Thalamus = ↑ ↑ ↑ 
  S1BF =  (↓) ↑ ↑ ↑ 
 Neuronal survival  = ↓ ↓ ↓ 
 Cortical thickness S1BF = ↓ ↓ ↓ 





Table 10. Summary of the comparison between Ppt1-/- and Ppt1-/-/Rag-1-/- mice. Table was based on 
all experiments described in Chapter 4. In the left column: “type of analysis”, across the top: “age of mice”. 
Symbols: = no difference, ↑ significant increase, ↓ significant decrease, = (↑) increasing trend without 
significance, = (↓) decreasing trend without significance. 
   1 Month 3 Months 5 Months 7 Months 
 Brain weight  = = ↑ =  (↑) 
 Astrocytosis Thalamus = ↓ ↓ =  (↓) 
  S1BF = =  (↓) =  (↓) = 
 Microglial activation Thalamus = ↓ ↓ ↓ 
  S1BF =  (↓) =  (↓) ↓ =  (↓) 
 Neuronal survival  = ↑ = = 
 Cortical thickness S1BF = ↑ ↑ ↑ 
 Cortical volume  = ↑ ↑ ↑ 
 
Figure 43. Schematic summary of altered phenotypes in the brain of Ppt1-/-/Rag-1-/- mice. 
We characterised astrocytosis (illustrated as ‘astrocytes’), microglial activation (illustrated as 
‘infiltrated macrophages, microglia’) and neuron survival (illustrated as ‘neurons’) in                
Ppt1-/-/Rag-1-/- mice. As a consequence of the Rag-1 deficiency, no adaptive immune cells (T- and 
B-cells) were in the body and thus no interactions between T-cells and other cell types in the brain 
can occur in Ppt1-/-/Rag-1-/- mice (B-cells are not depicted since they have not yet been described 
in Ppt1-/- mouse brains). Their absence results in decreased microglial activation at 3, 5 and 7 
months of age; decreased astrocytosis at 5 and 7 months of age; and increased neuron survival at 
3 months in the thalamus and at 5 months in the primary somatosensory barrel field (S1BF) 
cortex (summarised as ‘cortex’). Additionally, cortical volume and S1BF cortical thickness are 
increased at 3, 5 and 7 months of age. Overall, the lack of adaptive immune cells delays disease 
progression in Ppt1-/-/Rag-1-/- mice. 
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a) Early pathology in Ppt1
-/- 
mice 
Astrocytosis and microglial activation are characteristic features in the neuropathology 
of Infantile NCL mice (Bible et al., 2004; Kielar et al., 2007; Macauley et al., 2009). We 
have confirmed and extended the previous descriptions of glial activation from these 
mice (Bible et al., 2004; Kielar et al., 2007), by identifying an earlier onset of glial 
activation and neuronal loss that is already underway at 3 months of age.  
In contrast to our previous studies, which were restricted to using F4/80 as a 
microglial marker (Bible et al., 2004; Kielar et al., 2007), our data using CD68 
immunostaining revealed an earlier and more pronounced microglial activation in the 
brains of Ppt1-/- mice than had previously been described at 5 months of age (Kielar et 
al., 2007). Indeed, we could demonstrate that marked microglial activation in the 
thalamus was already present at 3 months of age, together with the first evidence of 
laminar specific microglial activation in S1BF at this age (see Figure 36, Figure 37 
and Figure 38). Remarkably in this cortical region there was a suggestion of microglial 
activation having already begun at 1 month of age, (see Figure 38B and Figure 39). 
This striking difference between the apparent onset of microglial activation in Ppt1-/- 
mice, simply by using a different marker, highlights the importance of using more than 
one antigen to investigate such reactive changes. The consequence is that we have to 
consider that microglia may play a role at much earlier time points in INCL 
pathogenesis than had been assumed previously. It was thought that microglia only 
became activated in Ppt1-/- mice once neuron loss was already underway (Kielar et al., 
2007), but our new data raise the possibility of an earlier involvement in disease 
progression and it will be important to determine whether this is a positive or negative 
contribution to pathogenesis. Regarding astrocytosis, similar to microglial activation, 
first indications of elevated GFAP immunoreactivity could be detected as early as 1 
month of age in the thalamus and in S1BF of Ppt1-/- mice (see Figure 32 and Figure 
34), but significant astrocytosis was only detected from 3 months onwards in the 
present study (see Figure 33 and Figure 35).  These findings are consistent with 
previous studies that demonstrated GFAP+ve up-regulation in Ppt1-/- mice from the 
same time point (3 months) onwards (Kielar et al., 2007; Macauley et al., 2011). Taken 
together, our new data from Ppt1-/- mice reveal that both astrocytosis and microglial 
activation appear to start in the thalamus and in S1BF at 3 months of age, highlighting 
this as a key stage in disease progression.  
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Another key finding of this study is that neuron loss in the thalamus of Ppt1-/- mice 
isalready underway at 3 months of age and that this loss becomes more pronounced 
with disease progression (see Figure 40). These data are again different to previous 
reports of thalamic neuron loss in these mice (Kielar et al., 2007), in which significant 
neuron loss in VPM/VPL was only found from 5 months of age onwards. There are 
two main reasons to potentially explain this difference. Firstly, these counts were made 
by different observers who may apply different criteria when making stereological cell 
counts from Nissl stained sections. For instance, two different investigators are likely 
to apply different criteria for what will be counted as a neuron during sampling, for 
which reason it is of uppermost importance that each analysis is performed by only 
one investigator. Secondly, and more importantly, natural variation in the rate of 
disease progression between different cohorts of mice could account for these 
observed differences. Being kept in a different animal facility, the mice used in this 
study may have been affected earlier than those in the (Kielar et al., 2007) study due to 
different food regimes, litter conditions which may potentially influence their 
phenotypes. Such potential differences are exaggerated further by small sampling sizes. 
In our study, the n of 5 as a sampling size of the entire population may be sufficient 
for statistical comparisons, but in reality reflects a relatively small sample size. 
However, such compromises are often necessary due to high animal costs and time 
taken to perform these studies.  
Our new data also shed further light on the relative timing of neuron loss and glial 
activation, suggesting that these events actually occur at the same time (see Figure 33, 
Figure 35, Figure 37, Figure 39 and Figure 40). These data suggest there is no prior 
activation of the innate immune response before neuron loss occurs in these mice, 
leaving the unanswered question of which is the primary effect. Does neuron loss 
cause glial up-regulation and T-cell infiltration or do the glial cells and/or T-cells cause 
neuronal death subsequently or are they independent events that are triggered by an 
(as yet) unidentified pathological trigger? Recently it has been shown that synaptic 
changes and altered cytokine expression occur before 3 months of age in Ppt1-/- mice 
(Kielar et al., 2009). These data suggest that sometime between 1 and 3 months of age 
a switch, or a threshold, must be reached to initiate immune reactions or/and 
neuronal loss at the same time. Speculatively, Ppt1 deficiency seems to be tolerated at 
early stages of the disease, but eventually manifests itself firstly in neurons by axonal 
and synaptic rearrangements which in turn activate microglia and astrocytes, as repair 
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mechanisms of the brain (Graeber and Streit, 2010; Sofroniew and Vinters, 2010). 
However, because the disturbance caused by Ppt1 deficiency persists, a self-enhancing 
cycle of immune activation is set in motion leading to chronic neurodegeneration 
(Gao and Hong, 2008). These immune activations incorporate on the one hand 
astrocytosis and microglial activation, but on the other hand, as demonstrated in 
Chapter 3, also include adaptive immune cell infiltration.   
b) Adaptive immune cells accelerate pathogenesis of Ppt1
-/-
 mice 
The most significant finding presented in this chapter is that the adaptive part of the 
immune system appears to have an enhancing effect on astrocytosis and microglial 
activation and to accelerate neuron loss. By genetically removing functioning T- and 
B-cells, we could reduce the degree of innate immune activation, as well as delay 
neuronal loss in INCL mice, and even prolong the life span of Ppt1-/- mice. 
Our data revealed that the timing of reactive changes was altered in Ppt1-/-/Rag-1-/- 
double knockouts, with astrocytosis and microglial activation both being relatively 
reduced in the thalamus of these mice from 3 months onwards (see Figure 33 and 
Figure 37). Nevertheless, by end stage of the disease, at 7 months, the astrocyte 
response appeared to have caught up and reached similar levels to that seen in Ppt1-/- 
mice, whereas microglial activation remained at lower levels throughout all age groups. 
Comparing the relative effects on astrocytosis and microglial activation in              
Ppt1-/-/Rag-1-/- mice, the adaptive immune response (T- and B-cells) appears to have a 
greater and more consistent influence on microglial activation (see Figure 33 and 
Figure 37). This is particularly obvious when considering the cortical S1BF region. 
CD68+ve up-regulation was reduced at all ages in the S1BF cortex of Ppt1-/-/Rag-1-/- 
mice (see Figure 39). The reduction in astrocytosis in S1BF was less pronounced and 
did not reach any significance in Ppt1-/-/Rag-1-/- mice (see Figure 35), but nevertheless 
followed the same patterns and temporal sequences as in the thalamus (see Figure 
33).  
Thus, it appears that the lack of T- (and B-) cells did not reverse or stop the neuronal 
death, but instead slowed it down (see Figure 40). This improved phenotype of 
immune deficient Ppt1-/- mice is consistent with similar findings of other studies using 
the Rag-1 deficiency in myelin-degenerative disease models (Ip et al., 2006; Kroner et 
al., 2010), which are also caused by a single genetic mutation and lead to chronic 
neurodegenerative phenotypes similar to the NCLs. These studies demonstrated that 
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secondary adaptive immune reactions (particularly CD8+ve T-cells) can be of clear 
pathological significance. However, in the present study this improvement vanished at 
5 and 7 months of age, indicating that other driving forces must be responsible for the 
neurodegeneration seen in Ppt1-/-/Rag-1-/- mice at these time points. These forces may 
include the continued Ppt1 deficiency, innate immune reactions or other (yet) 
unidentified mechanisms. It could be speculated that the thalamic VPM/VPL nuclei 
are too severely affected to be capable of being rescued at the later stages of the 
disease. Although most of the neurons in the thalamus are dead at this point, it may be 
possible to produce a greater improvement in other less affected brain regions, for 
example the cortex. Additional data of cortical neuron counts (S Duckett MSc student 
in PSDL, see Appendix II: Figure 79) in Ppt1-/-/Rag-1-/- mice confirmed this 
suggestion showing an improved survival of S1BF neurons in these mice at 5 months 
of age. These recent findings confirmed our previous expectations based on the 
cortical thickness and volume measurements that adaptive immune cells (most likely 
the T-cell infiltration from 3 months onwards) also play a significant role in disease 
deterioration in the cortex. Not only did we observe increased S1BF thickness, but 
also less overall cortical atrophy in Ppt1-/-/Rag-1-/- double knockouts (see Figure 41 
and Figure 42). As a side note, the extent and impact of infiltrating macrophages has 
not been quantified in our Ppt1-/-/Rag-1-/- mice, although they (being undistinguishable 
from activated CD68+ve microglia) may also influence the attenuation of disease 
phenotypes in the brain. This issue shall be examined in more detail in Chapter 5. 
c) Significance of findings 
The studies in this chapter have demonstrated that neuroinflammation, and in 
particular the adaptive immune responses, is a key feature of Infantile NCL. Genetic 
removal of the adaptive immune cells slowed down disease progression, but did not 
stop it. These data indicate that besides the adaptive immune cells, other disease 
driving forces must be in place. These may include innate immune reactions with 
exaggerated microglial activation or astrocytosis, other infiltrated immune cells like 
macrophages, other (yet) unidentified events in the periphery and brain or simply the 
persistent Ppt1 deficiency of every cell type in the brain and body. However, since the 
adaptive immune responses do clearly exert a negative influence upon disease 
progression, we are confident that our findings may pave the way for disease 
attenuating therapeutic approaches in the future. This suggestion is supported by the 
moderately improved life span of immune deficient Ppt1-/- mice reported by our 
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collaborators (J Groh, University of Würzburg, unpublished data and personal 
communication). Because the basis for successful therapeutic interventions will 
depend upon a better understanding of inflammatory events and their relevance to 
disease progression, our data, as proof of principle studies, form the basis for potential 





















In the previous chapter we demonstrated the influence of the adaptive immune 
response upon the neurodegenerative processes that occur in murine Infantile NCL. 
At the same time, we obtained more detail about the nature of the innate immune 
response that occurs in the early stages of this disease. Besides astrocytosis and 
microglial activation, other innate immune cells are also recruited to inflammatory sites 
within the brain (Andersson et al., 1992; Ousman and David, 2000; Hendriks et al., 
2005). These may include dendritic cells or neutrophils (although their infiltration may 
vary depending on CNS injury and/or BBB integrity (Perry et al., 1995; Schnell et al., 
1999; Campbell et al., 2008; Sayed et al., 2010) but, in particular peripheral 
macrophages infiltrate the brain parenchyma (Andersson et al., 1992; Greter et al., 
2005; Hendriks et al., 2005; King et al., 2009; Mildner et al., 2009; Prinz et al., 2011). 
These immune cells interact with other cells in the brain and influence the 
inflammatory response (Stoll and Jander, 1999; Hendriks et al., 2005; Carson et al., 
2006a).  Therefore, we hypothesised that altering the binding ability of infiltrated 
macrophages may have an impact on disease outcome and progression. The binding 
protein sialoadhesin (Sn) is a potential candidate to be important in such cell-cell 
communication. Indeed, in proteolipid protein (PLP) overexpressing mouse models of 
myelin-neurodegenerative conditions the lack of Sn can have an (attenuating) impact 
on brain and nerve pathology (Kobsar et al., 2006; Ip et al., 2007). As described in 
Chapter 1 (see section 1.11b), Sn, as a cell adhesion molecule, is found on the surface 
of macrophages in lymphoid tissues (particularly in spleen, lymph nodes) and the 
adrenal gland, but is absent in the brain parenchyma under healthy conditions 
(Dijkstra et al., 1985; Crocker and Gordon, 1986; Perry et al., 1992; van den Berg et al., 
2001). However, in the case of inflammation, injury or a BBB breach of any sort, Sn is 
expressed on infiltrating macrophages, as well as nearby microglia in the brain 
parenchyma (Perry et al., 1992). The exact role of Sn is still under debate, but this 
protein may function as a positive regulator of adaptive immune responses (Crocker 
and Redelinghuys, 2008) by interacting with CD4+ve T-regulatory cells (Wu et al., 
2009), and CD8+ve T-cells (Muerkoster et al., 1999; Ip et al., 2007) or, as most recently 
suggested, it may represent a general inflammatory and autoimmunity regulatory 
molecule via recognition of self and non-self (see section 1.11b in Chapter 1 and 
(Klaas and Crocker, 2012)). 
This chapter aims to elucidate the importance of the crosstalk between macrophages 
and other immune cells in the brain, in particular during inflammatory or 
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neurodegenerative events. After knocking out the macrophage binding protein Sn in 
Infantile NCL mice, we compared Ppt1-/-/Sn-/- mice with regular Ppt1-/- mice. 
Consequently, the same analyses, as described in the previous chapter for              
Ppt1-/-/Rag-1-/- mice, have also been performed in Ppt1-/-/Sn-/- mice. Besides brain 
weight measurements, astrocytosis, microglial activation, neuron survival and cortical 
atrophy were measured in the somatosensory thalamus (VPM/VPL) and cortex 
(S1BF), which have been shown to be the most affected brain regions in Ppt1-/- mice 
(Kielar et al., 2007). By performing these analyses at 1, 3, 5 and 7 months of age we 
could compare the progressive phenotypes of Ppt1-/-/Sn-/- mice with Ppt1-/- and the 
corresponding Sn-/- and wildtype control mice. 
5.1 Sialoadhesin positive cells in the CNS of Ppt1-/- mice 
Firstly, to investigate where and when Sn is expressed in Ppt1-/- and healthy control 
brains, we stained sections from these mice at all ages (n=2) for Sn, which is also 
referred to as CD169. Because Sn is only expressed in the brain on infiltrating 
macrophages, and microglia in vicinity of their infiltration or at inflammatory sites 
(Perry et al., 1992; Klaas and Crocker, 2012), we would hypothesise that CD169 can be 
used as a distinctive marker for identifying region-specific inflammation sites in the 
brain.  
CD169 immunostaining revealed very few immunoreactive cells in 1 month old 
mutant or wildtype brains. An exception was in the basal forebrain of 1 month old 
wildtype mice, where scattered Sn+ve microglia with ramified processes were present 
along the anterior commissure, the ventral parts of the globus pallidus and its rostral 
extension towards the bed nucleus of the stria terminalis (data not shown). Otherwise, 
in wildtype mice CD169 immunoreactive cells were mainly found in the meninges and 
in the choroid plexus lining the wall of the ventricles, which is consistent with 
previous observations (Perry et al., 1992) (see Figure 44E). However, elongated 
CD169+ve cells could be detected in the brain parenchyma along many brain vessels, 
indicating that Sn+ve macrophages are also present in the perivascular space of 
healthy control mice (see Figure 44E). 
In Ppt1-/- mice, many CD169+ve cells could be detected from 3 months onwards in 
various brain regions, which were characterised according to (Paxinos and Franklin, 
2001) (see next paragraphs below and Table 11 for a detailed summary of the  
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Figure 44. Progressive expression of sialoadhesin positive cells in the thalamus and the 
somatosensory barrel field (S1BF) cortex of Ppt1-/- mice. (see figure caption on next page) 
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distribution of CD169 immunoreactivity in Ppt1-/- mice over time). Generally, the 
quantity and intensity of CD169 immunoreactivity increased with disease progression 
and reached its maximal level at 7 months of age (see Figure 44). At each time point, 
cells with various morphologies stained for CD169, resembling microglia with 
ramified cell processes, as well as macrophages without any cell processes (see 
examples in Figure 44B and Figure 44D). Since via CD169 staining alone these two 
cell types cannot be distinguished, we subsequently will refer to cells with elongated 
and ramified processes as ‘microglia’ and round cells without any or only short 
processes as ‘macrophages’ (see Figure 15 in Chapter 3 for the morphological criteria 
used to distinguish between these cell types).  
a) CD169 expression in 1 month old Ppt1
-/- 
brains 
Similar to wildtype mice, the majority of CD169+ve cells were found at the borders of 
the brain parenchyma (meninges, choroid plexus, ventricle walls) and in the 
perivascular space around the blood vessels of 1 month old Ppt1-/- mice. These 
CD169+ve cells displayed macrophage-like cell morphology with either round, 
amoeboid or crescent-shaped soma along the meninges or vermicular, elongated cells  
Figure 44. Progressive expression of sialoadhesin positive cells in the thalamus and the 
somatosensory barrel field (S1BF) cortex of Ppt1-/- mice. (A) Immunohistochemical staining 
for the peripheral macrophage/microglial marker CD169 (sialoadhesin) in the thalamus of 1, 3, 5 
and 7 month old mice revealed localised CD169 expression within the ventral posterior nucleus 
(VPM/VPL) (---) of Ppt1-/- mice. Distinct macrophage-like cell staining could be observed in 
mutant mice, whereas similar staining was absent in wildtype (WT) mice. Scale bar = 200 μm. (B) 
Higher magnification pictures of the thalamus of Ppt1-/- and WT mice at 1, 3, 5 and 7 months of 
age demonstrated morphological changes of CD169+ve cells with disease progression. Whereas 
at 3 months of age, CD169+ve cells display small cell soma with elongated processes resembling 
partially activated microglia, at 5 and 7 months of age predominantly macrophage-like cells with 
round cell bodies, and short or absent processes were detected. Scale bar = 20 μm. (C) 
Immunohistochemical staining for CD169 in the somatosensory cortex S1BF of 1, 3, 5 and 7 
month old Ppt1-/- and WT mice revealed CD169 positive cells in Ppt1-/- mice most prominent in 
deeper laminae (mainly layer VI) from 3 months of age onwards. CD169 immunoreactive 
microglia/macrophages spread to more dorsal layers and increased in intensity with disease 
progression. At 7 months of age widespread CD169 immunoreactivity was present throughout all 
layers, but most prominently in laminae II+III and VI. Similar staining was absent in WT animals 
where only CD169+ve macrophages in the meninges could be detected. Scale bar = 100 μm. (D) 
Higher magnification pictures of lamina VI of the S1BF of Ppt1-/- and WT mice at 1, 3, 5 and 7 
months of age revealed CD169+ve cells in mutant mice from 3 months onwards. CD169+ve cells 
with darkly stained, small cell bodies resembling both microglia with and macrophage-like cells 
without elongated processes were seen in lamina VI at 3 months of age. With disease progression, 
the proportion of macrophage-like cells with round, darkly stained cell soma and no, or only 
short, processes increased at 5 months of age, eventually representing the predominant cell 
morphology at 7 months of age. Scale bar = 20 μm. (E) Examples of CD169+ve cell staining in 
WT mice. CD169+ve macrophages were found in the choroid plexus along the ventricle walls 
(along the fimbria of the hippocampus and the dorsal lateral geniculate nucleus (LGNd) in E1), in the 
meninges (E2), but also surrounding parenchymal blood vessel as perivascular macrophages (E3 
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wrapping themselves around blood vessels in the parenchyma (as seen in Figure 44E 
in WT mice). In addition, faintly stained CD169+ve microglia were present in the 
basal forebrain and in the ventral parts of the caudate putamen (striatum) (data not 
shown). The distribution of these CD169 immunoreactive cells extended over several 
nuclei, being present in parts of the interstitial nucleus of the posterior limb of the anterior 
commissure (IPACL and IPACM), within the ventral parts of the caudate putamen 
(striatum) and globus pallidus (GP) and the central amygdaloid nucleus (CeM and CeC). The 
distribution of these cells was in relatively close proximity to the anterior commissure and 
did not extend into the caudal parts of the amygdala. These findings suggest an early 
inflammatory reaction that is already underway at 1 month of age in these brain 
regions of Ppt1-/- mice, but since CD169+ve cells were found in similar locations in 1 
month old wildtype mice, an unknown stimulus specific to this brain region could also 
be a possible explanation.  
b) CD169 expression in 3 month old Ppt1
-/- 
mice 
At 3 months of age, distinct CD169 immunoreactivity could be detected on 
macrophage and/or microglial cells in several regions of the brain parenchyma of  
Ppt1-/- mice. Most prominently the thalamic ventral posteromedial and posterolateral nuclei 
(VPM/VPL, but most activated in VPL) displayed CD169+ve cells which resembled 
activated microglia with long and ramified processes, but also scattered round brain-
macrophage-like cells (see Figure 44A and Figure 44B). CD169+ve 
macrophage/microglial activation was also seen in other nuclei of the thalamus, 
namely in the medial geniculate nucleus (MGV and MGD) and the dorsal lateral geniculate 
nucleus (LGNd), albeit to a lower extent than in VPM/VPL. Interestingly, in the same 
basal forebrain regions which showed first signs of CD169 up-regulation in 1 month 
old Ppt1-/- mice, more pronounced microglial activation could now be detected at 3 
months of age. These CD169+ve cells were mostly microglia with ramified and 
elongated processes, besides some scattered cells with more brain-macrophage like 
morphology. As at 1 month of age, the distribution of this activation was not confined 
to one nucleus and its spread into caudal brain regions correlated with the presence of 
the anterior commissure (AC) or the interstitial nucleus of the posterior limb of the anterior 
commissure (IPAC). Compared to 1 month old Ppt1-/- mice, besides in the central 
amygdaloid nucleus (CeC), CD169 immunoreactivity additionally spread to the basolateral 
amygdaloid nucleus (BLA) and the anterior amygdaloid area (AAD) (data not shown). 
However, CD169 immunoreactivity could be also detected in more rostral parts of the 
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brain. In the olfactory bulb the first traces of microglial activation were noticeable, and 
the caudate putamen (striatum) was scattered with isolated CD169+ve 
macrophages/microglia. Likewise, weak CD169 immunoreactivity was also detected in 
the caudal parts of the brain, particularly in the substantia nigra, laterodorsal tegmental 
nucleus (LDTg) (which sends cholinergic projections to the thalamus, substantia nigra and 
hippocampus), but also the reticulotegmental nucleus of the pons (RtTg) showed CD169+ve 
macrophage/microglial staining (data not shown). In the cortex, CD169+ve cells 
could generally be seen in lamina VI of most sub-regions, but particular pronounced 
staining was observed in the motor cortex (M1 and M2), cingulate cortex (Cg1 and Cg2), 
somatosensory cortex (S1BF, S1Fl, S1HL and S2) (see Figure 44C and Figure 44D) and 
the retrosplenial granular cortex (RSG). In the cortical M1, M2 and RSG sub-regions 
CD169+ve cell staining could sometimes be detected in more dorsal laminae of the 
cortex. Additionally, occasional CD169+ve microglia were also found in the auditory 
cortex (Au1 and AuD) and the lateral orbital cortex (LO) of 3 month old Ppt1-/- mice.   
c) CD169 expression in 5 month old Ppt1
-/-
 mice 
As a consequence of disease progression, CD169 immunoreactivity intensified in 
those brain regions that were stained at earlier ages, but also spread to additional brain 
regions of 5 month old Ppt1-/- mice. At this stage of disease progression CD169+ve 
cells were widely present throughout the brain and took on a more activated and 
round macrophage-like morphology, with short or absent processes (see Figure 44B 
and Figure 44D). This was particularly obvious in the VPM/VPL nuclei of the 
thalamus, which contained many intensely stained cells with this morphology (see 
Figure 44D). Nevertheless, a series of specific brain regions also displayed intense 
CD169 immunoreactivity. Starting rostrally, the olfactory bulb was full of CD169+ve 
brain-macrophage-like cells, and macrophage/microglial CD169 immunoreactivity was 
seen throughout all sub-regions of the cortex with obvious brain-macrophage staining 
in lamina VI and II/III. This CD169+ve cell staining pattern was particularly 
pronounced in the motor cortex (M1 and M2), the cingulate cortex (Cg1 and Cg2), the 
primary somatosensory cortex (S1BF, S1HL, S1) (see Figure 44C and Figure 44D), the 
agranular insular cortex (AID and AIV), the retrosplenial granular cortex (RSG), the visual 
cortex (V1 and V2) and the auditory cortex (Au1 and AuD). Interestingly, in the piriform 
cortex (Pir) almost no CD169+ve cell staining could be seen, apart from mainly 
macrophage-like (and occasional microglial) CD169 immunoreactivity in the dorsal 
endopiriform nucleus (DEn). In subcortical structures CD169 immunoreactive 
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microglial/macrophage-like cells were present in the caudate putamen (striatum), in 
many nuclei of the thalamus, namely the anterodorsal and anteroventral thalamic nuclei (AV 
and AD), the ventral posterior nucleus (VPM/VPL) (see Figure 44A and Figure 44B), 
with activation spreading into the posterior thalamic nuclear group (PO) and the ventrolateral 
thalamic nucleus (VL), the mediodorsal thalamic nuclei (MDM and MDL), the central medial 
thalamic nucleus (CM), the dorsal lateral geniculate nucleus (LGNd) as well as the medial 
geniculate nucleus (MGM) which all showed intensely stained CD169+ve brain-
macrophages with round cell bodies. Besides these thalamic regions, for the first time 
CD169+ve brain-macrophages could also be detected in the hippocampus at this time 
point. However, their distribution was restricted to the CA1 sub-field, with no cell 
staining evident in CA2 to CA4 (data not shown). Moreover, intensely CD169+ve 
microglial staining (with sporadically present macrophage-like cells) was also seen in 
the ventral parts of the striatum around the interstitial nucleus of the posterior limb of the 
anterior commissure (IPACL and IPACM) which mirrored the location of CD169+ve 
immunoreactivity already detected in 1 and 3 month old Ppt1-/- mice. More caudally, 
the amygdalohippocampal area (AHipM) and the posteromedial cortical amygdaloid nucleus 
(PMCo) all displayed microglial/macrophage-like cell staining (data not shown). 
Additionally, CD169+ve microglia/macrophages were present throughout the ventral 
parts of the pons, with particularly intensely stained brain-macrophage cells present in 
the reticulotegmental nucleus of the pons (RtTg) and macrophage/microglial cells in the 
principal sensory trigeminal nucleus (Pr5VL). Last but not least, in contrast to weakly 
stained microglial cells that were seen in the substantia nigra, the external cortex of the 
inferior colliculus (EClC) and the central nucleus of the inferior colliculus (ClC) showed many 
activated CD169+ve brain-macrophages (data not shown).  
d) CD169 expression in 7 month old Ppt1
-/- 
brains 
With a life expectancy of about 8 months (Gupta et al., 2001), immune reactions in 
Ppt1-/- mice are actively progressing at 7 months of age. Correspondingly, high CD169 
immunoreactivity was observed in most brain regions of Ppt1-/- mice at this age. In 
those brain regions like the VPM/VPL nuclei of the thalamus that had shown highest 
CD169 staining at earlier ages, there were many darkly stained brain-macrophages (see 
Figure 44A and Figure 44B), whereas in brain regions that displayed CD169 staining 
for the first time at this age there were many macrophage/microglial cells in various 
states of activation. However, besides an overall higher activation of cells compared to 
previous ages, CD169 immunoreactivity followed a region-specific distribution with 
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the following nuclei and brain regions displaying distinctive CD169+ve cell 
activation/infiltration. Most prominently highly activated brain-macrophages were 
observed in various nuclei of the thalamus. These included, similar to the CD169+ve 
expression in 5 month old Ppt1-/- mice, the anterodorsal and anteroventral thalamic nuclei 
(AV and AD), the ventral posterior nuclei (VPM/VPL) (see Figure 44A) with adjacent 
parts of the posterior thalamic nuclear group (PO) and the ventrolateral thalamic nucleus (VL), 
the mediodorsal thalamic nuclei (MDM and MDL), the central medial thalamic nucleus (CM), 
the dorsal lateral geniculate nucleus (LGNd) as well as the medial geniculate nucleus (MGM). In 
addition, intensely stained round CD169+ve macrophages could be found in the 
reuniens thalamic nucleus (Re), the lateral posterior thalamic nucleus (LPLR) and the zona incerta 
(ZIV) of 7 month old Ppt1-/- mice (data not shown). As already seen at 5 months of 
age, intensely stained CD169+ve brain-macrophages were present along the CA1 sub-
field of the hippocampus at 7 months of age, but these cells were more numerous and 
more intensely stained than in 5 month old Ppt1-/- mice (data not shown). The 
pronounced accumulation of macrophages /microglia in CA1 is consistent with 
previous findings on pyramidal neuron and interneuron loss in this region of the 
hippocampus of 7 month old Ppt1-/- mice (Bible et al., 2004; Mitchison et al., 2004). 
Furthermore, the cortex of these mice displayed marked CD169+ve cell activation 
throughout many sub-regions with intensely stained brain-macrophages and some 
microglial cells found predominantly in laminae II/III and VI. This pattern of staining 
was clearly seen in the motor cortex (M1 and M2), cingulate cortex (Cg1 and Cg2), the 
auditory cortex (Au1 and AuV) and the visual cortex (V1) in which laminae II/III showed 
the most intense staining. Interestingly, the somatosensory cortex presented a mixed 
picture with lamina VI most prominently (and only to a moderate extent laminae 
II/III) showing CD169 staining within S1BF (see Figure 44C and Figure 44D), 
whereas S1HF, S1FL and S2 displayed the most pronounced CD169+ve brain-
macrophage activation in laminae II/III, or to a similar extent in laminae VI and 
II/III. Similarly, the piriform cortex showed CD169 immunoreactivity mainly in the 
dorsal and ventral endopiriform nuclei (DEn and VEn) near the corpus callosum. In the 
olfactory bulb, the entire parenchyma was scattered with CD169+ve activated 
microglial cells, but intensely stained CD169+ve brain-macrophages filled the mitral cell 
layer of the olfactory bulb (MI) (data not shown). Furthermore, in the midbrain and pons 
there were many intensely stained CD169+ve brain-macrophages, as at previous ages, 
in the reticulotegmental nucleus of the pons (RtTg), substantia nigra, the external cortex of the 
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inferior colliculus (EClC) and the central nucleus of the inferior colliculus (ClC). Additionally, 
besides a widespread CD169+ve microglial/macrophage activation in the ventral parts 
of the pons, the magnocellular and parvicellular part of the red nucleus (RMC and RPC), the 
motor trigeminal nucleus (Mo5) and dorsal parts of the subiculum of the hippocampus also 
displayed intensely CD169 stained round brain-macrophage-like cells (data not 
shown). In addition to widespread microglial/macrophage CD169 immunoreactivity 
in the caudate putamen (striatum), a specific accumulation of CD169+ve brain-
macrophages could be detected in lateral parts of the striatum, ventral to the S2 cortex 
and the corpus callosum, but only at the mid-levels of the forebrain. Last but not least, as 
detected throughout all age groups in Ppt1-/- mice, marked microglial/macrophage-like 
CD169 immunoreactivity was seen in the basal forebrain of 7 month old Ppt1-/- mice 
with CD169+ve cells in the ventral pallidum (VP), the magnocellular preoptic nucleus 
(MCPO) and the nucleus of the horizontal limb of the diagonal band (HDB), spreading 
dorsally around the anterior commissure into the globus pallidus (GP) and the caudate 
putamen (striatum) (data not shown).  
In summary, this qualitative survey of CD169 expression in Ppt1-/- mice demonstrated 
that increasingly more Sn+ve macrophages and microglia are present in the brain 
parenchyma with on-going disease progression (see Figure 44). This is in contrast to 
wildtype mice in which CD169 immunoreactivity is restricted to macrophages at the 
brain margins and in the perivascular spaces (see Figure 44E). As a side note, similar 
Sn+ve cell staining (along the meninges and in the perivascular spaces) was also 
detectable in Ppt1-/- mice at all ages, in addition to the CD169 immunoreactivity in 
various brain nuclei, described above. However, the morphology of Sn+ve cells within 
the parenchyma changed according to disease progression. At 3 months of age Sn+ve 
cells displayed various morphologies with long and ramified processes, at 5 months of 
age Sn+ve cells take on a more activated and round macrophage-like morphology; 
resulting in round and darkly stained cells with almost no cell processes present at 7 
months of age (see Figure 44B and Figure 44D). However, because it is impossible 
to distinguish between microglia and infiltrated macrophages with this CD169 marker, 
we must assume that at all ages a mix of macrophages and microglia are present in the 
thalamus. Nonetheless, according to their morphology, we can speculate that at earlier 
stages microglia with elongated processes and a subset of infiltrated macrophages are 
stained by this marker, but that predominately macrophages and brain macrophage-
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like microglia were visible at the end stages of the disease (see also discussion in 
Chapter 7). 
Taken together, our data confirmed that Sn is expressed by infiltrated macrophages 
and microglia in the vicinity of on-going inflammation in Ppt1-/- mice, consistent with 
sites observed previously in other models (Perry et al., 1992; Klaas and Crocker, 2012). 
To investigate the importance of these cell types to INCL pathogenesis and their 
interaction with other immune cells in the brain, we subsequently created Infantile 
NCL mice with Sn deficiency by crossing Ppt1-/- mice with Sn-/- mice (see Chapter 2). 
In the following parts of this chapter, these Ppt1-/-/Sn-/- double knockouts will be 
compared to single mutant Ppt1-/- mice using the characteristic neuropathological 
landmarks of murine INCL (Bible et al., 2004; Kielar et al., 2007). 
5.2 Reduced hemisphere mass of Ppt1-/- and Ppt1-/-/Sn-/- mice 
As a general indicator of mouse condition and potential pathological changes we 
measured the weight of each hemisphere, as we had performed in our analysis of   
Ppt1-/-/Rag-1-/- double knockouts in Chapter 4, after paraformaldehyde fixation and 
including the olfactory bulb, but after removal of the cerebellum (see section section 
2.2 in Chapter 2). Although the comparison of average hemisphere weights is rather a 
crude measurement, the ongoing effects of neurodegeneration already became evident 
in Ppt1-/- and Ppt1-/-/Sn-/- mice from 3 months onwards (see Figure 45). However, 
significant loss of hemisphere mass could only be detected from 5 months onwards. 
Ppt1-/-/Sn-/- double knockouts lost 12.8% of hemisphere mass, compared to age-
matched wildtype controls at 5 months of age, which represented a 5.5 % 
improvement in hemisphere mass vs. Ppt1-/- mice (although this difference was not 
significant). The double knockout hemispheres remained heavier than the 
corresponding Ppt1 single knockout brain hemispheres from this time point onwards. 
At 7 months of age Ppt1-/-/Sn-/- double knockout hemispheres showed 6.3% less 
weight loss compared to Ppt1-/- hemispheres, but were 19.1% lighter than those from 
wildtype mice. In summary, additionally knocking out Sn in Ppt1-/- mice marginally 
impacted hemisphere mass from 5 months onwards, but this improvement did not 
















5.3 Impact of Sn deficiency on reactive phenotypes in Ppt1-/- mice  
As described in Chapter 4 for Ppt1-/-/ Rag-1-/- mice, we stained sections from        
Ppt1-/-/Sn-/- mice, Ppt1-/-, Sn-/- and wildtype control mice (n=5) at 1, 3, 5 and 7 months 
of age for the glial fibrillary acidic protein (GFAP) and the microglial marker CD68. 
Subsequently, we quantified the intensity of staining for these markers via thresholding 
image analysis. Based on the findings of (Kielar et al. 2007) we focused our analysis 
upon two severely affected components of the thalamocortical system: the thalamic 
ventral posterior nucleus (VPM/VPL) and the cortical somatosensory barrier field (S1BF) (see 
Figure 10 in Chapter 2).      
Figure 45. Marginally reduced loss of brain mass in Ppt1-/-/Sn-/- mice. The weights of brain 
hemispheres from mice of each genotype (Ppt1-/-, Ppt1-/-/Sn-/-, Sn-/- and wildtype) were measured 
after PFA fixation and removal of the cerebellum, but before further processing. From 5 months 
onwards there was a significant loss in hemisphere mass in Ppt1-/- and Ppt1-/-/Sn-/- mice, compared 
to age-matched wildtype (WT) mice. Hemispheres from Ppt1-/-/Sn-/- mice were marginally heavier 
than those from Ppt1-/- mice at 5 and 7 months of age, but these differences were not significant. 
WT and Sn-/- controls showed no significant differences in hemisphere mass at any age. The same 
data are presented as both histogram (A) and line graph (B). Percentages indicate differences 
between Ppt1-/-and Ppt1-/-/Sn-/- mice in comparison to age-matched WT mice. Statistics: Two-way 
ANOVA with Bonferroni post hoc test. Data shown as mean ± SEM, n = 5.        
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As described in the previous Chapter 4 (see section 4.2a), astrocytosis becomes 
clearly apparent in the thalamus of Ppt1-/- mice from 3 months onwards. A similar 
onset of astrocytosis was seen in Ppt1-/-/Sn-/- mice (see Figure 46A). Although the 
first traces of astrocytosis could be detected at 1 month of age in Ppt1-/- mice, no 
appreciable activation of astrocytes was detected in Ppt1-/-/Sn-/- mice at this time point. 
However, from 3 months onwards intensely GFAP immunoreactive astrocytes could 
be observed in the thalamus of both INCL mice. This astrocytosis continued to 
increase in intensity with disease progression. Interestingly, the astrocytes in the 
macrophage/microglia deficient Ppt1-/-/Sn-/- mice appeared to be slightly more darkly 
stained at 3 and 5 months of age, and clearly showed more intense GFAP 
immunoreactivity at 7 months of age than that seen in age-matched Ppt1-/- mice (see 
Figure 46).  
Higher magnification pictures demonstrated this phenotype of more pronounced 
astrocytosis in Ppt1-/-/Sn-/- more clearly (see Figure 46B). The darkness and intensity 
of GFAP staining of astrocytes in the double knockout mice exceeded that in the 
single Ppt1-/- mice. Whereas at 3 months of age individual astrocytes with thickened 
processes could be distinguished, a continuous “carpet” of stained astrocytes could be 
seen by the end stage of the disease. This transition to a staining pattern that filled the 
entire thalamus was evident to a similar extent in both double and single knockout 
mice, but the density and intensity of GFAP staining was clearly greater in the       
Ppt1-/-/Sn-/- mice.  
Quantifying the intensity of GFAP immunoreactivity by thresholding image analysis 
defined the extent of this difference in astrocytosis between Ppt1-/-/Sn-/- and Ppt1-/-
mice (see Figure 47). Already at 3 months of age, a mean increase of 13.3% in 
GFAP+ve staining intensity in these double knockout mice could be observed, but 
this was not statistically significant due to the high variation between individual mice. 
A similar picture could be seen at 5 months of age, with a 3.4% increase in GFAP 
immunoreactivity in the double knockout mice, which again was not statistically 
significant. This is in contrast to the markedly increased level of astrocytosis in Ppt1-/-
/Sn-/- mice seen at 7 months of age, when the thalamus of these double knockout 
mice was completely filled with intensely stained astrocytes (see Figure 46), with more 





Figure 46. Progressive astrocytosis in the thalamus of Ppt1-/- and Ppt1-/-/Sn-/- double 




time point the double knockout mice displayed 84.4% higher levels of GFAP staining 
than age-matched wildtype mice (see Figure 47), and exhibited many more intensely 
activated astrocytes than Ppt1-/- mice. 
The astrocytosis present in Ppt1-/-/Sn-/- mice seemed to increase in a stepwise manner 
over time. The first wave of activation occurred at 3 months, which stayed constant at 
5 months of age, until some unknown factors triggered an even higher level of 
activation at 7 months of age. In comparison, the astrocytosis that occurred in Ppt1-/- 
mice steadily increased with disease progression. It seemed that as soon as a certain 
pathological threshold was reached in the double knockout mice, astrocytosis became 
uncontrolled. These data suggest that Sn+ve microglia may directly, or indirectly, 
influence astrocytosis in the INCL brain. The presence of a functioning sialoadhesin 
adhesion molecule on macrophages/microglia must in some fashion tame or restrain 
the activation of astrocytes either via direct cell to cell contact, or perhaps indirectly 
via the activation or down-regulation of other cells. Whether this hyper-activation of 
astrocytes has benign or negative consequences for neuron survival will be discussed 
in Chapter 7.  





Consistent with the astrocytosis seen in the thalamus, the activation of astrocytes in 
the somatosensory cortex (S1BF) of Sn deficient Ppt1 double mutants exhibited a 
similar pattern during disease progression (see Figure 48). From 3 months onwards a 
widespread astrocytosis could be detected throughout S1BF. Nevertheless, certain  
Figure 46. Progressive astrocytosis in the thalamus of Ppt1-/- and Ppt1-/-/Sn-/- double 
knockout mice. (A) Immunohistochemical staining for the astrocyte marker glial fibrillary acidic 
protein (GFAP) in the thalamus of 1, 3, 5 and 7 month old mice revealed localised astrocytosis 
within the ventral posterior nucleus (VPM/VPL) (---) of INCL mice. At all ages, Ppt1-/-/Sn-/- double 
knockout mice showed enhanced GFAP immunoreactivity compared to Ppt1-/- mice. From 3 
months of age localised astrocytosis was observed in the VPM/VPL of mutant mice which 
spread to involve the whole thalamus with increased age. GFAP immunoreactivity was virtually 
absent in age-matched Rag-1-/- mice or wildtype (WT) mice. Scale bar = 200 μm (B) Higher 
magnification reveals the morphology of GFAP+ve astrocytes in the VPM/VPL of Ppt1-/- and 
Ppt1-/-/Sn-/- mice at 1, 3, 5 and 7 month of age. Compared to the faintly immunoreactive 
protoplasmic astrocytes present in 1 month old mutant mice, many intensely stained fibrous 
astrocytes were present in the VPM/VPL from 3 months onwards in both strains of INCL mice. 
These astrocytes displayed thickened processes and became more numerous with increased age 
until the thalamic neuropil was completely filled with GFAP+ve astrocytes and their processes by 
7 months of age. A direct comparison between Ppt1-/- and Ppt1-/-/Sn-/- mice revealed that the 
astrocytosis was more pronounced in the double knockout mice at all ages. These Ppt1-/-/Sn-/- 
mice displayed astrocytes with more intensely stained cell bodies and thicker processes resulting in 
overall darker GFAP+ve staining than in Ppt1-/- mice at all ages. In WT and Sn-/- mice only 
occasional faintly stained protoplasmic astrocytes with many long thin branched processes could 
















laminae, including lamina V from 3 months, and laminae I and II from 5 months 
onwards, contained more prominent astrocytosis in Ppt1-/-/Sn-/- double knockout 
mice. In comparison to single mutant Ppt1-/- mice, the overall intensity of astrocytosis 
was enhanced in the double knockout mice. In Ppt1-/- mice astrocytosis followed a 
laminar-specific pattern, with deeper layers containing more darkly stained astrocytes 
at early ages. In contrast, Ppt1-/-/Sn-/- double knockout mice already displayed a more 
or less homogenous pattern of astrocytosis at 3 months of age, which only later lead 
to more subtle laminar-specificity (see Figure 48A).  
In summary, similar patterns of astrocytosis seemed to occur in Ppt1-/-/Sn-/- double 
Figure 47. Increased levels of astrocytosis in the thalamus (VPM/VPL) of Ppt1-/-/Sn-/- 
double knockout mice. Thresholding image analysis revealed that the mean level of GFAP 
immunoreactivity in double knockout mice was marginally enhanced at 3 and 5 months, but 
significantly at 7 months of age compared to Ppt1-/- mice. In contrast, almost no GFAP 
immunoreactivity was detected in the thalamus of either Sn-/- or wildtype (WT) mice. Both        
Ppt1-/- and Ppt1-/-/Sn-/- mice displayed significantly increased GFAP immunoreactivity from 3 
months onwards compared to WT mice. The same data are presented as both histogram (A) and 
line graph (B). Percentages indicate differences between Ppt1-/-and Ppt1-/-/Sn-/- mice. Statistics: 
Two-way ANOVA with Bonferroni post hoc test, ***p<0.001. Data shown as mean ± SEM, n = 





Figure 48. Progressive astrocytosis in the somatosensory barrel field (S1BF) cortex of   





knockout mice as seen in Ppt1-/- mice, but in general astrocytosis was more 
pronounced in these double mutant mice. Higher magnification pictures of lamina V 
of the S1BF cortex confirmed this phenotype of more pronounced astrocytosis in 
Ppt1-/-/Sn-/- (see Figure 48B). Both Ppt1-/- and Ppt1-/-/Sn-/- mice showed hypertrophic 
astrocyte staining with darkly stained processes from 3 months onwards in lamina V. 
But the intensity of GFAP immunoreactivity on cell bodies and processes was more 
pronounced in Ppt1-/-/Sn-/- mice compared to Ppt1-/- mice. This difference was 
marginally seen at 3 and 5 months of age, but clearly at 7 months of age when the 
neuropil of lamina V was completely filled with GFAP+ve astrocytes and their 
processes in Ppt1-/-/Sn-/- mice (see Figure 48B). 
Quantification of GFAP immunoreactivity via thresholding image analysis revealed 
that cortical astrocytosis in the double knockout mice was increased at all ages 
compared to single mutant Ppt1 mice: at 3 months by 7.5%, at 5 months by 3.5% and 
at 7 months by 22.5%, reaching significant levels at 3 and 7 months of age (see Figure 
49). Although lower levels of astrocytosis could be seen in the cortex, compared to the 
thalamus, the smaller variance in the Ppt1-/-/Sn-/- mice resulted in a more significant 
difference in astrocytosis in the somatosensory cortex (S1BF). As in the thalamus, the 
same stepwise manner of activation could be observed in the double mutant mice. 
Figure 48. Progressive astrocytosis in the somatosensory barrel field (S1BF) cortex of   
Ppt1-/- and Ppt1-/-/Sn-/- double knockout mice. Immunohistochemical staining for the 
astrocyte marker glial fibrillary acidic protein (GFAP) in the S1BF of 1, 3, 5 and 7 month old mice 
revealed differences between Ppt1-/- and Ppt1-/-/Sn-/- double knockout mice. Ppt1-/-/Sn-/- double 
knockout mice showed a clearly enhanced astrocytosis at all ages, but particularly at 7 months of 
age compared to Ppt1-/- mice. In single mutant Ppt1-/- mice widespread astrocytosis was present 
throughout all lamina of the cortex, which increased in intensity with disease progression. Most 
prominent GFAP immunoreactivity was seen in deeper laminae (especially lamina V) from 3 
months of age onwards and lamina I (and II) at 7 months of age. In contrast, in Ppt1-/-/Sn-/- 
double knockout mice more homogenous widespread astrocytosis throughout all layers was 
apparent from 3 months onwards compared to Ppt1-/- mice. But at 7 months of age the most 
prominent GFAP immunoreactivity was present in laminae V and I (and II) in Ppt1-/-/Sn-/- mice, 
as was seen in Ppt1-/- mice at this time point. In WT and Sn-/- mice only occasional faintly stained 
protoplasmic astrocytes with many long thin processes could be seen at all ages. Scale bar = 100 
μm. (B) Higher magnification revealed the morphology of GFAP+ve astrocytes in lamina V of 
the S1BF cortex of Ppt1-/- and Ppt1-/-/Sn-/- mice at 1, 3, 5 and 7 month of age. Compared to the 
faintly immunoreactive protoplasmic astrocytes present in 1 month old mutant mice, many 
intensely stained fibrous astrocytes were present in the S1BF from 3 months onwards in both 
strains of mutant mice. These astrocytes displayed thickened processes and became more 
numerous with increased age until the cortical neuropil of lamina V was completely filled with 
GFAP+ve astrocytes and their processes by 7 months of age. A direct comparison between Ppt1-/- 
and Ppt1-/-/Sn-/- mice revealed that the astrocytosis was more pronounced in the double knockout 
mice at all ages. These Ppt1-/-/Sn-/- mice displayed astrocytes with more intensely stained cell 
bodies and thicker processes resulting in overall darker GFAP+ve staining than in Ppt1-/- mice at 
all ages. In WT and Sn-/- mice only occasional faintly stained protoplasmic astrocytes with many 















This data potentially revealed an unexpected link between macrophage/microglia 
crosstalk and astrocytosis, and enforces the importance of studying and understanding 
how each cell type in the brain may be involved in pathogenesis.  





To reveal the extent of microglial activity in the brains of the different genotypes of 
mice, we stained Ppt1-/-/Sn-/-, Ppt1-/-, Sn-/- and WT control brains for CD68, which 
stains monocytes, macrophages and also microglia (Lee et al., 1992; Holness et al., 
1993; Holness and Simmons, 1993). We stained brains from mice of these genotypes 
(n=5) at all four ages groups (1, 3, 5 and 7 months) and quantified potential 
differences in CD68 staining intensity by thresholding image analysis.  
Figure 49. Increased levels of astrocytosis in the somatosensory barrel field (S1BF) cortex 
of Ppt1-/-/Sn-/- double knockout mice. Thresholding image analysis reveals that the mean level 
of GFAP immunoreactivity in double knockout mice was increased at all ages and reached 
significant levels at 3 and 7 months of age, compared to Ppt1-/- mice. In contrast, almost no 
GFAP immunoreactivity was detected in the thalamus of either Sn-/- or wildtype (WT) animals. 
Both Ppt1-/- and Ppt1-/-/Sn-/- mice displayed significantly increased GFAP immunoreactivity from 
3 months onwards compared to WT animals. The same data are presented as both histogram (A) 
and line graph (B). Percentages indicate differences between Ppt1-/- and Ppt1-/-/Sn-/- mice. 
Statistics: Two-way ANOVA with Bonferroni post hoc test, *p<0.05, ***p<0.001. Data shown as 
mean ± SEM, n = 5.   
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In Sn-/- and WT mice palely stained CD68+ve microglia were present in the thalamic 
VPM/VPL nuclei and throughout the brain, displaying the morphology of quiescent 
microglia with a small cell soma and thin ramified processes (see Figure 50B). 
However, in Ppt1-/- mice, evidence for microglial activation could be detected in the 
VPM/VPL nuclei from 3 months onwards, with an increased intensity of CD68 
immunoreactivity and the first signs of morphologically transformed microglia (see 
Figure 50). This process increased steadily over the course of the disease, as described 
in more detail in Chapter 4 (see section 4.2c in Chapter 4). In comparison,         
Ppt1-/-/Sn-/-double mutant mice showed a very similar microglial phenotype (see 
Figure 50). From 3 months onwards the first signs of microglial activation could be 
detected, which appeared similar or perhaps slightly less intense than that seen in  
Ppt1-/- single mutant mice. Although this microglial activation also increased in 
intensity with disease progression in Ppt1-/-/Sn-/- double mutant mice, the extent of this 
activation was reduced in Sn deficient double knockout mice as judged by the intensity 
of CD68+ve staining (see Figure 50), suggesting a role for Sn in the process of 
microglial activation. This difference in the relative level of microglial activation (as 
judged morphologically) was even clearer in higher magnification pictures (see Figure 
50B). Whereas at 3 months of age similar patterns and shapes of CD68+ve cells were 
detected in Ppt1-/-/Sn-/-double mutant mice, from 5 months onwards microglia in these 
mice showed clear morphological evidence for reduced levels of activation. A mix of 
microglial morphologies could be seen in Ppt1-/-/Sn-/- mice at 5 months of age with 
some microglia still possessing elongated processes, while others showed the typical 
darkly stained, swollen soma with a halo of shortened processes. Indeed, at this 5 
month time point the difference in microglial morphology in Ppt1-/-/Sn-/- and Ppt1-/- 
mice was more subtle, whereas at 7 months of age, all microglia in Ppt1-/-/Sn-/-double 
mutant mice seemed to be smaller and less intensely stained than those in Ppt1-/- mice. 
Most strikingly, the microglia in the double knockout mice lacked the intensely stained 
halo of short processes around their soma as was apparent in age-matched Ppt1-/- mice 
(see Figure 50B). Since these short processes serve as the sensing devices by which 
microglia interact with their immediate vicinity and other cell types, it is possible that 
these processes may particularly be affected by inactivation of Sn in Ppt1-/-/Sn-/- mice. 
Nevertheless, this awaits experimental verification by detailed characterisation of Sn-/- 
and Ppt1-/-/Sn-/- microglia in cell culture systems. Based on this interpretation, the 






Figure 50. Progressive microglial activation in the thalamus (VPM/VPL) of Ppt1-/- and 
Ppt1-/-/Sn-/- double knockout mice. (see figure caption on next page) 
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Quantification of CD68 immunoreactivity via thresholding image analysis defined 
more clearly the differences in the extent of microglial activation in the VPM/VPL, 
between Ppt1-/-/Sn-/- and single mutant Ppt1 mice (see Figure 51). At 3 months of age, 
both mouse populations showed significantly elevated CD68 immunoreactivity in the 
thalamus compared to control mice, but no overt difference could be observed in this 
response between the two INCL mouse strains. In contrast, from 5 months onwards a 
significant decrease in CD68 staining was apparent in Ppt1-/-/Sn-/- mice compared to 
Ppt1-/- mice, with 7.5% less CD68 immunoreactivity seen at 5 months of age and a 
similar reduction of 6.2% at 7 months of age in the double knockout mice. However, 
at these time points Ppt1-/-/Sn-/- mice still show highly activated microglial and 
macrophage staining and infiltration compared to control mice (see Figure 51). The 
additional lack of Sn did not appear to reverse the process of microglial activation in 
the brain, but delayed and diminished its extent.  This delay seemed to occur at 5 
months of age when the microglial activation is in full swing. Speculatively, this 
reduction could be due to the recruitment of peripheral monocytes/macrophages to 
the thalamic VPM/VPL nuclei between 3 and 5 months of age. Since Ppt1-/-/Sn-/- 
microglia seem to be initially able to become activated normally until 3 months of age, 
even without Sn, the subsequent differences in their morphology may reflect altered 
crosstalk between microglia and infiltrating immune cells/macrophages. 





To investigate whether Sn deficiency also results in similar effects in the cortex of 
INCL mice, the same analyses performed in the thalamus were undertaken in the  
Figure 50. Progressive microglial activation in the thalamus (VPM/VPL) of Ppt1-/- and 
Ppt1-/-/Sn-/- double knockout mice. (A) Immunohistochemical staining for the microglial 
marker CD68 in the thalamus of 1, 3, 5 and 7 month old mice revealed localised microglial 
activation within the ventral posterior nucleus (VPM/VPL) (---) of INCL mice. Ppt1-/-/Sn-/- double 
knockout mice showed reduced CD68 immunoreactivity at all ages, but more clearly seen from 5 
months onwards compared to Ppt1-/- mice. Microglial activation was observed in the VPM/VPL of 
INCL mice from 3 months onwards, which spread to involve the whole thalamus and gained in 
activation levels with increased age. Similar microglial activation was absent in Sn-/- and wildtype 
(WT) mice in which only quiescent microglia were stained. Scale bar = 200 μm. (B) Higher 
magnification pictures of CD68+ve microglia in the thalamus of 1, 3, 5 and 7 month old mice 
revealed differences in cell morphology and activation between Sn deficient double and single Ppt1 
mutant mice. Ppt1-/-/Sn-/- double knockout mice showed clearly reduced microglial activation in the 
thalamus from 5 months onwards in terms of cell size, staining intensity and transformation into 
brain macrophages. Microglia in Ppt1-/- mice were intensely CD68 immunoreactive with an enlarged 
and rounded cell soma from 3 months onwards, whereas microglia in Ppt1-/-/Sn-/- double knockout 
mice remained relatively smaller at all ages, with fewer short processes surrounding the microglial 
cell soma at 5 and 7 months of age. Only quiescent microglia could be detected in 1 month INCL 













somatosensory cortex (S1BF). As described in Chapter 4 (see section 4.2d), the 
relative level of CD68 imunoreactivity in Ppt1-/- mice was much lower in the cortex 
than in the thalamus. In addition to layer specific differences, there were also fewer 
activated microglia in the cortex. However, over the course of the disease this 
microglial activation became more pronounced and reached its maximum at 7 months 
of age (see Figure 52).  
In terms of CD68 staining, microglial activation appeared to occur to similar extents at 
all ages in the S1BF of Ppt1-/- mice and Ppt1-/-/Sn-/- double knockout mice (see Figure 
52A). Only a slight reduction could be suggested at 3 and 5 months of age. At these  
Figure 51. Reduced levels of microglial activation in the thalamus (VPM/VPL) of         
Ppt1-/-/Sn-/- double knockout mice. Thresholding image analysis revealed that the mean level 
of CD68 immunoreactivity in double knockout mice was significantly reduced at 5 and 7 months 
of age, compared to Ppt1-/- mice.  In contrast, almost no CD68 immunoreactivity was detected in 
the thalamus of either Sn-/- or wildtype (WT) animals. Both Ppt1-/- and Ppt1-/-/Sn-/- mice displayed 
significantly increased CD68 immunoreactivity from 3 months onwards compared to WT 
animals. The same data are presented as both histogram (A) and line graph (B). Percentages 
indicate differences between Ppt1-/-and Ppt1-/-/Sn-/- mice. Statistics: Two-way ANOVA with 





Figure 52.  Progressive microglial activation in the somatosensory barrel field (S1BF) 
cortex of Ppt1-/- and Ppt1-/-/Sn-/- double knockout mice. (see figure caption on next page) 
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time points the pattern of CD68 staining in Ppt1-/-/Sn-/- mice seemed a little more 
diffuse and less laminar specific than in Ppt1-/- mice. Whilst Ppt1-/- mice showed 
pronounced microglial activation in lamina VI at 3 and 5 months of age, the double 
mutants displayed the same general pattern of activation, but less prominently in 
lamina VI. Looking at the morphology of microglia at these time points (see Figure 
52B): At 3 months of age, both mouse genotypes displayed microglia of similar 
morphology with occasional CD68+ve cells with slightly swollen cell soma and 
elongated processes. At 5 months of age CD68+ve microglia in Ppt1-/- mice showed 
halo-like short processes around many cells in lamina VI. These short processes were 
absent in Ppt1-/-/Sn-/- double knockout mice at the same age, reflecting the similar 
microglial morphologies seen in the thalamus of these mice. However, at 7 months of 
age no qualitative differences in microglial morphology could be detected between 
Ppt1-/-/Sn-/- and Ppt1-/- mice (see Figure 52B). 
Quantifying CD68+ve immunoreactivity in the somatosensory cortex by thresholding 
image analysis showed no significant difference between Ppt1-/-/Sn-/- and Ppt1-/- mice 
at any time point (see Figure 53). Only at 5 months of age was there a small reduction 
in CD68 staining, but the high variance in the double knockout group at this time 
point precluded any statistical significance. As such, additionally knocking out Sn 
seemed to have relatively little effect on microglial activation in the S1BF region of the 
cortex. This strengthens the hypothesis that microglia themselves do not require Sn to  
Figure 52. Progressive microglial activation in the somatosensory barrel field (S1BF) 
cortex of Ppt1-/- and Ppt1-/-/Sn-/- double knockout mice. Immunohistochemical staining for 
the microglial marker CD68 in the S1BF of 1, 3, 5 and 7 month old mice revealed only marginal 
differences between Ppt1-/- and Ppt1-/-/Sn-/- double knockout mice. Ppt1-/-/Sn-/- double knockout 
mice showed slightly reduced microglial activation at 3 and 5 months of age, compared to Ppt1-/- 
mice. In Ppt1-/- mice intensely stained CD68 positive microglia were most prominent in deeper 
laminae (mainly layer VI) from 3 months of age onwards, but this microglial activation spread to 
upper layers and increased in intensity with disease progression. At 7 months of age widespread 
CD68 immunoreactivity was present throughout all layers, but most prominently in laminae 
II+III and VI. In Ppt1-/-/Sn-/- double knockout mice slightly weaker microglial activation could be 
seen in lamina VI at 3 and 5 months of age, leading to similar levels and distribution of microglial 
activation at 7 months of age, as that seen in Ppt1-/- mice. Similar activation was absent in Sn-/- and 
wildtype (WT) control animals where only quiescent microglial staining could be detected. Scale 
bar = 100 μm. (B) Higher magnification pictures of CD68+ve microglia in lamina VI of the S1BF 
of 1, 3, 5 and 7 month old mice revealed marginal differences in cell morphology and activation 
between Sn deficient double and single Ppt1 mutant mice. CD68+ve microglia in Ppt1-/-/Sn-/- 
double knockout mice showed marginally reduced microglial activation in terms of cell size and 
staining intensity at 3 and 5 months of age. Intensely stained microglia with an enlarged and 
rounded cell soma were seen in Ppt1-/- mice from 5 months onwards, whereas in Ppt1-/-/Sn-/- 
double knockout mice microglia of similar size and activation were only seen at 7 months of age. 
At this last time point no clear difference between the genotypes could be detected. Only 
quiescent microglia were observed in 1 month INCL mice and control animals (Sn-/- and WT). 







become activated initially, nor to maintain or increase activation among themselves. 
This suggests that Sn dependent crosstalk may not be as important in cortical regions. 
Alternatively, perhaps fewer other immune cells are present in, or recruited to, the 
cortex to enhance the on-going immune reaction via Sn, as appears to happen in the 
thalamus. Perhaps this external recruitment only occurs after a certain threshold of 
activation is reached. It is possible that the level of microglial activation in S1BF in 
INCL is too low to see any effect, and other brain regions would show a difference (as 
we have shown in the thalamus).     
Figure 53. Similar levels of microglial activation in the somatosensory barrel field (S1BF) 
cortex of Ppt1-/-/Sn-/- double knockout mice. Thresholding image analysis revealed that the 
mean level of CD68 immunoreactivity in double knockout mice was similar to that seen in Ppt1-/-
mice at all ages. Almost no CD68 immunoreactivity was detected in the thalamus of either Sn-/- or 
wildtype (WT) animals. Both Ppt1-/- and Ppt1-/-/Sn-/- mice displayed increased CD68 
immunoreactivity from 1 month onwards compared to WT animals, but this difference only 
reached significant levels from 3 months onwards. The same data are presented as both histogram 
(A) and line graph (B). Percentages indicate differences between Ppt1-/-and Ppt1-/-/Sn-/- mice. 
Statistics: Two-way ANOVA with Bonferroni post hoc test. Data shown as mean ± SEM, n = 5.        
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5.4 Impact of Sn deficiency on neuron survival in Ppt1-/- mice 
After detecting differences in the time course and extent of astrocytosis and microglial 
activation in Ppt1-/-/Sn-/- double knockout mice, we next asked if this change in innate 
immune responses has any effect upon somatosensory relay neuron survival in 
VPM/VPL.  





As described in Chapter 4 (see section 4.3), in mice deficient for Ppt1 alone a 
dramatic loss in neuronal VPM/VPL neuron number could be seen from 3 months 
onwards. Performing unbiased optical fractionator counts in Nissl stained sections 
from age-matched Ppt1-/-/Sn-/-, Ppt1-/-, Sn-/- and wildtype mice revealed the following 
results (see Figure 54): The first detectable significant loss of VPM/VPL neurons 
could be seen in Ppt1-/-/Sn-/- mice at 3 months of age, compared to wildtype mice. At 
this time point neuron survival was increased in Sn deficient double mutant mice by 
10.2% vs. Ppt1-/- mice, in comparison with age-matched control mice values. However, 
neuron survival was not significantly improved at later stages, even though a slight 
trend towards increased VPM/VPL neuron numbers was seen at 5 months, with 
6.9% more neurons, and subsequently 4.5% more VPM/VPL neurons in these 
double mutant mice at 7 months of age. Indeed, at 5 months of age, the mean survival 
of VPM/VPL neurons was at 27.9% of wildtype values in Ppt1-/-/Sn-/- mice, but the 
high variability between individual mice precluded any significant difference between 
these genotypes. This is in comparison to 7 month old mice in which only 9.7% of 
wildtype neuron numbers were present in the double knockout mice. At this time 
point the difference between Ppt1-/-/Sn-/- and Ppt1-/- mice was of such low magnitude 
that it was not statistically significant (see Figure 54). In summary, the extent of 
VPM/VPL thalamic neuron loss in Ppt1-/-/Sn-/- mice was consistently reduced vs.  
Ppt1-/- mice at all ages, but reached significant levels only in the earlier stages of the 
disease. Nevertheless, the VPM/VPL neurons in the thalamus of Sn deficient INCL 
mice still undergo a pronounced loss, indicating that other influences may be 
responsible for their death. Possible mechanisms and interpretations of these results 
shall be discussed in Chapter 7. However, most likely the VPM/VPL relay neurons 
in the thalamus represent a population of cells that are most vulnerable to the effects 
of Ppt1 deficiency. As such, it could be speculated that in other brain regions where 
microglial activation is less pronounced a greater effect of Sn inactivation may be seen. 
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This hypothesis could be tested by counting the neurons of other brain regions, for 





















As described by (Kielar et al., 2007) the entire thalamocortical system is affected in 
Ppt1-/- mice. Relay neurons from the thalamus are lost before neuron loss occurs in 
Figure 54. Progressive loss of thalamic (VPM/VPL) neurons in Ppt1-/- and Ppt1-/-/Sn-/- 
mice. Unbiased optical fractionator estimates of number of Nissl stained thalamic relay neurons 
in the ventral posterior nucleus (VPM/VPL) of Ppt1-/-, Ppt1-/-/Sn-/-, Sn-/- and age-matched wildtype 
(WT) control mice at different stages of disease progression. Significantly fewer VPM/VPL 
neurons were present in both single and double Ppt1 mutant mice from 3 months onwards 
compared to WT animals, and continued to decline in number with increased age. Nonetheless, 
neuron loss was significantly slowed down in Ppt1-/-/Sn-/- mice. Significantly more neurons were 
present in Ppt1-/-/Sn-/- mice at 3 months compared to Ppt1-/- mice. Marginally elevated VPM/VPL 
neuron numbers were also detected in Ppt1-/-/Sn-/- mice at later stages of the disease, but these 
differences did not reach statistical significance. Sn-/- and WT mice showed no significant 
difference in neuron numbers at any age.The same data are presented as both histogram (A) and 
line graph (B). Percentages indicate differences between Ppt1-/-and Ppt1-/-/Sn-/- mice compared to 
age-matched WT mice. Statistics: Two-way ANOVA with Bonferroni post hoc test, **p<0.01. 
Data shown as mean ± SEM, n = 5.        
210 
 
the target regions to which they project. Therefore, we planned to investigate the 
impact of Sn deficiency in the cortex of Ppt1-/- mice. Ideally, counts of neuron number 
within laminae IV, V and VI would have been performed, the laminae which receive 
projections from the thalamus or which project back to it. However, due to time 
constraints this full analysis could not be undertaken. Instead, to obtain a general 
overview of how Sn deficiency impacts the cortex in Ppt1-/- mice, two key cortical 
phenotypes were measured: namely total cortical volume and the cortical thickness of 
S1BF. These two factors are good indicators of disease progression and often coincide 
with neuron loss (Bible et al., 2004; Kielar et al., 2007). 
5.5 Impact of Sn deficiency on cortical atrophy in Ppt1-/- mice 
As in Chapter 4 (see section 4.4), we measured the total cortical volume and the 
thickness of the somatosensory cortex S1BF in the brains of Ppt1-/-/Sn-/- double 
knockout mice, Ppt1-/-, Sn-/- and WT control mice. These analyses of the total cortical 
volume and a vulnerable cortical sub-region (S1BF) should give sufficient indication of 
the extent and timing of degeneration in the cortex of Ppt1-/-/Sn-/- double knockout 
mice.  





As in the previous Chapter 4 (see section 4.4), we measured the volume of the 
cortical mantle in each mouse population at all four age groups (1, 3, 5 and 7 months 
of age) (see Figure 55). Compared to Ppt1-/-mice, which vs. wildtype mice 
demonstrated a significant loss of cortical volume from 3 months onwards,           
Ppt1-/-/Sn-/- double knockout mice showed a slight improvement in cortical volume 
from 3 months onwards. Whereas the mean difference of 2.5% (calculated vs. age-
matched wildtype mice) between Ppt1-/-/Sn-/- and Ppt1-/- mice did not reach 
significance at 3 months of age; at 5 months of age a significant improvement of 
12.5% in cortical volume was evident in Ppt1-/-/Sn-/- mice. However, this amelioration 
of cortical atrophy was reduced to 3.9% at the end of the disease and was no longer 
significant. At this time point of 7 months of age, the Ppt1-/-/Sn-/- double knockout 
mice also showed a significant cortical atrophy of 39.3% compared to age-matched 
wildtype mice. Cortical volume in Sn-/- mice did not differ from that in wildtype mice 
at any age point. Considered together, these data reveal that the cortical atrophy 






















 As a second disease-related cortical phenotype, Ppt1-/- mice display the first significant 
cortical thinning of 6.1% in S1BF from 3 months onwards compared to age-matched 
wildtype mice (see Figure 56). This thinning increased with disease progression and 
reached its maximum extent in severely affected 7 month old Ppt1-/- mice with a 19.7% 
reduction in S1BF thickness. In contrast, S1BF thickness measurements in Ppt1-/-/Sn-/- 
double knockout mice revealed that these mice not only showed an improved S1BF  
Figure 55. Reduced cortical atrophy in Ppt1-/-/Sn-/- mice. Unbiased Cavalieri estimates of 
cortical volume in Ppt1-/-, Ppt1-/-/Sn-/-, Sn-/- and age-matched wildtype (WT) control animals at 
different stages of disease progression. Cortical atrophy was significantly less pronounced in       
Ppt1-/-/Sn-/- mice at 5 months of age, compared to Ppt1-/- mice. A marginal improvement in 
cortical volume was also detected at 3 and 7 months of age in the double knockouts, compared to 
single Ppt1-/- mice, but these differences did not reach significant levels. Compared to WT mice, 
both Ppt1-/- and Ppt1-/-/Sn-/- mice displayed significant cortical atrophy from 3 months onwards. 
Sn-/- and WT mice showed no significant difference in cortical volume at any age. The same data 
are presented as both histogram (A) and line graph (B). Percentages indicate differences between 
Ppt1-/-and Ppt1-/-/Sn-/- mice compared to age-matched WT mice. Statistics: Two-way ANOVA 















thickness from 3 months onwards, but that they also resembled wildtype mice until 5 
months of age (see Figure 48A and Figure 52A for representative pictures, see  
Figure 56 for quantification).  The only significant reduction in these double mutant 
mice could be seen at 7 months of age, compared to wildtype mice. Increases of 2.8%, 
8.0% and 5.7% in S1BF thickness were apparent in Ppt1-/-/Sn-/- double knockout mice 
at 3, 5 and 7 months of age respectively compared to single Ppt1-/- mice (calculated vs. 
age-matched wildtype mice). These differences in S1BF thickness did not reach 
significant levels at 3 months, but were proved to be statistically robust at 5 and 7 
 Figure 56. Reduced cortical thinning of the somatosensory barrel field (S1BF) cortex in 
Ppt1-/-/Sn-/- mice. Cortical thickness measurements in Ppt1-/-, Ppt1-/-/Sn-/-, Sn-/- and age-matched 
wildtype (WT) controls at different stages of disease progression.  Thinning of the cortical mantle 
of S1BF was significantly reduced in Ppt1-/-/Sn-/- mice from 5 months onwards. Compared to WT 
mice, Ppt1-/- mice displayed significant cortical thinning in S1BF from 3 months onwards, whereas 
S1BF thickness in Ppt1-/-/Sn-/- mice was not significantly different from that in WT mice until 7 
months of age. Sn-/- and WT mice showed no significant difference in cortical thickness at any 
age. The same data are presented as both histogram (A) and line graph (B). Percentages indicate 
differences between Ppt1-/-and Ppt1-/-/Sn-/- mice compared to age-matched WT mice. Statistics: 
Two-way ANOVA with Bonferroni post hoc test, *p<0.05, ***p<0.001. Data shown as mean ± 
SEM, n = 5.        
213 
 
months of age. S1BF thickness in Sn-/- mice did not differ from wildtype controls at 
any age point. In summary, the additional absence of Sn did not reverse, but instead 
delayed the progression of cortical thinning in Ppt1-/- mice. Only at 7 months of age 
could the effects of disease progression be detected in the somatosensory cortex of 
Ppt1-/-/Sn-/- double knockout mice.  
Our data for both disease-associated cortical phenotypes indicated that the influence 
of Sn upon disease progression not only occurs in the thalamus, but also extends to 
the cortex. Comparing these effects upon these two regions (see Figure 54, Figure 55 
and  Figure 56), the alteration of immune responses seemed to have a greater and 
longer lasting impact upon the cortex, a brain region that exhibits less pronounced 
glial activation. The mechanisms that could underlie this amelioration of cortical 
pathology shall be discussed below (see section 5.6b). However, whether these 
improvements can actually be linked to reduced cortical neuron loss is only 
speculation at this point in time.  
5.6 Increased lifespan in Ppt1-/-/Sn-/- mice 
Last, but not least, our collaborators in Würzburg, Germany, performed life 
span/survival rate experiments of Ppt1-/- mice and Ppt1-/-/Sn-/- mice. These 
experiments formed the link between the characterisation of the Sn deficient Ppt1-/- 
mice described above. They demonstrated that Ppt1-/-/Sn-/- double knockout mice 
showed a prolonged life span and lived roughly 10% longer, until 271 days, whereas 
normal Ppt1-/- mice had an average lifespan of 245 days (unpublished data Janos Groh, 
University of Würzburg, Germany). These findings confirmed the improved 
pathological features in the brain described above. 
5.7 Summary and discussion 
In this chapter we have shown that that the deletion of Sn, a binding protein normally 
present on macrophages, has an ameliorating impact upon disease progression in 
INCL mice. After characterising Sn expressing cells and their distribution in the brain 
of Ppt1-/- mice, the absence of Sn resulted in cell type-specific alterations in           
Ppt1-/-/Sn-/- mice: Whereas microglial activation and neuronal loss were reduced, a 
surprising enhancement of astrocytosis could be observed (see also Table 12, 13 and 
Figure 57 for a summary overview) together with a moderately prolonged lifespan in 
Ppt1-/-/Sn-/- mice.  
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Table 12. Summary of the comparison between Ppt1-/- and WT mice. Table was based on the same 
analyses conducted in Chapters 4 and 5. In the left column: “type of analysis”, across the top row: “age of 
mice”. Symbols: = no difference, ↑ significant increase, ↓ significant decrease, = (↑) increasing trend without 
significance, = (↓) decreasing trend without significance. 
   1 Month 3 Months 5 Months 7 Months 
 Brain weight  = = ↓ ↓ 
 Sialoadhesin Thalamus = ↑ ↑ ↑ 
  S1BF = ↑ ↑ ↑ 
 Astrocytosis Thalamus = ↑ ↑ ↑ 
  S1BF = ↑ ↑ ↑ 
 Microglial activation Thalamus = ↑ ↑ ↑ 
  S1BF =  (↓) ↑ ↑ ↑ 
 Neuronal survival  = ↓ ↓ ↓ 
 Cortical thickness S1BF = ↓ ↓ ↓ 
 Cortical volume  = ↓ ↓ ↓ 
 
Table 13. Summary of the comparison between Ppt1-/- and Ppt1-/-/Sn-/- mice. Table was based on the 
same analyses conducted in Chapter 5. In the left column: “type of analysis”, across the top row: “age of 
mice”. Symbols: = no difference, ↑ significant increase, ↓ significant decrease, = (↑) increasing trend without 
significance, = (↓) decreasing trend without significance. 
   1 Month 3 Months 5 Months 7 Months 
 Brain weight  = = =  (↑) =  (↑) 
 Astrocytosis Thalamus = =  (↑) =  (↑) ↑ 
  S1BF = ↑ =  (↑) ↑ 
 Microglial activation Thalamus = = ↓ ↓ 
  S1BF = = =  (↓) = 
 Neuronal survival  = ↑ =  (↑) =  (↑) 
 Cortical thickness S1BF = =  (↑) ↑ ↑ 






a) Sialoadhesin expressing cells in the Ppt1
-/- 
CNS 
This study is the first to document Sn expression in Ppt1-/- mice. Although, a few Sn 
expressing cells were already seen at 1 month of age in the basal forebrain of Ppt1-/- 
mice, the first overt presence of Sn+ve macrophage-like cells occurred in the thalamus 
and S1BF cortex of Ppt1-/- mice from 3 months onwards (see Figure 44). The 
intensity of Sn immunoreactivity, as well as the number of stained cells increased with 
disease progression and reached their maximum at 7 months of age. In wildtype mice 
Sn+ve macrophages could generally, be found either in the meninges, in the choroid 
plexus lining the walls of the ventricles or in the perivascular spaces around 
parenchymal blood vessels (see Figure 44E), even though a weak up-regulation of 
Sn+ve microglial cells was also observed in the basal forebrain of 1 month old 
wildtype mice. In general, our observations were consistent with previous findings that 
demonstrated Sn brain expression on meningeal macrophages and inflammatory 
macrophages and/or microglia (Perry et al., 1992; Klaas and Crocker, 2012). Such 
ambiguity is a common feature of most macrophage/microglial markers. It is not 
possible to unambiguously distinguish Sn+ve infiltrated macrophages from Sn+ve 
Figure 57. Schematic summary of altered phenotypes in the brain of Ppt1-/-/Sn-/- mice. We 
characterised astrocytosis (illustrated as ‘astrocytes’); microglial activation (illustrated as ‘infiltrated 
macrophages, microglia’); and neuron survival (illustrated as ‘neurons’) in Ppt1-/-/Sn-/- mice. As a 
consequence of sialoadhesin (Sn) deficiency, no Sn dependent cell-cell communication occurs 
between macrophages and T-cells (respectively B-cells) in the body and in the brain of Ppt1-/-/Sn-/- 
mice (B-cells are not depicted, since they have not yet been described in Ppt1-/- mouse brains). 
The absence of Sn results in decreased microglial activation at 5 and 7 months of age; increased 
astrocytosis at 3, 5 and 7 months of age; and increased neuron survival at 3 months and 
marginally also at 5 and 7 months in the thalamus. Additionally, cortical volume and the thickness 
of the primary somatosensory barrel field (S1BF) cortex (abbreviated as ‘cortex’) are increased at 5 
and 7 months of age. Overall, the lack of Sn delays disease progression in Ppt1-/-/Sn-/- mice. 
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microglia, and as such the stained cells in our experiments could be either cell type 
(see discussion in Chapter 7).  
However, looking at their morphology in the thalamus at higher magnification (see 
Figure 44B and Figure 44D), we speculate that at 3 months of age mainly microglia 
with long and thin processes stain for Sn, with scattered infiltrated macrophages or 
microglia derived brain macrophages with amoeboid cell bodies and small processes. 
This morphological pattern of Sn+ve cells gradually shifts towards more cells 
resembling macrophages with short processes at 5 months of age. The morphology of 
Sn+ve cells was clearly further altered at 7 months of age, with predominantly round, 
brain-macrophage-like cells observed. A similar sequence of events occurred in the 
S1BF cortex, with an increased number and staining intensity of Sn+ve cells at 7 
months of age in both regions suggesting that a turning point in disease progression 
occurs between 5 and 7 months, in respect of Sn+ve expression and morphological 
activation of microglia, and the possible infiltration of peripheral macrophages in  
Ppt1-/- mice.  
Nevertheless, the distribution of Sn+ve staining in Ppt1-/- mice resembled that of 
other macrophage/microglial markers like F4/80, CD68 and CD45 in INCL mice (see 
Figure 50 and Figure 52; Figure 16 and section 3.1a in Chapter 3; (Kielar et al., 
2007)). All of these markers demonstrate distinctive and most pronounced cell 
staining in the thalamus of Ppt1-/- mice, with subsequent up-regulation in other cortical 
and midbrain regions during the course of the disease, leading to similar levels of 
highly activated brain-macrophages in most brain regions of the Ppt1-/- mice by the 
end of the disease (see for example Figure 44B and Figure 44D; Figure 50B and 
Figure 52B). However, comparing the distribution of Sn+ve staining specifically with 
that of CD68+ve microglia (see Figure 44A and Figure 44C; Figure 50A and 
Figure 52A), there were clearly many less cells expressing Sn than CD68 in the 
thalamus and cortex of Ppt1-/- mice, suggesting that Sn is only expressed in a subset of 
microglia in the brain. Furthermore, the Sn immunoreactivity observed in the basal 
forebrain near the amygdala and nuclei of the anterior commissure of 1 month old Ppt1-/- 
mice represented another striking difference between these two markers. Speculatively, 
this Sn+ve staining reflects a hitherto unknown, early vulnerability of certain neurons 
of the basal forebrain. This hypothesis is strengthened by the fact that the same brain 
region displayed enhanced Sn and CD68 immunoreactivity at subsequent ages. 
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However, since similar staining was also detected in 1 month old (but not in older) 
wildtype mice, this pattern could also be a relic of putative developmental expression 
of Sn in certain brain regions. Perhaps even more speculatively, this Sn expression 
pattern possibly could be caused by an altered BBB permeability and ‘leakage’ of Sn 
stimulating factors in this brain region at 1 month of age.  
However, since the qualitative assessment of Sn expression in Ppt1-/- brains was so far 
only restricted to 2 replicates, these findings have to be confirmed and extended to 
unambiguously explain these differences between the markers. Nevertheless, these 
observations strengthen our initial suggestion and hypothesis, that CD169 could be 
used as a distinctive marker for identifying region-specific sites of inflammation in the 
brain. Depending on the scientific question being asked, CD169 could even prove to 
be more sensitive than commonly used CD68 or F4/80 markers, since it is not 
expressed on every microglia/macrophage.    





By genetically removing Sn we demonstrated a series of specific cellular alterations 
that are accompanied by delayed neuronal loss (see Figure 54), and eventually result 
in a moderately prolonged lifespan of Ppt1-/-/Sn-/- mice. The lack of Sn resulted in 
reduced microglial activation, but only at the later stages of the disease in the thalamus 
and not within the cortex (see Figure 51 and Figure 53). The initial stages of 
microglial activation in Ppt1-/- mice therefore do not appear to be directly linked to Sn 
expressing macrophages. Instead, Sn seems important for the maintenance and further 
activation of microglia in the thalamus during the progression of INCL. Furthermore, 
the reduction in microglial activation in Ppt1-/-/Sn-/- mice is probably not linked to 
direct macrophage-microglia interactions themselves, as previous work demonstrated 
Sn to be a T- and B-cell specific binding protein with a rather low binding affinity to 
other macrophages (van den Berg et al., 1992). More likely, CNS microglia interact in a 
Sn dependent manner with adaptive immune cells (with CD8+ve T-effector cell 
functions (Muerkoster et al., 1999) or with CD4+ve T-regulatory cells (Wu et al., 
2009)), which as a consequence could speculatively re-activate and change the brain 
environment via the increased (or altered) expression of cytokines and inflammatory 
molecules in Ppt1-/- mice. Whatever the underlying mechanism, it clearly occurs in a 
regionally specific fashion, with no reduction in microglial activation evident in the 
S1BF cortex of Ppt1-/-/Sn-/- mice (see Figure 53). However, in this brain region of 
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these double knockout mice, microglial activation did display less pronounced laminar 
specificity (see Figure 52A), suggesting more subtle effects upon cortical microglial 
activation. Therefore, our data suggests that Sn+ve cells may indeed have a brain 
region-specific impact on microglial activation, and it would be important to 
understand the underlying cues and signals. These data also highlight the fact that in 
each brain region a different microclimate of cytokines and molecular signals may 
prevail, as a result of the complex crosstalk between cell types, although this awaits 
experimental verification.   
As a second key landmark in INCL disease progression, astrocytosis in the thalamus 
and S1BF cortex were also analyzed in Ppt1-/-/Sn-/- double knockout mice. To our 
initial surprise, this astrocytosis was increased in both brain regions (see Figure 47 
and Figure 49). This finding hints at a previously unsuspected functional link between 
Sn+ve macrophages/microglia and astrocytes. To our knowledge no other study has 
yet described the nature of astrocytosis in Sn-/- mice under either healthy or diseased 
conditions. Indeed, until now, Sn-/- mice have mainly been considered with respect to 
autoimmune diseases or myelin deficiencies where astrocytosis is present (Williams et 
al., 2007), but the nature and extent of this astrocyte response has not been looked at 
in any detail (Kobsar et al., 2006; Ip et al., 2007; Wu et al., 2009). As such, this study on 
Infantile INCL in which widespread astrocytosis is a characteristic feature (Bible et al., 
2004; Kielar et al., 2007), provides an ideal first platform to investigate the possibility 
of Sn dependent effects on astrocytes. So far we can only speculate about the link 
between Sn+ve macrophages and astrocytes: possible changes of cytokine levels, 
altered properties of the BBB or Sn dependent events in the body periphery are all 
putative explanations for the Sn dependent interlinking of these two cell types. These 
possibilities shall be discussed in more detail in Chapter 7. Future investigations will 
hopefully clarify the exact link between Sn+ve macrophages/microglia and astrocytes.  
In addition to these effects upon reactive changes, neuron survival was also improved 
in the thalamus of Ppt1-/-/Sn-/- double knockout mice at 3 months of age, and a slightly 
increased survival was even sustained until the end of the disease, although it did not 
reach statistically significant levels at 5 and 7 months of age (see Figure 54). 
Compared to Ppt1-/- mice, neuron loss occurred at a similar rate in the double 
knockout mice, just to a lower extent. The most likely explanation for this increased 
neuronal survival could be due to a reduction in the levels of CD8+ve T-cells in these 
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mice, due to the lack of activation stimuli from infiltrated Sn+ve macrophages. 
Although, the detailed negative and positive control measurements of T-cell 
infiltration in Sn-/- and Ppt1-/-/Sn-/- mice have not been conducted, we assume that T-
cell maturation and function in Sn-/- mice is not altered. We feel this assumption is 
justified by the previous characterisation of steady-state Sn-/- mice, which showed only 
a small increase in CD8+ve T-cell number in the spleen and lymph nodes, but no 
changes in T-cell development (Oetke et al., 2006). However, we would also surmise 
that due to compromised macrophage stimulation less T-cells may infiltrate the brain 
of Ppt1-/-/Sn-/- mice compared to Ppt1-/- mice. This hypothesis is coherent with 
previous studies in other neurodegenerative disease models that demonstrated a 
reduction of CD8+ve in diseased Sn-/- mice (Kobsar et al., 2006; Ip et al., 2007). 
Speculatively, the generation of a slightly more neuroprotective environment, via 
cytokines secreted by astrocytes, could explain the slightly improved neuronal survival 
in Ppt1-/-/Sn-/- double knockout mice over all ages, but particularly at the end of the 
disease (5 and 7 months of age). This would be consistent with the suggested 
neuroprotective role of astrocytes in the pathogenesis of INCL (Macauley et al., 2011). 
Nevertheless, the unexpected dramatic increase in astrocytosis in Ppt1-/-/Sn-/- mice at 7 
months of age was not reflected by an increase in neuronal numbers in the thalamus, 
suggesting that there may not necessarily be a direct link between these events in all 
brain regions.   
In the cortex, as a representative example of a less severely affected region in murine 
INCL, the additional deficiency of Sn had an impact that occurred later, but was also 
longer lasting, upon disease phenotypes (see Figure 55 and  Figure 56). The gradual 
course of cortical atrophy in Ppt1-/- mice is clearly altered in Ppt1-/-/Sn-/- mice, with an 
initial delay and subsequent alteration in the rate of disease progression at 5 months of 
age, which then succumbs to other disease accelerating mechanisms at the later stage 
of the disease (as was also seen for astrocytosis in these mice). The net result of these 
events is an only slightly improved phenotype at 7 months of age. However, it is 
tempting to think that these improved cortical phenotypes occur via similar 




c) Significance of findings 
Sn has drawn increasing attention to itself in recent years as an emerging immune 
regulatory protein involved in the crosstalk between the innate and adaptive immune 
system (Martinez-Pomares and Gordon 2012). In the context of INCL, we have 
shown that Sn appears to enhance disease manifestations in Ppt1-/- mice via 
accelerating neuron loss and cortical atrophy, and enhancing microglial activation, but 
also attenuating astrocytosis. This study is the first demonstration of a potential link 
between Sn and astrocyte activation. The mechanisms through which these 
interactions occur, either directly or indirectly would be an interesting area for future 
research. In the absence of Sn, Ppt1-/- mice have a moderately increased life 
expectancy, which might pave the way for testing whether drugs may have similar 
therapeutic effects via specifically blocking Sn activity. Nevertheless our data suggest 
that disease progression is only partially dependent on Sn expression and any 
therapeutic efforts in this direction are likely to be partial at the best, and would 
probably be most promising if used in combination with other therapeutic 
approaches.  
Furthermore, this part of our study again emphasizes how complex the crosstalk is 
likely to be between the different cellular components of the brain. Even the slightest 
change in binding properties of macrophages/microglia appears to have an influence 
on many other cell types. As demonstrated in this chapter, this can potentially be used 
to manipulate the balance of immune reactions in a neuroprotective direction. If this is 
to become a reality, it will be essential to understand the exact role of each cell type 
and how this changes over the course of the disease. This study has provided some 
clues about the importance of macrophage infiltration in INCL, and at the same time 
provides more insights into the inflammatory interactions of glial and immune cells in 
the brain. Considered collectively, this new information may ultimately lead to more 
targeted and specific therapeutic interventions against INCL that have maximal 




















After demonstrating a moderate delaying effect of sialoadhesin (Sn) deficiency upon 
disease progression in Ppt1-/- mice in the previous chapter, we next investigated 
whether Sn played a similar role in another major form of NCL. Juvenile NCL (JNCL) 
is caused by mutations in the CLN3 gene, and Cln3 deficient mice (Cln3-/-) mice have 
been widely used as a model for JNCL (see section 1.2c and Table 2 in Chapter 1). 
These mice also display a characteristic early activation of astrocytes and microglia 
(Pontikis et al., 2004; Pontikis et al., 2005). Therefore, we wanted to determine whether 
impairing macrophage/microglial cell communication by inactivating Sn in Cln3-/- 
mice would have any impact on their well-characterised neuropathological phenotype. 
To achieve this we crossed Cln3-/- mice with Sn-/- mutant mice and created Cln3-/-/Sn-/- 
double knockout mice. Since Cln3-/- mice display a much later onset and disease 
progression, these mice had to be aged for a much longer time than Ppt1-/-/Sn-/- mice 
to reach an equivalent stage of disease progression. As a consequence, the results 
shown here represent a pilot study to obtain an indication of potential phenotypic 
changes in Ppt1-/-/Sn-/- mice. We analysed a small number of mice (n = 4 for JNCL 
forms and n = 2 of control mice) and restricted the analysis to one age group (18 
months). In case of interesting findings, the intention is to continue these studies with 
other age groups and higher n numbers. All mice were analysed for the same 
phenotypes explored in Chapters 4 and Chapter 5, including brain hemisphere 
weight, astrocytosis, microglial activation, neuronal number, cortical thickness and 
cortical volume.  
6.1 Sialoadhesin positive cells in the CNS of Cln3-/- mice 
As in the previous chapter, we first wanted to define where Sn is expressed in Cln3-/- 
and WT control brains. To do this we stained sections from 18 month old mice of 
each genotype (n=2) for Sn or CD169. Since CD169 is only expressed by infiltrated 
macrophages and microglia in their vicinity (Perry et al., 1992; Klaas and Crocker, 
2012), this protein can be useful to identify region specific activation sites of 
inflammation in the brain (see Figure 44 in Chapter 5). However, since CD169 is 
expressed on both infiltrated systemic macrophages and CNS resident microglia, it is 
not possible to unambiguously distinguish them from each other simply by CD169 
staining. As such, we based any classification of Sn positive cells solely on 
morphological appearance. As in Chapter 5, we refer to microglia as cells with 
elongated ramified processes and (brain-) macrophages with round cells with only 
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short or no processes (see Figure 15 in Chapter 3 for the morphological criteria used 
to make this distinction). However, both cell morphologies could frequently be found 
in affected brain regions of Cln3-/- mice.   
In 18 month old wildtype mice CD169+ve macrophage-like cells were only found at 
the margins of the brain parenchyma (meninges and choroid plexus lining the walls of 
the ventricles), but also on macrophages in the perivascular spaces surrounding many 
cerebral blood vessels (see example in Figure 44 in Chapter 5). The Sn+ve cells in 
the meninges resembled macrophages of various morphologies (from round, crescent-
shaped over to amoeboid), whereas the Sn+ve cells around the blood vessels appeared 
elongated and wormlike. 
In 18 month old Cln3-/- mice CD169 staining could be detected in several regions of 
the brain parenchyma (see Table 14 for a detailed summary of the distribution of 
CD169 immunoreactivity in 18 month old Cln3-/- mice). Whereas no staining could be 
detected in the olfactory bulb, weak Sn+ve macrophage/microglial staining was 
spread throughout the entire cortex in laminae VI and V. Such Sn+ve expression was 
most prominently seen in the motor cortex (mainly in lamina VI of M2 and laminae VI 
and V of M1), the agranular insular cortex (AID and AIV), the somatosensory cortex (S1BF, 
S1FL and pronounced in caudal parts of S2) (see Figure 58B1), the auditory cortex 
(AuV, AuD and Au1 particularly pronounced in caudal parts) and the visual cortex (V1) 
to a lesser degree. Strikingly, the piriform cortex from mid-levels of the forebrain 
towards more caudal parts of the brain, displayed a variety of intensely stained 
CD169+ve macrophage/microglial cells (data not shown). In particular, the dorsal 
endopiriform nucleus (DEn) seemed to preferentially contain such cells. Similar CD169 
expression levels were also seen on microglia/macrophage-like cells in the lateral 
entorhinal cortex (LEnt) in more caudal parts of the brain (data not shown). However, in 
contrast to the rather scattered CD169+ve cell distribution in the cortex, the thalamus 
contained most pronounced CD169+ve cell staining. Intensely stained brain-
macrophage-like cells expressing CD169 were detected in the anterodorsal and 
anteroventral thalamic nuclei (AV and AD), the ventromedial and ventrolateral thalamic nucleus 
(VM and VL), the central medial thalamic nucleus (CM), the mediodorsal thalamic nuclei 
(MDM), the dorsal lateral geniculate nucleus (LGNd), the medial geniculate nucleus (MGM), the 
lateral posterior thalamic nuclei (LPMC and LPMR), and characteristically the ventral 
posterior nucleus (VPM/VPL) (see Figure 58A1) and some adjacent parts of the posterior  
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thalamic nuclear group (PO). Other brain regions that contained CD169+ve 
macrophages/microglia included the ventral parts of the subiculum of the 
hippocampus, the pontine nuclei (Pn), the reticulotegmental nucleus of the pons (RtTg), the 
magnocellular part of the red nucleus (RMC) and less intense microglial staining in the 
principal sensory trigeminal nucleus (Pr5VL) (data not shown). 
Out of all these brain regions that contained Sn+ve macrophages in 18 month old 
Cln3-/- mice, we focused our attention on the thalamus and the somatosensory cortex 
(S1BF) (see Figure 10 in Chapter 2), since the thalamocortical system is, similar to 
other NCL forms, a particular focus for JNCL pathology (Pontikis et al., 2005; Weimer 
et al., 2006).  
As described above, there was a particularly pronounced concentration of Sn+ve cells 
in the somatosensory thalamus of 18 month old Cln3-/- mice (see Figure 58A1). 
Macrophage-like cells of variable morphology could be detected particularly in the 
VPM/VPL nuclei of the thalamus, ranging from weakly stained cells with amoeboid  
Figure 58. Sialoadhesin positive cells in the thalamus and the somatosensory barrel field 
(S1BF) cortex of Cln3-/- mice. (A1) Immunohistochemical staining for the peripheral 
macrophage/microglial marker CD169 (sialoadhesin) in the thalamus of 18 month old mice 
revealed localised CD169 expression within the ventral posterior nucleus (VPM/VPL) (---) of Cln3-/- 
mice. Distinct macrophage-like cell staining could be observed in mutant mice, whereas similar 
staining was absent in wildtype (WT) mice. Scale bar = 200 μm. (A2) Higher magnification 
confirmed the morphology of CD169+ve cells in the thalamus of Cln3-/- mice as brain-
macrophages with short or no cell processes. Scale bar = 20 μm. (B) Immunohistochemical 
staining for CD169 in the somatosensory cortex S1BF revealed CD169 positive cells in the deeper 
laminae (mainly V, partly VI) which resemble intermediately activated microglia with elongated 
processes and some macrophage-like cells with small cell bodies without processes. Similar 
activation was absent in WT mice in which only macrophages in the meninges could be detected. 
Scale bar = 100 μm. (B2) Higher magnification of CD169+ve cells in lamina V of the S1BF 
demonstrated that mainly activated microglia-like cells with elongated cell processes stained for 
CD169 in Cln3-/- mice. Scale bar = 20 μm. 
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Table 14. Detailed summary of the distribution of CD169 immunoreactivity in Cln3-/- mice. Brains of 
18 month old Cln3-/- and wildtype mice were stained for CD169 and a list of brain nuclei showing CD169 
immunoreactivity in Cln3-/- mouse brains has been compiled. For each nucleus the extent of microglial (Mic) 
and macrophage (Mϕ) activation have been recorded, whereby cells with distinct processes were classified as 
‘microglia’; round intensely immunoreactive cells without processes were defined as ‘macrophages’ (see also 
Figure 15 for distinction). Symbols: ‘·’ = no immunoreactivity, (+) = traces of cell-staining, + = faintly 
stained cells, ++ = pronounced cell-staining, +++ = intense staining of activated cells. Colour intensity 
reflects the activation status of each cell type (green = microglia, red = macrophages) to visualise the 
differences of CD169 immunoreactivity between nuclei. I, II, III, IV, V or VI = lamina I-VI. Nuclei 
definition according to (Paxinos and Franklin, 2001). 
 
 
Brain region/nucleus 18 Months 
Thalamus  Mic Mϕ Comments 
VPM/VPL 
Ventral posteromedial and posterolateral thalamic 
nucleus 
++ +  
VL Ventrolateral thalamic nucleus ++ ++  
PO Posterior thalamic nuclei ++ ++  
VM Ventromedial thalamic nucleus · ·  
LGNd Dorsal lateral geniculate nucleus + +  
AM Anteromedial thalamic nucleus + +  
AD Anterodorsal thalamic nucleus ++ ·  
AV Anteroventral thalamic nucleus ++ ++  
AVDM/VL 
Anteroventral thalamic nucleus, 
dorsomedial/ventrolateral part 
++ ++  
CM Central medial thalamic nucleus ++ ++  
LPLR/MR 
lateral posterior thalamic nucleus, 
laterorostral/mediocaudal part 
++ +  
MD Mediodorsal thalamic nucleus · ·  
MDM/L Mediodorsal thalamic nuclei, medial/lateral part ++ ++  
MGV/D/M 
Medial geniculate nucleus, ventral /dorsal /medial 
part 
(+) ·  
Re Reuniens thalamic nucleus · ·  
ZIV/D Zona incerta ++ ++  
Rh Rhomboic thalamic nucleus ++ ++  
Midbrain  
RMC Red nucleus, magnocellular part (+) ·  
RPC Red nucleus, parvicellular part + +  
Hippocampus 
 
CA1 Cornu Ammonis 1, subfield of hippocampus · ·  
CA2 Cornu Ammonis 2, subfield of hippocampus · ·  
CA3 Cornu Ammonis 3, subfield of hippocampus · ·  
DG Dentate gyrus · ·  
S Subiculum + + (ventral) 
Amygdala 
 
AAD Anterior amygdaloid area (+) ·  
AHipM Amygdalohippocampal area · ·  
APir Amygdalopiriform transition area + +  
PMCo Posteromedial cortical amygdaloid nucleus · ·  
BLA Basolateral amygdaloid nucleus · ·  
CeC/M 
Central amygdaloid nucleus, capsular part/medial 
division 
· ·  
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Brain region/nucleus 18 Months 
Basal ganglia  Mic Mϕ Comments 
Cpu Caudate putamen (+) ·  
LGP Lateral globus pallidus (+) ·  
MGP Medial globus pallidus (+) ·  
SN Substantia nigra · ·  
VP Ventral pallidum (+) ·  
Cortex 
 
Cortex General pattern + + (VI/V) 
S1BF Primary somatosensory barrel field + + (VI/V) 
S1HL/S1FL Primary somatosensory cortex, hind-/forelimb region + + (VI/V) 
S2 Secondary somatosensory cortex + + (VI/V) 
Au1/AuD/V 
Auditory cortex (primary/secondary auditory cortex, 
dorsal/ventral) 
++ + (VI/V) 
AID/V Agranular insular cortex, dorsal/ventral + + (VI/V) 
V1 Visual cortex + + (VI/V) 
M1 Motor cortex 1 + + (VI/V) 
M2 Motor cortex 2 + + (VI/V) 
RSA The retrosplenial agranular cortex · ·  
RSG The retrosplenial granular cortex (+) · (V) 
Cig1/2 Cingulate cortex area 1/2 · ·  
Pir Piriform cortex ++ + 
(III &  
Mϕ in II) 
VO/LO Ventral/lateral orbital cortex · ·  
LEnt Lateral entorhinal cortex ++ + 
(all laminae)  
(VI: Mϕ) 
DEn Dorsal endopiriform nucleus + ++  




Interstitial nucleus of posterior limb of anterior 
commissure, med./lat. part 
· ·  
MCPO Magnocellular preoptic nucleus + ·  
HDB Nucleus of horizontal limb of the diagonal band + ·  
Pons & Medulla 
 
Pons General pattern + · 
(apart from 
specific nuclei) 
Pr5 Principal sensory trigeminal nucleus ++ +  
VLL Ventral nucleus of lateral lemniscus + +  
RtTg Reticulotegmental nucleus of the pons ++ ++  
ClC Central nucleus of the inferior colliculus · ·  
ECIC External cortex of the inferior colliculus · ·  
Pn Pontine nuclei ++ ++  
LDTg Laterodorsal tegmental nucleus · ·  
Mo5 Motor trigeminal nucleus (+) ·  
Olfactory bulb  
OB Olfactory bulb + +  
EPI External plexiform layer of the olfactory bulb + +  
GRO Granular cell layer of the olfactory bulb + +  
DTT Dorsal tenia tecta + ++  
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cell soma and short processes to more intensely stained cells with round soma and no 
processes (see Figure 58A2). Similarly, in the somatosensory cortex (S1BF) of Cln3-/- 
mice macrophage-like Sn+ve cells could be detected in the deeper layers (see Figure 
58B1), in particular within laminae V and VI. These contained many Sn-expressing 
cells which resembled partly activated microglia with enlarged cell soma and elongated 
branched processes, but some appearing like activated macrophages with very few 
processes (see Figure 58B2).  
Collectively, these data demonstrate that Sn+ve cells are not only present in severely 
affected Cln3-/- mice, but are concentrated in regions where pathological changes are 
on-going.  
6.2 Reduced hemisphere mass of Cln3-/- and Cln3-/-/Sn-/- mice 
As a general indicator of neurodegeneration, the weights of all brain hemispheres were 
measured after paraformaldehyde fixation and removal of the cerebellum (see Figure 
59). Both Cln3-/- and Cln3-/-/Sn-/- mice showed a significant reduction in hemisphere 
mass compared to WT controls at 18 months of age. Brain hemispheres from Cln3-/- 
mice were 19.9% lighter than those from WT controls, whereas Cln3-/-/Sn-/- double 
knockout mice displayed only a 14.2% reduction in hemisphere mass compared to 
wildtype mice. Indeed, Cln3-/-/Sn-/- double knockout hemispheres were 5.8% heavier 
than Cln3-/- single mutant mouse hemispheres in relation to wildtype mice. However, 
this difference between Cln3-/- and Cln3-/-/Sn-/- mice was not statistically significant.  
Although such weight measurements may be subject to many variable factors like 
moisture content, cerebellum separation or damage to the brain during harvesting, 
these data gave us the first indications of possible differences between Cln3-/- and 
Cln3-/-/Sn-/- double knockout mice and prompted us to perform further analyses of 
these brains. 
6.3 Impact of Sn deficiency on reactive phenotypes in Cln3-/- mice  
Because Sn is expressed on the surface of brain macrophages (Perry et al., 1992; Ip et 
al., 2007), it would be of great interest to determine the extent to which the absence of 
Sn affects innate immune responses in Cln3-/- mice. Therefore, we stained tissue from 
18 month old Cln3-/- and WT control mice for the astrocyte marker GFAP and the 










Cln3-/- mice: the thalamic ventral posterior nucleus (VPM/VPL) and the cortical 
somatosensory barrel field (S1BF) according to (Pontikis et al., 2004; Pontikis et al., 2005) 
(see Figure 10 in Chapter 2). Immunohistochemical staining and subsequent 
quantification via thresholding image analysis were performed for both regions in all 
brains. 







Whereas no staining, or only very occasional faintly stained protoplasmic astrocytes 
could be detected in Sn-/- as well as wildtype mice, both Cln3-/- and Cln3-/-/Sn-/- mice 
displayed a pronounced astrocytosis in the thalamus (see Figure 60A). Here, the 
presence of many intensely stained and hypertrophied GFAP+ve astrocytes with 
thickened processes that formed a dense meshwork was observed within the neuropil 
of 18 month old Cln3-/- mice. This staining was most pronounced, but not confined to 
VPM/VPL, spreading into adjacent thalamic nuclei. A similar distribution of GFAP 
immunoreactivity was evident in Cln3-/-/Sn-/- double knockout mice, but its intensity 
appeared to be slightly reduced compared to single mutant Cln3-/- mice, which was 
more apparent at higher power (see Figure 60B).  
 
Figure 59. Loss of brain mass in Cln3-/- and Cln3-/-/Sn-/- mice. The weights of 18 month old 
brain hemispheres from mice of each genotype (Cln3-/-, Cln3-/-/Sn-/-, Sn-/- and wildtype) were 
measured after PFA fixation and removal of the cerebellum, but before further processing. A 
significant loss in hemisphere mass was observed in Cln3-/- and Cln3-/-/Sn-/- mice, compared to 
age-matched wildtype (WT) mice. Hemispheres from Cln3-/-/Sn-/- mice were marginally heavier 
than Cln3-/- mice, but this difference was not significant. Percentage indicates difference between 
Cln3-/-and Cln3-/-/Sn-/- mice in comparison to WT mice. Statistics: One-way ANOVA with 
Bonferroni post hoc test, *p<0.05, **p<0.01. Data shown as mean ± SEM, n = 2 (WT and Sn-/-) 





Figure 60. Similar astrocytosis in the thalamus of Cln3-/- and Cln3-/-/Sn-/- double 







Subsequent thresholding image analysis revealed there was a mean 6.0% reduction of 
GFAP+ve staining intensity in the double knockout mice compared to Cln3-/- mice 
(see Figure 61). However, due to a high variation between individual mice, this 
difference did not reach a statistically significant level. However, the astrocytosis in the 
thalamus of both Cln3-/- and Cln3-/-/Sn-/- mice was significantly elevated compared to 
control WT or Sn-/- brains. These findings are consistent with data published in knock-
in mice at 12 months of age (Pontikis et al., 2005), in which a pronounced astrocytosis 








Figure 60. Similar astrocytosis in the thalamus of Cln3-/- and Cln3-/-/Sn-/- double 
knockout mice. (A) Immunohistochemical staining for the astrocyte marker glial fibrillary acidic 
protein (GFAP) in the thalamus of 18 month old mice revealed localised astrocytosis within the          
ventral posterior nucleus (VPM/VPL) (---) of JNCL mice. Cln3-/-/Sn-/- double knockout mice showed 
similar levels of GFAP immunoreactivity compared to Cln3-/- mice. GFAP immunoreactivity was 
virtually absent in age-matched Sn-/- mice or wildtype (WT) mice. Scale bar = 200 μm (B) Higher 
magnification revealed similar morphology and density of GFAP+ve astrocytes in the 
VPM/VPL of Cln3-/- and Cln3-/-/Sn-/- mice at 18 months of age. Marginally reduced intensity of 
GFAP immunoreactivity was apparent in Cln3-/-/Sn-/- mice, but many intensely stained fibrous 
astrocytes were present in VPM/VPL of single as well as double Cln3 mutant mice. These 
astrocytes displayed thickened processes and filled the thalamic neuropil completely with 
GFAP+ve astrocytes and their processes. In WT and Sn-/- mice only occasional faintly stained 
protoplasmic astrocytes with many long thin processes could be seen. Scale bar = 20 μm. 
Figure 61. Marginally reduced levels of astrocytosis in the thalamus (VPM/VPL) of      
Cln3-/-/Sn-/- double knockout mice. Thresholding image analysis revealed that the mean level 
of GFAP immunoreactivity in double knockout mice was marginally reduced in Cln3-/-/Sn-/- mice, 
compared to Cln3-/- mice, but this difference was not significant. Single as well as double Cln3 
mutant mice showed significant astrocytosis compared to WT mice. In contrast, almost no GFAP 
immunoreactivity was detected in the thalamus of either Sn-/- or wildtype (WT) mice. Percentage 
indicates difference between Cln3-/- and Cln3-/-/Sn-/- mice. Statistics: Two-way ANOVA with 
Bonferroni post hoc test, **p<0.01, ***p<0.001. Data shown as mean ± SEM, n = 2 (WT and    
Sn-/-) or n = 4 (Cln3-/- and Cln3-/-/Sn-/-). 
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In contrast to the widespread astrocytosis in the thalamus of Cln3-/- and Cln3-/-/Sn-/- 
mice, the S1BF region displayed more localised GFAP staining. A laminar-specific 
pattern of astrocytosis was evident in both of these strains of mutant mice, with the 
most intense staining largely confined to the deeper laminae (V and VI) of this cortical 
sub-region (see Figure 62A). This pattern was not restricted to S1BF and was seen in 
other regions of the cortex, but to a lesser extent. This pattern of astrocytosis within 
the more ventral layers of S1BF was similar in both lines of Cln3 deficient mice, but 
with additional scattered astrocytes present in the more dorsal layers in Cln3-/-/Sn-/-
double knockout mice that were more intensely stained than those in Cln3-/- mice. 
Similarly, higher magnification pictures of lamina VI of the S1BF cortex also revealed 
no overt differences between the two genotypes (see Figure 62B). In both mouse 
populations intensely stained fibrous astrocytes with hypertrophic cell bodies and 
thickened processes were present in lamina VI.  As only putative difference it could be 
suggested that the astrocytes in Cln3-/-/Sn-/- double knockout mice displayed 
marginally less ramified and less intensely stained cell processes (see Figure 62B). In 
contrast, astrocytosis in Sn-/- and wildtype control mice was largely confined to the 
most ventral parts of lamina VI, adjacent to the corpus callosum and the occasional 
GFAP positive astrocyte in laminae I and II (see Figure 62A).  
These findings are consistent with data published in Cln3 knock-in mice at 12 months 
of age (Pontikis et al., 2005), in which astrocytosis could be detected in the deeper, but 
also in the most superficial layers of S1BF. In our mice, the astrocytosis was present in 
both laminae VI and V, whereas in (Pontikis et al., 2005) the GFAP+ve activation in 
knock-in mice could only be found in laminae VI and I. This may reflect the slightly 
different targeting strategies employed in these two commonly used models of JNCL. 
Quantification of GFAP immunoreactivity in the S1BF region via thresholding image 
analysis revealed a 1.9% reduction in staining intensity in Cln3-/-/Sn-/- mice compared 
to single mutant mice (see Figure 63), but this difference between Cln3-/- and        
Cln3-/-/Sn-/- mice was not significant. Nevertheless, this level of astrocytosis present in 
S1BF of both Cln3-/- and Cln3-/-/Sn-/- mice was significantly higher than that seen in 





Figure 62. Similar astrocytosis in the somatosensory barrel field (S1BF) cortex of Cln3-/- 













Taken together, these data demonstrate that in 18 month old Cln3-/- mice pronounced 
astrocytosis is present in the thalamus as well as in S1BF, and that the lack of Sn 
results in a marginal, but not significant attenuation of GFAP immunoreactivity in 
both brain regions of Cln3-/-/Sn-/- mice.  
Figure 62. Similar astrocytosis in the somatosensory barrel field (S1BF) cortex of Cln3-/- 
and Cln3-/-/Sn-/- mice. (A) Immunohistochemical staining for astrocyte marker glial fibrillary 
acidic protein (GFAP) in the S1BF of 18 month old mice revealed no overt difference in 
astrocytosis between Cln3-/- and Cln3-/-/Sn-/- double knockout mice. In both single and double 
Cln3 mutant mice GFAP immunoreactivity was prominently seen in deeper laminae (mainly V 
and VI) of the cortex with some faintly stained protoplasmic astrocytes in more dorsal laminae. 
Only marginally, if at all, reduced, intensity of GFAP immunoreactivity was evident in Cln3-/-/Sn-/- 
mice. In control mice (Sn-/- and wildtype (WT)) astrocytosis was mainly confined to the most 
ventral parts of lamina VI, with  occasional faintly stained protoplasmic astrocytes with many long 
thin branched processes in more dorsal layers. Scale bar = 100 μm. (B) Higher magnification 
pictures of lamina VI of the S1BF revealed similar morphology and density of GFAP+ve 
astrocytes in Cln3-/- and Cln3-/-/Sn-/- mice at 18 months of age. Many intensely stained fibrous 
astrocytes with hypertrophic cell soma and thickened processes were present in the S1BF of single 
as well as double Cln3 mutant mice. Marginally less intensely stained and less ramified processes 
could be suggested in Cln3-/-/Sn-/- mice, compared to single Cln3-/- mice. In WT and Sn-/- mice 
only occasional faintly stained protoplasmic astrocytes with many long thin processes could be 
seen. Scale bar = 20 μm. 
Figure 63. Marginally reduced levels of astrocytosis in the somatosensory barrel field 
(S1BF) cortex of 18 month Cln3-/-/Sn-/- double knockout mice. Thresholding image analysis 
revealed that the mean level of GFAP immunoreactivity in Cln3-/-/Sn-/- double knockout mice was 
marginally reduced compared to Cln3-/- mice, but this difference was not significant. Nevertheless, 
both single and double Cln3 mutant mice showed significantly increased GFAP immunoreactivity 
compared to wildtype (WT) mice. Almost no GFAP immunoreactivity was detected in the 
thalamus of either Sn-/- or wildtype (WT) mice. Percentages indicate differences between Cln3-/-
and Cln3-/-/Sn-/- mice. Statistics: One-way ANOVA with Bonferroni post hoc test, ***p<0.001. 
Data shown as mean ± SEM, n = 2 (WT and Sn-/-) or n = 4 (Cln3-/- and Cln3-/-/Sn-/-). 
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To determine the impact of Sn deficiency upon microglial activation in Cln3-/- mice all 
brains were immunostained for CD68, an analysis that has not been conducted 
previously in 18 month old Cln3-/- mice. Pronounced activation of microglia could be 
detected with many intensely stained CD68+ve cells present in the thalamic 
VPM/VPL nuclei in 18 month old JNCL mice, similar to the distribution observed in 
INCL mice (see Figure 64A and compare Figure 37A in Chapters 4 and Figure 50A 
in Chapter 5). These CD68+ve cells displayed a range of morphologies, suggesting 
multiple stages of microglial activation were apparent. These morphologies ranged 
from more palely stained microglia with long ramified processes (mostly seen outside 
the VPM/VPL nuclei), to intermediately activated cells with a mixture of shorter 
ramified processes, to highly activated microglia with a brain macrophage-like 
appearance as darkly stained round cells with short stubby processes (see Figure 
64B). These most highly activated microglial cells were seen mostly just within the 
orders of the VPM/VPL, especially in its ventral portion. In contrast, CD68 staining 
was virtually absent in Sn-/- and wildtype control mice, revealing only quiescent 
microglia with small cell bodies and thin long ramified processes.  
Inactivating Sn, an important binding protein on brain macrophages (Perry et al., 1992; 
Ip et al., 2007) appeared to have only a slight alleviating effect on microglial activation 
in the thalamus of Cln3-/- mice. Morphologically some microglia could be interpreted 
as being in a less activated state, particularly in the VPL nuclei of the thalamus, as was 
evident at higher magnification (see Figure 64B). However, these effects were not 
very pronounced and there was no clear qualitative difference in microglial activation 
between Cln3-/- and Cln3-/-/Sn-/- mice.  
Quantification via thresholding image analysis confirmed the significant difference in 
the level of microglial activation between both Cln3 deficient mouse populations, and 
either Sn-/- or WT controls, both of which showed minimal CD68 immunoreactivity 
(see Figure 65). A mean reduction in staining intensity of 2.0% was detected in    
Cln3-/-/Sn-/- mice compared to single Cln3 mutant mice, but due to the high variation 
in mice of both genotypes, no significant difference could be detected. Compared to 
Ppt1-/- mice, the staining intensity of 18 month old Cln3-/- mice was equivalent to the 
level of microglial activation seen in 3 month old Ppt1-/- mice, confirming that a 




Figure 64. Marginally reduced microglial activation in the thalamus (VPM/VPL) of    
Cln3-/- and Cln3-/-/Sn-/- double knockout mice. (see figure caption on next page) 
236 
 
However, such comparisons should be interpreted with caution given the different 
mixed strain background of the Cln3-/- mice used, rather than the congenic C57Bl/6 
background of all other mice in this thesis. However, it is possible to get a qualitative 
impression of the relative extent of microglial activation in Cln3-/- and Ppt1-/- mice, 
which is consistent with unpublished observations comparing the reactive phenotypes 









Figure 64. Marginally reduced microglial activation in the thalamus (VPM/VPL) of   
Cln3-/- and Cln3-/-/Sn-/- double knockout mice. (A) Immunohistochemical staining for the 
microglial marker CD68 in the thalamus of 18 month old mice revealed localised microglial 
activation within the ventral posterior nucleus (VPM/VPL) (---) of both Cln3 mutant mice.          
Cln3-/-/Sn-/- double knockout mice showed marginally reduced CD68 immunoreactivity compared 
to Cln3-/- mice. Similar microglial activation was absent in Sn-/- and wildtype (WT) mice in which 
only quiescent stained microglia could be detected. Scale bar = 200 μm. (B) Higher magnification 
pictures of CD68+ve microglia in the thalamus of 18 month old mice revealed marginal 
differences in cell morphology and activation between double and single Cln3 mutant mice. It 
could be suggested that Cln3-/-/Sn-/- double knockout mice showed slightly reduced microglial 
activation in the thalamus in terms of cell size and processes. Microglia in Cln3-/- mice were 
intensely CD68 immunoreactive with an enlarged and rounded cell soma and small processes, 
whereas microglia in Cln3-/-/Sn-/- double knockout mice seemed little bit smaller with more 
elongated microglial processes. Only quiescent microglia were detected in control mice (Sn-/- and 
WT). Scale bar = 20 μm. 
Figure 65. Marginally reduced levels of microglial activation in the thalamus (VPM/VPL) 
of Cln3-/-/Sn-/- double knockout mice. Thresholding image analysis revealed that the mean 
level of CD68 immunoreactivity in double knockout mice was only marginally reduced compared 
to Cln3-/- mice. However, this difference did not reach statistical significance. Nevertheless, both 
single and double Cln3 mutant mice showed significantly increased CD68 immunoreactivity 
compared to wildtype (WT) mice. Almost no CD68 immunoreactivity was detected in the 
thalamus of either Rag-1-/- or wildtype (WT) mice. Percentage indicates differences between Cln3-/-
and Cln3-/-/Sn-/- mice. Statistics: One-way ANOVA with Bonferroni post hoc test, ***p<0.001. 
Data shown as mean ± SEM, n = 2 (WT and Sn-/-) or n = 4 (Cln3-/- and Cln3-/-/Sn-/-). 
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Similar to astrocytosis in the S1BF cortex (see Figure 62A), CD68+ve cell staining 
was detected in a layer specific manner in Cln3 mutant mice (see Figure 66A). In the 
deeper cortical laminae (VI and V) of S1BF, intensely stained CD68+ve brain 
macrophages could be identified with round, darkly stained cell bodies and short 
processes. In the other laminae less intensely stained microglia with a smaller cell body 
were present. This evidence for laminar-specific microglial activation is in contrast to 
previous F4/80 data (Pontikis et al., 2005), suggesting that CD68 provides a more 
sensitive marker of these events than F4/80. However, no overt differences in cell 
distribution, cell morphology or staining intensity could be seen between Cln3-/-/Sn-/- 
mice and single mutant Cln3-/- mice (see Figure 66). Higher magnification pictures of 
lamina VI of the S1BF revealed microglia with intensely stained cell soma and short 
processes resembling brain-macrophages, as well as less activated microglia with 
elongated processes to a similar extent in both Cln3-/- mutant mouse strains (see 
Figure 66B). Compared to the relative paucity of Sn (CD169) staining (see Figure 
58B) many more CD68+ve microglia were present in the cortex of Cln3-/- mice than 
CD169+ve macrophages. The difference between these two markers suggests on the 
one hand that Sn+ve cells in S1BF are predominantly not microglia, but perhaps 
infiltrated macrophages, or alternatively that Sn is only expressed and up-regulated on 
a subset of microglia. The mechanisms that trigger Sn expression in the brain are so 
far unknown, but Sn expression seems to coincide with sites of active 
neurodegeneration or inflammation in the brain. These issues shall be further 
discussed in Chapter 7.  
Thresholding image analysis of CD68+ve immunoreactivity in the S1BF of all 18 
month old brains revealed significantly more staining in both Cln3-/- mice and       
Cln3-/-/Sn-/- mice than in either Sn-/- or WT control mice. There was, however, no 
significant difference between CD68 immunoreactivity in Cln3-/- mice and Cln3-/-/Sn-/- 
mice (see Figure 67). Only 0.2% less mean staining intensity could be detected in the 
double knockout mice compared to the single Cln3-/- mice. The only obvious 
difference could be seen in the variation in these data, with Cln3-/-/Sn-/- mice showing 





Figure 66. Similar microglial activation in the somatosensory barrel field (S1BF) cortex of 















6.4 Impact of Sn deficiency on neuron survival in Cln3-/- mice 
Having defined the impact of Sn deficiency upon the innate immune responses in the 
thalamus and S1BF of Cln3-/- mice, we next investigated whether these changes in 
astrocytosis and microglial activation correlated with any effects upon neuronal 
survival.  







Unbiased estimates of the number of Nissl stained VPM/VPL neurons were obtained 
Figure 66. Similar microglial activation in the somatosensory barrel field (S1BF) cortex of 
Cln3-/- and Cln3-/-/Sn-/- double knockout mice. Immunohistochemical staining for the 
microglial marker CD68 in the S1BF of 18 month old mice revealed no overt differences between 
Cln3-/- and Cln3-/-/Sn-/- double knockout mice. In both single and double Cln3 mutant mice, 
intensely stained CD68 positive microglia were most prominent in laminae VI and V of the     
S1BF with only isolated activated microglia in more dorsal laminae. Similar activation was absent 
in control mice (Sn-/- wildtype (WT)) in which only quiescent microglial staining could be detected. 
Scale bar = 100 μm. (B) Higher magnification pictures of CD68+ve microglia in lamina VI of the 
S1BF cortex of 18 month old mice revealed no differences in cell morphology and activation 
between double and single Cln3 mutant mice. Both genotypes displayed intensely CD68 
immunoreactive microglia of various activation states, resembling either brain macrophages with 
an enlarged cell soma and small processes, or intermediately activated microglia with elongated 
processes. Only quiescent microglia were detected in control mice (Sn-/- and WT). Scale bar = 20 
μm. 
Figure 67. Unchanged levels of microglial activation in the somatosensory barrel field 
(S1BF) cortex of Cln3-/-/Sn-/- double knockout mice. Thresholding image analysis revealed 
that the mean level of CD68 immunoreactivity did not differ between Cln3-/-/Sn-/- double 
knockout and Cln3-/- mice in S1BF. Nevertheless, both single and double Cln3 mutant mice 
showed significantly increased CD68 immunoreactivity compared to wildtype (WT) mice. Almost 
no CD68 immunoreactivity was detected in S1BF of either Sn-/- or wildtype (WT) mice. 
Percentage indicates difference between Cln3-/-and Cln3-/-/Sn-/- mice. Statistics: One-way ANOVA 
with Bonferroni post hoc test, ***p<0.001. Data shown as mean ± SEM, n = 2 (WT and Sn-/-) or 
n = 4 (Cln3-/- and    Cln3-/-/Sn-/-). 
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from mice of all genotypes using the optical fractionator method, with this analysis 
performed blind to genotype. This analysis revealed a significant loss of VPM/VPL 
neurons in both Cln3-/-/Sn-/- and Cln3-/- mice compared to WT controls or Sn-/- mice, 
but these occurred to different extents (see Figure 68). Compared to WT controls 
52% of VPM/VPL neurons were lost in 18 month old Cln3-/- mice, whereas         
Cln3-/-/Sn-/- mice showed less neuron loss with only 33.1% loss of VPM/VPL 
neurons. This represented a significant 18.9% improvement in VPM/VPL neuron 
survival by inactivating Sn in Cln3-/- mice. These findings suggest that Sn may 
















Due to time constraints counts of neuron number in the S1BF cortex had to be 
omitted. Instead, as described in the previous chapters, cortical thickness and cortical 
volume measurements were performed to provide a first indication of pathogenesis in 
cortical regions.   
 
 
Figure 68. Increased survival of thalamic (VPM/VPL) neurons in Cln3-/-/Sn-/- mice. 
Unbiased optical fractionator estimates of number of Nissl stained thalamic relay neurons in the 
ventral posterior nucleus (VPM/VPL) of 18 month old Cln3-/-, Cln3-/-/Sn-/- and controls (Sn-/- and 
wildtype (WT)) revealed that significantly more VPM/VPL neurons were present in Cln3-/-/Sn-/- 
double knockout mice than in Cln3-/- mice. However, both single and double Cln3 mutant mice 
displayed significantly fewer neurons compared to WT mice. Percentage indicates difference 
between Cln3-/-and Cln3-/-/Sn-/- mice compared to age-matched WT mice. Statistics: One-way 
ANOVA with Bonferroni post hoc test, **p<0.01, ***p<0.001. Data shown as mean ± SEM, n = 
2 (WT and Sn-/-) or n = 4 (Cln3-/- and Cln3-/-/Sn-/-). 
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6.5 Impact of Sn deficiency on cortical atrophy in Cln3-/- mice 
Having defined the extent of neuron loss in the somatosensory thalamus of Sn 
deficient Cln3-/- mice we next examined its target cortical region, S1BF, by measuring 
its thickness and taking measurements of total cortical volume. This is the first time 
that Cln3-/- mice as old as 18 months have been analysed for these parameters.  







First of all, the total cortical volume of all 18 month old brains was measured and 
compared. Both JNCL mouse populations showed a significant reduction in cortical 
volume compared to the Sn-/- or WT controls (see Figure 69). Cln3-/- mice displayed a 
cortical atrophy of 22.5% compared to wildtype mice, but this was partially 
ameliorated in Cln3-/-/Sn-/- double knockout mice which showed only a 16.6% 
reduction in cortical volume compared to the wildtype mice, although this difference 











Cortical thickness measurements provide an overview of how severely a cortical 
region is affected. Our analysis focused on the somatosensory cortical region S1BF, 
Figure 69. Marginally reduced cortical atrophy in Cln3-/-/Sn-/- mice. Unbiased Cavalieri 
estimates of cortical volume of 18 month old Cln3-/-, Cln3-/-/Sn-/- and control mice (Sn-/- and 
wildtype (WT)) revealed a marginally reduced cortical atrophy in Cln3-/-/Sn-/- mice compared to 
Cln3-/- mice. However, this difference did not reach statistical significance. In contrast, both single 
and double Cln3 mutant mice demonstrated significantly reduced cortical volumes compared to 
WT mice. Percentage indicates difference between Cln3-/-and Cln3-/-/Sn-/- mice compared to age-
matched WT mice. Statistics: One-way ANOVA with Bonferroni post hoc test, *p<0.05, 
**p<0.01. Data shown as mean ± SEM, n = 2 (WT and Sn-/-) or n = 4 (Cln3-/- and Cln3-/-/Sn-/-). 
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which is the target of relay neurons in VPM/VPL and is atrophied in Cln3 deficient 
mice (Pontikis et al., 2005). 
Single mutant Cln3-/- mice showed a 7.5% reduction in thickness of S1BF compared to 
wildtype mice at 18 months of age (see Figure 62A and Figure 66A for representative 
pictures, see Figure 70 for quantification), but this difference was not statistically 
significant. Cln3-/-/Sn-/- double knockout mice showed a similar reduction in S1BF 
thickness. These mice displayed a 6.2% cortical thinning compared to wildtype mice, a 
very moderate 1.2% improvement compared to single knockout Cln3-/- mice. Although 
Sn may potentially have some effect on neuronal survival in the cortex, the cortical 
thinning in Cln3-/- mice is so marginal at this age that it is unlikely to be a very 
pronounced effect. Nevertheless, it will be important to explore this possibility by 








In summary, cortical atrophy does not seem to be strongly affected by the lack of Sn 
in Cln3-/- mice. It is likely that there are other mechanisms that have a greater influence 
upon pathological events in the cortical mantle. Nevertheless, the macrophage 
expressed binding protein sialoadhesin seemed to contribute at least partially to these 
events within the cortex.  
Figure 70. Similar thickness of the somatosensory barrel field (S1BF) cortex in Cln3-/- and 
Cln3-/-/Sn-/- mice. Cortical thickness measurements of 18 month old Cln3-/-, Cln3-/-/Sn-/- and 
control mice (Sn-/- and wildtype (WT)) revealed no significant difference between the genotypes. 
Compared to WT mice, marginal cortical thinning of S1BF could be suggested in Cln3-/- and     
Cln3-/-/Sn-/- mice, whereupon Cln3-/-/Sn-/- mice showed less thinning of the two. Percentage 
indicates difference between Cln3-/-and Cln3-/-/Sn-/- mice compared to WT mice. Statistics: One-
way ANOVA with Bonferroni post hoc test. Data shown as mean ± SEM, n = 2 (WT and Sn-/-) 
or n = 4 (Cln3-/- and Cln3-/-/Sn-/-). 
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Unfortunately, no lifespan experiments have yet been performed on Cln3-/-/Sn-/- mice. 
As this work was only a pilot study investigating the potential effect of Sn deficiency 
on Cln3-/- mice, hopefully future work will add the factor time to the equation by 
looking at mice at different (earlier) time points and also by defining the average life 
expectancy of Cln3-/-/Sn-/-  double knockout mice.  
6.6 Summary and discussion  
In this chapter, we have described three main findings: First of all, we successfully 
characterised for the first time the disease manifestations in the thalamocortical system 
of 18 month old Cln3-/- mice. Secondly, we have demonstrated that Sn+ve cells can be 
found in inflammatory regions of the Cln3-/- brain. Thirdly, and most importantly, we 
have shown that Sn actively contributes to the neurodegenerative process in JNCL 
mice (see also Table 15 and Figure 71 for a summary overview).  
Table 15. Summary of the comparisons between Cln3-/- and WT (middle column), plus Cln3-/- and 
Cln3-/-/Sn-/- mice (right column). Table was based on the same analyses conducted in Chapter 6. Please 
note that Cln3-/- were congenic on a 129Sv, Cln3-/-/Sn-/- mice on a mixed 129Sv and C57BL/6 and WT mice 
congenic on a C57BL/6 strain background. In the left column: “type of analysis”, across the top rows: 
“genotype comparison” and “age of mice”. Symbols: = no difference, ↑ significant increase, ↓ significant 
decrease, = (↑) increasing trend without significance, = (↓) decreasing trend without significan 
   Cln3-/- vs. WT Cln3-/- vs. Cln3-/-/Sn-/- 
   18 Months 18 Months 
 Sialoadhesin Thalamus ↑ . 
  S1BF ↑ . 
 Brain weight  ↓ =  (↑) 
 Astrocytosis Thalamus ↑ =  (↓) 
  S1BF ↑ =  (↓) 
 Microglial activation Thalamus ↑ =  (↓) 
  S1BF ↑ = 
 Neuronal survival  ↓ ↑ 
 Cortical thickness S1BF =  (↓) = 
 Cortical volume  ↓ =  (↑) 
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a) Pathological characterisation of 18 month old Cln3
-/-
 mice 
We have successfully performed the first complete analysis of glial activation, neuronal 
survival and cortical atrophy in 18 month old Cln3-/- mice. Compared to previous 
published studies in JNCL mice (Pontikis et al., 2004; Pontikis et al., 2005; Herrmann et 
al., 2008b), these were the oldest Cln3-/- mice analysed so far for glial activation and 
neuron survival. Other characterisations of glial responses in similarly aged Cln3 
deficient mice have so far only been performed in 14 month old Cln3-/- mice (Pontikis 
et al., 2004), or in 12 and 19 month old Cln3 knock-in mice (Pontikis et al., 2005; 
Herrmann et al., 2008b) and see section 1.10 in Chapter 1). In Cln3-/- mice early 
developmental changes have been reported in the cerebellum already at one week 
post-natal (Weimer et al., 2009), followed by optic nerve pathology and storage 
material accumulation occurring from 5-6 months onwards (Sappington et al., 2003). 
The first neuron loss to occur in these mice has been described in the dorsal lateral 
geniculate (LGNd) nuclei at 6 months of age. However, major neurological deficits and 
Figure 71. Schematic summary of altered phenotypes in the brain of 18 month old         
Cln3-/-/Sn-/- mice. We characterised astrocytosis (illustrated as ‘astrocytes’); microglial activation 
(illustrated as ‘infiltrated macrophages, microglia’); and neuron survival (illustrated as ‘neurons’) in 
Cln3-/-/Sn-/- mice. As a consequence of the sialoadhesin (Sn) deficiency, no Sn dependent cell-cell 
communication occurs between macrophages and T-cells (respectively B-cells) in the body and in 
the brain of Cln3-/-/Sn-/- mice (B-cells are not depicted, because only few or no significantly 
elevated B-cells levels have been detected in Cln3-/- mouse brains compared to wildtype animals 
(Lim et al., 2007a)). The absence of Sn results in no significant change in microglial activation or 
astrocytosis (decreasing trend indicated in brackets), but does lead to increased neuron survival in 
the thalamus. Additionally, the cortical volume and the thickness of the primary somatosensory 
barrel field (S1BF) cortex did not show any change (not shown). Overall, the lack of Sn only 
partially rescues the neurodegeneration in Cln3-/-/Sn-/- mice. 
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symptoms can only be seen from 16 months onwards leaving the mice with a survival 
age of just over 20 months (Mitchison et al., 1999; Cooper et al., 2006). Therefore, 18 
month old mice can be considered fairly severely affected, but are not in their terminal 
stages, leaving some room for potential improvements by a suitable therapeutic 
intervention.  
In terms of the innate immune responses, we could observe GFAP+ve astrocytosis 
and CD68+ve microglial activation in the thalamus and S1BF of 18 month old Cln3-/- 
mice (see Figure 60, Figure 62, Figure 64 and Figure 66). The distribution of 
astrocytosis in the thalamus was similar to that described in 12 month old Cln3 knock-
in mice (Pontikis et al., 2005). GFAP+ve astrocytosis in S1BF showed a more 
extensive spread into dorsal laminae (besides VI, V also partly IV) in 18 month old 
Cln3-/- mice (see Figure 62A, compared to 12 month old Cln3 knock-in mice (Pontikis 
et al., 2005); JD Cooper, personal communication). This discrepancy is possibly due to 
the difference in genetic backgrounds between these mice, but is more likely due to 
the age difference in these cohorts of mice. 
Our microglial staining with CD68 also stands in contrast to the so far described 
F4/80+ve microglial activation in 5, 12 or 14 month old JNCL mice and the 
CD11b+ve microglial activation in 19 month old JNCL mice (Pontikis et al., 2004; 
Pontikis et al., 2005; Herrmann et al., 2008b). Only a moderate or slight activation of 
microglial cells could be detected in these previous studies, whereas pronounced 
thalamic VPM/VPL and S1BF specific microglial activation was evident in 18 month 
old Cln3-/- mice (see Figure 64A and Figure 66A). As in our studies in Ppt1-/- mice 
(see Figure 36 and Figure 38 in Chapter 4) this discrepancy between earlier studies 
and the present study can probably be explained by the use of CD68 as a different 
microglial marker. This antigen appears to be more sensitive as a marker of microglial 
activation than either F4/80 or CD11b, and is now routinely used for this purpose in 
both mouse and human NCL tissue.  
In contrast to glial activation, which has been shown to already occur at one week 
postnatally in the cerebellum of Cln3-/- mice (Weimer et al., 2009) and from 3 months 
of age onwards in Cln3 knock-in mice (Herrmann et al., 2008b), neurodegenerative 
changes have been demonstrated at the earliest at 6 months of age in the dorsal lateral 
geniculate (LGNd) and VPM/VPL thalamic nuclei (Weimer et al., 2006); JD Cooper, 
personal communication), and of Purkinje cerebellar neurons in Cln3-/- mice (Weimer 
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et al., 2009). Further, neurodegeneration was described in 10 month old Cln3 knock-in 
mice in the retina (Cotman et al., 2002), and at 12 months of age in the thalamocortical 
system of the forebrain, including the VPM/VPL nuclei of the thalamus and the 
S1BF cortex of Cln3-/- mice (Pontikis et al., 2005). As such, it was no surprise to also 
find neuron loss in the thalamus of 18 month old Cln3-/- mice in this study (see Figure 
68), even if these were on a mixed and therefore different strain background to the 
studies mentioned above. These data highlight the robust nature of this phenotype, 
and emphasise the pathological targeting of the thalamus in multiple different strains 
of Cln3 deficient mice.  
Finally, we could not detect any reduction in the thickness of S1BF of 18 month old 
Cln3-/- mice (see Figure 70), but did find a small, but significant degree of overall 
cortical atrophy instead (see Figure 69). This first observation is at odds with data 
from 12 month old Cln3 knock-in mice in which thinning of S1BF was observed 
(Pontikis et al., 2005), although the usual caveats of strain background and the 
different targeting constructs used to generate these models must be borne in mind. 
Previous studies in Cln3 deficient mice (Pontikis et al., 2004; Pontikis et al., 2005) did 
not find any atrophy of the cortex up to 15 months of age. As such our new data from 
18 month old Cln3-/- mice suggest that cortical atrophy in these mice seems to have a 
relatively late onset, as it does in mouse models of other forms of NCL (reviewed in 
(Cooper et al., 2006; Cooper, 2010)).   
b) Sialoadhesin expressing cells in Cln3
-/-
 brains 
This study is the first to describe the distribution of Sn immunoreactivity in Cln3 
deficient mice. Besides several other brain regions, we could identify many intensely 
stained Sn+ve cells in the thalamus and in the S1BF cortex of 18 month old Cln3-/- 
mice (see Figure 58), compared to an absence of cell staining in the brain parenchyma 
or only perivascular and meningeal Sn+ve macrophage-like cells in age-matched 
wildtype mice, as previously described in other wildtype mice (see Figure 44E in 
Chapter 5; (Perry et al. 1992)). To our knowledge, this study is the first extensive 
characterisation of Sn+ve cells in a form of NCL. In general, very few studies have so 
far investigated the Sn expression in the brain at all (Perry et al., 1992; Ip et al., 2007), 
with most of them focusing on Sn+ve macrophages in the body periphery (Crocker et 
al., 1991; Muerkoster et al., 1999; Miyake et al., 2007; Phan et al., 2009; Revilla et al., 
2009; Asano et al., 2011; McGaha et al., 2011). In our study, the Sn+ve stained cells 
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were a mixed population of typical macrophage-like cells with amoeboid cell bodies 
and small short processes, together with microglial cells with elongated and ramified 
processes. Even though it is impossible to unambiguously distinguish whether Sn+ve 
cells are either peripheral infiltrated macrophages or resident microglial cells in the 
inflammatory brain (see discussion in Chapter 7), these Sn+ve cells were only located 
in the same areas of the brain where acute CD68+ve microglial activation could be 
detected (see Figure 64 and Figure 66). Qualitatively judged, fewer Sn+ve cells than 
CD68+ve microglia were seen in such regions, indicating that Sn is probably only 
expressed in a subset of microglia/macrophages (compare Figure 58 with Figure 64 
and Figure 66). Nevertheless, the location of Sn+ve cells clearly overlaps with sites of 
innate immune activation in the Cln3-/- brain, suggesting that Sn+ve cells could 
potentially be involved in these inflammatory responses and neurodegeneration. 
Subsequently, this hypothesis has been tested by the characterisation of Cln3-/-/Sn-/- 
double knockout mice, as was presented in this chapter.   
c) Sialoadhesin enhances neurodegeneration  
To address the role of Sn in JNCL pathogenesis we generated Cln3-/-/Sn-/- double 
knockout mice, which lacked this macrophage-expressed binding protein, and 
analysed their neuropathological phenotype at 18 months of age. This analysis 
revealed that the additional deficiency of Sn only marginally attenuated glial activation 
in the thalamus, and relatively to a similar extent also in the cortex, of Cln3-/-/Sn-/- 
mice (see Figure 60, Figure 62, Figure 64 and Figure 66). Indeed, no significant 
difference could be detected for any measurement of glial response in these mice (see 
Figure 61, Figure 63, Figure 65 and Figure 67). This was the case, even though Sn 
is abundantly expressed on macrophage-like cells in both the thalamus and the cortex 
of Cln3-/- mice (see Figure 58). As such, the impact of Sn expressing macrophages 
upon glia in 18 month old Cln3-/- mice appears to be limited. This is most likely 
explained by the relatively late onset of adaptive immune responses (see Figure 27 in 
Chapter 3) upon which Sn can act as an immune regulatory binding protein between 
macrophages and other (adaptive) immune cells in Cln3-/- brains.  
Furthermore, similar to Cln3-/- mice, no significant improvement in the thinning of 
S1BF was apparent in Cln3-/-/Sn-/- mice, but there was a slight reduction in overall 
cortical atrophy compared to these single mutant mice (see Figure 69 and Figure 70). 
These data suggest that Sn and/or Sn+ve cells potentially play a pathological role in 
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disease progression in the cortex, but it will be important to perform counts of neuron 
number in the cortex of Cln3-/-/Sn-/- mice to determine whether this is the case.  
Finally, the loss of thalamic relay neurons was significantly reduced in Cln3-/-/Sn-/- 
double knockout mice compared to Cln3-/- mice (see Figure 68). Therefore, it appears 
that Sn-mediated interactions have a direct impact on neurodegeneration, since when 
they are abolished neuron survival is improved. Plausibly, these interactions could be 
between adaptive immune cells (T-cells and B-cells) and Sn+ve macrophages 
(Muerkoster et al., 1999; van den Berg et al., 2001; Ip et al., 2007; Wu et al., 2009), or 
putative microglia and Sn+ve macrophages (van den Berg et al., 1992; Schadee-
Eestermans et al., 2000). Despite not quantifying the extent of T-cell infiltration in 
Cln3-/-/Sn-/- double knockout mice, we would speculate that less T-cells are likely to 
infiltrate the brains of these double mutant mice compared to Cln3-/- mice; mainly due 
to an expected lower level of activation of T-cells by macrophages. However, since the 
role of T-cells themselves in Cln3-/- mice (for example via creation and characterisation 
of Cln3-/-/Rag-1-/- mice) is yet to be investigated, and T-cells only appear to enter the 
brain at late stages of the disease (see Figure 27 in Chapter 3), the impact of T-cell 
infiltration on neuron survival in Cln3-/-/Sn-/- mouse brains remains speculative, but 
not unlikely. However, we did not see any obvious differences in glial activation in the 
thalamus of these Cln3-/-/Sn-/- mice where less neurodegeneration was observed, 
meaning, that other (as yet unidentified) events may be responsible. These may lie 
outside the CNS, with the systemic autoimmune response that occurs in Cln3 deficient 
mice perhaps contributing an influence (Chattopadhyay et al., 2002a; Lim et al., 2007b). 
Indeed, there could be several alternative explanations which will be discussed in more 
detail in Chapter 7. Firstly, Sn deficiency may have a direct impact on antigen 
presentation to B-cells, and reduce the amount of autoantibodies targeting brain 
antigens. Secondly, the lack of interactions between Sn and adaptive immune cells, 
which are essential for immune cell activation, may result in a less pronounced 
autoimmune response. Thirdly, the lack of Sn may enhance the abnormal signaling of 
immune cells in Cln3-/- mice, which are already compromised due to Cln3 deficiency 
(Dihanich, 2010; Parviainen, 2012). Taken together, this could lead to a less 
inflammatory micro-environment in the brain of Cln3-/-/Sn-/- double knockout mice, a 
slightly reduced glial activation and consequently better neuronal survival.  
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d) Significance of findings 
This study has investigated the role of Sn in JNCL and the part that a, so far 
overlooked, Sn+ve macrophage cell population plays in this disorder. By knocking out 
this binding protein on the surface of macrophages we were able partially to slow 
down the neurodegenerative process that occurs in Juvenile NCL. As an underlying 
hypothesis, we speculate that Sn attenuates the neuroinflammation and in particular 
the autoimmune responses in JNCL mice, which leads to a slowing down of disease 
progression. However, since we could not completely reverse these disease 
phenotypes, other detrimental forces must be present in the brain. Nevertheless, Sn 
may be an attractive target for immunosuppressive interventions in Juvenile NCL. 
Because there is still no effective treatment for this devastating disease, even slowing 
down disease progression could be beneficial. Furthermore, the specific blockade of 
Sn alone, or in combination with other treatment strategies, could potentially produce 
fewer side effects than a generalised immune suppression. Whatever the implications, 


















The main objectives of these studies were to investigate the possible pathogenic role 
of neuroinflammation in the brain of two forms of NCL, and to determine whether 
the adaptive immune cell response, in particular, is a primary or secondary cause of 
neurodegeneration. Via two different genetic manipulations of the immune system we 
have demonstrated that neuroinflammation appears to accelerate disease progression 
in Infantile and Juvenile NCL.  
Firstly, we identified that adaptive immune cells (T-cells) are widely present in the 
brain of both Infantile and Juvenile NCL mice, which is in stark contrast to their 
virtual absence in healthy wildtype mice. Subsequently, we crossbred Ppt1-/- mice with 
immune deficient Rag-1-/- mice (without T- and B-cells). Our findings suggest that the 
resulting lack of adaptive immune cells attenuates innate immune responses and delays 
neurodegenerative events in Ppt1-/-/Rag-1-/- mice.   
In a second set of experiments, we wanted to clarify to which extent a simple 
deficiency of sialoadhesin (Sn), an adaptive immune regulatory binding protein 
normally present on macrophages could affect disease progression in Infantile and 
Juvenile NCL mice. This protein was mainly chosen for three reasons. Firstly, our 
collaborators had previously demonstrated that Sn deficiency in a mouse model of a 
slowly progressing demyelinating CNS disorder leads to reduced CD8+ve T-cell 
infiltration and disease amelioration (Ip et al., 2007). Secondly, having demonstrated 
the presence and pathogenic nature of adaptive immune cells in the brain of Infantile 
(and Juvenile) NCL (see Chapter 3 and Chapter 4), as an adaptive immune cell 
regulatory protein Sn represented an interesting and promising therapeutic target. 
Thirdly, the role of infiltrating peripheral macrophages in the brain of INCL and 
JNCL has not yet been well characterised and investigating the effect of Sn deficiency 
would elucidate their pathological relevance in these two NCL forms in more detail. 
For all these reasons, we crossbred Ppt1-/- and Cln3-/- mice with Sn-/- mice to create 
double knockouts lacking the macrophage marker Sn, but having the appropriate form 
of NCL. Our results demonstrated distinct impacts of Sn deficiency between INCL 
and JNCL. Contrasting effects upon different types of glia were seen in Ppt1-/-/Sn-/- 
double knockout mice, whereas both microglial activation and neurodegeneration 
were decreased, astrocytosis was surprisingly elevated. In contrast, Cln3-/-/Sn-/- double 
knockout mice displayed only a marginal attenuation of innate immune responses 
(glial activation), but a significant reduction in neuron loss. Thus, we could prove that 
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Sn may play an accelerating role in neurodegenerative events in both INCL and JNCL.  
Taking a genetic approach rather than administering an immunosuppressive drug, as 
done in other studies (Seehafer et al., 2011), we could define the effect of adaptive 
immune cells and Sn on other CNS cell types, and upon disease progression. These 
‘proof of principle’ studies have demonstrated that immune cells do indeed have a 
pathogenic impact in Infantile and Juvenile NCL mice. Therefore our findings may 
prove to be valuable for future immunosuppressive therapeutic approaches with the 
aim of improving life expectancy and/or life quality of Infantile and Juvenile NCL 
patients.  
7.1 Adaptive immune cell infiltration in NCL brains 
In Chapter 3 we have supplied the first detailed characterisation of the extent, nature 
and distribution of T-cell infiltration, revealing both differences and similarities 
between the Infantile and Juvenile forms of NCL. Although our data demonstrated 
the presence of CD8+ve, as well as CD4+ve, T-cells in the brains of both forms of 
NCL, our findings also raised a number of unanswered questions.  
a) Sequence of T-cell infiltration 
Our lymphocyte data in Chapter 3 revealed contrasting sequences of T-cell 
infiltration in Cln3-/- and Ppt1-/- mice. In contrast to a simultaneous infiltration of 
CD8+ve and CD4+ve T-cells in Ppt1-/- mice at 3 months of age (see Figure 21 in 
Chapter 3), CD4+ve T-cells appeared to infiltrate the JNCL mouse brain only at the 
later stage of the disease and certainly following CD8+ve T-cell infiltration (see 
Figure 27 in Chapter 3). Although CD4+ve cells generally (but not invariably) 
facilitate the activation and expansion of CD8+ve T-cells in the secondary lymphoid 
organs (as described in section 1.7a in Chapter 1), the timing of infiltration of each 
T-cell sub-population into the inflammation site (brain, in our case) can vary as a 
consequence of different stimuli that trigger or maintain the immune activation (Taub 
and Oppenheim, 1994; Carson et al., 1999; Penna et al., 2002; Brisebois et al., 2006; 
Abbas and Lichtman, 2011). Furthermore, in comparison to the activation process in 
lymphoid tissue, the cooperation of T-cell subsets at the inflammation site varies 
between immune reactions and is less well understood (Bevan, 2004; Nakanishi et al., 
2009; Phares et al., 2012; Wiesel and Oxenius, 2012). However, both T-cell subsets 
would classically be expected to infiltrate the inflammation site (at least to some 
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extent) ((Andersson et al., 1992; Seder and Ahmed, 2003; Abbas and Lichtman, 2011; 
Phares et al., 2012; Wiesel and Oxenius, 2012); MJ Lim, personal communication). 
Therefore, our data revealed that Cln3-/- mice unexpectedly show an initial absence or 
“delayed” arrival of CD4+ve T-cells in the brain (see Figure 27 in Chapter 3), which 
raises questions about why this should be the case. However, a similar sequence of T-
cell infiltration to that we observed in Cln3-/- mice has been seen, for example, in 
Theiler’s virus or Sindbis virus (SINV) infected mice in which virus specific CD8+ve 
T-cells infiltrate the brain initially and CD4+ve T-cell arrival could only be 
documented much later in the brains of these mice, which eventually leads to a 
demyelinating auto-immune disease (Katz-Levy et al. 2000; Begolka et al. 2001; 
Mendez-Fernandez et al. 2003; Metcalf and Griffin 2011). In the body periphery, T-
effector cell recruitment to an inflammation site is thought to generally be antigen-
independent and solely rely upon adhesion molecules and chemokines, whereas 
subsequent preferential proliferation and retention of antigen-specific T cells within 
inflamed tissues ensures a successful immune response (Wakim et al., 2008; Ghani et 
al., 2009; Abbas and Lichtman, 2011). Similar recruitment processes occurring in the 
supposedly ‘immune privileged’ brain have not been definitively established, as most 
studies suggest antigen-independent crossing of the BBB into the perivascular space, 
but antigen-specific entry into the brain parenchyma (Ransohoff et al., 2003; Galea et 
al., 2007b; Melzer et al., 2009); yet, some researchers also favour the possibility of naïve 
T-cells entering the brain (Brabb et al., 2000; Greter et al., 2005; McMahon et al., 2005). 
However, the different timing of T-cell infiltration seen in Infantile and Juvenile NCL 
clearly demonstrate that disease subtype specific immune responses occur (see Figure 
21 and Figure 27 in Chapter 3). In the following sections we will discuss which 
mechanisms could account for these differences in T-cell infiltration between these 
NCL subtypes and in particular, for the delayed arrival of CD4+ve T-cell infiltration 
in Cln3-/- mice.  
Firstly, Cln3-/- astrocytes and microglia show alterations in the secretion of a range of 
cytokines (Dihanich, 2010; Kielian, 2012; Parviainen, 2012). Cell culture experiments 
on Cln3-/- microglia after ceramide or glutamate stimulation revealed increased levels of 
cytokines, for example interleukin 1-β (IL-1β), compared to stimulated wildtype 
microglia (Kielian, 2012); JD Cooper, personal communication). IL-1β is thought to 
act as a pro-inflammatory cytokine recruiting T-cells to inflammation sites (Gery et al., 
1972; Lidington et al., 1998). Likewise, the microglial expression of other cytokines 
254 
 
may also speculatively be altered in the Cln3-/- brain (e.g. IL-12) which could enhance 
Th1 directed cell immunity, increase CD8+ve T-cell cytotoxic activity and overall 
favour CD8+ve T-cell infiltration. However, other microglial cell culture experiments 
studying cytokine expression after lipopolysaccharides (LPS) stimulation (50ng/ml) 
showed reduced levels of microglial cytokine secretion, including for example 
RANTES, compared to wildtype microglia ((Dihanich, 2010); BP Williams, personal 
communication). These latter results resembled studies conducted on cultured Cln3-/- 
astrocytes stimulated with LPS plus interferon gamma (LPS: 1μg/ml and IFN-γ: 
100U/ml), which also demonstrated a significant reduction in the secreted levels of 
several cytokines and chemokines compared to stimulated wildtype astrocytes 
(Parviainen, 2012). Amongst many others, but of particular interest in this context, are 
the significantly reduced secretion of RANTES and Interleukin-4 (IL-4) from Cln3-/- 
astrocytes (Parviainen, 2012). Whereas, on the one hand, RANTES is a chemo-
attractant for T-cells and plays an active role in recruiting leukocytes into 
inflammatory sites (Schall et al., 1988; Miller and Krangel, 1992), on the other hand it 
also selectively supports the migration of monocytes and CD4+ve T-cells across the 
endothelial wall by increasing the adherence of CD4+ve lymphocytes to endothelial 
cells (Schall et al., 1990). In contrast, IL-4 induces Th2 cell differentiation and humoral 
immune responses as an antagonist of IL-12 (Jansen et al., 1990; Trinchieri, 1995; 
Asselin et al., 1997). Thus, reduced expression of both cytokines in Cln3-/- astrocytes 
could speculatively alter or hinder CD4+ve T-helper cell recruitment and infiltration 
into the JNCL brain. Interestingly, whereas mainly a reduction in cytokine secretion 
could be detected in Cln3-/-astrocytes, Cln3-/- microglia showed an up-regulated or 
reduced expression of cytokines compared to wildtype glial cells, depending on 
experimental setup (Dihanich, 2010; Kielian, 2012; Parviainen, 2012). These 
contrasting results are most likely explained by the different stimulation methods used, 
but it will be important to define which scenario reflects the in vivo situation. In any 
case, all experiments indicated an alteration in the cytokine secretion profile of both 
astrocytes and microglia due to Cln3 deficiency. Such altered profiles may favour 
CD8+ve T-cell infiltration and plausibly delay the recruitment and/or infiltration of 
CD4+ve T-cells into Cln3-/- brains. Different chemokines can alter the expression of 
selectin and integrin cell binding molecules on endothelial cells (Hickey, 1999), and/or 
the interactions of lymphocytes with the glia limitans (Ransohoff et al., 2003; Farina et 
al., 2007). This may result in one lymphocyte subset being more favoured to cross the 
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BBB than the other (see section 1.7b in Chapter 1). However, these interpretations 
are purely speculative at present and have to be interpreted with caution, especially, as 
the above experiments have been conducted in cell culture and thus, these 
observations need to be translated into in vivo situations.   
Other than the dysfunction of Cln3-/- glia, another possible explanation for the 
observed T-cell recruitment in Cln3-/- brains is the altered BBB integrity that has been 
reported in Cln3-/- mice (Lim et al., 2007b). This higher permeability of the BBB may 
suggest easier access via the glia limitans, but may also reflect a higher activation status 
or binding tendency of vascular endothelial cells at the BBB, each of which may have 
an influence upon the infiltration of different classes of lymphocytes into the JNCL 
CNS. Although the precise nature of the deficit of BBB integrity remains unknown, 
the secretion profiling of Cln3-/- astrocyte cultures mentioned above also revealed 
significantly decreased levels of the (soluble) vascular cell adhesion molecule 1 
(VCAM-1) and of CD40 which are likely to influence the capacity of endothelial cells 
to recruit leukocytes. VCAM-1 is an essential surface protein on brain endothelial 
cells, which is involved in the tethering and rolling of T-cells along vascular walls 
before their extravasation (Johnson-Leger et al., 2000; Matheny et al., 2000), but can 
also be expressed by astrocytes or as in a soluble form in acute brain 
inflammation/injuries (Hurwitz et al., 1992; Eddleston and Mucke, 1993; Blann et al., 
1999). VCAM-1 has been shown to be crucial for T-cell entry into the CNS 
parenchyma when expressed on astrocytes (Gimenez et al., 2004). CD40, on the other 
hand, is a co-stimulatory molecule mainly found on APCs and B-cells, which interacts 
with CD40-ligand on CD4+ve T-cells (reviewed in (Munroe, 2009)), but it also has 
been shown to be expressed by brain endothelial cells where it could potentially 
mediate CD4+ve T-cell migration across the BBB (Omari and Dorovini-Zis, 2003; 
Urban et al., 2011). The expression of CD40 on astrocytes is still controversial 
(reviewed in (Dong and Benveniste, 2001)), but it is also active in secreted soluble 
form (Fanslow et al., 1992; Mocali et al., 2004; Scalabrino, 2009). Thus, reduced 
expression levels of these two or similar proteins on astrocytes, or in the vicinity of 
astrocytes is likely to have an influence upon how lymphocytes, especially CD4+ve T-
cells, interact with different cellular components of the brain vasculature of Cln3-/- 
mice. Nevertheless, this is again only speculation and highlights the need to explore 
these issues experimentally.   
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Thirdly, different brain entry mechanisms of CD4+ve compared to CD8+ve T-cells 
could potentially be a factor. CD4+ve T-cell brain infiltration is thought to be 
dependent upon perivascular antigen presenting cells (APCs) to re-activate 
lymphocytes and enable brain parenchyma entry (Ransohoff et al., 2003; Becher et al., 
2006). In contrast, antigen-specific CD8+ve T-cell infiltration is not dependent on 
perivascular APCs, but via the luminal expression of MHC I molecules by cerebral 
endothelial cells (Galea et al., 2007b; Melzer et al., 2009). Furthermore, it has been 
speculated that T-cell brain infiltration might be less restrictive for CD8+ve T-cells 
than for CD4+ve T-cells (Cabarrocas et al., 2003). This hypothesis is based on studies 
demonstrating higher numbers and recruitment of CD8+ve T-cells compared to 
CD4+ve T-cells in mouse brains after injection of previously primed antigen 
presenting dendritic cells (DCs) (Carson et al., 1999), or in healthy wildtype mice 
(Brabb et al., 2000). Likewise, another study assessing T-cell infiltration in healthy and 
injured spinal cords showed similar results with higher CD8+ve T-cell infiltration 
compared to CD4+ve lymphocytes (Bradl et al., 2005). Such easier access of CD8+ve 
T-cells to the CNS could be explained by different entry mechanisms (Ransohoff et al., 
2003; Galea et al., 2007b), or perhaps better by their different responses to 
chemokines, as both subpopulations of T-cells show distinct chemokine receptors (i.e. 
CCR9 is only found on CD8+ve T-cells) which can result in altered interactions of 
lymphocytes with vascular endothelial cells or the glia limitans (Carramolino et al., 
2001; Svensson et al., 2002). Additionally, several chemokines preferentially recruit 
only one subset of T-cells (e.g. MIP-1 α recruits CD8+ve T-cells) (Serody et al., 2000). 
All of these mechanisms could explain the predominant CD8+ve T-cell infiltration in 
Cln3-/- mice. However, alternatively, it could also be possible that the resident brain 
APCs are dysfunctional in Cln3-/- brains, specifically impairing and delaying the 
CD4+ve T-cell infiltration, but this issue is yet to be investigated. For example, future 
culture experiments on isolated Cln3-/- APCs could clarify to what extent these cells are 
dysfunctional and whether their interaction with CD4+ve T-cells is impaired. 
Additionally, specific APC knockout or correction experiments in Cln3-/- mice could 
determine whether a selective APC dependent T-cell entry mechanism actually occurs 
in JNCL mice. Nevertheless, since recent studies also describe lymphocyte entry into 
the brain without previous T-cell activation or APC re-activation, these explanations 
may not be sufficient (Greter et al., 2005; McMahon et al., 2005).  
Next, the delayed infiltration of CD4+ve T-cells may speculatively result from the lack 
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of CD4+ve T-cell activation in the first place. As discussed in Chapter 1 (see section 
1.7a), a high level of antigen may trigger a CD8+ve T-cell activation without CD4+ve 
T-cell involvement, as long as the APCs become sufficiently primed (Bachmann et al., 
1998; Bevan, 2004). Or alternatively, the inflammatory stimuli in the brain may simply 
not require the typical CD4+ve T-cell immune properties of activating macrophages 
(and B-cells), but instead depend predominantly upon CD8+ve T-cell immune 
functions of apoptosis induction. Nevertheless, because JNCL has recently been 
shown to be (at least partly) an autoimmune disease (Lim et al., 2007b; Seehafer et al., 
2011), an irregular and unbalanced immune response could be predicted which 
possibly could reflect itself in distorted CD8+ve or CD4+ve T-cell activation and 
frequencies. Maybe auto-antibodies themselves react with GAD65 (Chattopadhyay et 
al., 2002a; Chattopadhyay et al., 2002b; Lim et al., 2006) or α-fetoprotein (Castaneda 
and Pearce, 2008), or other unknown early auto-reactive antigens, to cause CD8+ve 
T-cells to become activated in peripheral or cervical lymph nodes and initiate the 
inflammatory process without CD4+ve T-helper cells. This hypothesis is strengthened 
by previous findings of increased amounts of CD8+ve cells in the cervical lymph 
nodes and spleen (but not in the peripheral lymph nodes) of 2 month old Cln3-/- mice 
compared to wildtype animals (Lim et al., 2007b). Furthermore, decreased CD4/CD8 
ratios could be detected in the same mutant mice, indicating a localized immune 
irregularity in the draining lymph nodes of the brain as early as at 2 months of age 
(Lim et al., 2007b).  
Finally, Cln3 deficiency may directly, or indirectly, impair the immunological functions 
of CD4+ve T-cells themselves. Autophagy has been shown to be crucial for T-cell 
survival (Stephenson et al., 2009), and as dysfunctional autophagy already has been 
documented in JNCL (Cao et al., 2006; Cotman and Staropoli, 2012), reduced T-cell 
survival could be also expected in Cln3-/- mice. Indeed, reduced T-cell populations and 
CD4/CD8 ratios have been described in the blood of 4 month old Cln3 knock-in 
mice and, as mentioned above, in the cervical lymph nodes and spleen of 2 month old 
Cln3-/- mice (Lim et al., 2007b; Staropoli et al., 2012), although no direct correlation or 
explanation has been experimentally linked to these phenomena so far. Furthermore, 
endosomal/lysosomal pathways are essential for many immune functions, including 
antigen presentation via the loading of MHC I and MHC II molecules and cytotoxic 
T-cell functions, as described extensively in Chapter 1 (see section 1.9 and reviewed 
in (Castaneda et al., 2008)). Therefore, a functional deficit in immune cells or CD4+ve 
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T-cells themselves could be suspected in Cln3-/- mice. These findings go hand in hand 
with the appearance of vacuolated lymphocytes in JNCL patients, which is used as a 
clinical diagnostic tool for Juvenile NCL (Anderson et al., 2005), even though a direct 
link between vacuolisation and T-cell function has not yet been elucidated.  
Taken together, whatever the underlying mechanism, the contrasting sequence of 
adaptive immune cell infiltrations in Juvenile and Infantile NCL mice support the fact 
that these two forms of NCL, even though belonging to the same family of disorders, 
are clearly distinct disease entities which may display independent inflammatory and 
neurodegenerative mechanisms (Cooper, 2010).  
b) Relative frequencies of T-cell subsets  
More CD8+ve T-cells than CD4+ve T-cells could be detected in the brains of both 
Ppt1-/- and Cln3-/- mice (see Figure 21 and Figure 27 in Chapter 3). Furthermore, 
CD4+ve T-cell reached a saturation level of infiltration in Ppt1-/- mice (at 3 months of 
age), whereas CD8+ve T-cells steadily increased in quantity throughout disease 
progression in Ppt1-/- and Cln3-/- mice (see Figure 21 and Figure 27 in Chapter 3). 
These patterns are most likely explained by the function of each T-cell subtype. Since 
CD4+ve T-helper cells are traditionally thought to regulate and control the adaptive 
immune responses (Zhu and Paul, 2008; Zhu and Paul, 2010; Abbas and Lichtman, 
2011), a certain saturation of infiltrating T-cells at the inflammation site could be 
expected due to a putative trade-off between required cell numbers and regulatory 
effector functions. Similarly, the other CD4+ve T-cell effector function of enhancing 
macrophage (and B-cell) activation (see section 1.7a in Chapter 1, (Stout, 1993; Zhu 
and Paul, 2008; Abbas and Lichtman, 2011)) is likely to be restricted to the amount of 
macrophages in the brain/inflammation site. In contrast, due to the cytotoxic effector 
function of CD8+ve T-cells in inducing apoptosis of infected or malfunctioning cells 
(Nagata, 1996; Shresta et al., 1998; Abbas and Lichtman, 2011), CD8+ve T-cell 
infiltration would be predicted to steadily increase until complete clearance of the 
pathogenic stimuli (e.g. virus) is accomplished. Furthermore, the frequencies of each 
T-cell subset could be simply explained by different proliferation capacities which 
have been shown to be greater for CD8+ve T-cells (Homann et al., 2001), or by 
different antigen recognition efficiency due to the presence of more MHC I molecules 
than MHC II at the inflammation site (Seder and Ahmed, 2003). However, in chronic 
neurodegenerative disorders the mechanisms that trigger the immune system are 
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constantly maintained or even amplified (Gao and Hong, 2008), and no saturation of 
CD8+ve T-cell infiltration can be reached (as seen Figure 21 and Figure 27 in 
Chapter 3). Accordingly, CD8+ve T-cells often outnumber CD4+ve T-cells in 
chronic neurodegenerative disorders ((Neumann et al., 2002; Melzer et al., 2009); MJ 
Lim, personal communication), as seen for example in lesions of multiple sclerosis 
(Booss et al., 1983; Lassmann et al., 2001; Friese and Fugger, 2009), the substantia nigra 
of Parkinson disease (Baba et al., 2005; Brochard et al., 2009), in ALS (Holmoy, 2008), 
or in Alzheimer disease brains (Togo et al., 2002). This consistent increase in the 
number of CD8+ve T-cells in the chronically inflamed CNS may simply reflect the 
unchecked cytotoxic T-cell effector function described above, but speculatively could 
also suggest that similar stimuli or cues (like neuronal death or other hitherto 
unknown components) are present in neurodegenerative CNS disorders which favour 
a CD8+ve T-cell immune response. But even if such common stimuli exist, the 
pathogenic, regulatory or even neuroprotective role of CD8+ve T-cells in the CNS is 
likely to vary between diseases (Nicholson et al., 1999; Klein et al., 2005b; Schwartz and 
Kipnis, 2005; Chiu et al., 2008; Ip et al., 2012). However, taken together, the relative 
frequency of CD8+ve T-cells in Ppt1-/- and Cln3-/- mice reflects a consistent and 
common pattern, in contrast to the speculatively low frequencies of CD4+ve T-cell in 
Cln3-/- mouse brains (as discussed in section 7.1a above). 
c) Entry point of T-cells 
This is the first study to detail the distribution of T-cells in Ppt1-/- and Cln3-/- mice. 
Our findings suggest the preferential entrance of T-cells to the brain through the 
olfactory route, since the highest accumulation of T-cells was observed in the rostral 
part of both the Ppt1-/- and Cln3-/- brains, but, interestingly a similar distribution was 
also seen in wildtype brains (see Figure 22, Figure 23, Figure 28 and Figure 29 in 
Chapter 3). According to the literature, T-cells preferably enter the CSF/brain 
through the choroid plexus of the ventricles, or meninges via blood and the 
perivascular space (see Figure 3 in Chapter 1 (Ransohoff et al., 2003; Wilson et al., 
2010)). However, neither of these routes can fully explain the distribution of T-cells 
we observed in our NCL mouse models and speculatively, other anatomical features 
have to be considered too.  
In the rodent brain the subarachnoid space, including the CSF, directly interconnects 
with the nasal sub mucosa through the cribriform plate of the ethmoid bone alongside 
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the olfactory nerves (Kida et al., 1993; Walter et al., 2006). The CSF produced in the 
choroid plexus flows through the ventricle into the subarachnoid space, where it 
circulates forwards inferior to the olfactory bulb and drains through the cribriform 
plate into the nasal lymphatics, and eventually the deep cervical lymph nodes (Kida et 
al., 1993; Walter et al., 2006). Through this pathway putative antigens from the CNS 
can reach cervical lymph nodes for subsequent T-cell activation (Cserr et al., 1992; 
Hickey, 2001). Likewise, T-cell and dendritic cell exit from the CNS along with the 
CSF via the cribriform plate and into the cervical lymph nodes has been also 
demonstrated (Carson et al., 1999; Karman et al., 2004; Goldmann et al., 2006; Hatterer 
et al., 2006). But whether this cellular migration is an actively directed or rather passive 
process along the CSF flow has not been determined in these studies. Nevertheless, 
comparing our data with these findings, it would be tempting to speculate that T-cells 
coming from the cervical lymph nodes may potentially use the same route to enter the 
brain parenchyma of NCL mice, but such pathways have not been documented so far 
and therefore seem rather unlikely. Likewise, particle passage (or in our case T-cell 
transport) from the parenchyma via the drainage of interstitial fluid out of the brain 
along perivascular space, vessels or cranial nerves is not thought to occur (Zhang et al., 
1992; Carare et al., 2008). Accordingly, the transport of particles or cells in the 
opposite direction from the periphery along cranial nerves directly into the 
perivascular space seems an unlikely entry mechanism for lymphocytes into the brain, 
and indeed has not been described, even under inflammatory conditions and higher 
permeability of the BBB (Carrithers et al., 2000; Engelhardt and Ransohoff, 2005). 
Therefore, such anatomical explanations, as tempting they may seem to explain our 
data, are not sufficient to account for the increased T-cell distribution in the olfactory 
bulb.  
The best described entry route of T-cells into the brain is via the blood stream 
(Ransohoff et al., 2003; Wilson et al., 2010). Thus, as another explanation for the 
distribution of T-cells observed in our study, we could speculate that the vascular 
endothelial cells are more activated and express molecules more favourable for cell 
adhesion in the olfactory bulb than in other parts of the brain guaranteeing easier 
access to leukocytes. Indeed, BBB permeability has been described to be higher in the 
olfactory bulb of mice (Ueno et al., 1996; Ueno et al., 1998; Deckner, 2001). 
Furthermore, it has been shown that the permeability of the BBB increases with age 
and can vary between brain regions (Vorbrodt et al., 1995; Ueno et al., 1997). In 
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particular, capillaries of the olfactory bulb develop ultra-structural changes (like 
increased laminar cavitation) with increasing age (Hinds and McNelly, 1982). 
Speculatively, such enhanced permeability features of the olfactory bulb could lead to 
increased T-cell infiltration. Since increased BBB permeability, as is seen under 
inflammatory or irradiated conditions, is often associated with increased leukocyte 
adhesion to the brain vasculature (Petty and Lo, 2002; Yuan et al., 2003; Persidsky et 
al., 2006; Gavins et al., 2007), this hypothesis seems plausible. Therefore this feature 
could potentially not only explain the highest accumulation of T-cells in the rostral 
parts of the brain, but also the increasing T-cell infiltration observed in wildtype mice 
over time (see Figure 22, Figure 23, Figure 28 and Figure 29 in Chapter 3), and 
could possibly even explain the region specific T-cell distribution in 21 month old 
Cln3-/- mice, which shall be discussed in the next section (see Figure 28 and Figure 
29 in Chapter 3).  
Taken together, our findings are consistent with the proposed entry of T-cells into the 
CNS via the blood stream in the choroid plexus or the meninges similar to the 
lymphocyte infiltration seen in humans, but in rodents, the olfactory bulb seems the 
preferred route of T-cell infiltration into the brain. This may be due to higher 
permeability of the BBB and perhaps altered adhesion properties of the vascular 
endothelial cells in the olfactory bulb, but also could be explained by other unknown 
mechanisms like increased accumulation of perivascular APCs in the olfactory bulb or 
a more tightly arranged brain microvasculature. However, we cannot completely rule 
out that other routes of T-cell entry exist in rodents, as for example from the cervical 
lymph nodes along the pathways of the CSF via the cribriform plate. All in all, our 
study represents a classical example for how pivotal it is to consider species-dependent 
differences between animals and humans when interpreting data.  
d) T-cell distribution within brain parenchyma  
Interpreting the cellular distribution of both subsets of T-cells in the Ppt1-/-, or Cln3-/-, 
CNS is less straight forward. Besides the specific T-cell accumulation in mid-levels of 
the forebrain of 21 month old Cln3-/- mice (see Figure 28 and Figure 29 in Chapter 
3), the distribution of T-cells in Ppt1-/- and younger Cln3-/- mice generally followed a 
rostrocaudal gradient within the brain, with most of the cells being found in the 
olfactory bulb (see Figure 22, Figure 23, Figure 28 and Figure 29 in Chapter 3). 
Furthermore, while counting these T-cells we noticed that both T-cell subsets were 
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often detected near cerebral ventricles and/or in white matter tracts, but only 
occasionally were lymphocytes observed in the proximity of blood vessels (as putative 
entry point), suggesting that the blood vessels in the brain parenchyma of the fore- 
and midbrain are not the primary route for T-cells to infiltrate the brain (see section 
7.1c above). However, because only large cross-sectional capillaries were apparent in 
our brain sections, we did not directly investigate the interactions between 
lymphocytes and blood vessels (including small capillaries and venules) in the brain 
parenchyma, the possibility of lymphocyte entry via postcapillary venules into the 
brain cannot be ruled out and is likely to occur (see section 1.7b in Chapter 1 and 
(Owens et al., 2008). Future co-localisation studies of CD4+ve or CD8+ve T-cell 
staining with brain vasculature markers will hopefully shed further light on this matter 
in Ppt1-/- and Cln3-/- brains. Nevertheless, explanations for the distribution of T-cells 
could be many and varied.  
First of all, the ventricles, being in direct communication with the choroid plexus (that 
have fenestrated endothelial cells) may provide a general easy access route for T-cells 
(see section 7.1c above and (Wilson et al., 2010)). In contrast, white matter tracts 
possibly serve as easy passageways for lymphocytes to travel within the brain. The 
migration of T-cells through the brain parenchyma has been described as random 
search behaviour (Mrass et al., 2006; Melzer et al., 2009; Wilson et al., 2010), although a 
guided T-cell movement within the parenchyma has also been suggested (Mrass et al., 
2006; Wilson et al., 2009). This may be via conduits formed by follicular dendritic cells, 
fibroblastic reticular or stromal cells, as has been seen in peripheral lymph nodes 
(Bajenoff et al., 2006). Nevertheless, since other mechanisms of directed T-cell 
migration through the parenchyma via chemokines and cytokines remain controversial 
(Kawakami et al., 2005; Schaeffer et al., 2009), there have so far been no reports of a 
direct preference of white matter over gray matter for the passage of T-cells.  
As another explanation for the observed rostrocaudal distribution of T-cells, it has 
been suggested that T-cells may ‘hijack’ the rostral migratory stream, which consists of 
new-born neurons travelling from the subventricular zone to the olfactory bulb (Maria 
B, 1993; Lois and Alvarezbuylla, 1994). Remarkably, the sites of lymphocyte 
infiltration we observed in Ppt1-/- and Cln3-/- brains (see Figure 20 in Chapter 3) 
closely resembled that of brain dendritic cells (bDC) expressing CD11b in embryonic 
and adult mouse brains (Bulloch et al., 2008). These CD11b+ve bDCs were distributed 
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in the circumventricular organs (subfornical organ, posterior pituitary, pineal gland, 
subcommisural organ etc.) (Bulloch et al., 2008). These areas, due to an incomplete 
BBB, are known to allow direct access of pathogens or chemicals from the CSF and 
blood into the parenchyma (Ganong, 2000). Furthermore, the dendritic cells (and 
possibly also T-cells) were aligned along and around two extracellular pathways, the 
peripheral olfactory system connection between the nose and rostral brain, as well as 
along the pathways associated with the peripheral trigeminal system (Thorne et al., 
2004), which also connects the nasal passages with the brainstem and spinal cord 
regions (Liu et al., 2001). Both of these routes are used as a sensory and humoral input 
to transport molecular signals such as pheromones into the brain (McClintock et al., 
2001), but may potentially also serve as an easily accessible portal to the brain for T-
cells. In support of this hypothesis, a recent study in experimental autoimmune 
encephalomyelitis (EAE), the animal model for multiple sclerosis, demonstrated 
increased CD45+ve staining and inflammatory responses in the circumventricular 
organs (Schulz and Engelhardt, 2005). Additionally, inflammatory protein deposits 
have been found in the circumventricular organs of rat brains after systemic 
inflammations (Peress et al., 1989; Schroder and Linke, 1999), indicating this to be a 
potential portal of inflammatory cells to the brain (Siso et al., 2010).   
In summary, the observed distribution of CD8+ve and CD4+ve T-cells in both forms 
of NCL appears to be mainly defined by the different entrance routes these cells may 
possibly take (olfactory bulb, circumventricular organs and ventricles) which in turn 
depends on the immune subtype, the condition of migrating immune cells, the 
activation state of the neural parenchyma and the endothelial cells in the vicinity of 
each entry point (Hickey, 1999). However, the explanation for T-cell accumulation in 
the mid-levels of the forebrain of 21 month old Cln3-/- mice (see Figure 28 and 
Figure 29 in Chapter 3) is less clear, but is likely to reflect changes in one, or more, 
of the above mentioned parameters. Therefore, this T-cell distribution pattern could 
be linked to a leaky BBB barrier in Cln3-/- mice (Lim et al., 2007b), which is often 
associated with altered vascular endothelial cell activation/adhesion molecule 
expression, as has seen in other conditions (Yuan et al., 2003; Gavins et al., 2007; 
Comim et al., 2011), and subsequently allow T-cells easier access in, for example, 
ventricular regions of the brain. This hypothesis is strengthened by the suggestions of 
an age-dependent and region specific increase of the BBB permeability (see section 
7.1c above (Vorbrodt et al., 1995; Ueno et al., 1997).  
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Alternatively, altered cytokine expression by glial cells in Cln3-/- mice could plausibly 
attract T-cells to certain brain regions where glial activation is most pronounced 
(Kielian, 2012; Parviainen, 2012); JD Cooper personal communication). Whereas 
cytokine expression by Cln3-/- astrocytes is generally reduced in cell culture 
(Parviainen, 2012), Cln3-/- microglia displayed increased levels of cytokines and 
possibly represent the more relevant glial cells in this context of T-cell attraction 
(Kielian, 2012); JD Cooper, personal communication). This hypothesis is consistent 
with findings suggesting that astrocytes can restrict T-cell trafficking and infiltration 
into damaged or inflamed brain regions (John et al., 2005; Voskuhl et al., 2009), which 
shall be discussed further below in more detail (see section 7.3a). But then again, such 
restrictions could be compromised in Cln3-/- astrocytes due to their altered biology and 
protein secretion (Parviainen, 2012) and in turn, could speculatively lead to more T-
cell accumulation in Cln3-/- mice.  
Thus, neurodegenerative processes (like oxidative stress (Weimer et al., 2007), 
disturbances in autophagy (Cao et al., 2006) or calcium homeostasis (Chang et al., 2007) 
resulting in synaptic dysfunctions (Luiro et al., 2006; Tuxworth et al., 2009), which are 
likely to lead to axonal rearrangements and synaptic changes as seen in other NCL 
mice (Kim et al., 2008; Kielar et al., 2009)), could also stimulate (micro)glial activation 
and speculatively T-cell attractant cytokine release in affected thalamocortical brain 
regions of Cln3-/- brains (Pontikis et al., 2004; Pontikis et al., 2005). Such mechanisms 
could potentially explain the observed pattern of increased T-cell accumulation in the 
mid-levels of the forebrain of Cln3-/- mice at 21 month of age. This hypothesis is 
strengthened by the qualitative observation of a putative accumulation of CD8+ve T-
cells in the thalamic VPM/VPL nuclei of 21 month old Cln3-/- mice, whereas no 
similar distribution could be observed in Ppt1-/- mice (see section 3.2b in Chapter 3). 
Speculatively, such patterns could reflect a JNCL specific (auto-) immune response via 
CD8+ve T-cells which potentially are drawn to regions with increased 
neurodegeneration (Pontikis et al., 2004; Pontikis et al., 2005). Furthermore, this 
hypothesis could also explain the predominant CD8+ve T-cell infiltration in 
comparison to a delayed and moderate CD4+ve T-helper cells infiltration in Cln3-/- 
mice (see Figure 27 in Chapter 3 and section 7.1a above). However, more 
pragmatically, the accumulation of T-cells in the mid-levels of the forebrain could be a 
solely age-dependent phenotype since a similar rostrocaudal distribution of T-cells 
(but to a much lower extent) also was observed in 21 month old wildtype mice. 
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Therefore, we would favour an anatomical explanation for the increased T-cell 
accumulation in the mid-levels of the forebrain due to age-dependent alterations of 
the BBB around the ventricles, but would also not completely reject the possibility of 
CD8+ve T-cell specific accumulation in brain regions where neurodegeneration is 
more pronounced. Hopefully, BBB permeability and leukocyte-endothelial adhesion 
molecule expression analyses in 21 month old Cln3-/- and wildtype mice would clarify 
this issue. However, it will be just as important to conduct adaptive immune cell 
double knockout experiments on Cln3-/- mice (similar to the ones conducted in 
Chapter 4 for INCL mice with Ppt1-/-/Rag-1-/-) to investigate whether CD8+ve T-cells 
accumulate in the Cln3-/- brain as a secondary reaction due to on-going 
neurodegeneration, or if CD8+ve T-cells as an auto-immune reaction putatively cause 
neurodegeneration in the first place.  
e) T-cell surveillance 
It is well documented that T-cells are also present in the brain parenchyma of healthy 
mice and patients and carry out constant surveillance of the micro-environment of the 
brain (see section 1.7b in Chapter 1, (Hickey, 2001; Wilson et al., 2010)). Indeed, 
previously activated T-cells have the ability, by expressing the required molecules on 
their cell surface, to cross the BBB and enter the parenchyma even under non-
inflammatory conditions (Hickey et al., 1991; Carrithers et al., 2000).  However, there is 
still disagreement about the exact molecular phenotype of these monitoring T-cells. It 
is most commonly believed that predominately CD4+ve memory T-cells, which have 
been previously activated, monitor the healthy CNS (Wekerle et al., 1987; Hickey et al., 
1991; Engelhardt and Ransohoff, 2005; Wilson et al., 2010). However, it has been 
suggested that CD8+ve T-cells are also capable of surveillance in the CNS, and may 
even be the dominant cell type for this process (Cabarrocas et al., 2003; Loeffler et al., 
2011). In our experiments we detected only small amounts of CD4+ve cells, just 
predominantly CD8+ve cells in the brain of wildtype mice (see Figure 21 and Figure 
27 in Chapter 3). However, looking at the regional distribution of both T-cell 
subtypes in wildtype mice, the main accumulation of T-cells was observed in the 
olfactory bulb (as was also seen in both NCL mouse models). But from 5 months 
onwards, two to three times as many CD8+ve cells were found in the olfactory bulb 
of wildtype mice compared to CD4+ve cells (see Figure 23 and Figure 29 in 
Chapter 3). As such, these data suggest that the olfactory bulb is most likely an easy 
access portal for these T-cells (see section 7.1c above). Indeed, T-cells, in particular 
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CD8+ve T-cells are able to access the rostral brain parenchyma in wildtype mice, even 
in the absence of inflammation (see Figure 22, Figure 23, Figure 28 and Figure 29 
in Chapter 3). The relatively large numbers of CD8+ve cells, in comparison to 
CD4+ve cells, could potentially be explained by less restricted or different means of 
brain infiltration by CD8+ve vs. CD4+ve T-cells (see section 7.1a and 7.1c above, 
(Cabarrocas et al., 2003; Galea et al., 2007b; Melzer et al., 2009), or by the high turnover 
of olfactory neurons exposed to an ever-changing environment (Astic and Saucier, 
2001; Cowan and Roskams, 2002). However, it appeared that T-cells were unable to 
spread to more caudal regions of wildtype brains, probably due to the lack of 
sustaining antigen presenting cells and cytokines. Taken together, our data supply 
further evidence for a more prominent role of CD8+ve T-cells as the CNS monitoring 
cell type (Loeffler et al., 2011) and argue against CD4+ve memory T-cells being the 
predominant cellular mediator of surveillance in healthy wildtype brains (Hickey, 2001; 
Engelhardt and Ransohoff, 2005). 
Although the mechanisms that underlie T-cell infiltration in NCL mice remain 
speculative and need further investigation, to our knowledge our study is the first to 
characterise the lymphocyte infiltration in murine models of NCL in such detail. For 
example, future tracing and live imaging of T-cell trafficking into the brain as recently 
performed for dendritic cells or T-cells (Flugel et al., 1999; John et al., 2011; Odoardi et 
al., 2012) in combination with fluorescence-activated cell sorting (FACS), co-
localisation studies and more region specific immunohistochemical analyses of 
different brain parts (i.e. spinal cord, olfactory bulb, cranial nerve and cervical lymph 
nodes) could potentially clarify in more detail which T-cell subsets are present, exactly 
where in the brain they are, and with which cells they interact. Furthermore, brain 
region specific BBB analyses for putative trafficking determinants, as much as various 
knockout or tissue-specific induction experiments of, for example, cell endothelial 
molecules or APCs would give additional insights into the mechanisms involved in T-
cell entry into the brain. However, with our data we were able to directly compare the 
Infantile and Juvenile NCL forms (which was eligible as both mouse models were kept 
on the same strain background). We identified similarities, as well as discrepancies 
between these forms of NCL. For example, very similar CD8+ve T-cell density could 
be found at the end stages of both forms of NCL, even though completely different 
progression rates and mechanisms were evident in each disease subtype. Such 
paradoxes highlight the importance of understanding the role of the adaptive immune 
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cells in the pathogenesis of each form of NCL, which will hopefully become clearer in 
the future with increasing knowledge about the underlying mechanisms of these 
diseases. 
7.2 Sialoadhesin expression in NCL brains 
a) Macrophage vs. microglia 
As described in the Chapter 1 (see section 1.11b), Sn is only expressed on the 
meninges and choroid plexus of healthy brains, but under inflammatory conditions Sn 
is also evident in the brain parenchyma on infiltrated macrophages and nearby 
microglia (Perry et al., 1992). Therefore, it is not possible to directly distinguish 
between Sn+ve macrophages and microglia in the brain, and only co-localisation 
studies with Sn and additional macrophage markers can resolve this issue. Our 
collaborators demonstrated via such co-localisation that about 90% of CD11b+ve 
cells in the optic nerve also expressed Sn in proteolipid protein (PLP) overexpressing 
mice, a mouse model of a chronic myelin inflammatory disease (Ip et al., 2007). As it 
seems unlikely that all of these Sn+ve cells integrated in the optic nerve, our 
collaborators hypothesised that it is not only infiltrated macrophages that may express 
Sn, but rather that resident microglia can also do this in a slowly progressive chronic 
disease. Considering the fact that microglia can take on neuroprotective or neurotoxic 
roles in the brain (see section 1.6b in Chapter 1; (Ekdahl et al., 2009; Graeber and 
Streit, 2010)), our collaborators provocatively hypothesised that the expression of Sn 
on microglial cells could be predictive for the pathological versus protective role of 
these cells (Ip et al., 2007). Even though we did not perform co-localisation 
experiments ourselves, our data clearly demonstrated that less than 90% of CD68+ve 
microglia cells expressed Sn in the thalamus, and much fewer in the cortex of Ppt1-/- 
and Cln3-/- mice (see Figure 44, Figure 50, Figure 52 in Chapter 5 and Figure 58, 
Figure 64, Figure 66 in Chapter 6). However, since an undetermined, but 
considerable percentage of macrophage-like cells still express Sn in the thalamus of 
both models of NCL, it could be possible that we are not only looking at infiltrated 
macrophages, but also an expression pattern of Sn that indicates a more reactive (and 
neurotoxic) stage of microglial up-regulation. This hypothesis is supported by the 
sudden increase observed in Sn+ve cell numbers and change in morphology 
(amoeboid, round cells with no processes instead of cells with several processes) at 7 
months of age in Ppt1-/- brains (see Figure 44B and Figure 44D in Chapter 5). 
268 
 
However, this expression pattern could, of course, be simply explained as being a 
consequence of normal disease progression or a sudden influx of infiltrating 
macrophages in affected brain regions.  
Generally speaking, judged by their morphology, in most brain regions we 
predominantly observed a mix of Sn+ve microglia with ramified processes and Sn+ve 
brain-macrophages without any, or only short processes, in both types of NCL brains. 
Three possible scenarios may result in such a staining pattern in the brain. First of all, 
certain unknown cues (as for example on-going neurodegeneration) could trigger Sn 
expression in the brain on resident microglia, which during disease progression 
transform into Sn+ve brain-macrophages. Various degrees of on-going 
neurodegeneration and/or neuron vulnerability between brain regions would produce 
a mixed macrophage/microglial phenotype in each region. Secondly, Sn+ve 
macrophages could possibly infiltrate the brain parenchyma from the systemic 
circulation, attracted by on-going neurodegeneration and chemokines released by 
other glial or immune cells. Subsequently, resident microglia could up-regulate Sn in 
response to the infiltration of Sn+ve systemic macrophages in their vicinity. Or 
thirdly, cytokines or activation factors (for example IFN-α which has been shown to 
trigger up-regulation of Sn in many species (van den Berg et al., 1996; Delputte et al., 
2007; Rempel et al., 2008; Klaas and Crocker, 2012) in the blood serum could ‘leak’ or 
diffuse into inflammatory brain regions and induce Sn expression by microglia. 
Depending on their state of activation, Sn+ve microglia subsequently phenotypically 
resemble either microglia with ramified processes or brain-macrophages. Any of these 
scenarios are possible in INCL and JNCL brains, and since these mechanisms are not 
mutually exclusive, it is likely that a combination of these events could occur in the 
NCL brains, either simultaneously or variably during the course of the disease. 
Furthermore, due to differences in the integrity of the BBB between Ppt1-/- and Cln3-/- 
mice (Lim et al., 2007b; Saha et al., 2012), different events may occur in each of the two 
forms of NCL. However, our data does not allow us to unambiguously disentangle the 
true mechanism behind the up-regulation of Sn expression in the brain. We would 
speculate that in early disease stages, neurodegenerative cues in the brain, in 
combination with sporadic macrophage infiltration, induce Sn expression by brain 
resident microglia. However, with disease progression and the accompanying 
enhancement of inflammatory responses, vascular endothelial cell adhesion molecules 
could be up-regulated and the permeability of the glia limitans and the BBB increased 
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(Persidsky et al., 2006), with more macrophages and putatively cytokines from the 
blood entering the brain, while more microglia transform into brain-macrophages. 
Taken together, such events could then result in the mixed phenotypes of Sn+ve 
macrophages/microglia that we observed in our experiments at all ages (see Figure 44 
in Chapter 5 and Figure 58 in Chapter 6). Future studies will be needed to clarify 
which of these processes are occurring in Ppt1-/- and Cln3-/- mice. Bone-marrow 
transplantation of GFP-labelled macrophages, or the specific depletion of systemic 
macrophages by liposome uptake, as performed previously (Bauer et al., 1995; Tran et 
al., 1998; Tanaka et al., 2003; Chinnery et al., 2010), could investigate to which extent 
peripheral macrophages infiltrate the brain in INCL and JNCL mice. Furthermore, as 
previously performed in Cln3-/- mice (Lim et al., 2007b), peripheral injections of 
dextran or serum with subsequent immunohistochemical analysis of marker/serum 
proteins (e.g. albumin or immunoglobulins) in the brain could clarify the extent to 
which BBB integrity is compromised in Ppt1-/- mice; an issue which remains 
controversial.  
b) INCL vs. JNCL 
In both Ppt1-/- and Cln3-/- mice similar distributions of Sn+ve expression were 
observed, with the main site of activation being in the thalamic VPM/VPL nuclei 
where glial activation is also predominantly seen in NCL mice (Bible et al., 2004; 
Pontikis et al., 2004; Pontikis et al., 2005; Kielar et al., 2007; Partanen et al., 2008; von 
Schantz et al., 2009; Kuronen et al., 2012; Schmiedt et al., 2012; Thelen et al., 2012). 
Nevertheless, clear differences in Sn+ve activation patterns between these forms of 
NCL were also identified. Specific brain regions and nuclei including the retrosplenial 
granular cortex (RSG), CA1 of the hippocampus, the nuclei around the anterior commissure 
(IPAC/IPAM) together with the ventral pallidum (VP and the amygdaloid nuclei (Bal, CeC, 
CeM), the substantia nigra, the external cortex of the inferior colliculus (EClC) or the central 
nucleus of the inferior colliculus (ClC) only showed Sn staining in Ppt1-/- mice. In contrast, 
Sn+ve macrophages in the dorsal parts of the lateral posterior thalamic nuclei (LPMC and 
LPMR) were only found in Cln3-/- mice. Furthermore, the distribution of Sn 
immunoreactivity in the S1BF region of the cortex was clearly different between these 
two disease forms. Whereas Cln3-/- mice showed only restricted Sn+ve staining of the 
deeper laminae (V and VI), in Ppt1-/- mice Sn+ve cells were mainly found in lamina 
VI, but sporadically also in the upper layers of the cortex (apart from 7 month old 
animals where all laminae showed Sn+ve cells in Ppt1-/- mice) (see Figure 44C in 
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Chapter 5 and Figure 58B in Chapter 6). In both types of NCL, Sn+ve 
macrophages were present in the same laminae of S1BF and the same thalamic nuclei 
where most glial activation could also be observed (see Figure 44, Figure 46, Figure 
48, Figure 50, Figure 52 in Chapter 5 and Figure 58, Figure 60, Figure 62, Figure 
64, Figure 66 in Chapter 6, (Pontikis et al., 2005; Kielar et al., 2007)). Therefore, Sn 
may be a suitable marker or indicator for subsequent neuron loss in NCL brains, just 
as GFAP or CD68 haven proved to be in previous studies (Bible et al., 2004; Pontikis 
et al., 2004; Pontikis et al., 2005; Kielar et al., 2007). Even better, due to the fact that Sn 
is exclusively expressed on infiltrated macrophages and microglia in the most affected 
brain regions, Sn could potentially be used as indicator of the most acutely affected 
brain regions at any point in disease progression. In support of this suggestion, neuron 
loss has already been demonstrated in most regions of highest Sn expression: in the 
thalamic VPM/VPL nuclei in Ppt1-/-, as well as Cln3-/- mice (see Figure 44A in 
Chapter 5 and Figure 58B in Chapter 6, (Pontikis et al., 2005; Kielar et al., 2007)) and 
in lamina V of S1BF in Ppt1-/- mice (see Appendix II: Figure 79 by S Duckett, MSc 
project; JD Cooper, personal communication). Furthermore, in direct comparison of 
activation status, Sn+ve cells (judged by staining intensity and cell morphology) in 18 
month old Cln3-/- mice resembled 3 month old Sn+ve cells in Ppt1-/- mice. At these 
time points, the Sn+ve cells of both genotypes showed a mix of activated microglial 
cell staining with elongated processes and brain macrophage-like cells with amoeboid, 
round cell bodies without cell processes (see Figure 44B and Figure 44D  in 
Chapter 5 and Figure 58A2 and Figure 58B2  in Chapter 6). These comparisons are 
not exactly accurate as these mice have been bred on different backgrounds, but 
nevertheless it demonstrates the delayed and slower disease progression in JNCL mice 
compared to INCL mice. Taken together, clear differences in Sn+ve cell activation 
sites and morphologies were seen between the INCL and JNCL mouse models. These 
discrepancies are most simply explained by different rates of disease progression. 
Nevertheless, at the same time, these findings could suggest that Sn and Sn+ve 
macrophages/microglia play different roles in these two diseases. In any case, such 
differences strengthen the hypothesis that these NCL forms represent separate 




7.3 Interactions between adaptive immune cells and glial cells (INCL) 
a) Direct or indirect interactions 
As demonstrated in Chapter 4, the absence of functioning T- and B-cells had an 
attenuating effect on astrocytosis as well as microglial activation in the brains of            
Ppt1-/-/Rag-1-/- mice (see Figure 33, Figure 35, Figure 37 and Figure 39 in Chapter 
4). In other words, the adaptive immune response must have an accelerating and 
enhancing effect on glial activation in murine INCL. This may be explained by a direct 
interaction between glial cells and adaptive immune cells, or indirectly by an increased 
inflammatory brain environment created by adaptive immune cells in the brain 
(Benveniste, 1998; Schroeter and Jander, 2005). The pronounced reduction in 
microglial activation in the absence of adaptive immune cells in Ppt1-/-/Rag-1-/- mice 
confirmed that direct interactions between microglia and T-cells may also occur in the 
infantile form of NCL. At the same time, this finding may speculatively suggest that 
the number of Sn+ve macrophages (disguised by microglial activation) could be 
reduced in Ppt1-/-/Rag-1-/- mice due to a less inflammatory brain environment, created 
by the absence of T-cells. However, since the relative abundance of (Sn+ve) infiltrated 
macrophages has not yet been determined in Ppt1-/-/Rag-1-/- mice (via CD169+ve 
staining), the precise interactions that may occur between T-cells and infiltrated 
macrophages remain open to debate. Nevertheless, combined with the data from  
Ppt1-/-/Sn-/- mice (see Chapter 5) we would speculate that Sn+ve macrophages and T-
cells reciprocally activate or attenuate themselves. This issue is of course further 
complicated by the difficulty in distinguishing immunohistochemically between 
infiltrated macrophages and microglia (see section 7.2 above). 
In contrast to infiltrated macrophages, in a resting state microglia are poor antigen 
presenting cells (Matyszak et al., 1999; Lynch and Mills, 2011), but as soon as 
transformed into brain macrophage-like cells, they are very competent enhancers of 
the inflammatory response via the presentation of MHC II to CD4+ve T-cells as well 
as via MHC I cross-presentation to CD8+ve T-cells (Hickey and Kimura, 1988; 
Kreutzberg, 1996). These interactions between T-cells and glia cells are further 
influenced by a wide range of cytokines expressed by both cell types (Issazadeh et al., 
1995; Aloisi et al., 2000b). In contrast, astrocytosis did not seem to be as greatly 
reduced in Ppt1-/-/Rag-1-/- mice, as were the effects upon microglial activation (see 
Figure 33, Figure 35, Figure 37 and Figure 39 in Chapter 4), suggesting a less 
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direct link between astrocytes and T-cells. Astrocytes have also been proven to express 
MHC I/II molecules (Wong et al., 1984; Lavi et al., 1988), but are generally believed to 
be rather weak antigen presenting cells (reviewed in (Aloisi et al., 2000b; Dong and 
Benveniste, 2001)). Furthermore, astrocytes have been shown to play important roles 
in the regulation of leukocyte trafficking in the CNS under inflammatory conditions 
(John et al., 2005). After stroke or injury, astrocytic scars formed around damaged 
areas of the CNS have been shown to limit the spread of inflammatory cells from 
these damaged areas into neighbouring healthy tissue (Bush et al., 1999; Sofroniew, 
2005; Herrmann et al., 2008a). Conversely, a recent study directly demonstrated that 
astrocytosis restricts T-cell infiltration into damaged CNS parenchyma (Voskuhl et al., 
2009). This study is supported by work experimentally inhibiting or diminishing 
astrocytosis which leads to exacerbated immune cell infiltration (Liedtke et al., 1998; 
Bush et al., 1999; Macauley et al., 2011; Toft-Hansen et al., 2011). This property of 
astrocytes possibly explains why we did not observe any specific focal T-cell 
accumulation in the thalamic VPM/VPL nuclei of Ppt1-/- mice, even though 
widespread T-cell infiltration was observed in these mice (see Figure 16 in Chapter 
3). At the same time, the speculatively suggested accumulation of CD8+ve T-cells in 
the thalamic VPM/VPL nuclei of Cln3-/- mice (see Figure 17 and section 3.2b in 
Chapter 3), potentially argues against this hypothesis. However, since Cln3-/- 
astrocytes have been shown to display dysfunctions in morphological activation and 
cytokine secretion (Parviainen, 2012), the T-cell restrictive properties of Cln3-/- 
astrocytes are likely to be also compromised, and therefore the astrocytosis in Cln3-/- 
mice possibly does not display the typical restrictive features mentioned above. 
Moreover, the same restrictive influence of astrocytes upon T-cells may also explain 
the lack of any positive influence upon neuron survival in the thalamus at later stages 
of the disease in Ppt1-/-/Rag1-/- double knockouts (see Figure 40 in Chapter 4). 
Perhaps the intense and localized astrocytosis in this nucleus obliterates the 
accelerating influence of T-cells in the thalamus of these mice. Consequently, in 
regions with less astrocytosis, like the cortex, the absence of T-cells would possibly 
favour longer lasting neuronal survival, as has recently been demonstrated (see 
Appendix II: Figure 79 by S Duckett, MSc project). In summary, we are confronted 
with a complex symphony of activation processes and cell-cell interactions, which 
most likely vary between brain regions and at different stages of disease progression. 
Nevertheless, we have proven in our Ppt1-/-/Rag-1-/- studies that adaptive immune cells 
do have a direct effect on glial cells in the brain. 
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b) What comes first? 
By including different time points in our studies, we could address key “chicken or 
egg” questions – which immune response (astrocytes, microglia or T-cells) is activated 
first?  This was of utmost importance, in order to potentially identify the main initiator 
of pathology in Ppt1-/- mice (see overview of events in Figure 72). However, from our 
data, significant T-cell infiltration, astrocytosis, microglial activation and Sn+ve 
macrophage up-regulation (suggesting Sn+ve monocyte infiltration) all occurred at the 
same time (3 months of age) of disease progression of Ppt1-/- mice. Speculatively, the 
morphology of CD68+ve microglia in the thalamus of Ppt1-/- mice suggested these 
cells were already in the early stages of activation at 1 month of age, although this 
difference was not significant via thresholding image analysis at this age (see Figure 
36, Figure 37, Figure 38 and Figure 39 in Chapter 4). Likewise, judging by the 
qualitative observations, astrocytes in 1 month old Ppt1-/- mice already appear slightly 
more activated compared to wildtype mice, although this difference was not 
significant via thresholding image analysis, due to the patchy and heterogeneous nature 
of this GFAP staining (see Figure 31, Figure 32, Figure 33 and Figure 34). 
Additionally, as reported in Chapter 3, there are already many more CD8+ve and 
CD4+ve T-cells in the olfactory bulb of Ppt1-/- mice at 1 month of age (again not 
reaching significance) (see Figure 22 and Figure 23 in Chapter 3), which does not 
rule out the possibility of earlier immune-related changes occurring in the INCL brain. 
In support of this idea, another study demonstrated that significantly altered cytokine 
expression is detectable as early as 1 month of age in the brains of Ppt1-/- mice (Kielar 
et al., 2009). As described in Chapter 1 (see section 1.10) early glial up-regulation has 
been also described in other NCL forms, for example, prenatally (40 to 20 days before 
birth) in Cln6-/- sheep (Kay et al., 2006), or in the cerebellum of 1 week old Cln3-/- mice 
(Weimer et al., 2009). Nevertheless, since in our study we did not focus upon such 
early changes, such suggestions of earlier disease phenotypes remain speculative.  
What exactly triggers such glial responses and why these should be apparently 
“delayed” (being first seen at 3 months and not at 1 month of age), are crucial 
questions to be addressed in the future. Yet, an early developmental glial activation, 
which subsides temporarily to only reappear again at later stages of the disease, as seen 
for example in   Cln6-/- sheep (Oswald et al., 2005; Kay et al., 2006), cannot be ruled 
out completely, since our study did not include early developmental stages. 
Nevertheless, one possible explanation for the ‘delayed’ glial response in Ppt1-/- mice  
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could be a neuronal modulation of glial cells by suppressing the inflammatory  
responses of microglia and astrocytes via the secretion of neuroprotective substances 
and/or direct cell-cell interactions, as described in Chapter 1 (see section 1.8). 
Alternatively, preliminary data suggests that the biology of INCL astrocytes is also 
impaired, albeit differently to the defects seen in JNCL astrocytes (JD Cooper and BP 
Williams, personal communication). Whereas Cln3-/- astrocytes show an attenuated 
response to stimulation, by failing to morphologically transform from a flat polyglonal 
morphology to cells with small bodies and many processes (Parviainen, 2012), Ppt1-/- 
astrocytes under basal conditions morphologically appear to be already partially 
stimulated and subsequently only respond incompletely to further stimulation in 
culture by extending their processes, but not reducing their somal size (Milà, 2012). 
Figure 72. Schematic overview of temporal sequence of pathological events in the 
forebrain and midbrain of Ppt1-/- mice. With a life expectancy of 7-8 months of age (top row), 
we analysed Ppt1-/- mouse brains at four time points (1, 3, 5 and 7 months) for innate (microglial 
activation (CD68), astrocytosis (GFAP), Sn+ve macrophage activation (CD169)) and adaptive 
immune responses (cytotoxic T-cells (CD8), T-helper cells (CD4) infiltration) in relation to 
neurodegeneration (counts of Nissl stained neuron number). From 3 months onwards all of these 
parameters were significantly elevated in Ppt1-/- mice, compared to wildtype mice (solid line 
boxes). Each immune reaction became more pronounced with disease progression, except for 
CD4+ve T-helper cell infiltration, which already reached its saturation point by 3 months of age 
in Ppt1-/- mice. Earlier signs of immune reactivity could be suggested (dashed line boxes), on the 
basis of morphology and increased immunoreactivity, with CD68+ve microglial activation and 
GFAP+ve astrocytosis appearing marginally elevated at 1 month in Ppt1-/- mice. Likewise, 
elevated numbers of T-cells were detected in the olfactory bulb of Ppt1-/- compared to wildtype 
mice. But in all cases, when quantified, these differences did not reach statistical significance. In 
addition, early synaptic changes and neuronal re-arrangements have previously been reported 
before 3 months of age (Kielar et al., 2009). 
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Furthermore, both types of astrocytes display defects in their secretion of a range of 
mitogen, chemokines and pro- and anti-inflammatory cytokines, but in different ways: 
Ppt1-/- astrocytes generally secreted more and Cln3-/- astrocytes less of a wide (but not 
the same) range of secretory molecules compared to wildtype astrocytes (Milà, 2012; 
Parviainen, 2012). Such glial dysfunction is likely to influence disease progression in 
Ppt1-/- and Cln3-/- mice and it will be important to determine the underlying 
mechanisms.  
Nevertheless, we were definitively able to demonstrate in our Ppt1-/-/Rag-1-/- double 
knockout mice that the adaptive immune cell response is clearly not the cause of glial 
activation, since astrocytosis and microglial activation have not been completely 
abolished in the absence of adaptive immune cells. It is unclear whether the adaptive 
immune cell response would be completely suppressed if the innate immune response 
was abolished, and is not addressed by the studies we have performed. Previous 
studies suggested that astrocytes trigger T-cell infiltration into the brain via chemokine 
release (Glabinski et al., 1997; Ransohoff and Tani, 1998). However, it is possible that 
glial activation and T-cell responses are also independently triggered by another 
mechanism, for example the onset of neurodegeneration, or perhaps the primary or 
secondary downstream consequences of lipid storage in brain cells.   
All in all, with our studies we were not able to disentangle the exact sequence of all 
these events in the pathogenesis of Ppt1-/- mice. However, based on the above 
reasoning, we would speculate that microglial activation is the earliest type of glial 
activation to occur, which subsequently leads to GFAP+ve up-regulation in astrocytes 
sometime between 1 and 3 months of age, with these events leading eventually to T-
cell infiltration in Ppt1-/- mouse brains. Thus, studying an intermediate early time point 
of 2 months of age could possibly clarify these speculations in future studies of Ppt1-/- 
mice.  
In comparison to the analyses we performed in Ppt1-/- mice, we only investigated the 
glial activation and innate immune responses in detail at one time point (18 months) in 
Cln3-/- mice, and therefore cannot draw any conclusions about the progression of 
pathological events in these mice (see Figure 73 for overview). However, our data 
reveal that adaptive immune cell infiltration (see Figure 27 in Chapter 3) into the 




glial activation has previously been reported to occur as early as 5 months of age in the 
forebrain (Pontikis et al., 2004), or even 1 week after birth in the cerebellum (Weimer 
et al., 2009) of Cln3-/- mice. It is important to note that both of these earlier studies and 
our analysis of glial, Sn+ve macrophage and neurodegenerative responses (see 
Chapter 6) used mice bred on a 129/Sv strain background, in contrast to the C57Bl/6 
congenic Cln3-/- mice used in this study to characterised T-cell responses (see Chapter 
3), which means such comparisons may not be entirely valid (see Figure 73 for 
Figure 73. Schematic overview of temporal appearance of pathological events in the 
forebrain and midbrains of Cln3-/- mice. With a life expectancy of 21-22 months of age (top 
row), we analysed Cln3-/- mouse brains at four time points (6.5, 12 and 21 months) for adaptive 
immune responses (cytotoxic T-cells (CD8), T-helper cells (CD4) infiltration), and at one time 
point (18 months) for innate immune responses (microglial activation (CD68), astrocytosis 
(GFAP), Sn+ve macrophage activation (CD169)) in relation to neurodegeneration (Nissl stained 
neuron number). From 12 months onwards significantly increased numbers of CD8+ve cytotoxic 
T-cells were detected, whereas significantly more CD4+ve T-helper cells were only observed at 21 
months of age in Cln3-/- mice (solid line boxes). At 18 months of age, all innate immune responses 
and neurodegeneration were significantly increased in Cln3-/- mice compared to wildtype mice. 
These data are consistent with our previous studies showing elevated glial activation at 5, 12 and 
19 months of age and neurodegeneration at 6 and 14 months of age in the forebrain of Cln3 
deficient mice (Pontikis et al., 2004, 2005; Weimer et al., 2006; Hermann et al., 2008b). Additionally, 
autoantibodies have been described in 3 (western plot analysis) and in 18 (immunohistochemical 
analysis) month old Cln3-/- mice (Lim et al., 2007). Question marks indicate unknown parameters, 
because experiments have not yet been conducted. Please note that this overview includes data 
from Cln3 deficient mice on C57BL/6 (this study; Hermann et al., 2008b), 129Sv (this study; 
Pontikis et al., 2004; Weimer et al., 2006) and mixed 129Sv/CD1 (Pontikis et al., 2005) strain 
backgrounds. It also includes both knock-in (Pontikis et al., 2005; Hermann et al., 2008b) and 
knockout (this study; Pontikis et al., 2004; Weimer et al., 2006; Lim et al. 2007) mice. This 
comparison is made based on there being no overt differences in disease phenotypes between 
different mutant mice on each background strain (JD Cooper, personal communication). 
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overview). Therefore, the infiltration of (CD8+ve) T-cells may seem to occur later in 
disease progression than innate immune responses, but this speculation needs to be 
confirmed with the analysis of glial activation and neurodegeneration at earlier time 
points in C57Bl/6 congenic Cln3-/- mice, which will hopefully clarify the sequence of 
pathological events in Cln3-/- mice.  
7.4 Adaptive immune responses and neurodegeneration  
As one of the main focuses of this PhD thesis, we examined the impact of adaptive 
immune cells upon neuron survival in Ppt1-/- mice. Consequently, we demonstrated 
that the lack of adaptive immune cells has a delaying effect on neuron loss in the 
thalamic VPM/VPL nuclei of Ppt1-/-/Rag-1-/- mice at 3 months of age (see Figure 40 
in Chapter 4). Therefore, our data clearly suggests an influence of adaptive immune 
cells upon neurodegeneration in Ppt1-/- mice (see Figure 74 for summary overview of 
proposed events in Ppt1-/-/Rag-1-/- mice). These findings are consistent with studies in 
other diseases such as multiple sclerosis (Delgado and Sheremata, 2006; Stadelmann et 
al., 2011), leukodystrophies (Wu et al., 2000; Kovács et al., 2005; Ip et al., 2006) or 
Parkinson disease (Brochard et al., 2009), in which adaptive immune cells have been 
associated with neuron loss. Adaptive immune cells have been shown to act on 
neuron survival in either direct or indirect ways. They can damage axons which 
eventually leads to retrograde neurodegeneration (Stadelmann et al., 2011; Ip et al., 
2012), but may also directly induce apoptosis in the cell soma of neurons (Giuliani et 
al., 2003; Vogt et al., 2009).  
In each disease different adaptive immune cell-mediated mechanisms can cause 
neurodegeneration. Whereas B-cells can produce (auto-) antibodies against neuronal 
antigens, as for example neurofascin in multiple sclerosis (Mathey et al., 2007), T-cell 
activation can indirectly result in neuron loss via pro-inflammatory cytokine release 
and subsequent microglial activation, which in turn can harm neurons via non-specific 
immune mediators like nitric oxide (NO), proteases or other reactive oxygen species 
(Le et al., 2001; Dutta and Trapp, 2007; Lull and Block, 2010; Zhang et al., 2011). Such 
reactive oxygen species are thought to impair mitochondrial function in neurons, 
resulting in cellular energy failure and subsequent neuronal or axonal damage (Dutta et 
al., 2006; Di Filippo et al., 2010; Lassmann, 2011). Furthermore, T-cells may launch 
immune reactions directly against neuronal antigens, for example neurofilament,  
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contactin-2 or beta-synuclein  (Mor et al., 2003; Derfuss et al., 2009; Krishnamoorthy et 
al., 2009). Additionally, the direct induction of neuronal death via the secretion of T-
cell cytokines like tumour necrosis factor-α (TNF-α) itself has also been suggested, 
even though this hypothesis remains controversial (Rousselet et al., 2002; Gaur and 
Aggarwal, 2003; Ferger et al., 2004; Sriram et al., 2006). Furthermore, CD8+ve 
cytotoxic T-cells classically can induce apoptosis in neurons after MHC-I antigen 
recognition via Fas-FasL interactions or granzymes and perforin release at the 
‘immunological synapse’ (see section 1.7a in Chapter 1, (Rensing-Ehl et al., 1996; 
Medana et al., 2000; Abbas and Lichtman, 2011)). Moreover, during this induction of 
apoptosis, the leakage of effector molecules can cause collateral damage to bystander 
Figure 74. Proposed summary of events that occur in Ppt1-/-/Rag-1-/- mice. The effects of 
Rag-1 deficiency appear to be exerted at multiple levels (body periphery, blood and brain) in   
Ppt1-/-/Rag-1-/- mice. In the body periphery of these mice (particularly in the lymph nodes and 
spleen) no functional T- and B-cells are present (1). Consequently, therefore no antibodies or T-
cells can be found in the blood. However, (Sn+ve) circulating monocytes are normally 
transported to the blood brain barrier (BBB) via the systemic circulation, where they can cross 
into the brain after interactions with endothelial cells and astrocytes. In the brain, infiltrated 
macrophages reach the site of inflammation (only investigated in Ppt1-/- mouse brains, but 
assumed to be similar in Ppt1-/-/Rag-1-/- brains) where they are morphologically indistinguishable 
from microglia that have transformed into brain-macrophages. The amount of infiltrating Sn+ve 
monocytes has not yet been determined in Ppt1-/-/Rag-1-/- brains, but speculatively their numbers 
are reduced due to less inflammatory conditions in the brain (indicated by ↓?) (2). The extent of 
self-activation/interaction between microglia and infiltrated macrophages is unknown (indicated 
by circled arrow and ?). However, the absence of T-cells led to a significant reduction (indicated 
by ↓) in microglial activation (represented as ‘microglia’ and ‘infiltrated macrophages’) and 
astrocytosis (represented as ‘astrocytes’). As another consequence, neuron survival (represented as 
‘neurons’) was transiently increased (indicated by ↑) in Ppt1-/-/Rag-1-/- mice (at early disease 
stages). Speculatively, these changes have most likely been caused by less inflammatory conditions 
in the brain (1, 2) and/or other unmeasured cells or changes in the brain (3). 
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neurons (Isaaz et al., 1995; Wiedemann et al., 2006), and additionally are suggested to 
disturb electrical excitability and signalling of neurons, leading to further neuronal 
death (reviewed in (Melzer et al., 2009)). However, both T-cell subsets (CD4+ve and 
CD8+ve) are also capable of inducing apoptosis in neurons in an antigen- and MHC-
independent manner via direct cell-cell contact mediated by FasL, Lymphocyte 
function-associated antigen 1 (LFA-1) or CD40 molecules (Giuliani et al., 2003). 
However, these latter experiments were conducted in human cells and may not be 
directly translatable to mice. Last but not least, CD4+ve Th17 cells have been shown 
to express granzyme B and directly induce neuronal cell death (Kebir et al., 2007). 
Thus, taken together, adaptive immune cells display various mechanisms to potentially 
induce neurodegeneration and have a pathogenic impact on disease progression 
(reviewed in (Amor et al., 2009; Goverman, 2009).  
Several studies utilising Rag-1-/- mice in models of various CNS disorders have 
similarly reported improved phenotypes, in mostly (autoimmune) myelin/axonal 
disorders (Sun et al., 2001; Ip et al., 2006; Pirko et al., 2012). Depending on the disease, 
the main contribution to neuronal damage has been allocated either to the CD4 
and/or CD8+ve T-cell subsets (Neumann et al., 2002; Huang et al., 2009). As typical 
examples, in Rasmussen Encephalitis or X-linked adrenoleukodystrophy CD8+ve T-
cell subsets are mainly linked to neurodegeneration (Ito et al., 2001; Bauer et al., 2002), 
whereas CD4+ve T-cells have been classically linked to multiple sclerosis (Delgado 
and Sheremata, 2006), although there is also emerging evidence of pathological 
CD8+ve T-cell involvement in this disorder (Friese and Fugger, 2009). By 
reconstituting Ppt1-/-/Rag-1-/- mice with bone marrow transplants of CD4-/- or CD8-/- 
mice, using a well-established protocol (Ip et al., 2006), our collaborators have 
identified that it is CD8+ve T-cells that are the main mediator of disease pathology in 
the optic nerve of Ppt1-/- mice (unpublished data, J Groh and R Martini, University of 
Würzburg). It cannot be assumed that the same is also true for the pathology in the 
brain of INCL mice, but this is likely to be the case. As described above, CD8+ve T-
cells may act directly on neurons in Ppt1-/- brains via Fas-FasL contact or granzymes 
and perforin release to induce apoptotic cascades in neurons (Mullereberhard, 1988; 
Cherin et al., 1996; Nagata, 1996). Additionally, or independently, cytotoxic T-cells can 
indirectly activate microglia and macrophages in Ppt1-/- brains via pro-inflammatory 
cytokine release, which can subsequently cause neurodegenerative processes by 
additional nitric oxide and reactive oxygen release (Brookes et al., 2003; Gurlo and von 
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Grafenstein, 2003; Hendriks et al., 2005). Our findings of a pronounced reduction in 
microglial activation in Ppt1-/-/Rag-1-/- mice favours the validity of this second 
hypothesis with microglia contributing to neuron loss in Ppt1-/- mice. Furthermore, 
our findings from Sn deficient double knockout experiments in INCL (as well as 
JNCL) mice (see Chapter 5 and Chapter 6) also indirectly demonstrated the 
pathogenic influence of macrophages upon neuronal survival. Most likely a 
combination of direct apoptotic, as well as indirect effects of CD8+ve T-cells, results 
in the observed neuron loss in Ppt1-/- mice (see Figure 40 in Chapter 4). 
Nevertheless, divergent roles of adaptive immune cells upon neurons have also been 
suggested. As mentioned in Chapter 1 (see section 7.1a), adaptive immune cells may 
exhibit neuroprotective (Moalem et al., 2000; Bieber et al., 2003; Serpe et al., 2003; 
Jones et al., 2005) or neurodegenerative effects (Medana et al., 2001; Bien et al., 2002; 
Neumann et al., 2002). Indeed, this may vary between disorders or even within the 
progression of a specific disease (Kerschensteiner et al., 2003). Therefore, it seems 
likely that the role of adaptive immune cells also varies between different forms of 
NCL. In particular, in Cln3-/- mice where T-cells infiltrate in a completely different 
manner than is seen in Ppt1-/- mice (see Figure 21 and Figure 27 in Chapter 3), other 
cues and effector functions of adaptive immune cells may also be present. Based on 
the auto-immune responses in Cln3-/- mice (Chattopadhyay et al., 2002a; Lim et al., 
2007b), so far only B-cell deficient Cln3-/-/μMT-/- mice have been investigated 
(Seehafer et al., 2011). Even though increased neuron survival (alongside with reduced 
neuroinflammation and improved rotarod performances) has been demonstrated in 
Cln3-/-/μMT-/- mice (Seehafer et al., 2011), we would speculate, based on our 
(CD8+ve) T-cell infiltration data in Cln3-/- mice (see Figure 27 in Chapter 3), that 
possibly an even greater improvement could be achieved by knocking out T-cells (in 
particular CD8+ve T-cells). Hopefully future studies will investigate the exact impact 
of T-cells in mouse models of Juvenile and other forms of NCL.  
7.5 Glial cells and neurodegeneration 
As detailed in the Chapter 1 (see section 1.10), a characteristic feature of the NCLs is 
glial activation that characteristically precedes neuron loss, and is especially 
pronounced in the thalamocortical system (Bible et al., 2004; Pontikis et al., 2004; 
Pontikis et al., 2005; Cooper et al., 2006; Kielar et al., 2007; Partanen et al., 2008; von 
Schantz et al., 2009; Kuronen et al., 2012; Schmiedt et al., 2012; Thelen et al., 2012). 
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Consistent with these observations, in all the experiments performed in this thesis glial 
activation was evidently detected in both Ppt1-/- and Cln3-/- mouse brains (see Figure 
32, Figure 34, Figure 36, Figure 38 in Chapter 4 and Figure 60, Figure 62, Figure 
64, Figure 66 in Chapter 6), and was used as one of the outcome measures of disease 
progression in our studies. However, it is still not definitively known whether 
astrocytes and microglia take on neuroprotective or harmful roles in INCL and JNCL 
(see section 1.6 and 1.10 in Chapter 1). Although our focus in this thesis was on 
adaptive immune responses and infiltrating macrophages, our experiments in immune 
deficient Ppt1-/- and Cln3-/- double knockout mice also revealed some clues towards 
answering this question. Firstly, in all our double knockout experiments we 
determined that the absence of adaptive immune cells, or of Sn expression, cannot 
completely reverse neuron loss in the NCL brain (see Figure 40 in Chapter 4, Figure 
54 in Chapter 5 and Figure 68 in Chapter 6). However, at the same time, glial 
activation was always still apparent in these double knockout brains suggesting that 
astrocytes and/or microglia are probably greater contributors to neurodegenerative 
processes. In Ppt1-/- mice, this is particularly likely in the later stages of the disease 
when the influence of adaptive immune or Sn+ve macrophages on neuronal survival 
vanished, but glial activation and neuron loss both continued (see Figure 40 in 
Chapter 4, Figure 54 in Chapter 5). In contrast, in Ppt1-/-/Sn-/- double knockouts the 
slightly improved neuron survival at all ages could potentially be linked to the 
increased astrocytosis in these mice (see Figure 47 and Figure 49 in Chapter 5).  
Speculatively, astrocytes might generate a more neuroprotective environment via anti-
inflammatory cytokine release or formation of a glial scar around areas of neuron loss, 
which either could attenuate the effector functions of other immune cells or result in 
reduced immune cell infiltration via putatively altered BBB permeability in Ppt1-/-/Sn-/- 
mice. However, our study design did not allow us to disentangle the role of each glial 
cell type in INCL or JNCL and thus, any interpretation remains speculative. One 
approach to address this issue was undertaken in a recent study crossbreeding Ppt1-/- 
mice with a strain of mutant mice that are deficient in both of the astrocyte 
intermediate filament proteins GFAP and Vimentin (Vim), and therefore have 
dysfunctional astrocytes (Macauley et al., 2011). In this study, Ppt1-/-/GFAP-/-/Vim-/- 
triple mutant mice displayed an accelerated INCL disease phenotype and died 
significantly earlier than Ppt1-/- mice. Furthermore, these authors identified increased 
cytokine levels and accelerated immune cell (T-cell and monocyte) responses, but no  
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impaired BBB integrity in the brain of the triple knockout mice. These data suggested 
that astrocytes play a neuroprotective role in Ppt1-/- mice. The authors hypothesized 
that impaired astrocytes influence inflammatory cytokine levels in the brain and lead to 
an augmentation of microglial activation and immune cell infiltration, which 
accelerates disease progression. This interpretation is consistent with our findings in 
Chapter 4 where we linked adaptive immune cells with disease deterioration. 
However, direct effects of astrocytes upon neuron survival cannot be ruled out in 
Ppt1-/-/GFAP-/-/Vim-/- triple mutant mice. Similar data from other disease or lesion 
models including experimental autoimmune encephalomyelitis (EAE) (Voskuhl et al., 
2009), brain trauma (Wilhelmsson et al., 2004; Myer et al., 2006) or spinal cord injuries 
(Faulkner et al., 2004) provided further examples that manipulation or ablation of 
astrocyte function leads to increased neurodegeneration, increased tissue damage and 
neuroinflammation. All of these studies provide valid examples for a neuroprotective 
role of astrocytes in neurodegenerative disorders, and this also appears to be the case 
in INCL (Macauley et al., 2011). 
To our knowledge, no similar approach has yet been applied to microglial cells in the 
context of any form of NCL. However, the possibility of a changing role for 
astrocytes and microglia over the course of disease progression should not be 
neglected (Gao and Hong, 2008; Appel et al., 2011). Depending on the extent and 
stage of disease progression, astrocytes or microglia may initially be neuroprotective by 
initiating repair mechanisms and glial scar formation (Glezer et al., 2007; Muzio et al., 
2007; Li et al., 2008; Hines et al., 2009), but subsequently exert a negative effect on 
neuron survival if the neuroinflammation persists (Gao and Hong, 2008; Brambilla et 
al., 2009; Graeber et al., 2011). This is particularly true in the context of chronic 
neurodegenerative diseases like the NCLs, because the Ppt1 and Cln3 deficiency in our 
mice is persistent and cannot be eliminated or repaired by inflammatory responses, in 
contrast to other immune up-regulations like viral infections, which eventually can be 
eliminated (Gao and Hong, 2008; Griffin and Metcalf, 2011; Khatami, 2011). 
Furthermore, as described in Chapter 1 (see section 1.8), direct modulation of glial 
responses by neurons may also play a role in defining neuroprotective or neurotoxic 
effects of glial cells by attenuating or enhancing inflammatory responses (Biber et al., 
2007; Levite, 2008; Tian et al., 2009).  
Another approach to identify the exact effect of glial cells on neurodegeneration 
would be to create cell type-specific, so called “conditional knockout” mice 
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(Orban et al., 1992). Based for example on the most commonly used Cre/Lox system 
(Hoess et al., 1982; Sauer and Henderson, 1988) specific genes can be 
manipulated/knocked out in targeted organs or cell types, such as within the brain. 
Such a cell type-specific strategy is currently underway for JNCL, with mice bearing a 
floxed Cln3 allele now generated in readiness for crossing to appropriate cell-type 
specific cre driver lines (JD Cooper, personal communication). However, in INCL with 
a deficiency in a soluble enzyme (Ppt1), such an approach is complicated since healthy 
and deficient cells can cross-correct one another (see section 1.3a in Chapter 1, 
(Sands and Davidson, 2006)). One possibility would be to link the cell specific NCL 
mutation with a deficiency in mannose-6-phosphate receptor on which cross-
correction is dependent, or alternatively to breed mice with a membrane tethered form 
of Ppt1 to conduct these experiments with. Alternatively, one could manipulate an 
essential function of each specific glial cell type in the context of complete Ppt1 
deficiency, which would remove the complication of cross-correction. This approach 
would resemble our double knockout experiments, but restricting deficiency (for 
example Sn) to certain cells and/or tissues. Furthermore, there is also the possibility of 
producing stage-specific inducible knockouts of targeted genes, for example via 
tetracycline (tet/off or tet/on) (Gossen and Bujard, 1992; Gossen et al., 1995) or 
tamoxifen induction (Metzger et al., 1995). Therefore, any desired cell deficiency would 
be able to be induced in a flexible spatiotemporal manner (for review see (Zhang et al., 
2012)). On this basis, we are confident that in the near future new studies will come 
closer to elucidating the exact relationship between glia and neurodegeneration in the 
NCLs.   
7.6 Interactions between sialoadhesin and glial cells 
a) Microglia 
Reviewing our data from Ppt1-/-/Sn-/- (Chapter 5) and Cln3-/-/Sn-/- (Chapter 6) double 
knockout mice, we conclude that Sn has an enhancing effect on microglial activation, 
but only at the later stages of the disease in Ppt1-/- mice and only minimally in Cln3-/- 
mice. The observed reduction in microglial activation in both double knockout mice is 
consistent with other studies carried out by our collaborators in Würzburg, in which 
they showed reduced numbers of CD11b+ve cells in Sn-/- PLP overexpressing or 
heterozygous P0 deficient mice (Kobsar et al., 2006; Ip et al., 2007). In contrast, 
another study demonstrated increased microglial activation during prion pathogenesis 
284 
 
in Sn-/- mice (Bradford et al., 2012). Therefore, the exact role of Sn in the brain, and its 
effect on microglia is still elusive. However, we would speculate that the most likely 
explanation for the observed discrepancy between (Bradford et al., 2012) and other 
studies (including ours) is found in the extent of T-cell involvement in disease 
progression. Sn has been demonstrated in cell based studies to bind favourably to 
granulocytes (neutrophils), other myeloid cells and lymphocytes (Crocker et al., 1995; 
Hartnell et al., 2001). However, in the spleen or lymph nodes Sn was characterised as a 
lymphocyte-specific protein with rather low binding affinity for other macrophages 
(van den Berg et al., 1992; Schadee-Eestermans et al., 2000). In support of these 
findings, recent studies suggested a prominent involvement of Sn in adaptive immune 
response regulation (see section 1.11b in Chapter 1, (Crocker and Redelinghuys, 
2008)) and for Sn interacting directly with T-cells (Muerkoster et al., 1999; Ip et al., 
2007; Wu et al., 2009). Therefore, we would speculate that the significant reduction in 
microglial activation in Ppt1-/-/Sn-/- mice (see Figure 51 in Chapter 5) and also 
minimally seen in Cln3-/-/Sn-/- (see Figure 64 in Chapter 6) is probably not linked to 
direct macrophage-microglial interactions, but indirectly results from diminished T-cell 
activation. Our findings of early Sn+ve expression (from 3 months) in Ppt1-/- brains 
(see Figure 44 of Chapter 5) support this hypothesis. If direct macrophage-microglial 
interactions would stimulate each other, reduced microglial activation would be 
expected to be seen already at 3 months of age in Ppt1-/-/Sn-/- mice. Instead, an 
indirect interaction via T-cells could explain the delayed change in the phenotype of 
these mice. However, the discrepancy between the detection of Sn+ve cells in Ppt1-/- 
mice at 3 months of age (see Figure 44 of Chapter 5) and microglial reduction in 
Ppt1-/-/Sn-/- mice (see Figure 51 in Chapter 5) could also be explained simply by an 
up-regulation of Sn on microglia at 3 months of age, and actual peripheral 
macrophage infiltration occurring only at 5 months of age. This hypothesis is 
consistent with previous findings of initial microglial activation with a delayed 
macrophage infiltration from the body periphery during CNS inflammation 
(Andersson et al., 1992). Furthermore, this interpretation is strengthened by the 
morphological appearance of Sn+ve cells at these two time points, with the majority 
of Sn+ve cells resembling brain-macrophages at 5 months of age whereas mainly 
microglia-like Sn+ve cells with cell processes can be detected at 3 months of age (see 
Figure 44B and Figure 44D in Chapter 5). This whole topic is of course made even 
more complicated by the difficulties of unambiguously distinguishing Sn+ve 
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macrophages and Sn+ve microglia (see section 7.2a above). Nevertheless, it cannot 
be ruled out that crosstalk may occur between microglia, or with infiltrated 
macrophages. This may cause these cells to enhance each other’s activation in a Sn 
dependent manner, since similar Sn dependent macrophage-macrophage interactions 
have been reported in the spleen (Schadee-Eestermans et al., 2000). Future studies will 
hopefully elucidate the potential role of direct interactions between microglia and Sn 
in more detail. Last but not least, this reduction in microglial activation could 
hypothetically also be explained by less efficient and compromised infiltration of 
Sn+ve monocytes from the blood stream into the brain. Theoretically, a lack of Sn-
dependent mechanisms to cross the BBB would lead to less infiltration of monocytes 
into the brain, and eventually to a less inflammatory brain environment. This could be 
the case in Ppt1-/-/Sn-/- mice, but may also play a role in the attenuated phenotype of 
Cln3-/-/Sn-/- mice. Future co-culture studies of Sn+ve macrophages/monocytes and 
endothelial cells could elucidate such potential mechanisms, and the roles of astrocytes 
at the BBB should not be neglected. 
b) Astrocytes 
In our Sn deficient double knockout studies contrasting effects upon astrocytosis 
could be observed between Ppt1-/-/Sn-/- and Cln3-/-/Sn-/- mice. Whereas in Cln3-/-/Sn-/- 
mice only a marginal reduction in astrocytosis could be detected (see Figure 61 and 
Figure 63 in Chapter 6), to our initial surprise an enhanced astrocytosis was evident 
in Ppt1-/-/Sn-/- mice at all ages, but particularly at 7 months of age (see Figure 47 and 
Figure 49 in Chapter 5). To our knowledge, these studies represent the first 
demonstration of an, as yet, undescribed link between Sn and astrocytosis. Because in 
Ppt1-/-/Sn-/- mice none of the parameters showed changes similar to that seen for 
astrocytosis as consequence of Sn deficiency, it is important to consider what possible 
mechanisms could lead to such a phenotype.  
Each cell in the brain cell (glia, neuron and immune cell) is surrounded by, and reacts 
to, a wide range of cytokines and chemokines (Quan and Herkenham, 2002; Guyon et 
al., 2008). As such, the increased level of astrocytosis in Ppt1-/-/Sn-/- mice could simply 
reflect a Sn-dependent alteration in cytokine expression in the brain, a possibility 
which should certainly be investigated in future studies. Such cytokine alterations may 
be created, for example by a distorted CD8:CD4 balance in the brain. Consistent with 
previous findings of a reduction of CD8+ve T-cells and an up-regulation of CD4+ve 
286 
 
T-regulatory cells in Sn deficient mice (Kobsar et al., 2006; Ip et al., 2007; Wu et al., 
2009), a decreased inflammatory brain environment may be present in Ppt1-/-/Sn-/- 
mice. However, confronted with ongoing neurodegeneration, T-cells in the brain may 
simultaneously enhance the neuroprotective properties of astrocytes (Garg et al., 2008; 
Macauley et al., 2011), leading to enhanced astrocytosis in Ppt1-/-/Sn-/- mice. A 
complete absence of T-cells, as in the Ppt1-/-/Rag-1-/- mice, would not evoke such 
events and therefore represents a possible underlying mechanism. However, a possible 
flaw in this hypothesis is that immune down-regulation via CD4+ve T-regulatory cells 
may also decrease astrocyte responses, as observed for example in HIV studies (Liu et 
al., 2009). However in such viral systems no genetically caused, persistent 
neurodegenerative processes can be found as in Ppt1-/-/Sn-/- mice and therefore other 
inflammatory mechanisms are likely to be involved.   
As an alternative, but very speculative explanation, it could be suggested that increased 
factors like cytokines, hormones or growth factors (Morrison et al., 1985; Polikov et al., 
2010) in the serum as a consequence of Sn depletion in the body, or the entry of other 
systemic cells via the BBB, which have not been measured in our experiments, could 
possibly cause further astrocytosis in Ppt1-/-/Sn-/- mice. Since astrocytes help maintain 
the integrity and are a key part of the BBB (Bradbury, 1984), they are likely to be 
affected by such processes. Indeed, comparable events have recently been described in 
Ppt1-/- mice (Saha et al., 2012). It was shown that the up-regulation of CD4+ Th17 
effector cells and their production of IL-17R in the periphery (more precisely the 
spleen) and in the brain initiated endothelial cells to release matrix metalloproteinases 
(MMPs), which in turn degraded tight junction proteins (Saha et al., 2012). Increased 
levels of MMPs would then also further trigger the production of MMPs by astrocytes, 
which was postulated to lead to BBB leakage and most likely also enhance 
astrocytosis. Following up such ideas regarding the BBB, perhaps under inflammatory 
conditions infiltrating Sn+ve macrophages form specific Sn-dependent cell-cell 
interactions with endothelial cells or astrocytes while crossing the BBB into the brain 
(Dosquet et al., 1992; Ransohoff et al., 2003; Reijerkerk et al., 2012). Consequently, the 
lack of Sn may trigger further astrocytosis, but it is unclear how this happens. Taking 
this idea further, if Sn+ve macrophages themselves are the main cause for the 
enhanced astrocytosis in Ppt1-/-/Sn-/- mice, and assuming that astrocytes take over a 
neuroprotective role (Macauley et al., 2011), this would then confirm that Sn+ve 
macrophages may indirectly cause harm to neurons by attenuating astrocytosis in  
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Ppt1-/- mice. Furthermore, as mentioned in Chapter 1 (see section 1.10a), recent 
studies on Ppt1-/- astrocytes in cell culture suggested they are functionally 
compromised (Milà, 2012), and Sn deficiency may amplify such astrocyte deficits in 
Ppt1-/-/Sn-/- mice. These changes could also potentially have direct effects on 
astrocytosis and events at the BBB in these mice, although this would need to be 
investigated directly.  
Last but not least, systemic events may also be responsible for the enhanced 
astrocytosis in Ppt1-/-/Sn-/- double knockout mice. As already mentioned in Chapter 1 
(see section 1.11c), Sn+ve macrophages in the spleen have been suggested to be 
involved in the recognition and discrimination of self and non-self of apoptotic cell 
associated antigens (Klaas and Crocker, 2012). In other studies, depletion of Sn+ve 
macrophages resulted in a breach of self-tolerance by non-recognition of apoptotic 
cell debris via Sn+ve macrophages in the spleen (Miyake et al., 2007). Consequently, 
the lack of Sn+ve macrophages accelerated disease progression by enhanced T-cell 
activation and cytokine production towards self-antigens (Miyake et al., 2007; McGaha 
et al., 2011). Because Sn may play a putative role in phagocytosis, antigen intake and 
presentation, and the recognition of apoptotic cells (Jones et al., 2003; Revilla et al., 
2009; Delputte et al., 2011; Klaas and Crocker, 2012), Sn deficiency could speculatively 
result in similar phenotypes and stimulate autoimmune responses in Sn-/- mice. 
Therefore, similar events may take place systemically in Ppt1-/-/Sn-/- double knockout 
mice, which would potentially increase auto-immune responses and cytokines in the 
blood and therefore possibly could have a direct impact on astrocytosis. Alternatively, 
and even more speculatively, it is possible that Sn+ve macrophages in the brain 
normally facilitate the suppression of apoptotic cell (auto) antigens. As such, Sn 
deficiency could lead to an increased auto-immune reaction in the brain resulting in an 
enhanced pro-inflammatory environment, which could eventually be reflected in 
increased astrocytosis in Ppt1-/-/Sn-/- double knockout mice. Because neurons die in 
Ppt1-/- mice from 3 months onwards (see Figure 54 in Chapter 5), the increased 
astrocytosis in Ppt1-/-/Sn-/- mice from the same time point onwards could potentially 
be explained by the breach of self-tolerance which is normally regulated by Sn+ve 
macrophages. Furthermore, the rapid explosion of GFAP+ve up-regulation 
/astrocytosis at 7 months of age may then be explained by a sudden increase in cell 
death in these affected regions. However, such explanations remain pure speculation 
so far and the putative link between apoptotic cell debris and Sn+ve macrophages in 
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the brain still requires future investigation. Unambiguous proof of the involvement of 
Sn in phagocytosis, antigen presentation in general, but specifically also in the 
recognition of apoptotic cells (reviewed in (Klaas and Crocker, 2012)), would have to 
be obtained. This could be achieved, for example, by exposing pure cultures of Sn+ve 
and Sn-/- macrophages to cell debris or by setting up neuron and Sn-/- macrophages co-
cultures systems. In addition, the injection and tracing of labelled self-antigens into 
healthy and Sn-/- mouse brains could help to verify the putative role of Sn+ve 
macrophages in the uptake and recognition of apoptotic cell debris in the CNS.   
c) INCL vs. JNCL 
Finally in this context, it is important to address the question of how to explain the 
opposing effects of Sn deficiency upon astrocytosis in Ppt1-/-/Sn-/- and Cln3-/-/Sn-/- 
mice. In contrast to Ppt1-/- mice, the lack of Sn in Cln3-/- brains seems to marginally 
reduce astrocytosis, which could speculatively be explained by the ‘conventional’ 
CD8+ve T-cell and microglial down regulation as seen in other studies (Kobsar et al., 
2006; Ip et al., 2007). However, we have not quantified the T-cell infiltration in       
Ppt1-/-/Sn-/- mice so far and therefore, cannot be completely certain that such 
processes are actually occurring. Another explanation for the overt difference in 
astrocyte response between these mice could be the discrepancies in BBB integrity 
between these two forms of NCL. The BBB of Cln3-/- mice is already compromised at 
an early time point, namely from 3 months onwards (Lim et al., 2007b). Therefore, in 
18 month old Cln3-/- mice the BBB is perhaps already sufficiently leaky that the Sn 
deficiency, or any Sn related systemic impact, does not increase astrocytosis in the 
brain any further. In contrast, in Ppt1-/- mice the integrity of the BBB is still a 
controversial topic as some studies have not detected any impairments ((Macauley et 
al., 2011); MS Sands, personal communication), but others have demonstrated BBB 
leakage late in the disease (see paragraph above) (Saha et al., 2012). The autoimmune 
component of Cln3-/- mice is also likely to alter the effect of Sn deficiency upon 
disease manifestations including astrocytosis in Cln3-/-/Sn-/- mice (see section 1.10 in 
Chapter 1, (Lim et al., 2007b)), whereas no autoimmune component has so far been 
described in INCL mice. Ultimately, in Cln3-/- mice both astrocytes and (Sn+ve) 
macrophages may be dysfunctional (Pontikis et al., 2004; Getty et al., 2011; Parviainen, 
2012) and the lack of Sn may have a different effect, or no effect, on astrocytosis in 
Cln3-/-/Sn-/- mice as a consequence of Cln3 deficiency. However, until any clear 
connection between astrocytes and Sn+ve macrophages can be established, it will 
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remain unresolved which effect upon astrocytes in Sn deficient NCL mice represents 
the normal pathological influence of Sn. We surmise that the reactions in Juvenile 
NCL, with a clearly defined autoimmune influence in pathogenesis and 
transformational glial deficits, may possibly represent an abnormal pattern. This is in 
comparison to the pathogenesis of Infantile NCL, which displays no overt 
autoimmune effects and no dramatic glial abnormalities documented so far.  
Considering all these data together, in both Sn-/- NCL double knockout mice we are 
probably observing a mix of several consequences of Sn deficiency. We would 
hypothesise that on one hand, microglial activation and T-effector cell reactions are 
reduced due to the lack of interactions between Sn+ve macrophages and T-cells. On 
the other hand, other mechanisms may be enhanced such as T-regulatory cell type 
stimulation, Sn-dependent changes at the BBB barrier, increased susceptibility to auto-
antigens of apoptotic cell debris or unknown systemic effects. Even though these 
interpretations remain speculative, the sum of all these putative interactions, and the 
different disease mechanisms, does give rise to elevated astrocytosis in Ppt1-/-/Sn-/- 
mice, whereas the opposite is seen in Cln3-/-/Sn-/- double knockout mice. Therefore, 
these differences indicate diverse roles and implications for Sn and Sn+ve 
macrophages in these two forms of NCL, which would be interesting to follow up 
with future studies comparing for example Ppt1-/-/Sn-/- and Cln3-/-/Sn-/- macrophages 
in cell culture systems or Sn+ve macrophages in the spleen and lymph nodes of Ppt1-/- 
and Cln3-/- mice.  
7.7 Sialoadhesin and neurodegeneration  
We have demonstrated in this thesis that Sn has a direct influence on 
neurodegeneration in both Infantile (see Figure 54 in Chapter 5) and Juvenile NCL 
(see Figure 68 in Chapter 6), since the lack of Sn had an ameliorating effect on 
neuron survival in both forms of NCL. However, it is likely that Sn affects 
neurodegeneration by different mechanisms in these forms of NCL, since Cln3 and 
Ppt1 proteins exhibit contrasting functions and properties (see section 1.2b and 1.2c 
in Chapter 1), and their deficiency results in different disease manifestations (reviewed 
in (Jalanko and Braulke, 2009; Cooper, 2010)) for example, disease specific glial 
dysfunction or autoimmune responses in Cln3-/- mice (Ramirez-Montealegre and 
Pearce, 2005; Lim et al., 2006; Castaneda and Pearce, 2008; Parviainen, 2012). Based 
on all the measurements we have undertaken in Ppt1-/-/Sn-/- mice, and other Sn 
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deficient studies (Kobsar et al., 2006; Ip et al., 2007), we would speculate that in      
Ppt1-/-/Sn-/- mice the reduction of CD8+ve T-cell and/or Sn-dependent enhancement 
of astrocytosis (see section 7.6b above) act as the main neuroprotective force (see 
Figure 75 for an overview of proposed events in Ppt1-/-/Sn-/- mice). Quantifying T-
cell infiltration in Ppt1-/-/Sn-/- mice could potentially validate this hypothesis by 
detecting reduced amounts of (CD8+ve) T-cells in the brains of these mice. 
Furthermore, assessing Sn+ve monocyte infiltration, respectively Sn+ve macrophage 
activation in Ppt1-/-/Rag-1-/- mice may also indirectly shed light upon the potential 
interaction of T-cells with Sn+ve macrophages. 
In contrast, in Juvenile NCL, apart from the increase in neuron number, none of the 
parameters we measured in Cln3-/-/Sn-/- mice showed any real difference, leaving 
unanswered questions about the reasons for the observed amelioration of disease in 
these mice.  
Firstly, as suggested for Ppt1-/-/Sn-/- mice, a reduced inflammatory environment within 
the CNS could have a significant impact on neuronal survival via CD8+ve T-cell 
attenuation or CD4+ve T-cell proliferation (Kobsar et al., 2006; Ip et al., 2007; Wu et 
al., 2009). However, T-cells in Cln3-/- mice are only apparent at a later stage of the 
disease, with significant lymphocyte infiltration only evident at 21 months of age (see 
Figure 27 in Chapter 3), the impact on neuron survival and the brain environment 
may not be as substantial as that suggested for Ppt1-/- mice. Alternatively, the previous 
identification of autoimmune responses in Cln3-/- mice (Lim et al., 2007a; Castaneda 
and Pearce, 2008) may highlight that adaptive immune cells (including T-cells) could 
play a more prominent role in Cln3-/- mice than in Ppt1-/- mice. Indeed, even a late 
occurring (CD8+ve) T-cell infiltration in Cln3-/- mice could putatively have substantial 
impact on neurodegeneration. Therefore, the reduction of T-cell numbers in         
Cln3-/-/Sn-/- mice is a valid hypothesis for increased neuron survival, and counting the 
number of these cells in the brains of Cln3-/-/Sn-/- mice will hopefully clarify this issue.   
Similarly, as already mentioned for Ppt1-/-/Sn-/- mice, Sn deficiency could also 
theoretically compromise the infiltration of monocytes into the brain. If Sn is indeed 
necessary for monocytes to interact with endothelial cells and cross the BBB, then the 
lack of Sn would lead to a reduced infiltration of monocytes into Cln3-/-/Sn-/- mouse 
brains. This in turn could increase neuron survival, either directly via a reduced release  
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of nitric oxide (NO), proteases or other reactive oxygen species (Le et al., 2001; Dutta 
and Trapp, 2007; Lull and Block, 2010; Zhang et al., 2011), or indirectly via 
lessinflammatory conditions in the brains of Cln3-/-/Sn-/- mice. However, if this would 
be the case, a more pronounced reduction of microglial activation would have been 
expected in Cln3-/-/Sn-/- mice. Nevertheless, Sn-dependent BBB interactions have not 
been described so far, but co-cultures of Sn+ve monocytes/macrophages and 
endothelial cells may help to elucidate such mechanisms. 
As a third explanation for increased neuron survival in Cln3-/-/Sn-/- mice, systemic 
effects of Sn+ve macrophages may occur. As described in Chapter 1 (see section 
Figure 75. Proposed summary of events that occur in Ppt1-/-/Sn-/- mice. Sialoadhesin (Sn) 
deficiency may impact at multiple levels (body periphery, blood and brain) in Ppt1-/-/Sn-/- mice. In 
the lymph nodes and spleen, resident macrophages lack Sn-dependent interactions and putatively 
alter T- and B-cell activation (1). Antibodies, T-cells and Sn-deficient circulating monocytes are 
transported to the blood brain barrier (BBB) via the systemic circulation. However, deposition of 
IgGs has not yet been reported in brains of Ppt1-/- mice. Sn deficiency may also influence 
monocytes crossing the BBB via altering the interactions with endothelial cell and astrocytes in 
the brain (2). Speculatively, such changes could lead to enhanced (indicated as ↑) astrocytosis 
(represented as ‘astrocytes’). Similarly, T-cells are likely to cross the BBB and interact with brain 
cells (neurons, astrocytes and microglia) (oligodendrocytes not being a focus of this study are not 
depicted) (3), but the extent of T-cell infiltration and its influence in the brains of Ppt1-/-/Sn-/- 
mice has not yet been investigated. However, Sn deficiency led to a significant reduction 
(indicated by ↓) in microglial activation (represented as ‘microglia’ and ‘infiltrated macrophages’), 
and significant enhancement of astrocytosis (represented as ‘astrocytes’). The former could be a 
result of less (efficient) infiltration of circulating monocytes at the BBB due to their Sn deficiency 
(indicated by ↓?) (4). The extent of Sn dependent self-activation/interaction between microglia 
and infiltrated macrophages is unknown (indicated by circled arrow and ?). In contrast, neuron 
survival (represented as ‘neurons’) was increased (indicated as ↑) in Ppt1-/-/Sn-/- mice (at early 
disease stages). Speculatively, these changes may be caused by reduced T-cell activation (1), less 




1.11c), Sn+ve macrophages have been shown to present antigen to (and activate) B-
cells in the spleen and lymph nodes (Carrasco and Batista, 2007; Junt et al., 2007; Pape 
et al., 2007; Gonzalez et al., 2011). Thus speculatively, Sn deficiency could have a direct 
impact on B-cell activation and antibody production, although a direct role of Sn in 
antigen presentation and phagocytosis (as well as endocytosis) has yet to be proven 
unambiguously ((Revilla et al., 2009) and reviewed in (Klaas and Crocker, 2012)). In 
the context of reported autoimmune responses in Cln3-/- mice (see section 1.10 in 
Chapter 1, (Chattopadhyay et al., 2002a; Lim et al., 2007b; Castaneda and Pearce, 
2008)), Sn deficiency could lead to a reduced production of antibodies against self-
antigens and consequently increased neuron survival. In support of this hypothesis, 
the lack of detectable B-cells in the brain of Cln3-/- brains confirmed that auto-
antibody production most likely occurs systemically rather than in the CNS (Lim et al., 
2007b). Likewise, IgG deposition has been found in human JNCL, as well as Cln3-/- 
mice and has been linked to complement activation (Lim et al., 2007b). Even though 
IgG deposition has been proposed to be only a regular immunosurveillance function 
of IgGs in removing non-viable neurons (Stein et al., 2002), in other diseases 
neuropathological and apoptotic features of IgGs in the brain have already been 
demonstrated (D'Andrea, 2003; Jernigan et al., 2003). Sn deficiency could consequently 
also reduce IgG production in Cln3-/-/Sn-/- mice and increase neuronal survival, but 
this is yet to be verified experimentally. This potential reduction in auto-antibodies in 
the brain would also account for the slightly lower glial activation in Cln3-/-/Sn-/- 
double knockout mice, and therefore indirectly contribute to a less inflammatory 
environment in the brain and again enhance neuron survival. As such, it will be 
important to make measurements of auto-antibody concentration and IgG deposition 
in Cln3-/-/Sn-/- double knockout mice to test these hypotheses. 
In this context, as a potential confounder of our study, it should be noted that besides 
a small increase in CD8+ve T-cells, Sn-/- mice also show a small decrease in B220+ B-
cells in the spleen and lymph nodes (Oetke et al., 2006). As a consequence of this 
reduction, slightly reduced immunoglobulin M (IgM) levels were also detected, 
whereas no differences in IgG antibodies were seen in Sn-/- mice (Oetke et al., 2006). 
Even though the same measurements were not made in either Sn-/- mice, or in the Sn-/- 
NCL mice used in this study, we are confident that due to the magnitude of increased 
neuron survival in Cln3-/-/Sn-/- mice and of the disease attenuation in Ppt1-/-/Sn-/- mice, 
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these differences in neuron numbers and disease progression are not founded on these 
minor deviations of Sn-/- mice from wildtype mice. 
Furthermore, as already mentioned above in the context of Ppt1-/-/Sn-/- mice, other 
studies depleting Sn+ve macrophages in the spleen of various disease models have 
demonstrated enhanced autoimmune responses due to a breach of self-tolerance via 
non-recognition of apoptotic cell debris (Miyake et al., 2007; McGaha et al., 2011). 
Such events led to accelerated disease progression by activating CD8+ve T-cells, 
dendritic cells and cytokine production towards self-antigens (Miyake et al., 2007; 
McGaha et al., 2011). Although the lack of Sn may hypothetically lead to similar results 
in Cln3-/-/Sn-/- mice, we observed the opposite phenotype with attenuated 
neurodegeneration in the double mutants compared to Cln3-/- mice (see Figure 68 in 
Chapter 6). This, once more, suggests that the driving force of the autoimmune 
response reported in Cln3-/- mice is most likely found neither in apoptotic neurons and 
cell debris in the CNS nor in T-cell activation. Instead, B-cells (including interactions 
with Sn) and their production of autoantibodies are probably more crucial to disease 
pathology in Cln3-/- mice. Last but not least, whereas Cln3 deficiency in immune cells 
themselves possibly already lead to a marked autoimmune response in JNCL mice 
(Lim et al., 2007b), Sn deficiency may disturb or enhance existing immune cell 
dysfunction in Cln3-/-/Sn-/- mice. Alternatively, this could explain the less pronounced 
inflammatory response and increased neuron survival in these mice (see Figure 76 for 
proposed summary of events in Cln3-/-/Sn-/- mice).  
In summary, although we showed that Sn has an accelerating effect on 
neurodegeneration, with the parameters we measured it is not possible to identify 
unambiguously how Sn deficiency results in the ameliorated phenotypes of both NCL 
double knockout mice. Whereas we would hypothesize that Sn+ve macrophage-T-cell 
interactions are predominantly responsible for accelerating neurodegeneration in   
Ppt1-/- mice, Sn+ve macrophage-B-cell interactions are more likely to be important in 
Cln3-/- mice. Whether these interactions occur in the brain and/or in secondary 
lymphoid organs alone remains to be seen. However, our results further suggest that 
systemic events may play a more important role in both forms of NCL than has 
previously been anticipated.  
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7.8 Therapeutic implications of our findings 
In our studies we looked at two different immune modifications: The effect of Rag-1 
and Sn deficiencies were both investigated in Ppt1-/- mice, and the latter also 
investigated in Cln3-/- mice. The overall objective of our studies was to test the 
potential of these two immune modulations as therapeutic interventions in INCL and 
JNCL. The following paragraphs discuss the potential benefits of our studies and 
compare them to existing immune therapies. 
Figure 76. Proposed summary of events that occur in Cln3-/-/Sn-/- mice. Sialoadhesin (Sn) 
deficiency may exert its influence at multiple levels (body periphery, blood and brain) in Cln3-/-
/Sn-/- mice. In the lymph nodes and spleen, resident macrophages lack Sn-dependent interactions 
and this may putatively alter T- and B-cells activation. This could lead to either reduced or 
enhanced T-cell activation, and perhaps also reduced (auto-)antibody production (1). As a 
consequence less (auto-) antibodies may be present in the blood and in the brain (indicated as X?), 
which has been previously described in Cln3-/- mice due to BBB leakage (Lim et al., 2007). Besides 
antibodies, T-cells and circulating monocytes are also transported to the blood brain barrier 
(BBB) via the systemic circulation. Furthermore, Sn deficiency may also influence monocytes 
crossing the BBB via altered interactions between endothelial cells and astrocytes in the brain (2). 
Speculatively, less infiltrating monocytes (indicated by ↓?) could lead to slightly attenuated 
neuroinflammation and neuron loss (3). Likewise, T-cells are likely to cross the BBB and interact 
with brain cells (neurons, astrocytes and microglia) (oligodendrocytes not being a focus of this 
study are not depicted) (4), but the extent of T-cell infiltration and its influence in the brain of 
Cln3-/-/Sn-/- mice has not yet been investigated. However, Sn deficiency led to a marginal 
reduction (indicated by = (↓)) in microglial activation (represented as ‘microglia’ and ‘infiltrated 
macrophages’) and astrocytosis (represented as ‘astrocytes’). The extent of Sn dependent self-
activation/interaction between microglia and infiltrated macrophages is unknown (indicated by 
circled arrow and ?). In contrast, neuron survival (represented as ‘neurons’) was increased in 18 
month old Cln3-/-/Sn-/- mice. Speculatively, this may be caused by reduced (auto-)antibody levels 
(1), less inflammatory conditions in the brain (2, 3, 4) and/or other unmeasured cells or changes 
in the brain (5). 
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a) Rag-1 vs. Sn 
Since we conducted both Rag-1 and Sn deficient experiments in Ppt1-/- mice we were 
able to directly compare the effect of these genetic manipulations of the immune 
system upon neurodegeneration and most importantly upon lifespan. In immune 
deficient Ppt1-/-/Rag-1-/- mice we saw an overall reduction in inflammatory responses 
in the brain (see Figure 33, Figure 35, Figure 37 and Figure 39 in Chapter 4), 
combined with reduced neuron loss at early stages of the disease (see Figure 40 in 
Chapter 4) and an increase of lifespan to 265 days (unpublished data, J Groh, 
University of Würzburg). In contrast, the lack of Sn resulted in a weaker, but longer 
lasting improvement in neuron survival (see Figure 54 in Chapter 5) and mixed 
effects upon glial activation in Ppt1-/-/Sn-/- mice (see Figure 47, Figure 49, Figure 51 
and Figure 53 in Chapter 5), together with a similar or even slightly greater impact 
upon lifespan (271 days) (unpublished data, J Groh, University of Würzburg). These 
findings revealed that a minor modulation of the adaptive immune response in      
Ppt1-/-/Sn-/- mice can have a similar effect on lifespan as a complete eradication of 
adaptive immune cells in Ppt1-/-/Rag-1-/- mice. Likewise, a subtle alteration of the 
immune system showed a significant improvement in neurodegeneration in           
Cln3-/-/Sn-/- mice. Unfortunately, a directly comparable complete depletion of adaptive 
immune cells via Rag-1 deficiency is yet to be attempted in Cln3-/- mice. Nevertheless 
the question remains, which of the two immune modifications is ‘better’ or has a more 
significant impact? Or in other words, are the adaptive immune cells or Sn+ve 
macrophages more detrimental to disease outcome? The flaw in these questions is 
that, in our opinion, there is no oversimplified ‘good’ or ‘bad’ guy in inflammatory 
neurodegenerative CNS diseases. Indeed, because neuroinflammation is a dynamic 
process (Gao and Hong, 2008; Harry and Kraft, 2008; Frank-Cannon et al., 2009; 
Rivest, 2009), the cost-benefit ratio of each manipulation of the immune system may 
vary in different contexts. We agree with other authors that it is most likely that 
dynamic immune interventions will be the way forward in the future (Wyss-Coray and 
Mucke, 2002; Schwartz and Kipnis, 2005; Zipp and Aktas, 2006; Gao and Hong, 
2008). When inflammatory reactions are beneficial, boosting of the immune response 
should be considered, but when inflammation appears to be destructive, attenuation 
of the responsible immune cells, or their conversion into a beneficial role should be 
strived for. In summary, a more detailed understanding of the factors that contribute 
to disease progression will be essential for ultimately devising effective therapeutic 
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approaches. However, as long as there is a basic lack of knowledge about the 
underlying disease mechanisms in the NCLs (e.g. the function of deficient proteins, 
precise cellular involvements etc.), any improvement at all of neurodegeneration and 
lifespan is more than favourable in these disorders. Therefore we postulate that both 
Rag-1 as well as Sn could be considered as promising therapeutic targets. However, 
specific blockade of Sn (Halkes et al., 2003) could potentially produce fewer side 
effects than a generalised immune suppression. 
b) Other immune therapies 
Immune modulatory therapies have mainly focused on the Juvenile form of NCL, 
because in the other NCL forms no overt auto-immune involvement has been 
demonstrated so far. The identification of auto-immune responses in both human and 
murine Juvenile NCL (Chattopadhyay et al., 2002a; Chattopadhyay et al., 2002b; Lim et 
al., 2006; Lim et al., 2007b; Castaneda and Pearce, 2008) sparked off investigations into 
potential immune suppressive therapies in CLN3 deficient patients. Recently 
improvements in motor function and neuron survival have been reported after 
immune suppressive interventions in Cln3-/- mice (Seehafer et al., 2011), and initiated a 
Phase I clinical trial with the pharmacological drug CellCept on Juvenile NCL patients 
(http://clinicaltrials.gov/ct2/show/NCT01399047). Another previous study administered 
the steroid prednisolone to JNCL patients, which reduced the level of GAD65 auto-
antibodies, but did not significantly change the course of disease (Aberg et al., 2008). 
In this context, our studies examining Sn deficiency in Cln3-/- mice add another 
possible means to modulate of the immune system via Sn targeted therapy. 
In Ppt1-/- mice the therapeutic focus has so far been on methods to deliver the missing 
enzyme (via either direct enzyme replacement, gene therapy or stem cell grafts), plus 
some largely unsuccessful small molecule based therapies (Griffey et al., 2006; Tamaki 
et al., 2009; Dawson et al., 2010; Hu et al., 2012). Only in a recent study from Prof. M 
Sands’ laboratory did researchers administer an immune modulating drug called 
Minozac to Ppt1-/- mice (Shyng, 2012). This treatment was part of a combination 
therapeutic approach together with gene therapy (see section 7.8c below for more 
detailed discussion). Minozac can readily cross the BBB and inhibits pro-inflammatory 
cytokines production by activated glia in the brain (Lloyd et al., 2008; Hu et al., 2012). 
Despite moderately increased cortical thickness measurements the treatment with 
Minozac alone provided little or no benefit upon motor function or lifespan in Ppt1-/- 
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mice. Compared to our data for lifespan extensions following Sn or Rag-1 deficient 
interventions, we would speculate that drugs modulating the adaptive immune system 
and/or Sn as putative therapeutic target will most likely have a greater impact on 
disease progression than Minozac did in this study.  
c) Combination therapies 
Although moderate improvements in lifespan, or at least key disease phenotypes, have 
been observed in all our double knockout mice, these genetic interventions did not 
completely reverse the neurodegenerative outcome of either Ppt1-/- or Cln3-/- mice. 
Nevertheless, we would predict that immune modulations in combination with other 
treatment strategies may improve their efficacy. Such combination therapies have been 
attempted in several LSD mice including MPSVII (Sands et al., 1997), Sandhoff disease 
(Jeyakumar et al., 2001; Lee et al., 2007b) or Krabbe disease (Biswas and LeVine, 2002; 
Lin et al., 2007). The success of these approaches has been variable, but some 
promising results were produced in a mouse model of Krabbe disease with almost 2.5 
times extended lifespan (Lin et al., 2007).  
In recent years combination therapies have also been tested on NCL mice. A recent 
combination of CNS directed AAV2/5 mediated gene therapy with the 
immunosuppressant drug Minozac on Ppt1-/- mice (Shyng, 2012). The mice treated with 
both therapies showed significantly improved motor function and a lifespan extension 
of about 12 weeks (median survival of 47 weeks = 11.75 months or 329 days), 
compared to untreated Ppt1-/- mice (median survival of 35 weeks = 8.75 months or 
245 days). As already mentioned above, Minozac alone did not extend lifespan, but 
gene therapy alone resulted in a 10 week improvement in lifespan (median survival of 
45 weeks = 11.25 months or 315 days). Nevertheless, this study revealed for the first 
time that immune modulation may enhance the efficacy of other therapeutic 
approaches. However, recently the field of experimental therapies for Infantile NCL 
was revolutionized by the combination of BMT and CNS-directed gene therapy in 
Ppt1-/- mice (Macauley et al., 2012). In this study, AAV treatment alone resulted in an 
increase in lifespan of about 4.5 months (median survival of 54 weeks = 13.5 months 
or 378 days). This increase in lifespan is by far the most successful single therapeutic 
intervention for INCL mice up to date which is most likely explained by the usage of a 
new AAV2/5 vector that has a higher capacity for transducing neurons. BMT therapy 
alone produced no such improvement on lifespan, even resulting in a worse outcome 
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with increased glial activation in the CNS compared to untreated Ppt1-/- mice. 
However, the combination of both therapies more than doubled the lifespan of the 
treated Ppt1-/- mice to a median survival of 74 weeks or 18.5 months (= 518 days). 
These results are astonishing, particularly because BMT itself did not result in any 
improvement at all in either behavioural or pathological outcome measures. The 
authors hypothesized that two main reasons could account for these observed 
improvements. On the one hand, the combination treatment not only targeted the 
brain via gene therapy, but simultaneously treated the systemic effects of disease via 
the BMT. Indeed, INCL and all other NCLs are primarily thought of as 
neurodegenerative disorders, but since every cell in the body is affected by the same 
genetic defect the concept of systemic and visceral pathology is now emerging as 
being important (Galvin et al., 2008; Hu et al., 2012). On the other hand, the presumed 
reduction of neuroinflammatory processes via BMT, suggests that these mechanisms 
may play an, up to now, under-appreciated role in pathogenesis (Macauley et al., 2012). 
Interestingly, we could draw similar conclusions from our studies. We demonstrated 
that neuroinflammation (in particular adaptive immune cells) has an impact in the 
brains of INCL mice, but we also could speculate based on our findings of increased 
astrocytosis in Ppt1-/-/Sn-/- mice, that systemic effects (modulated by Sn+ve 
macrophages) in the body periphery could potentially account for changes in the 
brain.  
All in all, these recent therapeutic advances in mouse models are promising. In direct 
comparison to these effects upon lifespan, the improvements we observed in our         
Ppt1-/-/Rag-1-/- and Ppt1-/-/Sn-/- mice were rather moderate with 265, and 271 days 
respectively, compared to the expected 245 day lifespan of untreated Ppt1-/- mice 
(unpublished data, J Groh, University of Würzburg). Nevertheless, as a ‘proof of 
principle’ study we believe that our approach with similar combination therapies may 
have a greater impact than BMT – as we have already observed a more pronounced 
improvement in our studies on lifespan of Ppt1 deficient mice than seen after BMT 
treatment alone (Macauley et al., 2012). Therefore, in the future it would be of great 
interest to combine a blockade of Sn (Halkes et al., 2003; Magesh et al., 2011) or 
adaptive immune cells with other promising therapies like CNS-directed gene therapy.  
Interestingly, no such combination therapy approach has been attempted so far in 
Juvenile NCL. This is largely due to the lack of efficient therapies in the first place. 
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Minor successes in treatment have been seen in small molecule therapies such as 
glutamate receptor antagonist or immune suppressive drug administration (see section 
7.8b above, (Aberg et al., 2008; Seehafer et al., 2011)). But the first combinatory study 
for JNCL is now in preparation, which will investigate the treatment of CellCept in 
combination with other anti-inflammatory drugs in Cln3-/- mice (JD Cooper, personal 
communication). However, the lack of any real understanding of the CLN3 protein’s 
function and the mechanistic causes of the disease has limited the scope for successful 
therapeutic interventions. Nevertheless, based on the data of our Sn deficient studies, 
this may represent another contribution in moving towards a therapeutic strategy. 
Encouraged by the positive findings resulting from using combination therapies in 
Infantile NCL mice it is to be hoped that similar advances will one day be realized for 
















Our study has revealed that immune cells play a pathogenic role in both Infantile and 
Juvenile forms of NCL. We have demonstrated for the first time the extent and nature 
of T-cell infiltration in both forms of NCL. Furthermore, we could ameliorate 
neuroinflammation and increase neuronal survival in Ppt1-/- mice by genetically 
removing adaptive immune system components, providing proof of the pathogenic 
role of adaptive immune cells in Infantile NCL. It will be important to perform similar 
genetic manipulation studies in Cln3-/- mice to identify the exact role of T- and B-cells 
in Juvenile NCL.   
As a second goal of this study we wanted to characterise the role of sialoadhesin (Sn) 
expressing cells in the context of Infantile and Juvenile NCL. As a regulatory protein 
and functional link between innate and adaptive immune responses, a role for Sn 
could be predicted in disease progression. Indeed, in Infantile as well as Juvenile NCL, 
the lack of Sn increased neuron survival and attenuated disease progression, validating 
a pathogenic role for Sn in these forms of NCL. Furthermore, we demonstrated an 
unexpected link between macrophage-expressed Sn and astrocytosis in Ppt1-/- brains. 
These findings highlight the importance of understanding the role of each cell type in 
disease progression and how even the smallest irregularity in one cell type can affect 
the other cellular components of the brain. Furthermore, our data raised the 
possibility that peripheral immune cells and/or other systemic events may contribute 
to the neurodegenerative process in INCL and JNCL.  
In summary, we have demonstrated how two different immune modulatory 
approaches can have similar effects in ameliorating disease in two forms of NCL. 
Adaptive immune cells and Sn, which is essential for the proper function of infiltrated 
peripheral macrophages and microglia in the brain, could be promising targets for 
















‘The heights by great men reached and kept, 
Were not attained by sudden flight, 
But they, while their companions slept, 
Were toiling upward in the night.’ 
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Appendix I  
Volume measurements in Infantile and Juvenile NCL brains  
To be able to convert total lymphocyte counts into lymphocyte density values (see 
Figure 21 and Figure 27 in Chapter 3), we performed volume measurements of the 
entire brain volume and each rostrocaudally defined brain level of Ppt1-/-, Cln3-/- and 
age-matched wildtype brains using the unbiased Cavalieri method (see section 2.6a in 
Chapter 2). To date, previous volume measurements in Ppt1-/- or Cln3-/- mice only 
focused on regions that may be involved in these diseases, and no overall assessment 
of brain volume or how it was affected at different rostrocaudal levels has been 
attempted ((Bible et al., 2004; Pontikis et al., 2005); JD Cooper, personal 
communication). Therefore, this rostrocaudal approach represented a new way of 
analysing regional atrophy in NCL brains, with which we could confirm and extend 
previous findings (Bible et al., 2004; Pontikis et al., 2005; Kielar et al., 2007).  
a) Reduced brain volume in Ppt1-/- mice 
The total volume of each Ppt1-/- brain and the volume of each rostrocaudal level I to V 
(see Table 6 and Figure 14 in Chapter 2) were measured in Nissl stained sections 
using the Cavalieri method. By adopting this approach we were able to describe for 
the first time the rostrocaudal distribution of atrophy within the brain of 1, 3, 5 and 7 
month old animals. This added a new perspective to our previously neuroanatomically 
based description of regional atrophy in these mice (Kielar et al., 2007), and also 
allowed us to calculate lymphocyte density at each rostrocaudal level. 
Compared to our previous analysis (Kielar et al., 2007), our rostrocaudal level based 
analysis revealed that a significant reduction in total brain volume could already be 
detected from 5 months onwards in Ppt1-/- mice, compared to age-matched controls 
(Appendix I: Figure 77A). In terms of the rostrocaudal breakdown, these volume 
differences appeared initially in level III (forebrain with hippocampal structures) and 
II (forebrain from begin of cortex to first appearance of hippocampus) between 3 to 5 
months of age, becoming more widespread throughout almost the entire brain at 7 
months of age (Appendix I: Figure 77B). These regionally specific susceptibilities of 
levels III and II correlate with the brain regions of the thalamus, hippocampus and 
somatosensory cortex of Ppt1-/- mice that appear to be affected earliest. Therefore, 
speculatively, these volume changes could be explained by neuron loss, which 
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succeeds pronounced astrocytosis and microglial activations in these brain regions 
(Kielar et al., 2007). 
 
b) Reduced brain volume in Cln3
-/-
 mice 
To be able to calculate the mean lymphocyte density of each T-cell subset (CD8+ve 
cytotoxic T-cells and CD4+ve T-helper cells) throughout the brain, the same 
volumetric analysis performed in Ppt1-/- mice (see section a above) was applied to 
Nissl stained sections from Cln3-/- mice and wildtype controls at 6.5, 12 and 21 
Appendix I: Figure 77. Progressive reduction in the volume of Ppt1-/- brains. Unbiased 
Cavalieri estimates of total brain volume (A) and regional brain volume (B) of Ppt1-/-(—) and age-
matched wildtype (WT) (∙∙∙∙) mice at 1, 3, 5 and 7 months of age, calculated as mean 
volume/hemisphere in mm3. (A) A significant decrease in total brain volume was seen from 5 
months onwards in mutant compared to WT mice. (B) Rostrocaudal effects upon regional 
volume were revealed in regional volume measurements. A significant decrease in regional volume 
was seen from 3 months onwards in mutant animals compared to WT mice - starting in level III 
and level II until finally spreading throughout the brain. Brain levels: I = Olfactory bulb, II = 
Forebrain until hippocampus, III = Hippocampal forebrain, IV = Midbrain with superior colliculus, V 
= Midbrain with pons. Statistics: Two-way ANOVA with Bonferroni post hoc test, *p<0.05, 
**p<0.01, ***p<0.001. Data shown as mean ± SEM, n =5.  
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months of age. This allowed us to define changes in whole brain volume and 
rostrocaudal levels I to V (see Table 6 and Figure 14 in Chapter 2) at these ages.   
A significant reduction in total brain volume was first detected at 21 months of age in 
Cln3-/- mice compared to age-matched controls (see Appendix I: Figure 78A). By 
breaking the brain into rostrocaudal levels, we determined that this reduced volume at 
21 months of age occurred mostly within level III, which includes the thalamus, 
hippocampus and somatosensory cortex – all regions that show an early immune 














Appendix I: Figure 78. Late onset reduction in the volume of Cln3-/- brains. Unbiased 
Cavalieri estimates of total brain volume (A) and regional brain volume (B) of Cln3-/-(—) and age-
matched wildtype (WT) (∙∙∙∙) mice at 6.5, 12 and 21 months of age, calculated as mean 
volume/hemisphere in mm3. (A) A significant decrease in total brain volume was only seen at 21 
months of age in mutant compared to WT mice. (B) Rostrocaudal effects upon regional volume 
were revealed in regional volume measurements. A significant decrease in regional volume was 
seen at level III of 21 months old mutant mice compared to WT mice. Brain levels: I = Olfactory 
bulb, II = Forebrain until hippocampus, III = Hippocampal forebrain, IV = Midbrain with superior 
colliculus, V = Midbrain with pons. Statistics: Two-way ANOVA with Bonferroni post hoc test, 
*p<0.05, **p<0.01. Data shown as mean ± SEM, n =5. 
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Taken together, the volume measurements presented in this study not only enabled 
the calculation of lymphocyte density of both subsets of T-cells, but also revealed a 
new rostrocaudal perspective to the volumetric changes in Ppt1-/- and Cln3-/- mice. 
With our new approach we were able to demonstrate an earlier onset of volume 
changes in Ppt1-/- mice with regional volume reductions already seen at 3 months of 
age, and entire brain volume changes at 5 months of age compared to findings of 
previous studies ((Bible et al., 2004; Kielar et al., 2007); JD Cooper, personal 
communication). Furthermore, as our study included the oldest Cln3 deficient brains 
analysed so far, our volumetric data on 21 month old Cln3-/- mice represent the first 
time that entire (and regional) brain volume reductions have been demonstrated in 




Appendix II  
Increased neuron survival in the cortex of Ppt1-/-/Rag-1-/- mice 
After demonstrating significantly increased neuron survival in the thalamic ventral 
posterior nucleus (VPM/VPL) of Ppt1-/-/Rag-1-/- mice at 3 months of age, compared to 
age-matched Ppt1-/- mice (see Figure 40 in Chapter 4), we extended our analysis to 
the primary barrelfield of the somatosensory cortex (S1BF) which receives projections 
from VPM/VPL. Progressive neuron loss in the S1BF has previously been shown to 
occur subsequent to events within the thalamus (Kielar et al., 2007). Furthermore, our 
data demonstrated that weaker glial activation occurs in the S1BF of Ppt1-/- mice, 
compared to the thalamus (see Figure 33, Figure 35, Figure 37 and Figure 39 in 
Chapter 4). Thus, we wanted to investigate what effect this lack of lymphocytes has 
on neuron survival in the S1BF, as an example of a brain region that contains less glial 
activation and is affected later in disease progression.  
We quantified the number of lamina V neurons in S1BF of 3, 5 and 7 month old   
Ppt1-/-, Ppt1-/-/Rag-1-/-, Rag-1-/- and wildtype mice using the unbiased optical 
fractionator method (see section 2.6c in Chapter 2). This analysis incorporated the 
same mice that have been characterised in Chapter 4, but these cortical neuron counts 
were conducted by Steven Duckett within the scope of his MSc project. 
Whereas at 3 months of age no statistical difference was detected in the number of 
lamina V S1BF neurons between any of the genotypes, Ppt1-/- mice displayed a 
progressive loss of these neurons from 5 months onwards (see Appendix II: Figure 
79). In contrast, the neuron loss of Ppt1-/-/Rag-1-/- double knockout mice was rescued 
by the absence of adaptive immune cells at 5 months of age (see Appendix II: Figure 
79B).  Likewise, the number of lamina V S1BF neurons in these double mutant mice 
did not differ from those of wildtype mice at this time point. However, by 7 months 
of age this protective effect did not persist, and there was no difference in the number 
of lamina V S1BF neurons between Ppt1-/-/Rag-1-/- double knockout and Ppt1-/- mice, 
with both strains of mutant mice showing similar, significant degrees of neuron loss 
compared to age matched control mice (see Appendix II: Figure 79C).  
These data revealed that the genetic removal of adaptive immune cells also leads to 
reduced neuron loss in the S1BF sub-region of the cortex, but in a delayed manner, 
compared to events in the thalamus (see Figure 40 in Chapter 4). These findings are 












which demonstrated a similar delay in disease progression in Ppt1-/-/Rag-1-/- mice, 
compared to Ppt1-/- mice (see Figure 41 and Figure 42 in Chapter 4). In other words, 
collectively these data confirmed that the adaptive immune cells have a pathogenic 
influence on neuron survival, not only in the thalamus, but also in the S1BF cortex of 
Ppt1-/- mice. However, in general adaptive immune cells seem to have a similar effect 
on neuron survival in both brain regions. In the thalamus and the S1BF of             
Ppt1-/-/Rag-1-/- mice neuron survival was only improved at the time point when neuron 
loss would normally start in this brain region of Ppt1-/- mice, and this beneficial effect 
on neurodegeneration vanished with disease progression. Thus, our cortical data on 
neuron survival also highlight that, in addition to adaptive immune responses, other 
driving forces must contribute to disease pathogenesis in INCL mice (see section 7.4 
in Chapter 7 for discussion).  
Appendix II: Figure 79. Progressive neuron loss in lamina V of the somatosensory barrel 
field (S1BF) cortex of Ppt1-/- and Ppt1-/-/Rag-1-/- double knockout mice. Unbiased optical 
fractionator estimates of number of Nissl stained cortical neurons in lamina V of the S1BF of    
Ppt1-/-, Ppt1-/-/Rag-1-/-, Rag-1-/- and age-matched wildtype (WT) control mice at different stages of 
disease progression ((A) 3, (B) 5 and (C) 7 months). Neuron loss was significantly slowed down in 
Ppt1-/-/Rag-1-/- mice compared to single mutant Ppt1 mice. Significantly more neurons were 
present in Ppt1-/-/Rag-1-/- mice at 5 months of age, compared to Ppt1-/- mice. Whereas no 
difference between the genotypes could be detected at 3 months of age, Ppt1-/- mice displayed 
significant neuron loss from 5 months onwards, compared to WT mice. In contrast, the number 
of lamina V neurons in Ppt1-/-/Rag-1-/- mice resembled WT values until 5 months of age, and only 
showed significant loss at 7 months of age. Rag-1-/- and WT mice showed no significant difference 
in neuron numbers at any age. Statistics: One-way ANOVA with Bonferroni post hoc test, * 
indicate significance compared to Ppt1-/- mice (p<0.05), + indicate significance compared to WT 
mice (p<0.001), # indicate significance compared to Rag-1-/- mice (p<0.001). Data shown as mean 
± SEM, n =5. (Graph adapted from S Duckett, MSc thesis.) 
